Page last updated: 2024-11-04

isoproterenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isoproterenol, also known as isoprenaline, is a synthetic catecholamine with potent β-adrenergic agonist activity. It is a racemic mixture of two enantiomers, with the R-enantiomer being the more potent. Isoproterenol acts primarily on β1 and β2 receptors, leading to increased heart rate and contractility, bronchodilation, and relaxation of smooth muscle. It is synthesized through chemical reactions starting with catechol and involving several steps to introduce the appropriate substituents. However, due to its significant side effects, including tachycardia, arrhythmias, and potential for inducing myocardial ischemia, it is rarely used clinically. It is often studied in research as a tool to understand β-adrenergic receptor signaling pathways and to investigate the effects of β-receptor activation in various tissues and organs. '
```

Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3779
CHEMBL ID434
CHEBI ID64317
SCHEMBL ID4165
MeSH IDM0011781

Synonyms (211)

Synonym
AB00053487-10
isoproterenol dl-form
chebi:64317 ,
a-21
gtpl536
1,2-benzenediol, 4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-
3,4-dihydroxy-.alpha.-(isopropylaminomethyl)-benzyl alcohol
nsc33791
nsc-33791
KBIO1_000894
DIVK1C_000894
4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol
SGCUT00015
isonorin
saventrine
nsc 9975
isoproterenol [jan]
(+-)-isoprenaline
3,4-dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol
dl-isadrine
vapo-n-iso
protocatechuyl alcohol, alpha-(isopropylaminomethyl)-
isoprenalina [inn-spanish]
isorenin
isoprenalinum [inn-latin]
brn 2213857
(+-)-isoproterenol
dl(+-)-isoproterenol
isopropylaminomethyl-3,4-dihydroxyphenyl carbinol
4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol
einecs 231-687-7
isoproterenolum
nsc 33791
ccris 3081
benzyl alcohol, 3,4-dihydroxy-alpha-((isopropylamino)methyl)-
epinephrine isopropyl homolog
SPECTRUM_000949
LOPAC0_000711
asiprenol
asmalar
aleudrine
protocatechuyl alcohol,-
neodrenal
n-isopropylnorepinephrine
aludrine
isupren
lomupren
isopropylnoradrenaline
isopropylnorepinephrine
.alpha.-(isopropylaminomoethyl)protocatechuyl alcohol
aludrin
isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol
isadrine
assiprenol
isopropyladrenaline
wln: qr bq dyq1my1&1
bellasthman
neo-epinine
isonorene
aleudrin
isopropylarterenol
nsc9975
1, 4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-
novodrin
n-isopropylnoradrenaline
3,4-dihydroxy-.alpha.-[(isopropylamino)methyl]benzyl alcohol
norisodrine
benzyl alcohol,4-dihydroxy-.alpha.-[(isopropylamino)methyl]-
proternol
dihydroxyphenylethanolisopropylamine
respifral
1-(3,4-dihydroxyphenyl)-2-(isopropylamino)ethanol
nsc-9975
isopropydrin
win 5162
isoprenalin
4-(1-hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol
BSPBIO_002208
4-[1-hydroxy-2-(isopropylamino)ethyl]benzene-1,2-diol
isoprop
1,2-benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-
racemic isoproterenol
racemic isoprenaline
ici 46399
OPREA1_009434
IDI1_000894
PDSP1_001425
PDSP2_001409
PRESTWICK2_001097
isoproterenol-l
4-[1-hydroxy-2-(isopropylamino)ethyl]pyrocatechol;hydrochloride
bdbm25392
chembl434 ,
isoproterenol,(+)
4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol
4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol, 2
isoproteronol
isoproterenol (-)
isoprenaline
7683-59-2
C07056
isoproterenol
ISO ,
TO_000062
DB01064
isopropyl noradrenaline
3,4-dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol
(+/-)-isoproterenol
n-isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine
(+/-)-isoprenaline
1-(3,4-dihydroxyphenyl)-2-isopropylaminoethanol
alpha-(isopropylaminomethyl)protocatechuyl alcohol
SPECTRUM5_000880
NCGC00025274-04
KBIOGR_000427
KBIO3_001428
KBIO2_003997
KBIO2_001429
KBIO2_006565
KBIOSS_001429
SPBIO_003057
SPECTRUM2_001061
SPBIO_001042
SPECTRUM4_000024
PRESTWICK1_001097
SPECTRUM3_000474
NINDS_000894
PRESTWICK0_001097
NCGC00162220-01
NCGC00025274-03
noradrenaline, isopropyl
HMS2089A12
NCGC00015558-08
L000936
dl-isoproterenol
isoprenaline (inn)
D08090
NCGC00015558-06
dtxcid603175
cas-7683-59-2
tox21_110172
dtxsid4023175 ,
CCG-204796
CCG-204727
4-(1-hydroxy-2-(isopropylamino)ethyl)benzene-1,2-diol
NCGC00015558-05
NCGC00015558-12
NCGC00015558-09
NCGC00015558-07
NCGC00016665-02
NCGC00015558-04
NCGC00015558-11
NCGC00015558-10
isoprenalina
unii-l628tt009w
isoprenalinum
3-13-00-02387 (beilstein handbook reference)
l628tt009w ,
isoprenaline [inn]
isoproterenol chloride
AKOS015913894
isoproterenol [vandf]
isoproterenol dl-form [mi]
3,4-dihydroxy-.alpha.-((isopropylamino)methyl)benzyl alcohol
isoproterenol [mi]
isoprenaline [who-dd]
isoprenaline [mart.]
SCHEMBL4165
tox21_110172_1
NCGC00015558-14
AB00053487-09
4-[1-hydroxy-2-(isopropylamino)ethyl]-1,2-benzenediol #
izadrin (salt/mix)
euspiran (salt/mix)
isuprel (salt/mix)
benzyl alcohol, 3,4-dihydroxy-.alpha.-((isopropylamino)methyl)-
protocatechuyl alcohol,.alpha.-(isopropylamino-methyl),-
n-isopropyl-.beta.-dihydroxyphenyl-.beta.-hydroxyethylamine
(.+/-.)-isoprenaline
(.+/-.)-isoproterenol
dl(.+/-.)-isoproterenol
.alpha.-(isopropylaminomethyl)protocatechuyl alcohol
4-[1-hydroxy-2-(isopropylamino)ethyl]-1,2-benzenediol
(a+/-)-isoproterenol hydrochloride
AB00053487_11
AB00053487_12
114-45-4
149-53-1
SBI-0050689.P004
isoproterenol;
STL558077
4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol
FT-0724367
Q415550
BCP09043
AG-219/03618046
SDCCGSBI-0050620.P003
SDCCGSBI-0050689.P005
7683-59-2 (free)
NCGC00015558-25
HMS3742A11
EN300-148243
CS-0028436
HY-108353
isoprenalina (inn-spanish)
r03cb01
c01ca02
r03ab02
4-(1-hydroxy-2-(propan-2-ylamino)ethyl)benzene-1,2-diol
isoprenaline (mart.)
isoprenalinum (inn-latin)

Research Excerpts

Overview

Isoproterenol is a beta adrenergic agonist whose effects have been attributed to the generation of cAMP. It is a safe and reproducible method for pre-pacing evaluation of hypertrophic obstructive cardiomyopathy patients.

ExcerptReferenceRelevance
"Isoproterenol (ISO), is a non-selective beta-adrenergic agonist, that is used widely to induce cardiac injury in mice. "( Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice.
Chang, S; Mandelli, A; Ren, S; Tran, A; Wang, JJ; Wang, Y, 2019
)
2.29
"Isoproterenol is a nonselective beta-adrenergic agonist."( Isoproterenol-Induced Heart Failure Mouse Model Using Osmotic Pump Implantation.
Chang, SC; Rau, CD; Ren, S; Wang, JJ, 2018
)
2.64
"Isoproterenol (ISO) is a non-selective β-adrenergic agonist. "( The Role of Autophagy and Death Pathways in Dose-dependent Isoproterenolinduced Cardiotoxicity.
Czegledi, A; Gyongyosi, A; Lekli, I; Tosaki, A; Zilinyi, R, 2019
)
2.2
"Isoproterenol is a synthetic catecholamine found to cause toxicity leading to severe stress in the myocardium of experimental animals. "( Cardioprotective effect of lemon grass as evidenced by biochemical and histopathological changes in experimentally induced cardiotoxicity.
Gayathri, K; Jayachandran, KS; Rajamanickam, GV; Vasanthi, HR, 2011
)
1.81
"Isoproterenol is a safe drug in this porcine model and, hence, it is potentially useful during endourological procedures."( Local and systemic effects of endoluminal pelvic perfusion of isoproterenol: a dose response investigation in pigs.
Holst, U; Jakobsen, JS; Jakobsen, P; Mortensen, J; Steen, W, 2007
)
1.3
"Isoproterenol is a beta adrenergic agonist whose effects have been attributed to the generation of cAMP. "( Isoproterenol inhibits cyclic AMP-mediated but not insulin-mediated translocation of the GLUT4 glucose transporter isoform.
Kelada, AS; Macaulay, SL; Proietto, J, 1994
)
3.17
"Isoproterenol is a chiral catecholamine with a half-life of elimination of less than 10 min. "( Optimization of the separation and detection of the enantiomers of isoproterenol in microdialysis samples by cyclodextrin-modified capillary electrophoresis using electrochemical detection.
Biggin, ME; Hadwiger, ME; Lunte, CE; Park, S; Torchia, SR, 1996
)
1.97
"Isoproterenol is a safe and reproducible method for pre-pacing evaluation of hypertrophic obstructive cardiomyopathy patients."( Long-term effects of dual chamber pacing in patients with hypertrophic cardiomyopathy without outflow tract obstruction at rest.
Gadler, F; Juhlin-Dannfelt, A; Linde, C; Ribeiro, A; Rydén, L, 1997
)
1.02
"Isoproterenol is a potent pulmonary vasodilator with inotropic and chronotropic effects, and seemed to decrease the pulmonary vascular resistance allowing increased antegrade blood flow to the pulmonary artery and improved cardiac output."( Management of functional pulmonary atresia with isoproterenol in a neonate with Ebstein's anomaly.
Hayasaka, K; Komatsu, H; Nakasato, M; Sato, S; Suzuki, H, 1997
)
1.27
"Isoproterenol is a potent non-selective beta-adrenergic agonist, phenylephrine is an alpha1-selective adrenergic agonist."( Variability in vascular responsiveness between Mexican-Americans and White Americans.
Adubofour, KO; Dachman, WD; Kapoor, C; Rackleff, D, 1998
)
1.02
"Isoproterenol is a dilator in both circulations and its response is attenuated only by beta adrenergic blockade."( Hemodynamic effects of intra-arterial infusions of catecholamines on the canine gastric circulation.
Kerr, JC; Reynolds, DG; Zinner, MJ, 1975
)
0.98
"Isoproterenol is a potent dipsogen and antidiuretic agent. "( Beta-adrenergic thirst and its relation to the renin-angiotensin system.
Ramsay, DJ, 1978
)
1.7
"Isoproterenol is a pure vasodilator, and its response is attenuated following beta-adrenergic blockade with propranolol."( Primate gastric circulation: effects of catecholamines and adrenergic blockade.
Kerr, JC; Reynolds, DG; Zinner, MJ, 1976
)
0.98
"Isoproterenol is a potent lipolytic agent. "( Lipid accumulation in the perfused rat heart after isoproterenol administration.
Jodalen, H; Neely, JR, 1991
)
1.98
"Isoproterenol infusion is a better alternative to exercise testing."( Isoproterenol infusion--an alternative to exercise testing.
Balasubramaniam, V; Makilzhan, S; Nagarajan, R; Parthasarathy, V,
)
2.3
"Isoproterenol 5 micrograms is an effective marker of intravascular injection in laboring women; however, the safety and efficacy of epidural isoproterenol must be demonstrated in animals before isoproterenol can be incorporated in an epidural anesthesia test dose."( Isoproterenol is an effective marker of intravenous injection in laboring women.
Chayen, B; DeSimone, CA; Leighton, BL; Norris, MC, 1989
)
2.44

Effects

Isoproterenol has a direct renin-stimulatory effect on intrarenal beta-adrenergic receptors. It has a high affinity for this adenylate cyclase system but only 20-30% of the maximal activity of NE.

Isoproterenol has been used to terminate recurrent ventricular fibrillation in patients with Brugada syndrome and torsades de pointes resistant to magnesium therapy. It has no effect on the B-82 cells radiosensitivity, although it is known as a potent radioprotector.

ExcerptReferenceRelevance
"Isoproterenol has a direct renin-stimulatory effect on intrarenal beta-adrenergic receptors that may be reinforced by baroreceptor stimulation."( Renin stimulation by isoproterenol and theophylline in the isolated perfused kidney.
Lupu, AN; Maxwell, MH; Rosenfeld, S; Viskoper, RJ, 1977
)
1.3
"Isoproterenol, which has a high affinity for this adenylate cyclase system but only 20-30% of the maximal activity of NE, does not interfere with the agonist activity of NE."( Norepinephrine stimulated cyclic AMP accumulation in rat limbic forebrain slices: partial mediation by a subpopulation of receptors with neither alpha nor beta characteristics.
Mobley, PL; Sulser, F, 1979
)
0.98
"Isoproterenol has a more marked effect on the metabolism of adenine nucleotides in the heart only: it reduced the amount of adenine nucleotides and enhanced their synthesis from inosine."( [The effect of allopurinol on the synthesis of adenine nucleotides and ribonucleic acid from inosine via a salvage pathway in the brain of rats].
Pechán, I; Zimmer, HG, 1989
)
1
"Isoproterenol (ISO) has been widely used to establish cardiac injury in vivo and in vitro."( Shikonin ameliorates isoproterenol (ISO)-induced myocardial damage through suppressing fibrosis, inflammation, apoptosis and ER stress.
Chen, DL; Wang, Z; Yang, J, 2017
)
1.5
"Isoproterenol (ISO) has been reported to inhibit high mobility group box 1 (HMGB1) protein release via heme oxygenase-1 (HO-1) induction in lipopolysaccharide (LPS)-activated RAW 264.7 cells and increase the survival rate of cecal ligation and puncture (CLP)-induced septic mice. "( Isoproterenol‑mediated heme oxygenase‑1 induction inhibits high mobility group box 1 protein release and protects against rat myocardial ischemia/reperfusion injury in vivo.
Fu, W; Hu, X; Jiang, H; Wang, J; Xie, J; Zhou, X, 2014
)
3.29
"Isoproterenol has been used to terminate recurrent ventricular fibrillation in patients with Brugada syndrome and torsades de pointes resistant to magnesium therapy."( Isoproterenol as an adjunct for treatment of idiopathic ventricular fibrillation storm in a pregnant woman.
Mittadodla, PS; Salen, PN; Traub, DM, 2012
)
2.54
"Isoproterenol has been used to assess inducibility during catheter ablation for paroxysmal PAF. "( Inducibility of paroxysmal atrial fibrillation by isoproterenol and its relation to the mode of onset of atrial fibrillation.
Bogun, F; Chalfoun, N; Chugh, A; Crawford, T; Dey, S; Frederick, M; Gadeela, N; Good, E; Jongnarangsin, K; Kuhne, M; Morady, F; Oral, H; Pelosi, F; Sarrazin, JF; Wells, D; Wimmer, A, 2008
)
2.04
"Isoproterenol (ISO) has been found to cause severe injury in the myocardium. "( Protective effects of N-acetylcysteine in isoproterenol-induced myocardium injury in rats.
Fu, J; Li, H; Li, W; Li, Y; Liu, B; Liu, P; Wang, Z, 2009
)
2.06
"Isoproterenol has no effect on the B-82 cells radiosensitivity, although it is known to be a potent radioprotector."( [Effect of prostaglandin E1 on the cyclic adenosine-3',5'--monophosphate system and radiosensitivity of B-82 cells cultured in vitro].
Chirkov, IuIu; Malatsidze, MA; Serobian, GA; Sobolev, AS, 1984
)
0.99
"Isoproterenol has no effect on cGMP release but increases cAMP release dramatically."( Cyclic nucleotide concentrations in tissue and perfusate of isolated rat lung.
Bellamy, PE; Tierney, DF, 1984
)
0.99
"Isoproterenol has no effect on soluble phosphodiesterase activity but increases membrane-bound phosphodiesterase activity 3- and 2.2-fold in Phase II and Phase III cells, respectively."( Regulation of cyclic AMP metabolism in the rat erythrocyte during chronic beta-adrenergic stimulation. Evidence for calmodulin-mediated alteration of membrane-bound phosphodiesterase activity.
Clayberger, CA; Goodman, DB; Rasmussen, H, 1981
)
0.98
"Isoproterenol has been shown to cause severe liver damage in chick embryos. "( Isoproterenol--induced damage to the liver of chick embryos.
Dusek, J; Ostádal, B, 1984
)
3.15
"Isoproterenol has very specific indications, in acute phases and during short periods of time."( [Catecholamines in pediatric intensive care].
Albajara Velasco, L; Mar Molinero, F; Ruza Tarrió, F; Solorzano, C, 1982
)
0.99
"Isoproterenol has been the drug of choice to increase the sensitivity of this testing."( [Role of adenosine triphosphate (ATP) in head-up tilt-induced syncope].
Espinosa García, MD; Expósito Ordóñez, E; Florenciano Sánchez, R; González Caballero, E; Gonzálvez Ortega, M; Iñigo García, L; Pérez-Paredes, M; Picó Aracil, F; Ruipérez Abizanda, JA; Sánchez Villanueva, JG, 1998
)
1.02
"Isoproterenol has been suggested as an alternative marker for epidural test dosing in children receiving halothane anesthesia. "( Simulation of an epidural test dose with intravenous isoproterenol in sevoflurane- and halothane-anesthetized children.
Glaser, C; Kozek, ME; Kozek-Langenecker, SA; Krenn, CG; Marhofer, P; Semsroth, M, 1998
)
1.99
"Isoproterenol has been suggested as an alternative marker for epidural test dosing in children receiving halothane anesthesia. "( Simulation of an epidural test dose with intravenous isoproterenol in sevoflurane- and halothane-anesthetized children.
Glaser, C; Kozek, ME; Kozek-Langenecker, SA; Krenn, CG; Marhofer, P; Semsroth, M, 1998
)
1.99
"Isoproterenol has been previously shown to increase myometrial cyclic AMP levels, and changes in Ca2+-transport by cell membranes in relation to intracellular cyclic AMP levels may be the mechanism through which hormones modulate uterine contractility."( Hormonal control of uterine contraction. Characterization od cyclic AMP-dependent membrane properties in the myometrium.
Korenman, SG; Krall, JF; Swensen, JL, 1976
)
0.98
"Isoproterenol has a direct renin-stimulatory effect on intrarenal beta-adrenergic receptors that may be reinforced by baroreceptor stimulation."( Renin stimulation by isoproterenol and theophylline in the isolated perfused kidney.
Lupu, AN; Maxwell, MH; Rosenfeld, S; Viskoper, RJ, 1977
)
1.3
"Isoproterenol, which has a high affinity for this adenylate cyclase system but only 20-30% of the maximal activity of NE, does not interfere with the agonist activity of NE."( Norepinephrine stimulated cyclic AMP accumulation in rat limbic forebrain slices: partial mediation by a subpopulation of receptors with neither alpha nor beta characteristics.
Mobley, PL; Sulser, F, 1979
)
0.98
"Isoproterenol has its optimal activity at a much earlier time in gestation than that previously reported for testosterone or erythropoietin."( Isoproterenol stimulation of heme synthesis in cultures of human fetal liver from early gestation.
Congote, LF; Solomon, S, 1977
)
2.42
"l-Isoproterenol has been proposed to stimulate lipolysis in rat epididymal adipocytes via atypical beta adrenergic receptors, whereas radioligand binding studies only revealed the presence of beta 1 adrenergic receptors on adipocyte membranes. "( Multiple beta adrenergic receptor subclasses mediate the l-isoproterenol-induced lipolytic response in rat adipocytes.
Van Liefde, I; Van Witzenburg, A; Vauquelin, G, 1992
)
1.25
"1-Isoproterenol has equal affinity for beta 1- and beta 2-adrenoceptors and is a full agonist at both subtypes. "( Central administration of 1-isoproterenol in vivo induces a preferential regulation of beta 2-adrenoceptors in the central nervous system of the rat.
Frazer, A; Gambarana, C; Hauptmann, M; Ordway, GA; Tejani-Butt, S, 1991
)
1.3
"Isoproterenol has preferential effects on retrograde conduction and may have selective influence on distal AV nodal conduction."( Reassessment of AV and VA conduction and AV junctional reentry in the normal dog heart: the role of altered autonomic tone.
Hunt, GB; Ross, DL, 1988
)
1
"Isoproterenol has a more marked effect on the metabolism of adenine nucleotides in the heart only: it reduced the amount of adenine nucleotides and enhanced their synthesis from inosine."( [The effect of allopurinol on the synthesis of adenine nucleotides and ribonucleic acid from inosine via a salvage pathway in the brain of rats].
Pechán, I; Zimmer, HG, 1989
)
1
"Isoproterenol has been shown to constitute a useful reagent for detecting peroxidase activities in enzymatic tests, utilizing standard purified enzymes, and in the microbiological application proposed."( Whole-cell bacterial peroxidase test with isoproterenol as the hydrogen donor.
Galeazzi, L; Giunta, S; Grilli, G; Groppa, G; Rocchetti, R; Turchetti, G,
)
1.12
"Isoproterenol has been used experimentally and clinically to elicit ischemia. "( Relation between graded, subcritical impairments of coronary flow reserve and regional myocardial dysfunction induced by isoproterenol infusion in dogs.
DeBoe, SF; Friedman, HZ; Hramiec, JE; Mancini, GB, 1987
)
1.92
"Isoproterenol, as has been demonstrated previously, caused improvement in FEV1 FEF50, and the flow of a partial flow-volume curve at 75% of the VC (PFEF75)."( Comparison of the effects of intravenously administered aminophylline and inhaled isoproterenol on normal airways.
Howick, J; Kelly, HW; McWilliams, BC; Menendez, R, 1986
)
1.22

Actions

Isoproterenol prevented an increase in capillary filtration coefficient. Ca2+ increase and cADPR production, but not NAADP production, were markedly reduced in cardiomyocytes obtained from CD38 knockout mice. Isop roterenol blocked the increase in TNFalpha and apoptosis in the diabetic retina.

ExcerptReferenceRelevance
"Isoproterenol prevented an increase in capillary filtration coefficient (1.74 ± 0.4 vs."( Isoproternenol increases vascular volume expansion and urinary output after a large crystalloid bolus in healthy volunteers.
Asmussen, S; Kinsky, MP; Kramer, GC; Prough, DS; Salter, M; Sheffield-Moore, M; Svensen, C, 2014
)
1.12
"The isoproterenol-mediated Ca2+ increase and cADPR production, but not NAADP production, were markedly reduced in cardiomyocytes obtained from CD38 knockout mice."( Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) and Cyclic ADP-Ribose (cADPR) Mediate Ca2+ Signaling in Cardiac Hypertrophy Induced by β-Adrenergic Stimulation.
Gul, R; Im, SY; Jang, KY; Kim, D; Kim, UH; Ko, JK; Lee, SH; Nam, TS; Park, DR; Shawl, AI, 2016
)
0.92
"Isoproterenol blocked the increase in TNFalpha and apoptosis in the diabetic retina."( Application of isoproterenol inhibits diabetic-like changes in the rat retina.
Jiang, Y; Kern, TS; Steinle, JJ; Walker, RJ, 2010
)
1.43
"The isoproterenol-induced increase in the force of contraction in animals during hibernation is brief (within 3 min after the onset of treatment) and this parameter decreases by 30-50% of the control level (negative inotropic effect) at stimulation frequencies from 0.3 and 0.8 Hz."( [Effect of isoproterenol on contractility of the heart papillary muscles of a ground squirrel].
Averin, AS; Ignat'ev, DA; Nakipova, OV; Tarlachkov, SV; Zakharova, NM,
)
1
"Isoproterenol-induced increase in Rap1 activity was inhibited by silencing Epac1 in rat aortic SM cells."( The cAMP-responsive Rap1 guanine nucleotide exchange factor, Epac, induces smooth muscle relaxation by down-regulation of RhoA activity.
Artamonov, MV; Chrzanowska-Wodnicka, M; Franke, AS; Ho, R; Jin, L; Khromov, AS; Momotani, K; Neppl, RL; Somlyo, AV; Stevenson, AS; Zieba, BJ, 2011
)
1.09
"Isoproterenol did not enhance the effect of CCh on [Ca(2+)](i)."( Cyclic AMP has distinct effects from Ca(2+) in evoking priming and fusion/exocytosis in parotid amylase secretion.
Fujita-Yoshigaki, J; Murakami, M; Segawa, A; Yoshimura, K, 2002
)
1.04
"The isoproterenol-induced increase in left ventricular contractility (dP/dt) and relaxation (-dP/dt) and, consequently, cardiac output were also significantly reduced in both the Chol groups with or without STZ, compared to control group."( Reduction of cardiac functional reserve and elevation of aortic stiffness in hyperlipidemic Yucatan minipigs with systemic and coronary atherosclerosis.
Fitch, R; Halks-Miller, M; Li, W; Lillis, B; Post, J; Sullivan, ME; Vergona, R; Verhallen, PF; Wang, YX; Werner, M, 2002
)
0.8
"The isoproterenol-stimulated increase in I Ca(L) was significantly smaller in postinfarction myocytes (Emax: 63.6 4.3 vs 123.3 0.9% in sham myocytes), but EC50 was not altered."( Impaired beta-adrenergic response and decreased L-type calcium current of hypertrophied left ventricular myocytes in postinfarction heart failure.
Chedid, NG; Díaz G, LE; Masuda, MO; Quintero H, CC; Saraiva, RM, 2003
)
0.8
"Isoproterenol caused an increase in the level of cyclic AMP (rho;moles/10(5) myocytes) in the control (from 2.92 +/- 0.47 to 3.77 +/- 0.43) but not in the stunned myocytes (from 2.42 +/- 0.25 to 2.42 +/- 0.20)."( Effects of triiodothyronine pretreatment on beta-adrenergic responses in stunned cardiac myocytes.
Gandhi, A; He, YQ; Tse, J; Weiss, HR; Yan, L, 2003
)
1.04
"The isoproterenol-induced increase in [Ca2+]i in KCl-depolarized cardiomyocytes was augmented by low Na+; this augmentation was significantly depressed by treatment with KB-R7943."( Involvement of Na+/Ca2+ exchanger in catecholamine-induced increase in intracellular calcium in cardiomyocytes.
Dhalla, NS; Elimban, V; Saini, HK; Tripathi, ON; Zhang, S, 2006
)
0.81
"Isoproterenol caused an increase in myocardial oxidative stress in control rats, as evidenced by an increase in myocardial TBARS level, reduction in FRAP and myocardial SOD, catalase and GPx activity, along with focal necrosis of cardiac muscle fibres on light microscopy."( Dietary palm olein oil augments cardiac antioxidant enzymes and protects against isoproterenol-induced myocardial necrosis in rats.
Dinda, AK; Maulik, SK; Narang, D; Sood, S; Thomas, M, 2005
)
1.28
"The isoproterenol-induced increase in EGC was higher after the training."( Dynamic strength training improves insulin sensitivity and functional balance between adrenergic alpha 2A and beta pathways in subcutaneous adipose tissue of obese subjects.
Berlan, M; Hejnova, J; Klimcakova, E; Lafontan, M; Langin, D; Majercik, M; Moro, C; Polak, J; Stich, V; Viguerie, N, 2005
)
0.81
"The isoproterenol-induced increase in L-type Ca2+ current (ICa) was smaller in females versus in males, but NOS blockade increased ICa in females."( Hypercontractile female hearts exhibit increased S-nitrosylation of the L-type Ca2+ channel alpha1 subunit and reduced ischemia/reperfusion injury.
Bers, DM; Ginsburg, KS; Murphy, E; Picht, E; Steenbergen, C; Sun, J, 2006
)
0.81
"Isoproterenol was found to inhibit the release of RANTES from the human bronchial epithelial cells, at least in part, through the inhibition of JNK signaling pathway."( Isoproterenol suppresses cytokine-induced RANTES secretion in human lung epithelial cells through the inhibition of c-jun N-terminal kinase pathway.
Arai, N; Hayashi, R; Hounoki, H; Kanatani, Y; Kawagishi, Y; Kobayashi, M; Maruyama, M; Matsui, S; Miwa, T; Miyabayashi, K; Shinoda, C; Shinoda, K; Sugiyama, E; Suzuki, K; Yamada, T, 2006
)
2.5
"The isoproterenol-induced increase in the phosphorylation of Ser2815 site was prevented by the PKA inhibitor H-89 and mimicked by forskolin."( Ca2+/calmodulin kinase II increases ryanodine binding and Ca2+-induced sarcoplasmic reticulum Ca2+ release kinetics during beta-adrenergic stimulation.
Donoso, P; Ferrero, P; Mattiazzi, A; Mundiña-Weilenmann, C; Said, M; Sánchez, G; Valverde, C; Vittone, L, 2007
)
0.82
"The isoproterenol-associated increase in R amplitude variability occurred in controls in the absence of significant anxiety. "( Exaggerated beat-to-beat R amplitude variability in patients with panic disorder after intravenous isoproterenol.
Bär, KJ; Chokka, P; Pohl, R; Tancer, M; Yeragani, VK, 2007
)
1.11
"With isoproterenol infusion, the increase of LAAEV was greater in group 1 than in group 2."( Prognostic implication of the left atrial appendage mechanical reserve after cardioversion of atrial fibrillation.
Kim, YH; Lim, DS; Lim, HE; Oh, WJ; Pak, HN; Park, MY; Ro, YM; Shim, WJ; Shin, SH, 2008
)
0.8
"An isoproterenol-induced increase in the concentration of GIP and insulin was thus counteracted by propranolol."( Beta-adrenergic stimulation and blockade of the release of gastric inhibitory polypeptide and insulin in man.
Flaten, O; Myren, J; Sand, T, 1982
)
0.78
"The isoproterenol-induced increase in cyclic AMP level was not reduced by adenosine in IAP-treated atria."( Modification by islet-activating protein of direct and indirect inhibitory actions of adenosine on rat atrial contraction in relation to cyclic nucleotide metabolism.
Endoh, M; Maruyama, M; Taira, N,
)
0.61
"Isoproterenol was found to increase the cAMP content of gastric glands and to stimulate adenylyl cyclase activity in homogenates."( Pepsinogen release from isolated gastric glands.
Chew, CS; Hersey, SJ; Koelz, HR; Sachs, G, 1982
)
0.99
"The isoproterenol-induced increase in the Bmax value of the binding was higher in 50 mM Tris-HCl buffer (pH 7.7) than in Krebs-Ringer solution."( The interaction between beta- and alpha 2-adrenoceptors in cerebral cortical membranes: isoproterenol-induced increase in [3H]clonidine binding in rats.
Kawai, M; Nomura, Y; Segawa, T, 1984
)
0.97
"Isoproterenol infusions produce symptoms in a dose-related fashion in MVP patients but not in controls."( Mitral valve prolapse: a marker for anxiety or overlapping phenomenon?
Boudoulas, H; King, BD; Wooley, CF, 1984
)
0.99
"Isoproterenol induced an increase in Isc, G, and Cl- secretion of fetal trachea."( Bioelectric properties and ion transport of airways excised from adult and fetal sheep.
Boucher, RC; Cotton, CU; Gatzy, JT; Lawson, EE, 1983
)
0.99
"Isoproterenol was found to increase blood flows to brown fat, skeletal muscle, and cardiac muscle in normal animals and to brown fat and skeletal muscle in dystrophic hamsters, suggesting that these tissues contribute to NST."( Blood flow in normal and dystrophic hamsters during nonshivering thermogenesis.
Horwitz, BA; Wickler, SJ, 1984
)
0.99
"Isoproterenol prevented the increase in tracheal pressures produced by histamine challenge."( Characterization of intrapulmonary, rapidly adapting receptors of guinea pigs.
Bergren, DR; Sampson, SR, 1982
)
0.99
"Isoproterenol also did not produce any significant change in mean arterial blood pressure, heart rate or respiratory rate when it was administered centrally 15 min after instillation of either l- or dl-propranolol."( Central antihypertensive activity of propranolol.
Zawoiski, EJ, 1980
)
0.98
"Isoproterenol caused an increase of respiratory output within a few seconds if carotid bodies were intact; recordings of the carotid sinus nerves showed that the response was due to activation of carotid body chemoreceptors."( Mechanisms of hyperpnea induced by isoproterenol.
Eldridge, FL; Gill-Kumar, P, 1980
)
1.26
"Isoproterenol-induced increase in +dP/dt was not potentiated by Pi, showing that potentiation of +dP/dt is not a common effect of Pi."( Role of Na+/phosphate-cotransporter in myocardial contractile responses to alpha 1-agonist.
Onwochei, MO, 1995
)
1.01
"The isoproterenol-mediated increase in mAChR number was time dependent and reached a maximum by 48 h."( Subtype-specific regulation of muscarinic receptor expression and function by heterologous receptor activation.
Jackson, DA; Nathanson, NM, 1995
)
0.77
"The isoproterenol-mediated increase in NE release is inhibited by halothane anesthesia, indicating that halothane inhibits prejunctional beta 2-adrenergic receptor regulation of NE release."( Regulation of norepinephrine release by beta 2-adrenergic receptors during halothane anesthesia.
Deegan, R; He, HB; Krivoruk, Y; Wood, AJ; Wood, M, 1995
)
0.85
"3. Isoproterenol induced an increase in the frequency of spontaneous miniature EPSCs but did not affect the amplitude of these currents."( Presynaptic enhancement of excitatory synaptic transmission by beta-adrenergic receptor activation.
Conn, PJ; Gereau, RW, 1994
)
0.8
"Isoproterenol is used to increase sensitivity."( Esmolol tilt testing with esmolol withdrawal for the evaluation of syncope in the young.
Ovadia, M; Thoele, D, 1994
)
1.01
"Isoproterenol failed to activate the current in the presence of intracellular GDP beta S."( Isoproterenol stimulates Cl- current by a Gs protein-mediated process in beta-intercalated cells isolated from rabbit kidney.
Hayashi, M; Ikeda, M; Imai, M; Iyori, M; Kurokawa, K; Saruta, T; Yoshitomi, K, 1993
)
2.45
"Both isoproterenol induced increase in cAMP and inhibition of calcium mobilization were significantly correlated to basal plasma NA."( Catecholamine responsiveness in human lymphocytes evaluated by intracellular free calcium measurements.
Bouchelouche, P; Christensen, NJ; Jensen, EW, 1995
)
0.75
"Isoproterenol did not cause significant changes in these parameters."( A novel catecholamine, arbutamine, for a pharmacological cardiac stress agent.
Abou-Mohamed, G; Caldwell, RW; Myers, T; Nagarajan, R, 1996
)
1.02
"The isoproterenol-induced increase in maximum relengthening velocity was increased by 168 +/- 8% (n = 6) in PLB-deficient cells compared with 445 +/- 71% (n = 6) in wild-type myocytes."( Effect of ablation of phospholamban on dynamics of cardiac myocyte contraction and intracellular Ca2+.
Kranias, EG; Luo, W; Solaro, RJ; Stojanovic, MO; Wolska, BM, 1996
)
0.77
"Isoproterenol was used to activate the cAMP second-messenger system in a potassium-free environment."( Lack of cystic fibrosis transmembrane regulator-type chloride current in pediatric human atrial myocytes.
Berul, CI; Morad, M; Sweeten, T; Vetter, VL, 1997
)
1.02
"An isoproterenol-mediated increase in cardiomotor tone and a decrease in afterload contribute to the induction of vasovagal syncope. "( Hemodynamic analysis during isoproterenol-induced vasovagal syncope.
Bailey, KR; Fenton, AM; Hammill, SC; Lohse, CM; Low, PA; Shen, WK, 1997
)
1.21
"Isoproterenol-stimulated increase in cellular cyclic AMP levels was very similar in E18 and P2 astrocytes."( Developmental changes in cyclic AMP-stimulated stellation of cultured rat cortical astrocytes.
Abe, K; Saito, H, 1997
)
1.02
"Isoproterenol did not enhance the effect of substance P on [Ca2+]i."( Cyclic AMP potentiates substance P-induced amylase secretion by augmenting the effect of calcium in the rat parotid acinar cells.
Hiramatsu, Y; Murakami, M; Yoshimura, K, 1998
)
1.02
"The isoproterenol-induced increase in protein synthesis was also suppressed by inhibitors for PKA, Gi, tyrosine kinases, or Ras."( Both Gs and Gi proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy.
Kadowaki, T; Komuro, I; Kudoh, S; Uozumi, H; Yamazaki, T; Yazaki, Y; Zou, Y, 1999
)
1.04
"Isoproterenol did not cause alkalization of either cell type, whereas, noradrenaline and carbachol alkalized both types over the concentration ranges of 10(-6) M to 3 x 10(-3) M (HSG cell by noradrenaline), 10(-7) M to 2 x 10(-4) M (A-431 cell by noradrenaline), and 7 x 10(-5) M to 10(-4) M (A-431 cell by carbachol). "( Alkalization produced by high-dose carbachol in HSG cell line is independent of Ca2+.
Atsumi, T; Iwakura, I; Ueha, T, 1998
)
1.74
"Isoproterenol provoked an increase of peak amplitude (137% +/- 47%, n = 16 cells) and acceleration of activation kinetics in the outward K+ current (the time reaching a peak current reduced from 36 ms +/- 10 ms to 16 ms +/- 9 ms)."( Characterization of outward potassium current in embryonic chick heart cells.
Huang, LX; Mei, YA; Sun, JT; Wei, H; Zhang, ZH; Zhou, HQ, 1999
)
1.02
"Isoproterenol caused an increase in cellular cyclic AMP (cAMP) concentration."( Beta-adrenergic stimulation of volume-sensitive chloride transport in lamprey erythrocytes.
Bogdanova, A; Nikinmaa, M; Salama, A; Virkki, LV,
)
0.85
"The isoproterenol-associated increase in QT interval occurred in controls in the absence of significant anxiety."( QT interval variability in panic disorder patients after isoproterenol infusions.
K Yeragani, V; Pohl, R, 2001
)
1.04
"The isoproterenol group had a lower global critical oxygen delivery than the other groups (8.8 +/- 1.3 vs."( Effects of alpha - and beta -adrenergic stimulation on hepatosplanchnic perfusion and oxygen extraction in endotoxic shock.
Cherkaoui, S; De Backer, D; De Jongh, R; Vincent, JL; Vray, B; Zhang, H, 2001
)
0.79
"Isoproterenol failed to activate ERKs in either the cultured cardiomyocytes or the hearts of mice that overexpress the dominant negative mutant of calcineurin."( Isoproterenol activates extracellular signal-regulated protein kinases in cardiomyocytes through calcineurin.
Hiroi, Y; Kohmoto, O; Komuro, I; Kudoh, S; Nagai, R; Shibasaki, F; Shimoyama, M; Takahashi, T; Uozumi, H; Yao, A; Yazaki, Y; Zhu, W; Zou, Y, 2001
)
2.47
"Isoproterenol alone did not increase LV ANG II and, combined with losartan or quinapril, actually decreased LV ANG II."( Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system.
Leenen, FH; White, R; Yuan, B, 2001
)
2.47
"3. Isoproterenol, known to increase cyclic nucleotide concentration of the cortical tubules by activation of adenyl cyclase, decreases p-aminohippurate transport."( Inhibition by cyclic AMP and dibutyryl cyclic AMP of transport of organic acids in kidney cortex.
Boumendil-Podevin, EF; Podevin, RA, 1975
)
0.77
"The isoproterenol-induced increase in plasma cyclic adenosine 3':5'-monophosphate (cAMP) reflects the response of adenylate cyclase to beta-adrenergic stimulation, whereas a non-beta-receptor-mediated increase occurs with the administration of glucagon."( Plasma cyclic adenosine 3':5'-monophosphate response to isoproterenol and glucagon in hyperkinetic borderline (labile) hypertension.
Fraysse, J; Genest, J; Guthrie, GP; Hamet, P; Kuchel, O; Messerli, FH; Nowaczynski, W; Tolis, G, 1976
)
0.98
"Isoproterenol did not increase pancreatic blood flow and induced no variations in the plasma levels of immunoreactive secretin."( Isoproterenol induced pancreatic secretion in rats. A comparison with secretin.
Chariot, J; de la Tour, J; Dupont, C; Jean, E; Rozé, C; Souchard, M; Vaille, C; Wepierre, J, 1976
)
2.42
"For isoproterenol, the maximum increase in cAMP occurred at 1 X 10(-6) M, a concentration without effect on transmission."( Transmission blockade and stimulation of ganglionic adenylate cyclase by catecholamines.
Alkadhi, K; Quenzer, L; Volle, RL; Yahn, D, 1979
)
0.74
"Isoproterenol did cause insulin release in this system, but insulin responses to theophylline were diminished by somatostatin."( Inhibition by somatostatin of glucagon and insulin release from the perfused rat pancreas in response to arginine, isoproterenol and theophylline: evidence for a preferential effect on glucagon secretion.
Gerich, JE; Grodsky, GM; Lovinger, R, 1975
)
1.19
"DL-Isoproterenol did not increase the amount of guanylnucleotide bound, it merely accelerated and potentiated activation."( Activation of pigeon erythrocyte membrane adenylate cyclase by guanylnucleotide analogues and separation of a nucleotide binding protein.
Helmreich, EJ; Pfeuffer, T, 1975
)
0.77
"Isoproterenol caused a 39% increase in force and a 43% increase in pyruvate dehydrogenase activity but no change in mitochondrial Ca2+ (0.46 +/- 0.19 (S.E.) mmol of Ca2+/kg, dry weight) compared with control (0.54 +/- 0.12)."( Effect of inotropic stimulation on mitochondrial calcium in cardiac muscle.
Bond, M; Moravec, CS, 1992
)
1
"Isoproterenol could enhance the amplitude of this current once it developed."( Swelling-induced chloride-sensitive current in canine atrial cells revealed by whole-cell patch-clamp method.
Sorota, S, 1992
)
1
"The isoproterenol-induced increase in 6-keto-PGF1 alpha was diminished by adenosine (10 microM), the A1 receptor antagonist 1,3-dipropyl, 8-cyclopentylxanthine (DPCPX 0.06 microM), and the A2 receptor agonist CGS-21680 (0.6 microM); CGS-21680 did not decrease heart rate (HR) or myocardial contractility (dP/dt(max))."( Contribution of adenosine to isoproterenol-stimulated prostacyclin production in rabbit heart.
Cano, C; Carter, S; Malik, KU; Qureshi, Z, 1992
)
1.06
"The isoproterenol-stimulated increase in cardiac contractility, moreover, is reduced by 10 nM beta-CM-5."( Nonopioid effects of beta-casomorphin-5 in guinea pig heart: alterations to the beta-adrenoceptor-G-protein complex and inhibition of myocardial responses to isoproterenol.
Barth, A; Liebmann, C; Mentz, P; Neubert, K; Schnittler, M; Schrader, U,
)
0.81
"Isoproterenol does not inhibit histamine release induced by any stimuli, but enhances the response to concanavalin A and compound 48/80."( [Effect of isoproterenol on the liberation of histamine from rat lung mast cells].
Botana, LM; de la Cruz, LF; Louzao, MC; Vieytes, MR, 1991
)
1.39
"Isoproterenol did not increase unloaded shortening velocity at optimal [Ca2+]o, regardless of the thyroid state."( Lack of effect of isoproterenol on unloaded velocity of sarcomere shortening in rat cardiac trabeculae.
de Tombe, PP; ter Keurs, HE, 1991
)
1.34
"isoproterenol) to activate a specific apical membrane chloride channel in epithelial cells is characteristic of cystic fibrosis (CF)."( Chloride ion transport in transformed normal and cystic fibrosis epithelial cells.
Chin, L; Cozens, AL; Friend, DS; Gruenert, DC; Simon, EM; Yezzi, MJ, 1991
)
1
"Isoproterenol-induced increase in HR and a shortening of AH, FRPAV, ERPVM were inhibited competitively by pretreatment with nipradilol at greater than 10(-8) M."( Electrophysiological effects of nipradilol (K-351) on isolated rabbit hearts and guinea pig ventricular muscles.
Anno, T; Kodama, I; Toyama, J; Yamada, K,
)
0.85
"This isoproterenol-induced increase in [Ca2+]i in depolarized cells could be reversed by prior exposure of the cells to the Ca2+ channel blocker, verapamil (5 microM)."( Voltage-dependent effects of isoproterenol on cytosolic Ca concentration in rat heart.
Korth, M; Sharma, VK; Sheu, SS, 1987
)
1.02
"Isoproterenol did not cause a significant change in ciliary beat frequency."( Ovum transport in the rat oviductal ampulla in the absence of muscle contractility.
Becker, DR; Halbert, SA; Szal, SE, 1989
)
1
"Isoproterenol did not increase [3H]prostaglandin E1, [3H]prostaglandin E2 and [3H]prostaglandin F2 alpha bindings to platelets."( Beta 2-adrenergic regulation of prostaglandin D2 receptor in rabbit platelets.
Hanasaki, K; Ichikawa, A; Ikeda, M; Mizuno, Y; Shimonishi, M; Tomita, K; Yoshimura, S, 1987
)
0.99
"Isoproterenol is known to cause severe myocardial lesions when given in toxic doses to adult homoiotherms. "( Ultrastructure of isoproterenol-induced myocardial damage in chick embryos.
Dusek, J; Ostádal, B, 1985
)
2.05
"Isoproterenol was able to increase cAMP concentrations in myometrial cultures in both the absence and presence of MIX and to elevate cAMP levels rapidly within 1 min."( The effect of relaxin on cyclic adenosine 3',5'-monophosphate concentrations in rat myometrial cells in culture.
Hsu, CJ; McCormack, SM; Sanborn, BM, 1985
)
0.99
"The isoproterenol-stimulated increase in cyclic AMP was greatest at early ages, whereas the inhibitory effect of carbachol remained constant at 75%."( Stimulation of phosphoinositide hydrolysis and inhibition of cyclic AMP formation by muscarinic agonists in developing chick heart.
Brown, JH; Orellana, SA, 1985
)
0.75
"Isoproterenol caused an increase of contractile force in the upper pelvic strip and a decrease in the lower pelvic and whole pelvic strips."( Characteristics of spontaneous contraction and effects of isoproterenol on contractility in isolated rabbit renal pelvic smooth muscle strips.
Morita, T, 1986
)
1.24
"isoproterenol to increase RSR were not mediated by changes in renal perfusion pressure since this was held constant by adjusting a suprarenal aortic clamp."( An effect of extrarenal beta adrenergic stimulation on the release of renin.
Earley, LE; Reid, IA; Schrier, RW, 1972
)
0.97

Treatment

Rats treated with isoproterenol (85 mg/kg, administered subcutaneously twice at an interval of 24 h) showed a significant increase in heart rate and blood pressure. Pretreatment with iso, an agonist of beta-adrenergic receptors, resulted in robust LTD.

ExcerptReferenceRelevance
"Isoproterenol treatment inhibited insulin-stimulated glucose transport by 26%, whereas sucralose did not affect the intrinsic activity of the glucose transporter, indicating that it inhibited insulin-induced GLUT4 translocation to the plasma membrane."( T1R3 homomeric sweet taste receptor negatively regulates insulin-induced glucose transport through Gαs-mediated microtubules disassembly in 3T3-L1 adipocytes.
Inagaki, T; Kojima, I; Ma, J; Masubuchi, Y; Shibata, H; Suzuki, T, 2022
)
1.44
"Isoproterenol was treated by intraperitoneal injection for one week (5 mg/kg/day)."( Pinocembrin alleviates the susceptibility to atrial fibrillation in isoproterenol-induced rats.
Chen, X; Liu, Z; Wan, W; Yang, B; Ye, T; Yu, Y; Zhang, C, 2022
)
1.68
"Isoproterenol treatment caused a significant increase in cardiac markers, malondialdehyde, and caspase-3 levels with a considerable decrease in reduced glutathione, superoxide dismutase and catalase enzyme levels. "( Renin Inhibition by Aliskiren Protects Rats Against Isoproterenol Induced Myocardial Infarction.
Akhtar, M; Hassan, MQ; Khan, V; Najmi, AK, 2018
)
2.17
"Isoproterenol treatment affected gene expression profiles in parotid (ACE, ACE-2, AT1-a, MAS, AGT), and submandibular (ACE, AT2, AGT) glands, thus promoting acinar hypertrophy in serous acini, without significant changes in salivary flow or total protein content."( Losartan and isoproterenol promote alterations in the local renin-angiotensin system of rat salivary glands.
Calvo, AM; Cano, IP; Cestari, TM; Colombini-Ishikiriama, BL; Dionisio, TJ; Faria, FAC; Santos, CF; Siqueira, WL, 2019
)
1.6
"Isoproterenol-treated mice had elevated heart weight/tibia length ratios (HW/TL). "( Diazoxide Modulates Cardiac Hypertrophy by Targeting H2O2 Generation and Mitochondrial Superoxide Dismutase Activity.
Araújo, MTS; Caldas, FRL; Coelho, BN; David, CEB; de Lacerda Alexandre, JV; Facundo, HT; Kowaltowski, AJ; Lucas, AMB; Ponte Viana, YI; Varela, ALN, 2020
)
2
"In isoproterenol-treated DBA/2 mice, there was also a greater expression level of the hypertrophy marker, ANF, compared to C57BL/6 mice."( Mouse strain determines cardiac growth potential.
Grimes, B; Kiper, C; Satin, J; Van Zant, G, 2013
)
0.9
"Isoproterenol twice treated fetuses exhibited significant changes in histological evaluation, and mitochondrial damages were significantly severe with increased apoptotic rate."( The study of fetal rat model of intra-amniotic isoproterenol injection induced heart dysfunction and phenotypic switch of contractile proteins.
Fang, J; Hua, Y; Li, Y; Mu, D; Wang, C; Zhou, K, 2014
)
1.38
"In isoproterenol-treated rats, Zn(ASA)2 treatment normalized significantly impaired left-ventricular contractility index (Emax 2.6 ± 0.7 mmHg/µL vs."( Superiority of zinc complex of acetylsalicylic acid to acetylsalicylic acid in preventing postischemic myocardial dysfunction.
Atmanli, A; Barnucz, E; Hegedűs, P; Hirschberg, K; Karck, M; Korkmaz, S; Li, S; Loganathan, S; Radovits, T; Szabó, G; Yasui, H; Yoshikawa, Y, 2015
)
0.93
"Isoproterenol treatment suppresses the levels of first entry peak of quiescent osteoblastic cells into cell cycle phase by shifting from G1 /G0 to S/G2 /M and also suppresses the levels of second major peak population that enters into S/G2 /M."( Beta Adrenergic Receptor Stimulation Suppresses Cell Migration in Association with Cell Cycle Transition in Osteoblasts-Live Imaging Analyses Based on FUCCI System.
Ezura, Y; Harada, K; Izu, Y; Katsumura, S; Miyawaki, A; Noda, M; Shirakawa, J, 2016
)
1.16
"Isoproterenol treatment significantly reduced 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid formation and significantly increased their corresponding 8,9-, and 14,15-dihydroxyeicosatrienoic acid and the 20-hydroxyeicosatetraenoic acid metabolite."( Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats.
Aboutabl, ME; El-Kadi, AO; Zordoky, BN, 2008
)
1.29
"Isoproterenol treatment of Brown Norway and Lewis rats (high and low plasma angiotensin-I-converting enzyme activity, respectively) results in similar cardiac hypertrophy but higher cardiac fibrosis in Brown Norway rats."( Early expression of monocyte chemoattractant protein-1 correlates with the onset of isoproterenol-induced cardiac fibrosis in rats with distinct angiotensin-converting enzyme polymorphism.
Copaja Soto, M; Díaz-Araya, G; Jalil, JE; Lavandero, S; Lijnen, P; Ordenes, GE; Paz Ocaranza, M; Saldaña, A; Valenzuela, R; Vio, C; Vivar Sanchez, R, 2008
)
2.01
"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart."( Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.
Du, GH; Tian, S; Wang, SB; Yang, F; Yang, HG; Yang, XY, 2009
)
1.33
"Isoproterenol treatment moderates structural injury and improves secretory function in the transplanted submandibular gland through up-regulating beta(1)- and beta(2)-adrenoceptor expression and post-receptor signal transduction."( Isoproterenol improves secretion of transplanted submandibular glands.
Cong, X; Li, YM; Shi, L; Wu, LL; Xiang, B; Yu, GY; Zhang, Y; Zhang, YY, 2009
)
2.52
"In isoproterenol-treated cells, MRP4 siRNA decreased the ratio of extracellular cAMP to intracellular cAMP by 72% (P = 0.0019)."( Multidrug resistance protein 4 mediates cAMP efflux from rat preglomerular vascular smooth muscle cells.
Cheng, D; Jackson, EK; Ren, J, 2010
)
0.87
"Isoproterenol treatment (80 mg/kg given over 2 days in two equal doses) caused arrhythmias and 60% mortality within 24 h of the last injection in the control group (C + ISO) group when compared with the saline control group (saline)."( Exercise training provides cardioprotection via a reduction in reactive oxygen species in rats submitted to myocardial infarction induced by isoproterenol.
Barbosa, VA; Boeck, CR; Da Luz, G; Da Silva, S; De Pinho, RA; De Souza, CT; Frederico, MJ; Justo, SL; Medeiros, C; Silva, LA, 2009
)
1.28
"Isoproterenol treated rats showed decreased levels of heart creatine kinase and lactate dehydrogenase. "( Pretreatment with a combination of quercetin and alpha-tocopherol ameliorates adenosine triphosphatases and lysosomal enzymes in myocardial infarcted rats.
Prince, PS; Punithavathi, VR, 2010
)
1.8
"Isoproterenol treatment caused significant increase in mitochondrial lipid peroxides with significant decrease in mitochondrial antioxidants."( Protective effects of combination of quercetin and α-tocopherol on mitochondrial dysfunction and myocardial infarct size in isoproterenol-treated myocardial infarcted rats: biochemical, transmission electron microscopic, and macroscopic enzyme mapping evi
Punithavathi, VR; Stanely Mainzen Prince, P,
)
1.06
"Isoproterenol treatment of serum-limited fibroblasts and proliferating myoblasts results in the promotion of mitochondrial complex I activity and decrease of the cellular level of reactive oxygen species."( The β-adrenoceptor agonist isoproterenol promotes the activity of respiratory chain complex I and lowers cellular reactive oxygen species in fibroblasts and heart myoblasts.
Cocco, T; De Rasmo, D; Gattoni, G; Larizza, M; Micelli, L; Milano, S; Pacelli, C; Papa, F; Santeramo, A; Sardaro, N; Scivetti, M; Signorile, A, 2011
)
1.39
"Isoproterenol treatment also induced a large intranuclear Ca(2+) transient of cardiomyocytes in tail-suspended rats."( Nuclear translocation of calpain-2 regulates propensity toward apoptosis in cardiomyocytes of tail-suspended rats.
Chang, H; Chen, Y; Li, Q; Sheng, JJ; Wang, YY; Xu, PT; Yu, ZB; Zhang, L; Zhang, LN, 2011
)
1.09
"Isoproterenol-treated rats showed increased levels of serum troponins and increased intensities of serum lactate dehydrogenase-1 and -2 isoenzyme bands."( The cardioprotective effects of a combination of quercetin and α-tocopherol on isoproterenol-induced myocardial infarcted rats.
Punithavathi, VR; Stanely Mainzen Prince, P,
)
1.08
"Post-isoproterenol treatment cardiac troponin I concentrations were greater in CD/IGS and Sasco rats compared with Harlan rats."( A comparison of mortality and cardiac biomarker response between three outbred stocks of Sprague Dawley rats treated with isoproterenol.
Ackermann, BL; Hall, DG; Hoffman, WP; Lee, HY; Main, BW; Pritt, ML; Schultze, AE; Smith, HW, 2011
)
1.03
"Isoproterenol-treated rats showed increased intensity of lactate dehydrogenase-1 and 2 isoenzyme bands and elevated ST segments."( Protective effects of caffeic acid on lactate dehydrogenase isoenzymes, electrocardiogram, adenosine triphosphatases, and hematology on isoproterenol-induced myocardial infarcted rats.
Senthil Kumaran, K; Stanely Mainzen Prince, P,
)
1.06
"Isoproterenol treatment produced considerable histopathological changes, including myonecrosis in mice gastrocnemius, resulting in a leaky sarcolemma and the release of marker enzyme, LDH into the serum (more evident after 20 and 48 hours). "( Analysis of isoproterenol-induced changes in gastrocnemius muscle and serum lactate dehydrogenase expression in mice.
Kaundal, M; Sharma, S, 2011
)
2.19
"Isoproterenol treatment caused significant increase in mitochondrial lipid peroxides and lipids except phospholipids with significant decrease in mitochondrial antioxidants."( An in vivo and in vitro study on the protective effects of N-acetylcysteine on mitochondrial dysfunction in isoproterenol treated myocardial infarcted rats.
Basha, RH; Priscilla, DH, 2013
)
1.32
"Isoproterenol-treated rats showed reductions in left ventricular systolic pressure as well as in maximum and minimum rate of developed left ventricular pressure, together with an increase in left ventricular end-diastolic pressure. "( Cardioprotective effect of water and ethanol extract of Salvia miltiorrhiza in an experimental model of myocardial infarction.
Chao, RB; Du, JR; He, LF; Li, YJ; Shen, Y; Zhou, R, 2012
)
1.82
"Isoproterenol treatment induced cardiac hypertrophy and increased collagen content, both of which were normalized by spironolactone treatment."( Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1.
Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012
)
1.32
"Isoproterenol treatment diminished the differences in shortening amplitude and shortening and relengthening velocities, whereas the prolonged durations of relengthening and Ca(2+) transient in the transgenic cardiomyocytes remained."( Chronic coexistence of two troponin T isoforms in adult transgenic mouse cardiomyocytes decreased contractile kinetics and caused dilatative remodeling.
Jin, JP; Wei, H; Yu, ZB, 2012
)
1.1
"Isoproterenol treatment induced a 42% increase in alveolar fluid clearance (18.9 ± 1.4%) vs. "( Enhanced alveolar fluid clearance following 72 h of continuous isoproterenol infusion in rats.
Amtorp, O; Christensen, S; Jonassen, TE; Müllertz, KM; Pedersen, LR, 2012
)
2.06
"isoproterenol-treated hearts (P < 0.01)."( Acetoacetate augments beta-adrenergic inotropism of stunned myocardium by an antioxidant mechanism.
Caffrey, JL; Mallet, RT; Squires, JE; Sun, J; Yoshishige, D, 2003
)
1.04
"Isoproterenol treatment increased in IL-6 secretion compared to controls with and without CS, while angiotensin II reduced IL-6 concentration only in combination with CS."( Myocardial IL-6 regulation by neurohormones--an in vitro superfusion study.
Jeron, A; Kaiser, T; Muders, F; Riegger, GA; Straub, RH; Weil, J, 2003
)
1.04
"Isoproterenol treatment, but not forskolin treatment, of HEK293T cells overexpressing beta1 ARs led to a rapid decrease (within 2 hours) in the number of the cell surface receptor, which was negated in the presence of concanavalin A."( Ischemic preconditioning prevents ischemia-induced beta-adrenergic receptor sequestration.
Ebina, T; Fujita, T; Ishikawa, Y; Iwatsubo, K; Minamisawa, S; Schwencke, C; Toya, Y; Umemura, S, 2003
)
1.04
"Isoproterenol treatment eliminated the differential force-frequency and afterload response between TnIDD22,23 and controls."( Frequency- and afterload-dependent cardiac modulation in vivo by troponin I with constitutively active protein kinase A phosphorylation sites.
Janssen, PM; Kass, DA; Murphy, AM; Soergel, DG; Stull, LB; Takimoto, E, 2004
)
1.04
"Isoproterenol treatment showed antagonistic effect against endothelin-1 induced MAP duration prolongation, early after depolarisation and ventricular fibrillation formation, while endothelin-1 showed protective effect against the development of isoproterenol induced atrial fibrillation."( Intracoronary endothelin-1 infusion combined with systemic isoproterenol treatment: antagonistic arrhythmogenic effects.
Juhász-Nagy, A; Kékesi, V; Kiss, O; Merkely, B; Soós, P; Zima, E, 2004
)
1.29
"Isoproterenol-treated A/J mice demonstrated greater percent increases in echocardiographic LV mass/body weight (97 +/- 11 vs."( Strain-dependent beta-adrenergic receptor function influences myocardial responses to isoproterenol stimulation in mice.
Ernsberger, P; Faulx, MD; Hoffman, RD; Hoit, BD; Lewis, W; Strachan, R; Vatner, D, 2005
)
1.27
"Isoproterenol treatment for 1 week resulted in 36% and 44% (P<0.05) increase in left ventricle mass in both control and chronic salt loading rats and induction of cardiac angiotensin-converting enzyme activity and expression (P<0.05) with no changes in serum angiotensin-converting enzyme."( Chronic beta-adrenoceptor stimulation and cardiac hypertrophy with no induction of circulating renin.
Krieger, JE; Oliveira, EM, 2005
)
1.05
"Isoproterenol treatment of first passage scar myofibroblasts increased protein synthesis and induced BNP mRNA expression, whereas ANP mRNA levels remained unchanged."( Scar myofibroblasts of the infarcted rat heart express natriuretic peptides.
Bel-Hadj, S; Calderone, A; Clement, R; Drapeau, J; El-Helou, V; Gosselin, H; Villeneuve, L, 2006
)
1.06
"In isoproterenol-treated female versus male hearts, there was also more endothelial NO synthase (eNOS) associated with cardiomyocyte caveolin-3, and more neuronal NOS (nNOS) translocation to caveolin-3 during ischemia/reperfusion."( Hypercontractile female hearts exhibit increased S-nitrosylation of the L-type Ca2+ channel alpha1 subunit and reduced ischemia/reperfusion injury.
Bers, DM; Ginsburg, KS; Murphy, E; Picht, E; Steenbergen, C; Sun, J, 2006
)
0.85
"Isoproterenol treatment resulted in a significant increase in tumor volume and infiltration in the SKOV3ip1 in vivo model, which was blocked by propranolol."( Stress hormone-mediated invasion of ovarian cancer cells.
Bhatty, R; Cole, SW; Gershenson, DM; Han, L; Kamat, AA; Landen, CN; Li, Y; Lutgendorf, S; Sood, AK; Thaker, PH, 2006
)
1.06
"Isoproterenol-treated rats showed lower maximal rate of increase and decrease of left-ventricle pressure development (+/-left-ventricle dp/dtmax) and higher left-ventricle end-diastolic pressure (all P<0.01), which suggested severe heart failure and myocardial injury."( Intermedin1-53 protects the heart against isoproterenol-induced ischemic injury in rats.
Chang, JK; Geng, B; Gerns, H; Jia, YX; Pan, CS; Qi, YF; Tang, CS; Wen, JK; Xiao, Y; Yang, J; Yang, JH; Zhang, J; Zhao, J, 2006
)
1.32
"In isoproterenol-treated rats, neurotensin has no significant impact on myocardial norepinephrine release."( Impact of chronic beta-adrenoceptor activation on neurotensin-induced myocardial effects in rats.
Deftereos, D; Muller, D; Norton, G; Osadchii, O; Woodiwiss, A, 2006
)
0.85
"Isoproterenol treatment for 6 h to human retinal endothelial cells grown in high glucose medium reduced iNOS protein expression, but had no effect on PGE2 levels or PGE2 receptor protein expression."( Sympathetic neurotransmission modulates expression of inflammatory markers in the rat retina.
Steinle, JJ, 2007
)
1.06
"Isoproterenol treatment significantly decreased protein levels of iNOS, TNF-alpha, and IL-1B, in rMC-1 cells cultured in high glucose as early as 1 hour, compared with cells receiving no treatment. "( Role of beta-adrenergic receptors in inflammatory marker expression in Müller cells.
Steinle, JJ; Walker, RJ, 2007
)
1.78
"Isoproterenol-treated rats showed lower of left-ventricular systolic pressure (LVSP), maximum (LVdP/dtmax) and minimum rate of developed left ventricular pressure (LVdP/dtmin), and higher of left ventricular end-diastolic pressure (LVEDP), in addition, a significant rise in ST-segment and increase in content of lactate dehydrogenase, glutamic oxalacetic transaminase, creatine kinase and malondialdehyde, as well as fall in activities of glutathione peroxidase, superoxide dismutase and catalase were observed."( Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat.
Dai, G; Xu, Q; Yan, L; Zheng, J; Zheng, P; Zhou, R, 2008
)
1.33
"Isoproterenol treatment led to changes in the cell morphology of rat C6 glioma cells, which were reverted by the addition of PA and LPA."( Dioleoyl phosphatidic acid induces morphological changes through an endogenous LPA receptor in C6 glioma cells.
Chang, YJ; Im, DS; Jo, JY; Kim, HL; Kim, YL; Kyeok, K, 2008
)
1.07
"Isoproterenol treatment increased LV weight but did not change hemodynamic parameters."( Effects of isoproterenol treatment for 7 days on inflammatory mediators in the rat aorta.
Cachofeiro, V; Davel, AP; De Sá, LL; Fukuda, LE; Lahera, V; Munhoz, CD; Rossoni, LV; Sanz-Rosa, D; Scavone, C, 2008
)
1.46
"Isoproterenol pretreatment led to a significant decrease in myocardial content of ATP, ADP."( [Effect of pretreatment with isoprenaline on functional and metabolic characteristics of isolated rat heart].
Mezin, P; Verdetti, J, 1980
)
0.98
"Isoproterenol treatment of both normal and dystrophic muscles raised the phosphorylase activity ratio of normal muscles to 0.446 +/- 0.054, which was not significantly different from that of the dystrophic muscles."( Glycogen cycle enzymes and cyclic nucleotides in avian muscular dystrophy.
Anderson, DM; Schliselfeld, LH,
)
0.85
"Isoproterenol pretreatment for 7 days resulted in a statistically significant reduction of beta-adrenergic aortic relaxation, whereas the alpha-adrenergic responses to phenylephrine remained unchanged compared with controls."( Alteration of sensitivity of adrenergic vascular responses after prolonged exposure to agonists via osmotic minipump.
Hanig, JP; Sun, CL, 1983
)
0.99
"Isoproterenol treatment increased peptide a phosphorylation 4-6 fold but did not decrease peptide b phosphorylation."( Insulin stimulates the dephosphorylation of phosphothreonine from fat-pad ATP-citrate lyase.
Benjamin, WB; Pucci, DL; Ramakrishna, S, 1984
)
0.99
"Isoproterenol treatment induced the greatest enlargement of cells and granules."( Morphological and biochemical changes in the rat parotid gland after compensatory and isoproterenol-induced enlargement.
Morgan, AH; Schneyer, CA; Sheetz, JH, 1983
)
1.21
"Isoproterenol pretreatment (1 mg/kg s.c., 1 h prior) decreased the slope of the dose-response curve, and saturation was achieved at a lower concentration."( Age-dependent changes in electrophysiologic characteristics of fast and slow action potentials in rat papillary muscle.
Balazs, T; Ehrreich, S; Johnson, G; Kojima, M; Sperelakis, N, 1983
)
0.99
"The isoproterenol-treated rat is considered an appropriate model system for studying the overall effects of catecholamine beta-agonists on gene expression in these secretory tissues."( Induction of protein and glycoprotein synthesis in rat submandibular glands by isoproterenol.
Carlson, DM; Mehansho, H, 1983
)
0.97
"Isoproterenol treatment (80 mg/kg given over two days in two equal doses) caused more than 100 percent increase in the MDA content which was prevented by pretreatment of the animals with vitamin E (alpha-tocopherol acetate, 10 mg/kg) for two weeks."( Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease.
Beamish, RE; Dhalla, NS; Singal, PK, 1983
)
0.99
"Isoproterenol treatment (80 mg/kg given over 2 days in two equal doses) caused arrhythmias and 25% mortality within 24 h of the last injection."( Role of free radicals in catecholamine-induced cardiomyopathy.
Beamish, RE; Dhalla, NS; Dhillon, KS; Kapur, N; Singal, PK, 1982
)
0.99
"Isoproterenol or forskolin treatment decreased beta 2AR mRNA levels in a time-dependent manner, with maximal loss of approximately 50% being observed after 2 hr."( Regulation of beta 2-adrenergic receptor mRNA and gene transcription in rat C6 glioma cells: effects of agonist, forskolin, and protein synthesis inhibition.
Duman, RS; Feussner, GK; Fishman, PH; Fitzgerald, LR; Hosoda, K; Vaidya, VA, 1995
)
1.01
"In isoproterenol (0.1 microM)-treated preparations, adenosine decreased the peak of Ca2+ transients but did not alter the peak of tension."( Effects of adenosine on Ca2+ transients and tension in aequorin-injected ferret papillary muscles.
Komukai, K; Kurihara, S, 1994
)
0.8
"Isoproterenol treatment of C6 cells altered beta 1 AR mRNA levels in a biphasic manner; i.e., short-term exposure (30-60 min) increased by 50%, whereas longer exposure (2-6 h) decreased by 50% the levels of beta 1 AR mRNA."( Agonist and cyclic AMP-mediated regulation of beta 1-adrenergic receptor mRNA and gene transcription in rat C6 glioma cells.
Duman, RS; Feussner, GK; Fishman, PH; Hosoda, K; Rydelek-Fitzgerald, L, 1994
)
1.01
"In isoproterenol treated rats, marked increases in cholesterol, free fatty acids, triglycerides and lipid peroxides in heart mitochondria were observed."( Effect of aspirin on mitochondrial lipids in experimental myocardial infarction in rats.
Devi, CS; Manjula, TS, 1993
)
0.8
"Isoproterenol treated rats showed an increase in the levels of heart cholesterol, triglycerides and free fatty acids."( Effect of aspirin on isoproterenol induced changes in lipid metabolism in rats.
Devi, CS; Manjula, TS, 1993
)
1.33
"Isoproterenol treatment rapidly (5 min) inhibited the insulin-induced autophosphorylation of the insulin receptor on tyrosine residues in intact adipocytes."( Isoproterenol inhibits insulin-stimulated tyrosine phosphorylation of the insulin receptor without increasing its serine/threonine phosphorylation.
Combettes, M; Ferre, P; Issad, T, 1995
)
2.46
"Isoproterenol treatment leads to down-regulation of the total receptor number by 56 +/- 4%, due to a decrease in beta 2-ARs, while maintaining the beta 1-AR number constant."( Regulation of beta-adrenoceptor density and mRNA levels in the rat heart cell-line H9c2.
Dangel, V; Giray, J; Ratge, D; Wisser, H, 1996
)
1.02
"Isoproterenol pretreatment failed to cause beta-receptor down-regulation in 6-d-old animals, but by 15 d of age, down-regulation was detected along with slight desensitization of the cyclase response."( Atypical regulation of hepatic adenylyl cyclase and adrenergic receptors during a critical developmental period: agonists evoke supersensitivity accompanied by failure of receptor down-regulation.
Galluzzo, JM; McCook, EC; Seidler, FJ; Slotkin, TA; Thai, L, 1996
)
1.02
"Isoproterenol pretreatment of the cells induced, like forskolin, partial inhibition of inositol phosphate generation in response to G-protein activators and to P2y purinoceptor and beta-adrenoceptor agonists."( Cyclic AMP-induced desensitization of G-protein-regulated phospholipase C in turkey erythrocyte membranes.
Galas, MC; Harden, TK, 1996
)
1.02
"Isoproterenol-treated cardiomyocytes increased the phosphorylation of the 28-kDa protein by 232 +/- 20% (n = 3 expts) compared with untreated cardiomyocytes."( Evidence for presence and hormonal regulation of protein phosphatase inhibitor-1 in ventricular cardiomyocyte.
Gupta, RC; Lesch, M; Neumann, J; Sabbah, HN; Watanabe, AM, 1996
)
1.02
"Isoproterenol treatment resulted in a three-fold increase in OTR mRNA."( Beta2-adrenoceptor desensitization in non-pregnant estrogen-primed rat myometrium involves modulation of oxytocin receptor gene expression.
Bratholm, P; Christensen, NJ; Engstrøm, T; Vilhardt, H, 1998
)
1.02
"Isoproterenol treatment caused an increase of 67% in the total number of binding sites (Bmax=12.1+/-1."( Cross-talk between beta-adrenergic and metabotropic glutamate receptors in rat C6 glioma cells.
Albasanz, JL; Fernández, M; Martín, M; Ros, M, 1998
)
1.02
"Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate."( Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats.
Duarte, GP; Lahlou, S; Leão-Filho, CS; Lima, GC, 2000
)
1.3
"Isoproterenol-treatment significantly increased acid phosphatase concentration in the ventral prostate of intact rats, whereas propranolol prevented a glandular zinc loss induced by dexamethasone administration."( beta-Adrenergic receptor manipulation and acid phosphatase and zinc levels in the ventral prostate of the adult rat.
Hristić, M; Lalić, N; Pesić, V; Plećas, B; Solarović, T, 2000
)
1.03
"Isoproterenol and forskolin treatment of cells decreased glycogen synthase binding to FLAG-G(M), thereby limiting synthase activation by PP1."( Glycogen synthase association with the striated muscle glycogen-targeting subunit of protein phosphatase-1. Synthase activation involves scaffolding regulated by beta-adrenergic signaling.
Brautigan, DL; Liu, J, 2000
)
1.03
"In isoproterenol (10(-7)m)-treated myocytes, transcription of genes encoding the alpha(1C), alpha(2)- delta, and beta(2A)subunits was enhanced."( Transcriptional regulation of L-type calcium channel expression in cardiac myocytes.
Chen, B; Fan, IQ; Marsh, JD, 2000
)
0.82
"Isoproterenol pretreatment caused cardiac hypertrophy (29%) as shown by a significant increase in the ratio of ventricular dry weight to body weight."( Effects of long-term pretreatment with isoproterenol on inotropic responsiveness to alpha-adrenoceptor stimulation: study in isolated perfused rat hearts.
Duarte, GP; Lahlou, S; Monteiro-Filho, WO; Silva, CO, 2001
)
1.3
"Isoproterenol (ISO) treatment increased intracellular cyclic AMP levels; however, cyclic AMP-elevating agents had no effect on protein synthesis."( beta-Adrenergic stimulation of rat cardiac fibroblasts promotes protein synthesis via the activation of phosphatidylinositol 3-kinase.
Calderone, A; Colombo, F; Mayers, P; Mercier, I; Noël, J, 2001
)
1.03
"Isoproterenol treatment increased ventricular to body weight ratio (4.6 vs 3.7) and collagen area (22.6 vs 8.2%), and reduced systolic (89.93 vs 107.5 mm Hg) and diastolic (59.6 vs 70.8 mm Hg) pressure."( Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats.
Casis, O; Echevarria, E; Espiña, L; Gallego, M; Iriarte, MM; Vegas, L, 2001
)
1.3
"Isoproterenol pre-treatment reverses the alkalinizing effects of insulin and leads to attenuation of insulin-stimulated glucose transport activity and exposure of GLUT4 to photolabeling reagents at the cell surface."( Insulin and isoproterenol have opposing roles in the maintenance of cytosol pH and optimal fusion of GLUT4 vesicles with the plasma membrane.
Hodel, A; Holman, GD; Yang, J, 2002
)
1.41
"The isoproterenol-treated rats had increased output of EGF in the saliva, but the salivary secretion of protein was also increased."( Altered secretion and processing of epidermal growth factor in adrenergic-induced growth of the rat submandibular gland.
Bor, MV; Jørgensen, PE; Nexø, E; Poulsen, SS; Thulesen, J; Thulesen, S, 2002
)
0.8
"In isoproterenol-treated Purkinje fibers, pA2 for nadolol was 8.2 and 7.7 for propranolol."( Direct and beta adrenergic blocking actions of nadolol (SQ 11725) on electrophysiologic properties of isolated canine myocardium.
Bassett, AL; Gelband, H; Gibson, JK, 1977
)
0.77
"Isoproterenol treatment causes a decrease of the number of the immigrating neutrophils within the first two days and an increase of the lymphocytes during almost the entire experiment."( The influence of a permanent isoproterenol (ISO) application on the dynamics of the Sephadex inflammation.
Egger, G; Porta, S, 1979
)
1.27
"Isoproterenol treatment did not alter the mortality of endotoxin shock."( Isoproterenol, endotoxin shock, and the generalized shwartzman reaction.
Brunson, JG; Collins, AD; Henson, EC; Izard, SR, 1976
)
2.32
"Isoproterenol treatment did not alter the number or affinity of 125I-labeled NPY binding sites, the amount of pertussis toxin substrates, or NPY-mediated inhibition of cAMP accumulation."( NPY-stimulated Ca2+ mobilization in SK-N-MC cells is enhanced after isoproterenol treatment.
Feth, F; Michel, MC; Rascher, W, 1992
)
1.24
"In isoproterenol-treated cells, however, little receptor antigen was detected at the cell surface."( Ligand-regulated internalization and recycling of human beta 2-adrenergic receptors between the plasma membrane and endosomes containing transferrin receptors.
Kobilka, BK; von Zastrow, M, 1992
)
0.8
"In isoproterenol-treated rats, the above parameters, except for putrescine content on day 14, were significantly increased on both day 7 and day 14."( Effect of captopril on isoproterenol-induced cardiac hypertrophy and polyamine contents.
Hamaya, K; Isogai, Y; Kato, H; Mizokami, T; Namiki, A; Ogawa, K; Sanjo, J; Sasaki, H; Shimizu, M; Yagi, T, 1992
)
1.11
"Isoproterenol treated rats showed decrease in the activities of hepatic and extrahepatic lipoprotein lipase."( Effect of aspirin on serum lipoprotein profile in rats subjected to myocardial stress by isoproterenol.
Devi, CS; Manjula, TS; Prema, A, 1992
)
1.23
"In isoproterenol treated rats marked increase in cholesterol, free fatty acids and triglycerides in both serum and heart were observed."( Reversal of changes of myocardial lipids by chronic administration of aspirin in isoproterenol-induced myocardial damage in rats.
Devi, CS; Geetha, A; Manjula, TS; Ramesh, TG, 1992
)
1.02
"Isoproterenol treatment inhibited agonist-induced contraction by decreasing [Ca2+]i and thereby light chain phosphorylation."( Regulation of the Ca2+ dependence of smooth muscle contraction.
Kamm, KE; Kubota, Y; Stull, JT; Tang, DC, 1992
)
1
"Isoproterenol pretreatment also inhibited the rapid formation of Ins(1,4,5)P3 and [2-3H]inositol 1,3,4,5-tetrakisphosphate stimulated by endothelin and reduced the sustained formation of these compounds."( Regulation of endothelin-mediated calcium mobilization in vascular smooth muscle cells by isoproterenol.
Watkins, WD; Whorton, AR; Xuan, YT, 1991
)
1.22
"Isoproterenol treatment leads to endomyocardial fibrosis with muscle fibers encircled by fibrillar collagen. "( Fibrosis-induced reduction of endomyocardium in the rat after isoproterenol treatment.
Abrahams, C; Jalil, JE; Janicki, JS; Pick, R; Weber, KT, 1989
)
1.96
"Isoproterenol treatment of beta 2AR-transfected Kin8 and Y1 cells resulted in a rapid loss of surface beta 2AR, as determined by the binding of the hydrophilic beta 2AR radioligand [3H]CGP 12177 [( 3H]CGP), followed by a decrease in adenylate cyclase activity."( Beta 2-adrenergic receptor regulation after transfection into a cell line deficient in the cAMP-dependent protein kinase.
Abrass, IB; Allen, JM; Palmiter, RD, 1989
)
1
"Isoproterenol pretreatment inhibited methacholine-stimulated myosin light chain phosphorylation, shortening velocity, and force during the early stages of force generation."( Isoproterenol attenuates myosin phosphorylation and contraction of tracheal muscle.
de Lanerolle, P; Obara, K, 1989
)
2.44
"Isoproterenol treatment resulted in a marked Leydig cell hypertrophy but the development of the spermatogenic epithelium was unaffected compared to that in saline treated controls."( The effect of long-term variation in sympathetic activity on testicular morphology in immature rats.
Bergh, A; Blom, H; Damber, JE; Henriksson, R,
)
0.85
"Isoproterenol treatment in vitro reduced beta-adrenoceptors on lymphocytes."( Stress induced desensitization of lymphocyte beta-adrenoceptors in young and aged rats.
Algeri, S; Costantini, C; Cotecchia, S; De Blasi, A; Fratelli, M; Lipartiti, M; Sacchetti, G, 1986
)
0.99
"When isoproterenol-treated cells were washed free of agonist, there was a time-dependent recovery of agonist responsiveness and [3H]CGP-12177-binding sites."( Desensitization of the beta-adrenergic receptor-coupled adenylate cyclase in cultured mammalian cells. Receptor sequestration versus receptor function.
Fishman, PH; Kassis, S; Olasmaa, M; Sullivan, M, 1986
)
0.73
"Isoproterenol treatment of K+-contracted tissues led to relaxation that was slow and incomplete, and it had very little effect on calmodulin-stimulated phosphodiesterase activity."( Effects of isoproterenol on active force and Ca2+ X calmodulin-sensitive phosphodiesterase activity in porcine coronary artery.
Miller, JR; Wells, JN, 1987
)
1.38
"Isoproterenol treatment of adult male rats results in rapid and extensive growth of the submandibular and the parotid glands, which double their weights in just a few days."( Epidermal growth factor and insulin-like growth factor I are localized in different compartments of salivary gland duct cells. Immunohistochemical evidence.
Hansson, HA; Tunhall, S, 1988
)
1
"In isoproterenol-treated and permeabilized cells both presumptive Golgi and cell surface staining was apparent."( Cell surface expression of 4 beta-galactosyltransferase accompanies rat parotid gland acinar cell transition to growth.
Humphreys-Beher, MG; Kidd, VJ; Marchase, RB; Rivera, AA, 1988
)
0.79
"Isoproterenol pretreatment of the parotid slices caused a significant increase in 32P-labeling of phosphatidylinositol and a decrease in that of phosphatidic acid."( Effects of isoproterenol pretreatment on phosphatidylinositol turnover in rat parotid gland.
Akino, T; Miyamoto, A; Ohshika, H, 1986
)
1.38
"Treatment with isoproterenol (100 nM) shortened action potential duration at 80% repolarization and increased incidence of premature ventricular contractions ("( Electrophysiology and Arrhythmogenesis in the Human Right Ventricular Outflow Tract.
Ajijola, OA; Aras, K; Bernus, O; Brennan, J; Chiang, CH; Chivers, J; Efimov, IR; Faye, NR; Gams, A; Goldrick, K; Hanna, P; Hoover, DB; Li, J; Mori, S; Poston, MD; Rogers, JA; Shivkumar, K; Smith, EH; Viventi, J; Zhong, Y, 2022
)
1.06
"Treatment with isoproterenol led to a marked impairment of global longitudinal strain and the E/e' ratio of transmitral flow to mitral annular velocity, which were both significantly improved by the LXR agonist."( Liver X Receptor Agonist AZ876 Induces Beneficial Endogenous Cardiac Lipid Reprogramming and Protects Against Isoproterenol-Induced Cardiac Damage.
Beyhoff, N; Blumrich, A; Foryst-Ludwig, A; Goeritzer, M; Grune, J; Jaeger, C; Kasch, J; Kintscher, U; Klopfleisch, R; Luettges, K; Müller, OJ; Ritter, D; Smeir, E; Thiele, A, 2021
)
1.17
"Rats treated with isoproterenol (ISO, 85 mg/kg, sc, twice at an interval of 24 h) showed a significant increase in heart rate, mean arterial blood pressure, pressure rate index, ST elevation on ECG, and a significant increase in the levels of cardiac marker enzymes- lactate dehydrogenase, and creatine kinase in serum and a significant reduction in superoxide dismutase, and catalase and increase in thiobarbituric acid reactive substance activity in heart tissue. "( Intravenous human umbilical cord blood improves electrophysiological and metabolic properties in ISO induced myocardial necrosis in rats.
Kasturet, S; Mohan, M; Rokade, R, 2013
)
0.72
"Pretreatment with isoproterenol, an agonist of beta-adrenergic receptors, resulted in robust LTD (<24 h)."( Hippocampal long-term depression in freely behaving mice requires the activation of beta-adrenergic receptors.
Goh, JJ; Manahan-Vaughan, D, 2013
)
0.71
"Treatment with isoproterenol (ISO), an analog of the stress signal epinephrine, increased the expression of HDAC6 protein and mRNA in H1299 lung cancer cells."( Isoproterenol increases histone deacetylase 6 expression and cell migration by inhibiting ERK signaling via PKA and Epac pathways in human lung cancer cells.
Juhnn, YS; Lim, JA, 2016
)
2.22
"Treatment with isoproterenol (iso) for 7 days caused myocardial damage and left ventricular (LV) dysfunction in the cardiomyopathic mice."( Granulocyte-colony stimulating factor increases donor mesenchymal stem cells in bone marrow and their mobilization into peripheral circulation but does not repair dystrophic heart after bone marrow transplantation.
Adachi, Y; Enoki, C; Ikehara, S; Imamura, H; Iwasaka, T; Kaneko, K; Otani, H; Sato, D; Taniuchi, S; Tatsumi, K, 2008
)
0.69
"Rats treated with isoproterenol (85 mg/kg, administered subcutaneously twice at an interval of 24 h) showed a significant increase in heart rate and ST elevation in ECG, and a significant increase in the levels of cardiac marker enzymes - lactate dehydrogenase (LDH), creatine kinase (CK) and aspartate aminotransferase (AST) in serum."( Cardioprotective potential of myricetin in isoproterenol-induced myocardial infarction in Wistar rats.
Ballero, M; Kasture, S; Maxia, A; Mohan, M; Tiwari, R, 2009
)
0.94
"Pre-treatment with isoproterenol, adenosine, and the consecutive isoproterenol/adenosine treatment was also combined with the PKC inhibitor chelerythrine."( Consecutive pharmacological activation of PKA and PKC mimics the potent cardioprotection of temperature preconditioning.
Halestrap, AP; Khaliulin, I; Parker, JE, 2010
)
0.68
"Pretreatment with isoproterenol for 15min markedly reduced the cAMP-elevating effect of a subsequent treatment with isoproterenol 18h later."( Regulation of the cAMP-elevating effects of isoproterenol and forskolin in cardiac myocytes by treatments that cause increases in cAMP.
Cui, H; Green, RD, 2003
)
0.9
"Rats treated with isoproterenol developed myocardial hypertrophy, and NDPK in the sarcolemma rose by 60% during 14 days of treatment."( Plasma membrane-associated nucleoside diphosphate kinase (nm23) in the heart is regulated by beta-adrenergic signaling.
Hippe, HJ; Lutz, S; Mura, RA; Niroomand, F; Tiefenbacher, C, 2003
)
0.64
"Treatment with isoproterenol did not alter [Ca2+]i in quiescent cardiomyocytes, whereas the ATP (purinergic receptor agonist)-induced increase in [Ca2+]i was significantly potentiated by isoproterenol."( Involvement of Na+/Ca2+ exchanger in catecholamine-induced increase in intracellular calcium in cardiomyocytes.
Dhalla, NS; Elimban, V; Saini, HK; Tripathi, ON; Zhang, S, 2006
)
0.67
"Treatment with isoproterenol or S(p)-cAMPS, a potent activator of PKA, increased the incorporation of (32)P into P-Rex1."( Phosphorylation of P-Rex1 by the cyclic AMP-dependent protein kinase inhibits the phosphatidylinositiol (3,4,5)-trisphosphate and Gbetagamma-mediated regulation of its activity.
Garrison, JC; Mayeenuddin, LH, 2006
)
0.67
"Pretreatment with isoproterenol (2 nM), E-4031 (1 microM), and injection of inward current pulses were applied to modify action potential configuration."( Contribution of I Ks to ventricular repolarization in canine myocytes.
Bányász, T; Birinyi, P; Horváth, B; Magyar, J; Nánási, PP; Szentandrássy, N, 2006
)
0.66
"Pre-treatment with isoproterenol or the cyclic AMP analogue, dibutyryl cyclic AMP, induced refractoriness to forskolin."( Forskolin-stimulated cyclic AMP accumulation mediates protein synthesis-dependent refractoriness in C6-2B rat glioma cells.
Barovsky, K; Brooker, G; Pedone, C, 1983
)
0.58
"Treatment with isoproterenol caused more rapid desensitization than treatment with glucagon."( Mechanism of heterologous desensitization of the adenylate cyclase system by glucagon in primary cultures of adult rat hepatocytes.
Ichihara, A; Kato, S; Nakamura, T; Noda, C; Shinjyo, F; Tomomura, A, 1984
)
0.61
"Treatment with isoproterenol and tolazoline was initiated but was unsuccessful: the child died at 18 months."( [Primary pulmonary hypertension in children].
Bein, G; Jimenez, E; Lange, L; Lichtenstern-Peters, E; Schachinger, H; Schartl, S; Stoltenburg-Didinger, G, 1982
)
0.6
"Pretreatment with isoproterenol just prior to tamponade does not significantly increase heart rate or the double product."( Role of autonomics in the initiation of electromechanical dissociation.
Castaner, A; Kampine, JP; Kostreva, DR, 1981
)
0.59
"Sham-treated, isoproterenol-treated and irradiated animals provided reference data."( The role of secretory granules in radiation-induced dysfunction of rat salivary glands.
Konings, AW; Peter, B; s-Gravenmade, EJ; Van Waarde, MA; Vissink, A, 1995
)
0.64
"Treatment with isoproterenol caused an expected elevation of NAT activity and melatonin content but was unable to modify TH activity."( Changes in tyrosine hydroxylase activity and melatonin synthesis in rat pineal glands throughout 72 hours of incubation.
Abreu, P; Castañeira, A; Fajardo, N; Hernández, FJ; Moujir, F; Santana, C, 1994
)
0.63
"Treatment with isoproterenol, forskolin, or a cAMP analog increased RI alpha mRNA in a time- and concentration-dependent manner (maximal, 4-fold, at 4-8 h)."( Reciprocal regulation of mRNA and protein for subunits of cAMP-dependent protein kinase (RI alpha and C alpha) by cAMP in a neoplastic B cell line (Reh).
Andersson, KB; Blomhoff, HK; Hansson, V; Jahnsen, T; Skålhegg, BS; Taskén, K; Taskén, KA, 1993
)
0.63
"Pretreatment with isoproterenol significantly decreased bile acid-induced net transmucosal ion fluxes and luminal accumulation of DNA, suggesting mucosal protection."( Effects of topical isoproterenol on bile acid-induced gastric mucosal injury.
Dempsey, DT; Mercer, DW; Podolsky, RS; Ritchie, WP, 1993
)
0.94
"Pretreatment with isoproterenol or nitroprusside reduces the increase in pulmonary arterial pressure caused by the protein kinase C activators but does not reverse vasoconstriction, even though subsequent treatment with verapamil does."( Protein kinase C-mediated pulmonary vasoconstriction in rabbit: role of Ca2+, AA metabolites, and vasodilators.
Farrukh, IS; Gurtner, GH; Michael, JR; Yang, J, 1993
)
0.61
"Rats treated with isoproterenol (30 mg/100 g body weight) showed a significant increase in serum lysosomal hydrolase activities, which were found to decrease after curcumin treatment."( Effect of curcumin on certain lysosomal hydrolases in isoproterenol-induced myocardial infarction in rats.
Nirmala, C; Puvanakrishnan, R, 1996
)
0.87
"Treatment with isoproterenol (10(-5)-10(-3) M) or furocemide (10(-3) M) in Ca(2+)-containing medium did not significantly affect the ultrastructure of JG cells. "( Exocytosis of secretory granules in the juxtaglomerular granular cells of kidneys.
Ogawa, K; Taniguchi, K; Yamasato, M, 1995
)
0.64
"Treatment with isoproterenol plus adenosine deaminase rapidly inhibited insulin-stimulated glucose transport by 40%, and at the same time GLUT4 disappeared from the caveolae-rich fraction and from plasma membranes as a whole."( Insulin-stimulated glucose uptake involves the transition of glucose transporters to a caveolae-rich fraction within the plasma membrane: implications for type II diabetes.
Gustavsson, J; Parpal, S; Strålfors, P, 1996
)
0.63
"Pretreatment with isoproterenol (10 mg/kg) blunted the LPS-induced TNF response, increased the LPS-induced formation of interleukin-10 and interleukin-6 and reduced the LPS-induced production of NO in conscious mice."( Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia.
Haskó, G; Kvetan, V; Németh, ZH; Pastores, SM; Salzman, AL; Szabó, C; Vizi, ES; Zingarelli, B, 1997
)
2.06
"Pretreatment with isoproterenol and forskolin yielded superoxide generation of 3.2 +/- 0.6 and 3.1 +/- 1.2 nmole/2.5 x 10(5) PMN/min compared to 9.0 +/- 0.6 nmole/2.5 x 10(5) PMN/min for PAF/fMLP alone, whereas isoproterenol and forskolin did not significantly affect PAF-mediated neutrophil elastase release, 22.4 +/- 5.3 and 24.0 +/- 3.6%, respectively, compared to 39.4 +/- 9.1% for PAF/fMLP alone."( Beta-adrenergic stimulation down-regulates neutrophil priming for superoxide generation, but not elastase release.
Barnett, CC; Moore, EE; Partrick, DA; Silliman, CC, 1997
)
0.62
"Pretreatment with isoproterenol for 5 days reduced bromocriptine-induced tachycardia without affecting hypotension."( Bromocriptine-induced tachycardia in conscious rats: blunted response following isoproterenol pretreatment for 5 days.
Duarte, GP; Lahlou, S, 1998
)
0.85
"Pretreatment with isoproterenol shifted both dose-response curves of acetylcholine and ATP rightward."( Effects of atropine, isoproterenol and propranolol on the rabbit bladder contraction induced by intra-arterial administration of acetylcholine and ATP.
Horan, P; Levin, RM; Liu, SP, 1998
)
0.94
"Pretreatment with isoproterenol significantly inhibited both contractile stimulation by acetylcholine and ATP."( Effects of atropine, isoproterenol and propranolol on the rabbit bladder contraction induced by intra-arterial administration of acetylcholine and ATP.
Horan, P; Levin, RM; Liu, SP, 1998
)
0.94
"Posttreatment with isoproterenol, a beta(2)-adrenergic-receptor agonist, reduced the H(2)O(2)-induced decrease in sigma to 0.65 and augmented the increase in lung weight."( Oxidant-increased endothelial permeability: prevention with phosphodiesterase inhibition vs. cAMP production.
Johnston, WK; Mahoney, JR; Minnear, FL; Morton, CA; Vincent, PA; Waypa, GB, 2000
)
0.63
"Treatment with isoproterenol on PN2-5 did not result in any significant changes in G(s)alpha expression but robustly decreased G(i)alpha1,2."( Ontogeny of G-protein expression: control by beta-adrenoceptors.
Seidler, FJ; Slotkin, TA; Zeiders, JL, 2000
)
0.65
"Pre-treatment with isoproterenol or atropine resulted in post-exercise values for specific conductance which were significantly greater than those following disodium cromoglycate by virtue of the bronchodilator effect of these drugs independent of or in addition to any specific inhibition of exercise-induced asthma."( Comparison of aerosolized atropine, isoproterenol, atropine plus isoproterenol, disodium cromoglycate and placebo in the prevention of exercise-induced asthma.
Katz, RM; Kerschnar, H; Rachelefsky, GS; Siegel, SC; Tashkin, DP, 1977
)
0.85
"The treatments (isoproterenol and saline solution) were administered in a period-balanced two-way crossover design with randomly allocated sequences."( Relative sensitivity of four noninvasive methods in assessing systolic cardiovascular effects of isoproterenol in healthy volunteers.
Belz, GG; Butzer, R; de Mey, C; Erbel, R; Meyer, J; Nixdorf, U; Schroeter, V, 1992
)
0.84
"Treatment with isoproterenol was safe and effective without any complications."( Isoproterenol infusion in the management of respiratory failure in children with status asthmaticus: experience in a small community hospital and review of the literature.
Nangia, BS; Tayaba, RG; Victoria, MS, 1991
)
2.06
"In 9 treated dogs, isoproterenol (0.1 microgram/kg/min intravenously for 30 minutes starting 3 hours after reperfusion) increased thickening fraction to values (24.8 +/- 4.5%) that were similar to those at baseline."( Beta-adrenergic stimulation reverses postischemic myocardial dysfunction without producing subsequent functional deterioration.
Bolli, R; Hartley, CJ; Myers, ML; Roberts, R; Zhu, WX, 1985
)
0.59
"Pretreatment with isoproterenol prevented any increase in lung weight (0.5 +/- 0.5 g over 30 min, p less than 0.01)."( Isoproterenol or aminophylline attenuate pulmonary edema after acid lung injury.
Farrukh, I; Gurtner, GH; Michael, JR; Mizus, I; Summer, W, 1985
)
2.04
"Treatment with isoproterenol (0.3-5.0 mg/Kg) increased significantly PDE activity within 2 hours."( Interaction between alpha- and beta-adrenoceptors in rat pineal adenosine cyclic 3',5'-monophosphate phosphodiesterase activation.
Cardinali, DP; Keller Sarmiento, MI; Vacas, MI, 1985
)
0.61
"Treatment with isoproterenol or dibutyryl cAMP for 2 h affected glycosylation of immunoadsorbable lipoprotein lipase, so that the ratio of [3H]galactose to [14C]mannose in the heparin-releasable enzyme increased from 3.8 (control) to 13.0 (isoproterenol-treated)."( Beta-adrenergic stimulation enhances translocation, processing and synthesis of lipoprotein lipase in rat heart cells.
Chajek-Shaul, T; Etienne, J; Friedman, G; Noe, L; Stein, O; Stein, Y, 1986
)
0.61

Toxicity

"Low-dose isoproterenol continuous nebulization" is an effective and safe method for childhood status asthmaticus. The sc LD50 values for isop roterenol in 4- to 5-month-old, 500-600 g (heavy) and 1. In DCA-saline pretreated rats the LD50 of isop Roterenol was determined to be 14.

ExcerptReferenceRelevance
" In DCA-saline pretreated rats the LD50 of isoproterenol was determined to be 14."( Potentiation of isoproterenol cardiotoxicity by corticoids.
Green, M; Guideri, G; Lehr, D, 1978
)
0.87
"5 mg/ml) has a marked toxic effect on rat heart muscle cells cultivated in vitro."( Direct toxic effect of isoproterenol on cultured cardiac muscle cells.
Sartore, S; Schiaffino, S; Severin, E, 1977
)
0.57
" No toxic effects of the drug have been found."( The therapeutic value of oral long-term treatment with terbutaline (Bricanyl) in asthma. A follow-up study of its efficacy and side effects.
Formgren, H, 1975
)
0.25
"Patients had electrophysiologic testing before and after the initiation of oral flecainide therapy and were followed long-term for the presence of symptoms, new physical limitations, and adverse effects of therapy."( Safety and efficacy of oral flecainide therapy in patients with atrioventricular re-entrant tachycardia.
Cockrell, JL; Griffin, JC; Helmy, I; Langberg, JJ; Lee, MA; Scheinman, MM; Titus, C, 1991
)
0.28
" Of the 44 patients discharged from the hospital, 33 (75%) have continued to receive flecainide therapy and have shown no adverse effects (mean follow-up, 24 +/- 10 months)."( Safety and efficacy of oral flecainide therapy in patients with atrioventricular re-entrant tachycardia.
Cockrell, JL; Griffin, JC; Helmy, I; Langberg, JJ; Lee, MA; Scheinman, MM; Titus, C, 1991
)
0.28
" The phenomenon described might elucidate pathogenetic mechanisms behind toxic myocardial cell degeneration and may possibly have relevance for acute cardiovascular complications in diabetic patients."( Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in streptozotocin diabetic rats. A morphometric study of isoproterenol induced myocardial fibrosis.
Gøtzsche, O, 1985
)
0.5
"Primary cultures of rat myocytes were used to study the cardiac damage induced by toxic doses of L-isoproterenol (ISO)."( Cytotoxicity of isoproterenol to cultured heart cells: effects of antioxidants on modifying membrane damage.
Acosta, D; Combs, AB; Ramos, K, 1983
)
0.83
" It thus seems that streptozotocin diabetic rats are protected against the toxic effect of ISO, leaving the haemodynamic response unaffected."( Lack of cardiotoxic effect of isoproterenol in streptozotocin diabetic rats. A morphometric study of isoproterenol induced fibrosis.
Gøtzsche, O, 1982
)
0.55
" The viability of cultures exposed to toxic doses of ISO for 4 h was not affected."( Prevention by L(-) ascorbic acid of isoproterenol-induced cardiotoxicity in primary cultures of rat myocytes.
Acosta, D; Ramos, K, 1983
)
0.54
" Our results suggest that the following factors may participate in the IPRO-induced embryotoxicity: (1) IPRO, (2) its toxic metabolites, (3) cAMP."( Analysis of the cardiotoxic effect of isoproterenol in chick embryo.
Janatová, T; Krause, EG; Ostádal, B; Pelouch, V; Rychter, Z,
)
0.4
"5 mg), especially N-acetylcysteine, which tripled the total toxic effect."( Pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for beta-adrenergic compounds.
Alberts, DS; Dorr, RT,
)
0.13
" The dose of aminophylline (125 mg/hour) previously recommended results in a toxic serum theophylline concentration in a majority of patients if the infusion is continued for more than 24 to 48 hours."( Theophylline toxicity after the use of aminophylline in the treatment of cerebral vasospasm.
Bailey, RT; Blouin, RA; Rapp, RP; Young, B, 1981
)
0.26
") reduced the "average total body clearance" (as measured by dose/AUC) and the LD50 of various compounds that are eliminated almost entirely by the kidneys."( Effects of isoproterenol on the toxicity in rats of compounds eliminated by the kidneys.
Gillette, JR; Maling, HM; Saul, W; Yasaka, WJ, 1980
)
0.65
" This study indicates the potential for spontaneous reversal of some of epinephrine's toxic effects, and further implies that the loss in adrenergic sensitivity in epinephrine-treated animals may be a desensitization phenomenon, while the alterations in calcium response are less readily reversed."( Spontaneous reversibility of catecholamine-induced cardiotoxicity in rats.
Billingham, ME; Bristow, MR; Deisher, TA; Fowler, MB; Ginsburg, R, 1995
)
0.29
" We conclude that "low-dose isoproterenol continuous nebulization" is an effective and safe method for childhood status asthmaticus."( [Isoproterenol continuous nebulization of childhood status asthmaticus. II. Efficacy and side effects of low-dose method comparing with high-dose method].
Goto, K; Inomata, N; Kurihara, K; Takamasu, T, 1998
)
1.5
" Adverse effects resolved within 1 minute of dose reduction."( Safety and tolerability of an aggressive tilt table test protocol in the evaluation of patients with suspected neurocardiogenic syncope.
Brodsky, C; Vlay, LC; Vlay, SC, 2000
)
0.31
"Chlorpyrifos has been hypothesized to interact with receptors and transduction proteins involved in the production of cyclic AMP, contributing to adverse effects on cell replication and differentiation."( Neonatal chlorpyrifos exposure targets multiple proteins governing the hepatic adenylyl cyclase signaling cascade: implications for neurotoxicity.
Auman, JT; Seidler, FJ; Slotkin, TA, 2000
)
0.31
" isoprenaline was selectively depressed by doxorubicin (no changes in chronotropic responses) and this adverse effect of doxorubicin was also prevented in zofenopril+doxorubicin pretreated rats."( Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat.
Bigioni, M; Evangelista, S; Goso, C; Maggi, CA; Manzini, S; Sacco, G, 2001
)
0.31
" This toxic damage was initiated at lower doses of isoprenaline than in the myocardium (1 vs."( Characterisation of isoprenaline myotoxicity on slow-twitch skeletal versus cardiac muscle.
Burniston, JG; Clark, WA; Colyer, J; Goldspink, DF; Ng, Y; Tan, LB, 2002
)
0.31
" Mangiferin also increased the level of heart tissue phospholipids significantly in isoproterenol induced cardio toxic rats."( Efficacy of mangiferin on serum and heart tissue lipids in rats subjected to isoproterenol induced cardiotoxicity.
Nair, PS; Shyamala Devi, CS, 2006
)
0.79
" This may indicate that certain drugs have a minimum concentration level that must be reached before the cells experience apoptosis from the toxic levels."( Novel tissue engineered tubular heart tissue for in vitro pharmaceutical toxicity testing.
Comer, GR; Franchini, JL; Propst, JT; Yost, MJ, 2007
)
0.34
"Sublingual ISDN is less sensitive and less safe compared to intravenous ISOP in assessing pediatric age patients with suspected neurocardiogenic syncope and with a negative result in tilt test without provocation."( Head-up tilt table testing in syncope: safety and efficiency of isosorbide versus isoproterenol in pediatric population.
Caspi, A; Epstein, M; Paz, O; Shimoni, S; Swissa, M, 2008
)
0.57
"Cardiac glycosides, which inhibit the plasma membrane Na(+) pump, are one of the four categories of drug recommended for routine use to treat heart failure, yet their therapeutic window is limited by toxic effects."( Role of mitochondrial dysfunction in cardiac glycoside toxicity.
Brown, DA; Liu, T; O'Rourke, B, 2010
)
0.36
"Liver dysfunction is a common side effect associated with the treatment of dasatinib and its mechanism is poorly understood."( Autophagy protects against dasatinib-induced hepatotoxicity via p38 signaling.
Chen, C; Dai, J; He, Q; Luo, P; Ma, J; Ma, S; Shao, J; Wang, J; Yang, B; Yang, X, 2015
)
0.42
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" Cardio toxic rat model was induced by subcutaneous administration of Isoproterenol (ISO) (30mg/kg) for two consecutive days in adult male rats."( In vivo ameliorative effect of cerium oxide nanoparticles in isoproterenol-induced cardiac toxicity.
Abdelazim, SM; El Shaer, SS; Saied, NM; Salaheldin, TA, 2017
)
0.93
"Taken together these results suggest that at smaller dose of ISO autophagy may cope with the toxic effect of ISO; however, at higher dose apoptosis is initiated and at the highest dose substantial necrosis occurs."( The Role of Autophagy and Death Pathways in Dose-dependent Isoproterenolinduced Cardiotoxicity.
Czegledi, A; Gyongyosi, A; Lekli, I; Tosaki, A; Zilinyi, R, 2019
)
0.76
" Although there is not a specific drug for the challenge in pediatric patients yet, the most commonly drugs used are nitrates and isoproterenol, the latter related to a great number of adverse effects."( Pediatrics patients head-up tilt test with pharmacological challenge, it is safe?
Bustillos-García, GA; García, A; Rivera-Rodríguez, L, 2020
)
0.76
" Although there is not a specific drug for the challenge in pediatric patients yet, the most commonly drugs used are nitrates and isoproterenol, the latter related to a great number of adverse effects."( Pediatric patients' head-up-tilt-test with pharmacological challenge, it is safe?
Bustillos-García, GA; García, A; Rivera-Roodríguez, L, 2020
)
0.76
" Furthermore, curcumin can efficiently rescue cardiomyocytes from these adverse effects."( Mitochondrial ROS-Mediated Metabolic and Cytotoxic Effects of Isoproterenol on Cardiomyocytes Are p53-Dependent and Reversed by Curcumin.
Jung, KH; Kim, DH; Kim, M; Lee, JH; Lee, KH, 2022
)
0.96
"781) levels with EESA treated groups compared to toxic control."( Protective Effects of Sauropus Androgynus Leaf Extract against Isoproterenol Induced Cardiotoxicity.
A, SB; Ajmeer, R; C, R; Jain, V; K, N; Kumar, H; S, P, 2022
)
0.96

Pharmacokinetics

The purpose of the current study was to evaluate the possible pharmacodynamic interaction of GH with CAP on isoproterenol-induced myocardial damage in rat.

ExcerptReferenceRelevance
" The processes of distribution and elimination are of first order; the intravenous biological half-life is 6 to 8 hours."( Studies on the pharmacokinetics and pharmacodynamics of the beta-adrenergic blocking agent sotalol in normal man.
Klein, G; Schinz, A; Schnelle, K,
)
0.13
" The isolated vagus nerve-trachea tube preparation of the guinea-pig is well suited for the concommitant study of pharmacodynamic and pharmacokinetic properties of bronchodilator drugs."( Pharmacodynamic and pharmacokinetic aspects on the transport of bronchodilator drugs through the tracheal epithelium of the guinea-pig.
Jeppsson, AB; Roos, C; Waldeck, B; Widmark, E, 1989
)
0.28
" Pretreatment with desipramine did not alter any of the pharmacokinetic parameters of ISO."( Haemodynamics as a determinant of the pharmacokinetics of and the plasma catecholamine responses to isoprenaline.
Graefe, KH; Halbrügge, T; Ludwig, J; Vey, G; Walter, J, 1989
)
0.28
"The pharmacodynamic activity of (+/-)-1-[4-(2-isopropoxyethoxymethyl)-phenoxy]-3-isopropylamino-2- propranol- hemifumarate (bisoprolol, EMD 33 512) has been investigated under in vitro and in vivo conditions."( Pharmacodynamic profile of the selective beta 1-adrenoceptor antagonist bisoprolol.
Becker, KH; Bergmann, R; Bourgois, R; Enenkel, HJ; Fuchs, A; Harting, J; Jonas, R; Lettenbaur, H; Minck, KO; Schelling, P, 1986
)
0.27
"beta-Adrenergic agonist analogs (congeners) of isoproterenol in which the N-isopropyl group has been linked to a p-methyl- (119) or p-trifluoromethyl- (143) anilide moiety through a four carbon methylene spacer have been investigated with respect to their plasma pharmacokinetic profiles and biliary and urinary elimination characteristics in rats."( Pharmacokinetics and excretion of unique beta-adrenergic agonists.
Akita, Y; Asscher, Y; Benet, LZ; Castagnoli, N; Ferraiolo, BL; Halldin, MM; Melmon, KL, 1987
)
0.53
"The pharmacodynamic activities of two beta adrenergic antagonists, propranolol and practolol, were compared in eight hypertensive patients."( Pharmacodynamic studies of beta adrenergic antagonism induced in man by propranolol and practolol.
Bodem, G; Brammell, HL; Chidsey, CA; Weil, JV, 1973
)
0.25
"beta-Adrenergic blocking agents--esmolol hydrochloride, pharmacokinetic profile, metabolism."( Esmolol: a pharmacokinetic profile of a new cardioselective beta-blocking agent.
Kartzinel, R; Lai, CM; Sum, CY; Yacobi, A, 1983
)
0.27
" Thus, although there are differences in routes of metabolism, the selectivity of action within the airways when the drugs are inhaled is to a large part dependent on pharmacokinetic and metabolic factors."( Pharmacokinetic studies with inhaled drugs.
Davies, DS, 1982
)
0.26
"Recirculatory pharmacokinetic models for indocyanine green (ICG), inulin, and antipyrine facilitate description of intravascular mixing and tissue distribution following intravenous administration."( Drug-induced hemodynamic perturbations alter the disposition of markers of blood volume, extracellular fluid, and total body water.
Avram, MJ; Krejcie, TC; Wang, Z, 2001
)
0.31
" The aim was to validate heart rate as a pharmacodynamic endpoint under continuous isoprenaline-induced tachycardia by means of PK-PD modelling of S(-)-atenolol."( Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint.
Danhof, M; de Lange, EC; Freijer, J; van Steeg, TJ, 2007
)
0.34
"Reduction of heart rate during isoprenaline-induced tachycardia is a reliable pharmacodynamic endpoint for beta-blockers in vivo in rats."( Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint.
Danhof, M; de Lange, EC; Freijer, J; van Steeg, TJ, 2007
)
0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Comparative pharmacokinetic-pharmacodynamic studies with four beta blockers were performed in conscious rats, using heart rate under isoprenaline-induced tachycardia as a pharmacodynamic endpoint."( Influence of plasma protein binding on pharmacodynamics: Estimation of in vivo receptor affinities of beta blockers using a new mechanism-based PK-PD modelling approach.
Boralli, VB; Danhof, M; de Lange, EC; Freijer, J; Krekels, EH; Slijkerman, P; van Steeg, TJ, 2009
)
0.35
" Thus the purpose of the current study was to evaluate the possible pharmacodynamic interaction of GH with CAP on isoproterenol (ISO)-induced myocardial damage in rat."( Pharmacodynamic interaction of captopril with garlic in isoproterenol-induced myocardial damage in rat.
Asdaq, SM; Inamdar, MN, 2010
)
0.82
" For pharmacodynamic study, histopathological and biochemical analysis were performed to assess the anti-myocardial ischemic effects."( Pharmacodynamics and pharmacokinetics of Danshen in isoproterenol-induced acute myocardial ischemic injury combined with Honghua.
Bai, JQ; Chen, YY; Duan, JA; Liu, F; Qu, C; Shen, LF; Tang, YP; Wang, XP; Xu, DQ; Yue, SJ; Zhao, BC; Zhou, GS, 2020
)
0.81
"Our findings demonstrated the greater effects of DH after the compatibility in ISO-induced acute myocardial ischemia rats at pharmacodynamic and pharmacokinetic levels and provided valuable information for clinical application of herb pairs."( Pharmacodynamics and pharmacokinetics of Danshen in isoproterenol-induced acute myocardial ischemic injury combined with Honghua.
Bai, JQ; Chen, YY; Duan, JA; Liu, F; Qu, C; Shen, LF; Tang, YP; Wang, XP; Xu, DQ; Yue, SJ; Zhao, BC; Zhou, GS, 2020
)
0.81

Compound-Compound Interactions

The results also implied that the HUT test combined with isoproterenol infusion is useful for the provocation of coronary spasm. Sixty three patients had a bicycle ergometric tests, 48 underwent 201Tl myocardial scintigraphy along with a dipyridamole test.

ExcerptReferenceRelevance
" A selective beta1-receptor blocker can be used in asthmatics when it is combined with optimal anti-asthmatic therapy, while a non-selective drug is contra-indicated in patients with broncho-obstructive diseases."( Use of beta-adrenoreceptor blockers in combination with beta-stimulators in patients with obstructive lung disease.
Johnsson, G, 1976
)
0.26
"The effect of chronic ethanol exposure alone or in combination with desipramine on agonist and antagonist binding to beta-adrenoceptors was studied in membrane preparations from rat frontal cortex and hippocampus."( Effects of chronic exposure to ethanol alone and in combination with desipramine on beta-adrenoceptors of rat brain.
Gurguis, G; Karanian, J; Linnoila, M; Potter, WZ; Turkka, J, 1990
)
0.28
"9% NaCl solution; vehicle) was given, alone and in combination with lidocaine (L), to groups of six pentobarbital (32."( Effects of metoprolol, alone and in combination with lidocaine, on ventricular fibrillation threshold: comparison with atenolol, propranolol, and pindolol.
Beil, ME; Cabot, CF; Coram, WM; Olson, RW; Weiss, GB, 1987
)
0.27
" Sixty three patients had a bicycle ergometric tests, 48 underwent 201Tl myocardial scintigraphy along with a dipyridamole test, 19, the scintigraphy in combination with an isoproterenol test."( [Tl-201 scintigraphy of the myocardium in combination with pharmacological tests in the diagnosis of ischemic heart disease].
Sergienko, VB; Sidorenko, BA; Tokareva, EA, 1989
)
0.47
" The results also implied that the HUT test combined with isoproterenol infusion is useful for the provocation of coronary spasm."( Head-up tilt test combined with isoproterenol infusion provokes coronary vasospastic angina.
Hamasakai, S; Horimoto, M; Igarashi, K; Inoue, H; Matsushima, H; Miyata, S; Ohizumi, S; Shibuya, E; Takenaka, T; Yoshimura, H, 1998
)
0.83
" We previously demonstrated that Ang II combined with evolving cardiodepression (48-hour tachycardia pacing, 48hP) induces marked chamber stiffening and increases metalloproteinases (MMPs)."( beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction.
Crow, MT; Gluzband, YA; Janicki, JS; Kass, DA; Lindsey, ML; Paolocci, N; Senzaki, H, 2000
)
0.31
"The effects of high-dose epinephrine (HDE) combined with isoprenaline (Iso) on myocardial hemodynamics of isolated rabbit heart were studied."( The effects of high-dose epinephrine combined with isoprenaline on isolated rabbit heart and cardiomyocytes after cardioversion of ventricular fibrillation.
Zhang, W; Zhao, L; Zheng, Y, 2000
)
0.31
" The biosensor was optimized regarding the type of cantilever, temperature and exchange of media; in combination with standardized protocol, it allowed testing of compounds and conditions affecting the biomechanical properties of EB."( Atomic force microscopy combined with human pluripotent stem cell derived cardiomyocytes for biomechanical sensing.
Acimovic, I; Dvorak, P; Jelinkova, S; Lacampagne, A; Meli, AC; Pesl, M; Pribyl, J; Rotrekl, V; Salykin, A; Skladal, P; Vilotic, A, 2016
)
0.43
" We hypothesized that experimental diabetes in rats combined with a cardiac or renal stressor, would mimic diabetic cardiomyopathy and nephropathy, respectively."( Rat pancreatectomy combined with isoprenaline or uninephrectomy as models of diabetic cardiomyopathy or nephropathy.
Fink, LN; Jelsing, J; Johansen, TT; Lindsay, RT; Murray, AJ; Pedersen, AA; Pedersen, PJ; Pedersen, TX; Secher, T; Skarsfeldt, T; Thisted, L; Thomsen, MB; Thrane, ST; Zois, NE; Østergaard, MV, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" dl-Timolol maleate is also extremely well absorbed when given orally, being then about 10 times more active than propranolol."( Timolol maleate, a new beta-adrenergic receptor blocking agent.
Hall, RA; Robson, RD; Share, NN, 1975
)
0.25
" A comparison of beta-adrenoreceptor blocking activity after oral and intravenous administration provides information on the bioavailability of these drugs."( Experiments with pindolol (Visken) in healthy volunteers.
Aellig, WH, 1977
)
0.26
" N-Nitro-L-arginine (NOLA) (5 x 10(-5) to 10(-4) M), an inhibitor of NO synthase, and haemoglobin (10(-5) M), which reduces bioavailability of NO, both reduced the amplitude of nerve-mediated relaxations to less than 50%, without affecting the ability of the muscle to relax."( Evidence that nitric oxide participates in non-adrenergic inhibitory transmission to intestinal muscle in the guinea-pig.
Furness, JB; Murphy, R; Shuttleworth, CW, 1991
)
0.28
" This leads to in situ formation of a super-saturated ME that possesses a particularly high absorption rate due to the enhanced diffusion pressure of the drug."( Pharmacodynamic effects of transdermal bupranolol and timolol in vivo: comparison of microemulsions and matrix patches as vehicle.
Kemken, J; Müller, BW; Ziegler, A, 1991
)
0.28
" Its bioavailability after oral administration amounts to about 70%."( Clinical pharmacological studies with the long-acting beta-adrenoceptor blocking drug bopindolol.
Aellig, WH, 1986
)
0.27
" The absorption rate of the free forms of sulfanilamides was increased (significantly for sulfalen and sulfapyridazine)."( [Sulfanilamide absorption and acetylation in rats with experimental hyperlipidemia and cellular regulation of the process of acetylation].
Lubiankina, SV; Makarov, VA; Suetina, IV; Vasilenko, IuK; Vaskanian, VL,
)
0.13
" Oral bioavailability averaged 33% and was independent of dose."( Cardioselectivity of prenalterol and isoproterenol.
Bobik, A; Hargreaves, M; Jennings, G; Korner, P; Oddie, C, 1983
)
0.54
" Bioavailability was 90 +/- 9% after oral administration."( Pharmacokinetics of atenolol in clinically normal cats.
Dyer, DC; Mehvar, R; Quiñones, M; Ware, WA, 1996
)
0.29
"AT has high oral bioavailability in cats, resulting in small interindividual variability in its kinetics in this species."( Pharmacokinetics of atenolol in clinically normal cats.
Dyer, DC; Mehvar, R; Quiñones, M; Ware, WA, 1996
)
0.29
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"36 mg/kg) and is 25% orally bioavailable in the dog."( Human beta3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides.
Brockunier, LL; Candelore, MR; Cascieri, MA; Colwell, LF; Deng, L; Feeney, WP; Fisher, MH; Forrest, MJ; Hom, GJ; MacIntyre, DE; Ok, HO; Parmee, ER; Tota, L; Weber, AE; Wyvratt, MJ, 2000
)
0.31
"A novel class of biphenyl analogues containing a benzoic acid moiety based on lead compound 8i have been identified as potent and selective human beta 3 adrenergic receptor (beta 3-AR) agonists with good oral bioavailability and long plasma half-life."( Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.
Hamada, K; Hamashima, H; Hattori, K; Imamura, E; Imanishi, M; Ishikawa, H; Itou, S; Matsui, S; Matsumura, Y; Nakajima, Y; Nakano, K; Sakurai, M; Takamura, F; Tomishima, Y; Ueshima, K; Unami, N; Washizuka, K; Yamamoto, N; Yamamoto, T, 2008
)
0.35
" Furthermore, 29b was found to have low oral bioavailability in rat and dog and also to have long duration of action in an in vivo model of bronchodilation."( Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups.
Barrett, VJ; Bevan, NJ; Biggadike, K; Butchers, PR; Coe, DM; Conroy, R; Edney, DD; Field, RN; Ford, AJ; Guntrip, SB; Looker, BE; McLay, IM; Monteith, MJ; Morrison, VS; Mutch, PJ; Procopiou, PA; Richards, SA; Sasse, R; Smith, CE, 2009
)
0.35
" These compounds have been identified as potent and selective human beta(3)-AR agonists with improved oral bioavailability compared to the previous series."( Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5.
Araki, T; Hamada, K; Hamashima, H; Hattori, K; Imamura, E; Imanishi, M; Ishikawa, H; Itou, S; Matsui, S; Matsumura, Y; Nakajima, Y; Nakano, K; Sakurai, M; Takamura, F; Toda, S; Tomishima, Y; Ueshima, K; Unami, N; Washizuka, K; Yamamoto, N; Yamamoto, T, 2009
)
0.35
" Compound 13f had high potency, selectivity, fast onset, and long duration of action in vitro and was found to have long duration in vivo, low oral bioavailability in the rat, and to be rapidly metabolized."( Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.
Barrett, VJ; Bevan, NJ; Biggadike, K; Box, PC; Butchers, PR; Coe, DM; Conroy, R; Emmons, A; Ford, AJ; Holmes, DS; Horsley, H; Kerr, F; Li-Kwai-Cheung, AM; Looker, BE; Mann, IS; McLay, IM; Morrison, VS; Mutch, PJ; Procopiou, PA; Smith, CE; Tomlin, P, 2010
)
0.36
" It had lower oral absorption than salmeterol in rats, and lower bioavailability than salmeterol in vivo in both rats and dogs (2% and 5%, respectively)."( The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating hydantoin or uracil rings.
Barrett, VJ; Bevan, NJ; Butchers, PR; Conroy, R; Emmons, A; Ford, AJ; Jeulin, S; Looker, BE; Lunniss, GE; Morrison, VS; Mutch, PJ; Perciaccante, R; Procopiou, PA; Ruston, M; Smith, CE; Somers, G, 2011
)
0.37
" It had lower oral absorption and bioavailability than salmeterol in both rat and dog."( The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating a urea group.
Barrett, VJ; Ford, AJ; Looker, BE; Lunniss, GE; Needham, D; Procopiou, PA; Smith, CE; Somers, G, 2011
)
0.37
" Spironolactone, but not losartan, restored NO bioavailability in association with lower endothelial nitric oxide synthase-derived superoxide production, increased endothelial nitric oxide synthase dimerization, and aortic HSP90 upregulation."( Spironolactone Prevents Endothelial Nitric Oxide Synthase Uncoupling and Vascular Dysfunction Induced by β-Adrenergic Overstimulation: Role of Perivascular Adipose Tissue.
Alonso, MJ; Clerici, SP; Davel, AP; Jaffe, IZ; Palacios, R; Rossoni, LV; Vassallo, DV; Victorio, JA, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Ginkgolides are widely used in cardio-protective therapy; however, poor bioavailability currently limits their application."( Preparation of Ginkgolide Solid Dispersions with Low-Molecular-Weight Chitosan and Assessment of their Protective Effect on Isoproterenol- Induced Myocardial Injury.
Cui, L; Ding, W; Liu, B; Liu, D; Xia, Z; Zhang, L, 2020
)
0.76
"Solid dispersions prepared with low molecular weight chitosan improved the oral bioavailability of ginkgolide and enhanced its protective effect on myocardial injury."( Preparation of Ginkgolide Solid Dispersions with Low-Molecular-Weight Chitosan and Assessment of their Protective Effect on Isoproterenol- Induced Myocardial Injury.
Cui, L; Ding, W; Liu, B; Liu, D; Xia, Z; Zhang, L, 2020
)
0.76
" The absorption rate and cumulative absorption were calculated to analyze the intestinal absorption characteristics of six components in normal and myocardial ischemia model rats."( [Intestinal absorption characteristics of Polygonum orientale extract in normal and isoproterenol-induced myocardial ischemia model rats via everted intestinal sac models].
Li, N; Li, YJ; Liu, CH; Lu, Y; Pan, J; Sun, J; Wang, MJ; Wang, YL; Yang, ST, 2021
)
0.85
"The objective of the present paper is to formulate nanostructured lipid carriers (NLCs) of a calcium channel blocker, isradipine, to enhance its oral bioavailability and prolong its antihypertensive effect apart from evaluating efficacy of the formulation in isoproterenol induced myocardial infarction in rats."( Nanostructured lipid carriers of isradipine for effective management of hypertension and isoproterenol induced myocardial infarction.
Alam, T; Ali, J; Ansari, MA; Baboota, S, 2022
)
1.12
" The finding of an acute effect suggests that it may be clinically important to maintain an adequate bioavailability of colchicine."( Colchicine enhances β adrenoceptor-mediated vasodilation in men with essential hypertension.
Aalkjaer, C; Ehlers, TS; Gliemann, L; Hellsten, Y; Jepps, TA; Møller, S; Piil, PK; van der Horst, J, 2023
)
0.91

Dosage Studied

beta-Adrenoceptor blocking agents were found to interact with isoproterenol in a manner consistent with a simple competitive antagonism. In the presence of 22 mM K+, but not tetrodotoxin, the dose-response and temporal relationships between isop roterenol and elevations in cAMP concentration were shifted to the right. The close temporal relation of isop Roterenol overdosage with mycardial necrosis provides presumptive evidence that the well-documented association of myocardium necrosis with high dosage catecholamines may also occur in man.

ExcerptRelevanceReference
" Dose-response curves which demonstrate the effect of norepinephrine and isoproterenol on the rate of electrical activity in the presence of Ca++ or Sr++ were made."( Adrenergic drug-receptor interaction in the presence of strontium (Sr++) in mammalian myocardium.
Ahlquist, RP; Carrier, GO; Matheny, JL, 1975
)
0.49
" Inotropic and chronotropic dose-response studies to isoproterenol in the anesthetized dog demonstrated that the quarternary compound lacked beta adrenergic receptor blocking properties."( The antiarrhythmic and cardiovascular properties of 1-dimethyl isopropylamino-3-(2-phenylphenoxy)-propan-2-ol chloride, UM-424.
Counsell, RE; Kniffen, FJ; Lucchesi, BR; Winokur, S, 1976
)
0.51
" The two drugs caused comparable shifts of the isoproterenol dose-response curve during anesthesia."( Interaction of anesthesia, beta-receptor blockade, and blood loss in dogs with induced myocardial infarction.
Bennett, MJ; Clarke, TN; Foëx, P; Prys-Roberts, C; Roberts, JG; Ryder, WA, 1976
)
0.51
"Isoprenaline dose-response curves plotting increases in heart rate before and after labetalol are suggestive of competitive antagonism at beta-adrenoceptor sites."( Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol.
Prichard, BN; Richards, DA; Tuckman, J, 1976
)
0.26
" In contrast to other broncholytic substances, a very small dosage of clenbuterol is sufficient to protect rats against the liberation of histamine and serotonin caused by the anaphylactic reaction."( [Profile of pharmacological actions of NAB 365 (clenbuterol), a novel broncholytic agent with selective activity on adrenergic beta2-receptors (author's transl)].
Engelhardt, G, 1976
)
0.26
" In atria incubated with phenoxybenzamine from guinea-pigs pretreated with reserpine only the dopamine dose-response curves were displaced to the right indicating a considerable indirect sympathomimetic component."( Analysis of the inotropic: chronotropic selectivity of dobutamine and dopamine in anaethetised dogs and guinea-pig isolated atria.
Broadley, KJ; Levy, GP; Lumley, P, 1977
)
0.26
" Propranolol shifted the dose-response curves downward and to the right for all agonists; phentolamine, shifter the curves upward and to the left."( Effects of adrenergic amines on electrophysiological properties and automaticity of neonatal and adult canine Purkinje fibers: evidence for alpha- and beta-adrenergic actions.
Danilo, P; Hordof, AJ; Ilvento, JP; Rosen, MR, 1977
)
0.26
" Each agent was evaluated at concentrations ranging from 10-8 to 10-5 m and three different dose-response curve patterns were observed: (1) Metoprolol, acebutolol, labetalol, and d-propranolol had no effect on isoproterenol-stimulated renin release at any concentration, whereas pindolol and bufuralol demonstrated minimal inhibition at 10-5 m only."( Effect of beta-blocking agents and angiotensin II on isoproterenol-stimulated renin release from rat kidney slices.
Capponi, AM; Gourjon, M; Vallotton, MB, 1977
)
0.69
" Dose-response data were obtained and ED50 values for pulmonary and cardiovascular blockade were compared."( Differences in pulmonary and cardiovascular beta receptors in the guinea pig and rabbit.
Alvarez, R; Bradshaw, J; Marian, J; Weissberg, RM, 1977
)
0.26
"3 Dose-response curves to the four drugs for tracheal relaxation were almost parallel."( Assessment of the selectivity of OPC-2009, a new beta2-adrenoceptor stimulatn, by the use of the blood-perfused trachea in situ and of the isolated blood-perfused papillary muscle of the dog.
Himori, N; Taira, N, 1977
)
0.26
" Each agonist was compared with (--)-isoprenaline as the reference by constructing dose-response curves."( Evidence from agonist and antagonist studies to suggest that the beta1-adrenoceptors subserving the positive inotropic and chronotropic responses of the heart do not belong to two separate subgroups.
Broadley, KJ; Lumley, P, 1977
)
0.26
"The effect of diazoxide, verapamil and compound D600 on calcium and isoproterenol dose-response relationships was investigated in isolated rabbit atrial preparations."( Effect of diazoxide, verapamil and compound D600 on isoproterenol and calcium-mediated dose-response relationships in isolated rabbit atrium.
Bristow, MR; Green, RD, 1977
)
0.74
" Isoprenaline evoked vasodilation and propranolol (beta-adrenoceptor antagonist) caused a parallel shift to the right of the isoprenaline log dose-response curve."( Identification of beta-adrenoceptors and histamine receptors in the cat nasal vasculature.
Hiley, CR; Wilson, H; Yates, MS,
)
0.13
"1 In spontaneously active Purkinje fibres of young cows the dose-response curves of the action of isoprenaline upon different electrophysiological parameters were measured."( The effects of isoprenaline and a new beta-sympathomimetic amine upon spontaneous activity, diastolic depolarization and plateau height in cardiac Purkinje fibres.
Grabowski, W; Lüttgau, HC; Schulze, JJ, 1978
)
0.26
" Propranolol shifted the dose-response curves for the isoproterenol-induced flow increases in the common hepatic, gastro-duodenal, and cranial mesenteric arteries to the right."( alpha- and beta-receptor blockade of isoproterenol- and norepinephrine-induced effects on regional blood flow and blood flow acceleration.
Beijer, HJ; Charbon, GA; Immink, WF, 1978
)
0.78
" The slopes of the salbutamol dose-response curves were flatter than those for isoprenaline and noradrenaline; the slopes of the procaterol dose-response curves were flatter than those for salbutamol."( Comparative study of chronotropic and inotropic responses to 5-(-hydroxy-2-isopropylaminobutyl)-8-hydroxycarbostyril hydrochloride hemihydrade (procaterol), salbutamol, noradrenaline and isoprenaline in the dog heart.
Chiba, S,
)
0.13
" Additionally, dose-response curves of CF in response to injected norepinephrine, isoproterenol, glucagon, and calcium were depressed when compared to the normal group while the response of heart rate and blood pressure was not different."( Volume overload heart failure: length-tension curves, and response to beta-agonists, Ca2+, and glucagon.
Newman, WH, 1978
)
0.48
" The mathematical form of the model suggests that the dissociation constants of classical competitive partial agonists may be assessed using dose ratios by exactly the same method as that currently used for agonist-antagonist interactions, provided that the log dose-response curves are first suitably normalized."( An application of receptor models to the analysis of data on beta-adrenoceptor blockade.
Bilski, AJ; Ferguson, RA; Robertson, HH; Wale, JL,
)
0.13
" The results obtained by this method in 10 healthy subjects after 60 mg penbutolol were compared with those given by chemical dosage and ergometry."( [Biological determination of the beta blocking activity of human serum].
Auclair, MC; Carli, A; Giudicelli, JF; Kolsky, H; Lechat, P; Moisson, P; Weber, S; Witchitz, S, 1979
)
0.26
" The slopes of the dose-response curves to isoprenaline were depressed for up to 24 h by Ro 03-7894 but this was not so with Ro 03-5255."( The in vivo examination of the irreversible beta-adrenoceptor antagonist Ro 03-7894 on cardiac rate and contractility.
Broadley, KJ; Burden, DT; Natoff, IL; Nicholson, CD,
)
0.13
" Aminobenzylpropranolol inhibited catecholamine-stimulated intracellular cyclic AMP accumulation; with increasing blockade, isoproterenol dose-response curves became progressively shifted to the right but the maximal response was unaltered."( Quantitative relationship between beta-adrenergic receptor number and physiologic responses as studied with a long-lasting beta-adrenergic antagonist.
Brooker, G; Linden, J; Terasaki, WL, 1979
)
0.47
" In view of the clinical dosage levels, it is sugg ested that the antiarrhythmic effects of OPC-1085 depend predominantly on its beta blocking action."( Cardiac electrophysiologic action of carteolol hydrochloride (OPC-1085), a new beta-adrenergic blocking agent.
Ozawa, M; Toda, H; Watanabe, Y, 1978
)
0.26
" Dose-response data suggested that maximal bronchodilatation may be achieved by 10 to 20 mug of Sch 1000; larger doses did not result in significantly greater increases in forced expiratory volume in 1 sec or maximal mid-expiratory flow."( Sch 1000: a new anticholinergic bronchodilator.
Gross, MJ, 1975
)
0.25
"The effect of ipratropium bromide administered at two dosage levels, 40 and 80 mug, isoproterenol, 150 mug, and placebo using a metered dose inhaler was evaluated in ten adult patients with asthma in a double-blind, crossover study."( Asthma: comparative bronchodilator effects of ipratropium bromide and isoproterenol.
Katz, S; Kaufman, LV; Weinberg, RM; Yeager, H, 1976
)
0.71
" 2 Blood pressure and heart rate recordings made before dosing was started showed the streptozotocin-treated animals to have a significantly reduced heart rate and increased pulse pressure as compared with controls."( Effect of experimental diabetes, food deprivation and genetic obesity on the sensitivity of pithed rats to autonomic agents.
Foy, JM; Lucas, PD, 1976
)
0.26
" The dose-response aspects of the study indicate that in bronchial asthma the optimal range of dosage is 40 mug to 80 mug of ipratropium bromide."( Bronchodilator action of the anticholinergic drug, ipratropium bromide (Sch 1000), as an aerosol in chronic bronchitis and asthma.
Baigelman, W; Chodosh, S, 1977
)
0.26
" In both tissues, dose-response curves for production of mechanical effects were greater than 2 log units to the left of those for increases in cyclic AMP levels."( Changes in mechanical events and adenosine 3',5'-monophosphate levels induced by enantiomers of isoproterenol in isolated rat atria and uteri.
Abel, PW; Amidon, GL; Birnbaum, JE; Buckner, CK, 1975
)
0.47
" With respect to inhibition of norepinephrine-stimulated adenylate cyclase, the dose-response curve of NSILA-S is similar to that already found with intact cells."( Effect of partially purified NSILA on adenylate cyclase, phosphodiesterase and 3',5'-cyclic AMP in fat cells.
Häring, HU; Hepp, KD; Langley, J; Renner, R, 1975
)
0.25
" An association between increased cAMP contents and increased contractile activity was revealed by both the time-response and the dose-response curves of hearts exposed to isoprenaline and dopamine."( Adenosine 3',5'-cyclic monophosphate in perfused rat hearts exposed to isoprenaline and dopamine.
Osnes, JB; Oye, I, 1976
)
0.26
" Dose-response relationships for isoproterenol (IP) reveal a noncompetitive inhibition of the inotropic action of the catecholamine by ACh."( Catecholamine antagonism of acetylcholine and dibutyrl guanosine 3',-5'-monophosphate in the mammalian ventricular myocardium.
Jacob, R; Schwegler, M, 1975
)
0.54
" Propranolol administration abolished the hemodynamic effects of isoproterenol and significantly decreased the response of plasma cyclic AMP; the same blocking dosage had little effect on plasma cyclic AMP changes induced by glucagon wheras the response in blood sugar was significantly reduced."( Effects of beta-adrenergic blockade on plasma cyclic AMP and blood sugar responses to glucagon and isoproterenol in man.
Fraysse, J; Genest, J; Hamet, P; Kuchel, O; Messerli, FH; Tolis, G, 1976
)
0.71
" The receptors were tested by infusion of increasing doses of isoprenaline, so that dose-response curves for isoprenaline were recorded."( Lack of bronchial beta adrenoceptor resistance in asthmatics during long-term treatment with terbutaline.
Larsson, S; Svedmyr, N; Thiringer, G, 1977
)
0.26
" The dose-response curves for the two agonists were parallel, but salbutamol was approximately 1/15 as potent as isoprenaline on a weight basis."( Profile of beta-adrenoceptors in femoral, superior mesenteric and renal vascular beds of dogs.
Taira, N; Yabuuchi, Y; Yamashita, S, 1977
)
0.26
" Construction of dose-response curves, however, revealed antagonism of all three parameters by propranolol and different sensitivities of the parameters to isoprenaline."( The beta-adrenoceptors responsible for a direct relaxation of the uncontracted nictitating membrane of the anaesthetized cat.
Broadley, KJ, 1977
)
0.26
"13 The vasoconstrictor actions of phenylephrine, noradrenaline and adrenaline were all antagonized by the systemic administration of phentolamine, all three dose-response curves being shifted to the right."( The role of beta-adrenoceptors in the responses of the hepatic arterial vascular bed of the dog to phenylephrine, isoprenaline, noradrenaline and adrenaline.
Richardson, PD; Withrington, PG, 1977
)
0.26
" Dose-response curves in response to isoproterenol and ACTH-(1--24) indicated that the capacity of the lipolytic process was reduced."( Lipolysis and cyclic AMP levels in epididymal adipose tissue of obese-hyperglycaemic mice.
Christophe, J; Dehaye, JP; Winand, J, 1977
)
0.53
" Subsequent to obtaining the first dose-response curve for norepinephrine, aortic strips were less sensitive to norepinephrine."( Specific alpha-adrenergic receptor desensitization in vascular smooth muscle.
Barron, KW; Carrier, O; Wedell, EK, 1978
)
0.26
" As with the time courses for isoprenaline, dose-response curves for the effect of isoprenaline and papaverine on cAMP content and force of contraction also appeared to be shifted towards higher levels at hypothemia."( The role of cyclic AMP in temperature-dependent changes of contractile force and sensitivity ot isoprenaline and papaverine in guinea-pig atria.
Brodde, OE; Butzheinen, R; Reinhardt, D; Schümann, HJ, 1978
)
0.26
" We have found that the effect of colchicine on capping is also both time- and dose dependent, and that the dose-response relationships conform to those required to increase cyclic AMP levels."( Microtubules and cyclic AMP in human leukocytes: on the order of things.
Malawista, SE; Oliver, JM; Rudolph, SA, 1978
)
0.26
" Isoprenaline, salbutamol and ritodrine caused a dose-dependent reduction of the spontaneous contractions of the pregnant myometrium and a dose-related and parallel shift to the right of the isoprenaline dose-response curve was obtained with butoxamine but not with practolol."( Beta-adrenoceptors in the pregnant and non-pregnant myometrium of the goat and cow.
Larsen, JJ, 1979
)
0.26
"The inotropic response induced by beta-adrenergic and H1 histaminergic receptor stimulation was characterized in guinea pig left atria by obtaining dose-response relationships for isoproterenol and histamine under various experimental conditions."( Characterization of the inotropic response induced by stimulation of beta-adrenergic and H1 histaminergic receptors in guinea pig left atria.
McNeill, JH; Tenner, TE, 1978
)
0.45
" Therefore, 50 mg of propanolol are recommended as the proper dosage with which to examine cardiac and extracardiac beta-adrenergic receptors in cattle."( [Electrocardiographic functional diagnosis of the vegitative nervous system in cattle. 2. Determination of the propranolol blockade effect on cardiac beta-receptors under application of maximum isoprenaline doses].
Schumann, S, 1978
)
0.26
" The accumulation of cAMP due to isoproterenol was similar in both groups for every dose of isoproterenol so that the initial difference between groups in cAMP concentration was maintained in an additive fashion over the entire dose-response curve."( Depressed cyclic AMP levels in airways smooth muscle from asthmatic dogs.
Brunton, LL; Mayer, SE; Rinard, GA; Rubinfeld, AR, 1979
)
0.54
" Particularly with the primarily cardioselective beta-stimulating agent dobutamine a marked positive inotropic effect can be achieved in a range of dosage not significantly affecting heart rate and peripheral resistance."( [Catecholamines for treatment of severe heart failure (author's transl)].
Kübler, W; Mäurer, W; Tillmanns, H, 1979
)
0.26
"Peripheral beta-adrenergic receptor sensitivity was characterized in 24 patients with essential hypertension and in 13 age-matched normotensive subjects using an isoproterenol hydrochloride bolus dose-response technique."( Peripheral beta-receptor responsiveness in patients with essential hypertension.
Dominic, JA; Guthrie, GP; Kotchen, TA; Love, DW; McAllister, RG, 1979
)
0.46
"Cumulative log dose-response curves of soterenol, isoproterenol, phenylephrine and norepinephrine on isolated pregnant rat uterus at different days of gestation, were investigated."( Adrenoceptors involved in the contractile activity of islated pregnant rat uterus.
Borda, E; Gimeno, AL; Gimeno, MF; Sauvage, J; Sterin-Borda, L, 1979
)
0.51
" Time relationships are described for isoproterenol and glycerol release and for cyclic AMP levels in the fat cells, and the dose-response relationship between isoproterenol and glycerol release is shown."( Characterization of the multiple-chamber perifused fat cell system.
Allen, DO; Long, KJ; Majors, JT, 1979
)
0.53
"In human adipose tissue in vitro, dose-response curves of lipolytic agents in releasing free fatty acids and glycerol into an albumine-containing medium were followed."( Adrenergic lipolysis in human adipose tissue in vitro.
Kuhn, E; Wenke, M; Wenkeová, J, 1975
)
0.25
" Log dose-response curves to isoprenaline from spontaneously contracting muscle strips from rabbit uterus have been obtained."( Action of beta-adrenoceptor antagonists on the response to isoprenaline in the oestrogen dominated rabbit uterus.
Nesheim, BI, 1975
)
0.25
" Statistical tests of parallelism revealed a significant difference between the log dose-response curves of Sch 15280 and ephedrine but not between those of Sch 15280, atropine and aminophylline."( Experimental study of a potential anti-asthmatic agent: SCH 15280.
Adams, GK; Bleidt, B; Diamond, L; Williams, B, 1975
)
0.25
" In these studies, it is shown that increasing concentrations of carbamylcholine (carbachol) result in a shift to the right of the dose-response curves to (-)-isoproterenol and (-)-soterenol and a reduction of the maximum degree of relaxation produced by these agonists relative to that produced by papaverine."( On the use of functional antagonism to estimate dissociation constants for beta adrenergic receptor agonists in isolated guinea-pig trachea.
Buckner, CK; Saini, RK, 1975
)
0.45
" Dose-response curves for acetylcholine with and without dopamine, isoprenaline, phenylephrine and noradrenaline were obtained."( The depressor effect of dopamine on the electrical and mechanical activities of cat small intestine.
Okawa, H; Wantanabe, M, 1975
)
0.25
" Isoproterenol, isoetharine and N-t-butylnorepinephrine, individually, had similar dose-response curves and ED50 values when tested as antagonists of histamine and carbamylcholine-induced bronchoconstriction in dogs."( The role of bronchoconstrictors in evaluating smooth muscle relaxant activity.
Minatoya, H; Spilker, B, 1975
)
1.16
" Dose-response curves of isoprenaline were constructed in nine hypertensive patients before and after either propranolol or metoprolol."( Effect of selective and non-selective beta-adrenoreceptor blockade on calf blood flow in hypertensive patients.
Clement, DL, 1978
)
0.26
" The dose-response relation between K concentrations and net KAHs follows Michaelis-Menten kinetics; the log dose-response relation showed a sigmoid curve and the Lineweaver-Burk Plot of dose-response relation showed a straight line when nH=1."( An analysis of the effect of adrenaline on electrogenic Na+ pump of visceral nerve fibers in bullfrogs.
Koketsu, K; Morita, K, 1979
)
0.26
"Aerosolized fenoterol in a dosage of 400 microgram was compared to isoproterenol 150 microgram in 31 asthmatic subjects during the course of a double-blind parallel 90-day study."( Comparison of the bronchodilator effects of aerosol fenoterol and isoproterenol.
Beall, GN; Kuo, J; Smith, R; Steen, SN; Ziment, I, 1977
)
0.73
" Lowering the antigen (ovalbumin) dosage from 400 microgram/ml to 10 microgram/ml reduced the control release of SRS-A by 70% and increased the inhibitory effect of prostaglandins I2, E1 and isoprenaline."( A possible modulatory role for prostacyclin (PGI2) INIgGa-induced release of slow-reacting substance of anaphylaxis in rats.
Burka, JF; Garland, LG, 1977
)
0.26
" In order to evaluate the importance of the Iso dose, dose-response studies were performed in 9 diabetics (fasting plasma glucose greater than 150 mg/dl) and 10 age-matched controls."( Mechanisms of impaired acute insulin release in adult onset diabetes: studies with isoproterenol and secretin.
Halter, JB; Porte, D, 1978
)
0.48
" Intravenous isoproterenol resulted in prompt improvement in most patients; except for one patient who experienced cardiac arrhythmia (reversed when the dosage was decreased), this medication was well-tolerated."( Review of intensive care unit admissions for asthma.
Carney, J; Church, JA; Lew, C; Platzker, A; Richards, W, 1979
)
0.63
" The aerosol/infusion dosage ratio for comparable reductions of blood pressure were 1 for isoprenaline, and 10 for NP."( Comparison of sodium nitroprusside and isoprenaline aerosols in histamine-induced bronchial asthma of the guinea pig.
Kreye, VA; Marquard, E, 1979
)
0.26
"The effect of inhibiting isoprenaline-induced intracellular calcium accumulation on the degree of damage produced in the rat myocardium by this amine has been investigated by simultaneously dosing rats with the calcium antagonistic drug D600."( The effect of a calcium antagonist (D600) on isoprenaline-induced myocardial necrosis in the rat.
Powell, T; Rowles, PM; Steen, E; Woolf, N, 1979
)
0.26
" The dose-response curves for isoprenaline were shifted to the right on treatment with practolol."( Distribution and characterization of the adrenoceptors in dog coronary arteries.
Morishita, H, 1979
)
0.26
" Sublingual isoproterenol (Isuprel) has been effective in a few cases but the every-two-hour dosage schedule is inconvenient on a long-term basis."( Primary pulmonary hypertension. Responses to indomethacin, terbutaline, and isoproterenol.
Person, B; Proctor, RJ, 1979
)
0.87
" However, the dose-response curve to EPI was shifted horizontally to the right 4 days after mating suggesting a tissue desensitization."( The absence of sensitivity changes of the rabbit oviduct to phenylephrine and isoproterenol during early gestation.
Heilman, RD; Reo, RR, 1977
)
0.49
" Dose-response curves for the pressor effect of norepinephrine were not altered by debrisoquin."( The cardiovascular effects of the antihypertensive drug debrisoquin: a contribution to the pharmacology of chronic treatment. I. One-week administration to dogs.
Cavero, I; Gerold, M; Haeusler, G; Saner, A, 1978
)
0.26
" The order of potency for the agonists, together with blocking experiments (including a parallel shift in the log dose-response curve induced by bulbocapnine), indicated that the vasodilatation is mediated by specific dopamine receptors."( Effects of dopaminergic agonists and antagonists on isolated cerebral blood vessels.
Edvinsson, L; Hardebo, JE; McCulloch, J; Owman, C, 1978
)
0.26
"Isoprenaline dosed 50 mg/kg was injected intraperitoneally into rats aged 42 days, 3 months, and 18 months."( Age-dependent variations in the intensity of isoprenaline-induced myocardial lesions in rats.
Kalincák, M; Kohút, A; Machán, V; Nicák, A; Vilcek, S, 1978
)
0.26
" Drug dosage was one 4-mg tablet, of two inhalations of 100 mug of salbutamol aerosol or a combination of both, four times daily."( The efficacy, as modified by the circadian rhythm of salbutamol administered by different routes.
Alanko, K; Lahdensuo, A, 1976
)
0.26
" The dose-response pattern for insulin release (first phase) following two chemically unrelated insulin secretagogues, the potent sulphonyl-urea derivative, glibenclamide, and the beta-adrenegic agonist L-isopropylnoradrenaline, (L-IPNA), was tested with and without vinblastine pretreatment."( Effect of vinblastine in vivo on ultrastructure and insulin releasing capacity of the B-cell following sulphonylurea and isopropyl-noradrenaline.
Ericson, LE; Lundquist, I, 1975
)
0.25
" When keeping the heart rate constant by means of a pace maker, carbocromen even at higher dosage caused a clear-cut improvement."( [The effect of carbocromen on the ST segment of the epicardial electrocardiogram in a model of intermitting myocardial ischemia (author's transl)].
Kunath, B; Nitz, RE; Scholtholt, J; Sirbulescu, R, 1976
)
0.26
" Graded dose-response curves (0."( A depressed response of left ventricular contractile force to isoproterenol and norepinephrine in dogs with congestive heart failure.
Newman, WH, 1977
)
0.5
"1 Dose-response curves for the positive inotropic and chronotropic responses to isoprenaline were obtained in atria from untreated guinea-pigs and those receiving various reserpine pretreatments."( Selective reserpine-induced supersensitivity of the positive inotropic and chronotropic responses to isoprenaline and salbutamol in guinea-pig isolated atria.
Broadley, KJ; Lumley, P, 1977
)
0.26
" Cumulative dose-response curves for the positive inotropic and chronotropic responses of isolated guinea-pig atria to isoprenaline and the partial agonist salbutamol were plotted as a percentage of the maximum response to isoprenaline."( The influence of temperature upon reserpine-induced supersensitivity of guinea-pig isolated atria to isoprenaline and salbutamol.
Broadley, KJ; Duncan, C, 1977
)
0.26
" These complications may necessitate diminishing the dosage of the medications."( Aminophylline and isoproterenol in the treatment of cerebral vasopasm.
Fleischer, AS; Raggio, JF; Tindall, GT, 1977
)
0.59
" Compared with basal anesthesia with pentobarbital, 15 mg/kg, neither morphine nor halothane increased sensitivity to any measured effect of propranolol expressed as the slope of the log dose-response relationship."( Failure of general anesthesia to potentiate propranolol activity.
Bragg, DA; Edmonds, CH; Hibbs, CW; Keats, AS; Slogoff, S, 1977
)
0.26
"5 mg of isoproterenol at 8-hour intervals did not alter the total number of microscopical lesions at the 3 dosage levels of endotoxin."( Isoproterenol, endotoxin shock, and the generalized shwartzman reaction.
Brunson, JG; Collins, AD; Henson, EC; Izard, SR, 1976
)
2.13
" It is concluded that the effect of propranolol on heart rate is a predictable function of free drug concentration in man and that the contribution of individual variation in receptor sensitivity to differences in oral dosage requirement is minor compared to that of variations in bioavailability."( Plasma binding and the affinity of propranolol for a beta receptor in man.
Frisk-Holmberg, M; Hollifield, JW; McDevitt, DG; Shand, DG, 1976
)
0.26
" Gpp(NH)p also shifted agonist dose-response curves for stimulation of adenylate cyclase, but to the left."( Regulation of beta-adrenergic receptors by guanyl-5'-yl imidodiphosphate and other purine nucleotides.
Caron, MG; Lefkowitz, RJ; Mullikin, D, 1976
)
0.26
" At this time DMI treatment of pineal glands taken from intact rats shifted the dose-response curve for epinephrine (EPI) stimulation of N-acetyltransferase activity by two orders of magnitude, but caused only a slight change in the dose-response curve for isoproterenol, which is not taken up into nerve endings."( Sympathetic nerve endings in the pineal gland protect against acute stress-induced increase in N-acetyltransferase (EC 2.3.1.5.) activity.
Klein, DC; Parfitt, AG, 1976
)
0.44
" It can be concluded that echocardiography is a feasible tool in determining changes of left ventricular dynamics during administration of vasoactive drugs, in indicating the individual dosage of a vasoactive drug in each patient and the follow-up the course of the therapeutic success."( [Echocardiographic evaluation of left ventricular function during therapy with cardiovascularly effective drugs].
Stefan, G, 1976
)
0.26
"Inhaled atropine sulfate is a bronchodilator in man, but its efficacy and optimal dosage are still unknown."( Inhaled atropine sulfate: dose response characteristics.
Cavanaugh, MJ; Cooper, DM, 1976
)
0.26
" For all parameters studied the four compounds produced similar maximal responses and dose-response curves were close to parallel."( Comparison of the effects of (--)-isoprenaline, orciprenaline terbutaline, and Me506 on heart rate, soleus muscle contractility and pulmonary resistance of anaesthetized cats.
Malta, E; Raper, C,
)
0.13
"05) between estrous and ovulatory ligaments either in terms of the dose-response curves or maximal force of contraction."( In vitro response of rabbit utero-ovarian ligament to catecholamines.
Azzam, ME; Fredericks, CM; Hafez, ES, 1976
)
0.26
"Changes in bath temperature caused changes in the adrenergic responsiveness of rabbit iris dilator muscle as indicated by shifts in dose-response curves along the log axis and changes in maximum responses."( Role of neuronal and extraneuronal factors in temperature mediated responsiveness of adrenoceptors.
Ahlquist, RP; Matheny, JL, 1976
)
0.26
" Neither can the observed biological activity be attributed to 6-aminoisoproterenol, since this compound's dose-response is shifted 3 orders of magnitude to the right of l-isoproterenol and 1-2 orders of magnitude to the right of the polymeric derivatives."( Biological activity of catecholamines covalently linked to synthetic polymers: proof of immobilized drug theory.
Goodman, M; Kaplan, NO; Saks, B; Venter, JC; Verlander, MS, 1976
)
0.49
" After the strips had been contracted by 3x10-6M phenylephrine, a concentration which was able to produce an about 90% maximal contraction, dose-response curves to the relaxant effect of isoprenaline were determined in the absence and in the presence of U-0521 (10-4M)."( Relation between the amount of smooth muscle of venous tissue and the degree of supersensitivity to isoprenaline caused by inhibition of catechol-O-methyl transferase.
Azevedo, I; Cardoso, W; Guimarães, S; Oliveira, MC, 1975
)
0.25
" Dose-response curves to intravenous infusions of isoproterenol were obtained after three doses of each beta-antagonist."( Comparison of cardiac effects of timolol and propranolol.
Achong, MR; Ogilvie, RI; Piafsky, KM, 1975
)
0.51
" In this dosage it was found that the peak effect of the two drugs was the same but that the effect of rimiterol was less prolonged than that of sulbutamol."( Comparison between the bronchodilator and cardiovascular effects of inhaling 0.5 mg. rimiterol ('Pulmadil') and 0.2 mg. salbutamol.
Bianco, S; Kamburoff, PL; Prime, FJ, 1975
)
0.25
" The dose-response curve for phenylephrine was markedly shifted to the right by raising the temperature (pD2=0."( Influence of temperature on the positive inotropic effects mediated by alpha-and-beta-adrenoceptors in the isolated rabbit papillary muscle.
Endoh, M; Schümann, HJ; Wagner, J, 1975
)
0.25
" The effects of phenylephrine and isoprenaline on the isometric contraction of guinea-pig ventricle were compared over the whole range of their respective dose-response curves."( Studies on the positive inotropic effect of phenylephrine: a comparison with isoprenaline.
Ledda, F; Marchetti, P; Mugelli, A, 1975
)
0.25
" 3-0-methyl isoprenaline (10 muM) shifted the isoprenaline dose-response curve to the right, but did not affect the inotropic responses to CaCl2, confirming that 3-0-methyl isoprenaline possess beta-adrenoceptor antagonist activity."( Effects of blockade of extraneuronal uptake on responses to isoprenaline in perfused rat heart.
Jarrott, B; Picken, GM,
)
0.13
" The close temporal relation of isoproterenol overdosage with mycardial necrosis provides presumptive evidence that the well-documented association of myocardial necrosis with high dosage catecholamines in animals may also occur in man."( An electrocardiographic pattern of acute myocardial infarction associated with excessive use of aerosolized isoproterenol.
Aelony, Y; Beall, G; Laks, MM, 1975
)
0.75
" In contrast, dose-response data from fasted rabbits have shown that EPI is more potent than ISO in increasing plasma glucose levels and in lowering hepatic glycogen levels."( The influence of propranolol on catecholamine-induced changes in carbohydrate metabolism in the rabbit.
Ellis, S; Moratinos, J; Potter, DE,
)
0.13
" At the peak of the dose-response curve, glucagon increased right ventricular isovolumic pressure 25% (39."( The positive inotropic effect of glucagon in the chronically failed right ventricle as demonstrated in the isolated cat heart.
Lucchesi, BR; Nobel-Allen, NL; Winokur, S,
)
0.13
" The dose-response curves obtained during infusions of beta-adrenergic-stimulating drugs are linearly related to the dose given and are highly reproducible."( Evaluation of skeletal muscle tremor due to bronchodilator agents.
Svedmyr, N; Thiringer, G, 1975
)
0.25
" Dose-response curves of isoproterenol were shifted significantly to the left by 2 x 10(-5) M aminophylline."( Comparison of the relaxing effect of dopamine with that of adenosine, isoproterenol and acetylcholine in isolated canine coronary arteries.
Hojo, M; Sakae, K; Toda, N; Usui, H, 1975
)
0.79
" In the present study, log dose-response lines were obtained for dl-isoprenaline (ISO), l-adrenaline (ADR) l-noradrenaline (NOR), salbutamol (SALB), and orciprenaline on isolated tracheal chains prepared from both the laryngeal (L) and bronchial (B) ends of the trachea."( The effect of cocaine on the responses of the differently innervated laryngeal and bronchial ends of the guinea pig trachea in vitro to clinically used bronchodilators.
Hamilton, JT; Jones, TR; Lefcoe, NM, 1975
)
0.25
" The results provide a basis for further studies to establish a dosage schedule suitable for prolonged therapy."( Plasma level and broncholytic effect of choline theophyllinate after a single dose of a press-coated tablet formulation.
Bülow, KB; Larsson, H; Leideman, T, 1975
)
0.25
" The dose-response curve of TM was parallel to that of nitroglycerin and papaverine and steeper than that of dipyridamol or adenosine."( [Pharmacology of cornary dilator agent, trapymin. (2) Analysis of its mode of action].
Ogawa, N; Ohnishi, H; Tsukuda, S; Yamaguchi, K, 1975
)
0.25
" Intraventricular injection of phenylephrine produced a dose-dependent hypothermia, whereas no dose-response relationship was obtained by isoproterenol."( [Role of brain biogenic amines in the central thermoregulatory mechanism of the rat (author's transl)].
Fukushima, N, 1975
)
0.46
"Complete in vitro dose-response curves for (see article) -isoproterenol (isoprenaline) sulfate showed no functional defects in bronchial muscular beta-adrenergic receptors in three patients with chronic intrinsic asthma, as compared to 60 patients with normal pulmonary function."( Development of "resistance" in beta-adrenergic receptors of asthmatic patients.
Larsson, SA; Svedmyr, NL; Thiringer, GK, 1976
)
0.5
" Significant dose-response curves to isoproterenol could not be obtained in single animals because of the time-dependent lowering of the inhibitory effect of the drug."( Nature of the inhibition by amiodarone of isoproterenol-induced tachycardia in the dog.
Bauthier, J; Broekhuysen, J; Charlier, R; Richard, J, 1976
)
0.79
" In aging, the overall effect of standard phenylephrine dosage has been found to decrease."( [Hemodynamic effects of stimulation of alpha 1-adrenoreceptors in healthy elderly and aged persons].
Korkuschko, OW; Mistrjukow, WM; Moros, GS; Sarkisow, KG; Schatilo, WB; Tarasenko, OB,
)
0.13
" The pA2 values of the beta adrenergic antagonists propranolol, metoprolol and atenolol were calculated from the rightward shifts that they impose on dose-response curves of both l-isoproterenol and CGP12177."( Multiple beta adrenergic receptor subclasses mediate the l-isoproterenol-induced lipolytic response in rat adipocytes.
Van Liefde, I; Van Witzenburg, A; Vauquelin, G, 1992
)
0.72
" However, the isoproterenol dose-response curves for the beta 2AR were shifted to the left, compared with those for the beta 1AR (EC50 of 52."( Beta 1- and beta 2-adrenergic receptors display subtype-selective coupling to Gs.
Green, SA; Holt, BD; Liggett, SB, 1992
)
0.64
" Isoproterenol dose-response curves were generated in isolated perfused hearts from sham-burned and burned guinea pigs."( Burn-induced alterations in cardiac beta-adrenergic receptors.
Horton, JW; Kaufman, TM, 1992
)
1.19
" Epinephrine dose-response curves were analyzed for the threshold and slope for changes in mean blood pressure, systolic blood pressure, and heart rate versus plasma epinephrine levels."( Prolonged beta-agonist infusion does not induce desensitization or down-regulation of beta-adrenergic receptors in newborn sheep.
Chappell, BA; Oyama, K; Padbury, JF; Sapien, R; Stein, HM, 1992
)
0.28
" Moreover, these agonists caused a shift of the dose-response curve for phenylephrine to the right in a parallel fashion in non-preconstricted preparations."( Vascular alpha-1 antagonistic and agonistic effects of beta adrenoceptor agonists in rabbit common carotid arteries.
Chiba, S; Fujiwara, T, 1992
)
0.28
" After the administration of carvedilol on day 8, the cirazoline vasopressor response was 2 +/- 1 mmHg and the isoproterenol-induced tachycardia was 4 +/- 3 beats/min, indicating effective alpha 1- and beta-adrenergic blockade after chronic dosing with carvedilol."( Single and repeated doses of the vasodilator/beta-adrenergic antagonist, carvedilol, block cirazoline- and isoproterenol-mediated hemodynamic responses in the conscious rat.
Gagnon, R; Slivjak, MJ; Smith, EF, 1992
)
0.71
"025), and resulted in decreases in % success at each of two energy levels, falling in the midrange of the dose-response curve."( Isoproterenol increases defibrillation energy requirements in dogs.
Dorian, P; Ogilvie, RI; Wang, M, 1992
)
1.73
" After constructing a dose-response curve to either the beta-agonist isoproterenol or to PGE1 in a phenylephrine preconstricted vein, isoproterenol (271 ng/min), PGE1 (956 pg/min), or saline was infused for 4 h in separate experiments."( Desensitization of beta-adrenoceptor- and prostaglandin E1 receptor-mediated human vascular smooth muscle relaxation.
Blaschke, TF; Hoffman, BB; Vincent, J, 1992
)
0.52
" In the absence of other secretagogues, VIP produced a modest, sustained saliva flow with a biphasic dose-response curve in which saliva volume was greatest at 1 nM VIP (28."( Regulation of secretion by vasoactive intestinal peptide in isolated perfused rat submandibular glands.
Camden, JM; Turner, JT, 1992
)
0.28
" At the end of the treatment period the hearts were perfused as described by Langendorff, and a cumulative dose-response curve of isoprenaline was obtained in each heart."( Captopril modifies the response of infarcted rat hearts to isoprenaline stimulation.
Bartels, H; de Graeff, PA; de Langen, CD; Monnink, SH; van Gilst, WH; van Wijngaarden, J; Wesseling, H, 1992
)
0.28
" Compound MV 8612 (8 and 16 microM) and MV 8610 (12 and 24 microM) caused a graded rightward displacement of BK dose-response curves in the isolated guinea pig trachea (dose ratio 2- to 4-fold)."( Effect of compounds from Mandevilla velutina on bradykinin-mediated contractile and relaxant responses of the isolated guinea pig trachea.
Calixto, JB; Cruz, AB; Medeiros, YS; Yunes, RA, 1992
)
0.28
" isoproterenol tachycardia dose-response curves by dose ratios of 5, 18, and 90 in sham rabbits, respectively, and 5, 11, and 23 in wrap rabbits, respectively, indicating significant cardiac beta 1-adrenoceptor antagonism."( Relationship between the sympatholytic action of nebivolol and hypotension.
Angus, JA; Coles, P; Cox, H; Eisenhofer, G; Ward, JE, 1992
)
1.19
" Solutions of epinephrine and phenylephrine were infused into the vasculature of pithed tadpoles, and the resulting changes in vascular resistance (Rv) were used to construct log dose-response relationships."( Adrenergic receptors and the regulation of vascular resistance in bullfrog tadpoles (Rana catesbeiana).
Kimmel, PB, 1992
)
0.28
" There were no significant differences between ET and SED cardiac preparations in either the efficacy (maximal response) or potency (EC50) of isoproterenol dose-response relationships for chronotropic or inotropic responses."( Adrenergic responsiveness and intrinsic sinoatrial automaticity of exercise-trained rats.
Adams, HR; Allert, JA; Laughlin, MH; Schaefer, ME, 1992
)
0.48
" Dose-response curves of AV nodal conduction time (expressed as percent increase in AH interval) were studied during the control state and during isoproterenol infusion."( Negative dromotropism of adenosine under beta-adrenergic stimulation with isoproterenol.
Lai, WT; Sung, RJ; Wu, SN, 1992
)
0.71
"0 micrograms) were injected into the functionally isolated hindlimb, and dose-response curves were generated."( Reduced vascular responsiveness after a single bout of dynamic exercise in the conscious rabbit.
DiCarlo, SE; Howard, MG, 1992
)
0.28
" Dose-response curves for bradykinin were constructed using the dorsal hand vein compliance technique in veins preconstricted with phenylephrine in 27 volunteers (16 male, 11 female) aged 18 to 81 years."( Bradykinin-induced venodilation is not impaired with aging in humans.
Blaschke, TF; Dachman, WD; Ford, GA; Hoffman, BB, 1992
)
0.28
" The inhibitory dose-response curve of NPY on isoproterenol-stimulated adenylate cyclase activity was shifted parallel to the right by NPY(17-36) (1 microM), suggesting that it is an antagonist of NPY at high concentrations."( Inhibitory and stimulatory effects of neuropeptide Y(17-36) on rat cardiac adenylate cyclase activity. Structure-function studies.
Balasubramaniam, A; Sheriff, S, 1992
)
0.54
" CVP and PCWP were depressed at both dosage levels."( [Effects of dobutamine and isoproterenol on systemic hemodynamics and myocardial metabolism in children after open heart surgery].
Anzai, T; Hamada, Y; Iijima, T; Ishikawa, S; Kodama, H; Obayashi, T; Otaki, A; Sakata, Y; Yanagisawa, H; Yoshida, I, 1992
)
0.58
" In tissues precontracted with methacholine, 11-([[2-(diethylamino)methyl]-1-piperidinyl]acetyl)5,11- dihydro-6H-pyrido[2,3-6][1,4]benzodiazepine-6-one (AF-DX 116), a selective M2 antagonist, shifted dose-response curves to both isoproterenol and forskolin significantly to the left."( M2 muscarinic receptors inhibit isoproterenol-induced relaxation of canine airway smooth muscle.
Fernandes, LB; Fryer, AD; Hirshman, CA, 1992
)
0.75
" Neither adrenergic dose-response studies, adrenergic antagonist studies nor experiments in which alpha- and beta-agonists were added together provided any evidence for a positive alpha/beta synergism on either MEL release or cAMP accumulation by bovine pinealocytes."( Bovine pinealocytes in monolayer culture: studies on the adrenergic regulation of melatonin secretion.
Olcese, J; Rüppel, R, 1991
)
0.28
" Isoproterenol-stimulated dose-response activation of adenylate cyclase was unchanged between 3 and 12 months but decreased at 24 months (p less than ."( Beta-adrenergic signal transduction in aging parotid and submandibular salivary glands.
Rajakumar, G; Scarpace, PJ, 1991
)
1.19
" In contrast, the dose-response curve for T-wave amplitude was best described by a quadratic function: an initial reduction in T-wave amplitude at low levels of isoproterenol infusion was followed by a significant reversal of this effect at higher doses."( Effects of isoproterenol on T-wave amplitude and heart rate: a dose-response study.
Contrada, RJ; Dimsdale, J; Levy, L; Weiss, T, 1991
)
0.87
" The behavior as antagonists of both [4-Cl-D-Phe6,Leu17]VIP and [Ac-Tyr1,D-Phe2]GRF1-29-NH2 was confirmed by: (a) the parallel shifts of the VIP dose-response curves for stimulation of adenylate cyclase activity in the presence of the antagonists; (b) the close agreement between the binding affinity and the inhibition of adenylate cyclase activity for the two peptides; and (c) the lack of effect of the two antagonists upon the adenylate cyclase activity stimulated by the beta-adrenoceptor agonist isoproterenol which indicates the specificity of the interaction."( Vasoactive intestinal peptide receptor antagonists in rat seminal vesicle membranes.
Guijarro, LG; Prieto, JC; Rodríguez-Pena, MS, 1991
)
0.44
" For each drug dose-response curves could be constituted in single hippocampal tissues at each of the time points of sacrifice."( Dose-dependent stimulation of adenylate cyclase in rat hippocampal tissue by isoprenaline, Gpp(NH)p and forskolin: lack of circadian phase-dependency.
Carlebach, R; Lemmer, B; Nitsch, R; Ohm, TG; Stiller, M, 1991
)
0.28
"Determination of the alpha-adrenergic blocking potency of drugs in humans is usually done by measuring the shift in the blood pressure versus logarithm of intravenous phenylephrine dose-response relationship."( Determination of alpha-adrenergic blocking potency.
Brodie, CL; Jamieson, MJ; Kwan, CM; Shepherd, AM, 1991
)
0.28
" Furthermore, the dose-response relation to isoproterenol was similar in both groups."( Limb vascular responsiveness to beta-adrenergic receptor stimulation in patients with congestive heart failure.
Colucci, WS; Creager, MA; Quigg, RJ; Ren, CJ; Roddy, MA, 1991
)
0.54
" beta-Blockade was evaluated by displacement of the bronchodilator (specific airway conductance), positive chronotropic (heart rate), and tremorogenic (finger tremor amplitude) dose-response curve for inhaled isoproterenol."( Assessment of systemic effects of different ophthalmic beta-blockers in healthy volunteers.
Bauer, K; Binkowitz, B; Brunner-Ferber, F; Distlerath, LM; Kaik, G; Lippa, EA; Till, P, 1991
)
0.47
" Dose-response curves were constructed, and doses of isoprenaline required to increase finger tremor by 100% (IT100), heart rate by 25 beats/min (IH25), SBP by 25 mmHg (IS25), cardiac output by 35% (IC35), and decrease DBP by 10 mmHg (ID10), after each treatment were calculated."( A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol.
Irvine, NA; Lipworth, BJ; McDevitt, DG, 1991
)
0.28
" Consequently, isoproterenol shifted the dose-response curve for GTP[S] to the left (10-fold) and increased the maximal response."( Beta-adrenergic receptor-mediated phospholipase C activation independent of cAMP formation in turkey erythrocyte membranes.
Hager, R; Rooney, TA; Thomas, AP, 1991
)
0.63
" Dose-response curves showed that in foetal rat hepatocytes glucose release was already increased by 10(-8) M isoproterenol, whereas in female rat hepatocytes at least 10(-6) M isoproterenol was required."( Differences in the accessibility of the beta-adrenergic receptor in isolated hepatocytes from foetal and adult rats.
Dettmer, D; Hermsdorf, T; Hofmann, E, 1991
)
0.49
" This reduced response was due to a decrease in the maximal relaxation induced by isoprenaline rather than by a shift to the right of its dose-response curve."( Evidence for a decrease in sympathetic control of intestinal function in the aged rat.
Baker, DM; Santer, RM; Watson, SP,
)
0.13
"The electrical and contractile activity of isolated intracellularly stimulated ventricular myocytes has been recorded and dose-response curves to [Ca2+]o, and to beta adrenergic, alpha adrenergic, and muscarinic agonists and antagonists were examined."( Neurohumoral regulation of excitation-contraction coupling in ventricular myocytes from cardiomyopathic hamsters.
Beresewicz, A; Horackova, M; Rowden, G; Wilkinson, M, 1991
)
0.28
" The dose-response curves of medetomidine and its analogs showed that the ranked order of intrinsic activity at lowering IOP was medetomidine greater than or equal to MPV-1440 greater than detomidine greater than MPV-1441 and MPV-305 BII."( Ocular hypotensive effects of medetomidine and its analogs.
Elko, EE; Jin, Y; Wilson, S; Yorio, T, 1991
)
0.28
" Prostaglandins E1 or E2, vasoactive intestinal peptide, carbachol, phenylephrine, or platelet-activating factor did not affect either the maximal cAMP response or the isoproterenol dose-response relationship."( Beta-adrenergic receptors on human tracheal epithelial cells in primary culture.
Davis, PB; Infeld, M; Kercsmar, CM; Silski, CL, 1990
)
0.47
" Flestolol shifted the dose-response curves of isoprenaline-induced changes in heart rate, positive left ventricular dp/dtmax, and diastolic arterial pressure dose dependently to the right, while its main effect during exercise was a decrease in positive left ventricular dP/dtmax."( Effects of flestolol, an ultra-short acting beta-adrenoceptor antagonist, on hemodynamic changes produced by treadmill exercise or isoprenaline stimulation in conscious dogs.
Fischer, G; Grohs, JG; Raberger, G, 1990
)
0.28
" Genomic Southern blot and gene dosage analyses indicate that the rat beta 1-AR gene is a single copy gene."( Molecular cloning and expression of the rat beta 1-adrenergic receptor gene.
Bunzow, JR; Civelli, O; Machida, CA; Neve, KA; Nipper, V; Searles, RP; Teal, P; Tester, B; Van Tol, H, 1990
)
0.28
" Isoproterenol dose-response curves performed in trachea preparations, were shifted to the right by about fivefold as compared with the control group."( Modulation of adrenoceptor-mediated cardiovascular effects by short-term in vivo infusion of isoproterenol in rats.
Porsius, AJ; van Rooij, HH; Vleeming, W; Wemer, J, 1990
)
1.41
" Sixty percent D2O also depressed a calcium contraction dose-response curve by approximately 25%."( Deuterium oxide reduces agonist and depolarization-induced contraction of rat aortic rings.
Liepins, A; McWilliam, TM; Rankin, AJ, 1990
)
0.28
" The non-selective phosphodiesterase inhibitor isobutylmethylxanthine (IBMX) (1 mM) resulted in a more severe suppression of the histamine and pilocarpine responses and also produced a significant suppression of the maximal response to oxotremorine and a small shift in the carbachol dose-response curve."( Beta-adrenoceptor induced inhibition of muscarinic receptor-stimulated phosphoinositide metabolism is agonist specific in bovine tracheal smooth muscle.
Chilvers, ER; Nahorski, SR; Offer, GJ, 1991
)
0.28
" Under essentially identical conditions, the dose-response curve for IPR stimulation of AC activity in the absence of 3-isobutyl-1-methylxanthine was similar in trained and control rats."( Enhanced coupling of adenylate cyclase to lipolysis in permeabilized adipocytes from trained rats.
Izawa, T; Komabayashi, T; Mochizuki, T; Suda, K; Tsuboi, M, 1991
)
0.28
" Cyclic AMP-dependent kinase shifted the dose-response curve for inositol 1,4,5-trisphosphate-mediated Ca2+ release to the left by a factor of 4 and increased the total amount of Ca2+ released by 25%."( The mechanism for synergism between phospholipase C- and adenylylcyclase-linked hormones in liver. Cyclic AMP-dependent kinase augments inositol trisphosphate-mediated Ca2+ mobilization without increasing the cellular levels of inositol polyphosphates.
Bird, GS; Burgess, GM; Obie, JF; Putney, JW, 1991
)
0.28
" To ascertain whether test dosing with other agents might be more useful, we sought to determine if and at what dose levels three different intravenous drugs (adrenaline, isoprenaline and 1% lignocaine with 1/200,000 adrenaline) produced an increase in heart rate (HR) in halothane-anaesthetized lambs."( Efficacy of adrenaline, lignocaine-adrenaline and isoprenaline as a test dose in halothane-anaesthetized lambs.
Berde, CB; Desparmet, JF; Hershenson, MB; Lunn, RJ; Schwartz, DC, 1991
)
0.28
" The alpha-adrenoceptor-mediated contractile responses of the nictitating membrane to intravenous adrenaline were greater on the decentralized side than the control side, with a significant shift of the dose-response curve to the left."( Evidence from lack of decentralization-induced supersensitivity that beta 2-adrenoceptors of the cat nictitating membrane are non-innervated.
Broadley, KJ, 1990
)
0.28
" This dosage regimen of dexamethasone also suppressed renal cyclic AMP responses to isoproterenol, but exposure to a lower dose (0."( Dose-dependent effect of prenatal dexamethasone treatment on beta-adrenergic receptor coupling to ornithine decarboxylase and cyclic AMP.
Bartolome, J; Bartolome, M; Bian, XP; Kavlock, RJ; Seidler, FJ; Slotkin, TA, 1990
)
0.5
" Cumulative dose-response curves constructed for the effect of these amines during diestrous, and at days 3-7, 10-15, 17-21 of gestation, showed that EC50 values increased gradually as term approached, which could imply a lower capacity of the uterus to respond to adrenergic drugs."( Changes in the response to adrenergic drugs on mouse uterine contractions during pregnancy.
Cruz, MA; Rudolph, MI; Sepúlveda, WH, 1990
)
0.28
" IC50s determined from dose-response curves of inhibition are consistent with the known abilities of these ligands to modulate cyclic AMP and physiological responses in other tissues."( Neuropeptide Y and somatostatin inhibit stimulated cyclic AMP production in rabbit ciliary processes.
Bausher, LP; Horio, B, 1990
)
0.28
" However, propranolol significantly shifted the methacholine dose-response curve to the left so that methacholine (0."( Pulmonary reactivity to methacholine during beta-adrenergic blockade: propranolol versus esmolol.
Hirshman, CA; Sauder, RA; Tobias, JD, 1990
)
0.28
" The dose-response curves for these agonists were shifted slightly to the right when the amplitude of the twitch was increased up to twice its original size."( Dissociation constants and relative efficacies estimated from the functional antagonism of beta-adrenoceptor agonists on transmural stimulation in rat vas deferens.
Diaz-Toledo, A; Jurkiewicz, A, 1990
)
0.28
" AC dose-response curves were obtained by incubating membrane fractions with different concentrations of isoproterenol and BRL37344 (1 nM-100 microM) at 25 degrees C for 15 min."( [Adenylate cyclase response to beta-adrenergic agonists in heart and brown adipose tissue].
Cignarelli, M; De Pergola, G; Garruti, G; Giorgino, R; Stock, M,
)
0.35
" DSPM at higher dosage also lowered the normal myocardial Ca2+ content."( [Protective effect of 2-[p-(dimethylamino) styryl] pyridine methiodide (DSPM) on acute experimental myocardial ischemia].
Wang, XF; Wang, XW; Wei, Y; Zhang, KJ; Zhou, CM, 1990
)
0.28
" Xamoterol did not produce a noteworthy decrease in heart rate or positive dp/dtmax during exercise, even at a dosage of 1 mg/kg."( Haemodynamic and metabolic effects of xamoterol in exercising dogs.
Ehrendorfer, S; Fischer, G; Grohs, JG; Raberger, G; Schneider, W, 1990
)
0.28
" In addition, the similarity of the dose-response curves for the bradykinin-mediated increase in Ca2+, PGE2, and cAMP (half-maximal stimulation of 12, 11, and 13 nM, respectively) and the ability of the B2-antagonist (B4307) to block each of these effects of bradykinin suggest that all three effects are mediated by the same bradykinin (B2) receptor."( Effects of kinins on cultured arterial smooth muscle.
Breckon, R; Dixon, BS; Fortune, J; Linas, SL; Marzec-Calvert, R; Stewart, JM; Vavrek, RJ, 1990
)
0.28
" The slope of the dopamine dose-response curve was, however, similar to that of the dose-response curve of clonidine."( Inhibitory effects of clonidine and dopamine on adenylate cyclase of rabbit ciliary processes.
Cepelík, J; Hynie, S, 1990
)
0.28
" Porcine and human NPY and porcine PYY gave similar dose-response curves."( Characterization of functional neuropeptide Y receptors in a human neuroblastoma cell line.
Fishman, PH; Gordon, EA; Kohout, TA, 1990
)
0.28
" SK&F S-106203 produced dose-dependent rightward shifts in the LTC4 and LTE4 dose-response curves."( SK&F S-106203 inhibits leukotriene C4, leukotriene D4 and leukotriene E4 vasopressor responses in the conscious rat.
Eckardt, RD; Egan, JW; Newton, JF; Slivjak, MJ; Smith, EF, 1990
)
0.28
" Consistent with this observation, the presence of NPY (18-36) (1 microM) shifted the inhibitory adenylate cyclase activity dose-response curve of NPY to the right in a parallel fashion."( Neuropeptide Y (18-36) is a competitive antagonist of neuropeptide Y in rat cardiac ventricular membranes.
Balasubramaniam, A; Sheriff, S, 1990
)
0.28
" This study examines the dose-response effects of isoprenaline, a non-selective beta-adrenoceptor agonist, on mean circulatory filling pressure (MCFP), an index of body venous tone, in conscious and unrestrained rats."( Differential venous effects of isoprenaline in conscious rats.
Abdelrahman, A; Pang, CC, 1990
)
0.28
"min-1) in pretreated groups was performed 7 d after digoxin dosing was stopped, when plasma digoxin concentrations were zero."( Increased sensitivity to isoprenaline following digoxin pretreatment in anaesthetised and conscious dogs.
Einstein, R; Gray, P; Hunyor, SN; Jones, MP; Mihailidou, AS; Richardson, DP, 1990
)
0.28
" Dose-response curves for negative chronotropic action of adenosine in the sinus node and ventricular pacemakers were obtained in group 1 under base-line conditions, during isoproterenol infusion, and after subsequent administration of propranolol; in group 2 before and after administration of quinidine; in group 3 before and after administration of aminophylline; and in group 4 before and after administration of 1,3-dipropyl-8-phenylxanthine amine congener (XAC)."( Differential sensitivity of cardiac pacemakers to exogenous adenosine in vivo.
Dreifus, LS; Hurt, C; Michelson, EL; Miyagawa, A; Pelleg, A, 1990
)
0.47
" Infusion of PGI2 at a dosage of 100 ng/kg/min caused a decrease in arterial blood pressure and an increase in heart rate, but had no effect on regional myocardial function."( Transient drug-induced myocardial dysfunction is not ameliorated by PGI2 in dogs.
Fitscha, P; Krumpl, G; Raberger, G; Seitelberger, R; Sinzinger, H; Winkler, M,
)
0.13
" Unlike Org 6001, quinidine failed to produce a shift in calcium log dose-response curves in driven depolarized preparations and induced positive inotropy in the presence of functional sodium channels."( Effects of selective channel blocking agents on contractions and action potentials in K+-depolarized guinea-pig atria.
Brown, J; Marshall, RJ; Winslow, E, 1985
)
0.27
" Dose-response curves were constructed both for the autonomic agonists and the histamine-releasing agents."( Characterization of purified dog mastocytoma cells. Autonomic membrane receptors and pharmacologic modulation of histamine release.
Barnes, PJ; Gold, WM; Phillips, MJ, 1985
)
0.27
" A dose-response study showed that FSH pretreatment produced three separate effects on Sertoli cell steroidogenesis: an increased basal production of estrogen; a decreased maximal response when doses of 10 ng/ml FSH or higher were employed in the preincubation; and a decreased sensitivity of the Sertoli cell to FSH."( Effect of phosphodiesterase inhibitors on Sertoli cell refractoriness: reversal of the impaired androgen aromatization.
Conti, M; Geremia, R; Monaco, L; Stefanini, M, 1986
)
0.27
" According to the dose-response curves for isoproterenol and tyramine, left ventricular dP/dtmax was significantly depressed in infarcted hearts, whereas the dose-response curve for the inotropic effect of phenylephrine was markedly enhanced."( Defibrotide, an antithrombotic substance that preserves postsynaptic alpha- and beta-adrenergic function in post acute infarcted rabbit hearts.
Berti, F; Folco, G; Niada, R; Omini, C; Rossoni, G; Tondo, C,
)
0.39
") shifted the dopamine dose-response curve to the right in a parallel fashion, indicating competitive antagonism."( Characterization of vascular dopamine receptors in the gastric circulation of the rabbit.
Kullmann, R; Reinsberg, J,
)
0.13
" Neither xanthine shifted the calcium dose-response when PMNs were activated with calcium ionophore."( Therapeutic concentrations of theophylline and enprofylline potentiate catecholamine effects and inhibit leukocyte activation.
Crowley, JJ; Cusack, BJ; Nielson, CP; Vestal, RE, 1986
)
0.27
" In dose-response curves, the isoproterenol-sensitive K+ efflux was half-maximally inhibited (IC50) with 2-5 X 10(-10) M of isoproterenol concentration."( Stimulation of beta-adrenoceptors inhibits calcium-dependent potassium-channels in mouse macrophages.
Braquet, P; Dausse, JP; Garay, R; Hannaert, P; Rosati, C, 1986
)
0.56
" Dose-response curves were constructed and the doses of isoprenaline required to increase heart rate by 25 beats/min (I25), forearm blood flow by 3 ml/100 ml/min (IF3), and finger tremor by 200% (IT200), and decrease diastolic blood pressure by 25 mm Hg (ID25), after each treatment were compared."( A comparison of the cardioselectivity of five beta-adrenoceptor blocking drugs.
Pringle, TH; Riddell, JG; Shanks, RG, 1987
)
0.27
" 3 The dose-response curves to isoprenaline (an endothelium-independent vasodilator) were also markedly altered by the presence of atherosclerotic lesions, while aging and the presence of cardiac failure did not alter the maximal relaxation."( The influence of atherosclerosis on the mechanical responses of human isolated coronary arteries to substance P, isoprenaline and noradrenaline.
Berkenboom, G; Depierreux, M; Fontaine, J, 1987
)
0.27
" Isoprenaline potency was increased by the sheep fat-supplemented diet, which induced significant three- to eightfold leftward parallel shifts of isoprenaline dose-response curves for papillary muscle and left atrial inotropy and right atrial chronotropy."( Dietary lipid modulation of myocardial beta-adrenergic mechanisms, Ca2+-dependent automaticity, and arrhythmogenesis in the marmoset.
Abeywardena, MY; Charnock, JS; McLennan, PL; McMurchie, EJ, 1987
)
0.27
" Addition of 10(-8) M SP caused a shift to the left in the secretion dose-response curve caused by ISO, but did not enhance ISO-induced maximal response."( [3H]protein secretion in rat parotid gland: substance P-beta-adrenergic synergism.
Dreux, C; Imhoff, V; Rossignol, B, 1987
)
0.27
" Higher concentrations of these antagonists shifted the Ca2+ dose-response curve to the right."( Adrenergic-cholinergic interactions in left atria. II. Comparison of the antagonism of inotropic responses to alpha- and beta-adrenoceptor stimulation and BAY K 8644 by carbachol, D-600, and nifedipine.
MacLeod, KM, 1987
)
0.27
" Synergistic responses were observed with combinations of any two of the three secretagogues such that subthreshold doses of one caused a pronounced shift in the dose-response curve to the second."( Synergistic interactions between forskolin, isoprenaline and substance P as secretagogues in rat parotid glands.
Cowburn, R; Cripps, HE; Iversen, LL; Poat, JA, 1987
)
0.27
" Dexamethasone administration led to a sigmoidal dose-response curve in the case of alpha 2-APG whereas a biphasic sinusoidal-like dose-response curve was obtained for CRP."( Modulation of rat C-reactive protein serum level by dexamethasone and adrenaline--comparison with the response of alpha 2-acute phase globulin.
Bürger, W; Göhler, K; Hirschelmann, R; Schade, R, 1987
)
0.27
" Mean arterial pressure (MAP) began to fall 2-3 h after dosing in parallel with a decrease in SVR."( Acute and long-term effects of acebutolol on systemic and renal hemodynamics, body fluid volumes, catecholamines, active renin, aldosterone, and lymphocyte beta-adrenoceptor density.
Boomsma, F; Derkx, FH; Fischberg, DJ; Man in 't Veld, AJ; Molinoff, PB; Schalekamp, MA; van den Meiracker, AH; van Eck, HJ, 1988
)
0.27
" In conscious instrumented normotensive rats and dogs, intravenous and oral administration of BW A575C causes a dose-dependent rightward displacement of the pressor dose-response curve to angiotensin I (dose ratio of 29."( BW A575C: pharmacological profile in vivo of a novel angiotensin converting enzyme inhibitor and beta-blocker.
Allan, G; Cambridge, D; Follenfant, MJ; Ford, A; Hardy, GW; Oliver, PL, 1987
)
0.27
" MIX at 100 microM potentiated the effects of submaximal doses of isoproterenol and shifted the dose-response curve for cAMP to the left but did not affect the dose-response curve for 8-bromo-cAMP."( Role of phosphodiesterase in regulation of calcium current in isolated cardiac myocytes.
Hartzell, HC; Simmons, MA, 1988
)
0.51
" However, the inhibitory dose-response curves of adenylate cyclase to R-PIA, nicotinic acid, GTP, guanylylimidodiphosphate, and guanosine 5'-O-(3-thiotriphosphate) were unaltered by adrenalectomy, indicating that the inhibitory function of Gi is unimpaired by adrenalectomy."( Role of adenosine 3',5'-monophosphate and the Ri-receptor Gi-coupled adenylate cyclase inhibitory pathway in the mechanism whereby adrenalectomy increases the adenosine antilipolytic effect in rat fat cells.
de Mazancourt, P; Giot, J; Giudicelli, Y; Lacasa, D, 1989
)
0.28
" Whereas isoprenaline exerted equipotent effects on amylase secretion and [Ca2+]i, the dose-response relationship for stimulation of secretion by substance P was dissociated by three orders of magnitude to the right of that for elevation of [Ca2+]i by this peptide."( The relationship of intracellular free calcium activity to amylase secretion in substance P- and isoprenaline-stimulated rat parotid acini.
Arkle, S; Michalek, R; Templeton, D, 1989
)
0.28
" In contrast, isoproterenol shifted the entire dose-response curve for nifedipine to the right."( Interaction between isoproterenol and dihydropyridines in heart cells.
Briand, V; Laurent, S; Schmitt, H, 1989
)
0.96
" Dose-response experiments revealed that insulin stimulated D-glucose transport and 2-deoxyglucose uptake between 10(-11) and 10(-7) M with a maximal four- to sixfold stimulation."( Stimulation of glucose transport by insulin and norepinephrine in isolated rat brown adipocytes.
Bukowiecki, LJ; Marette, A, 1989
)
0.28
" Myocardial fibrosis, on the other hand, appears to be more closely related to myocyte necrosis with respect to collagen accumulation in the same areas of the heart, its dose-response relation to the amount of isoproterenol administered, and the timing of increased DNA synthesis, or fibroblast proliferation, after myocyte loss."( Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis.
Benjamin, IJ; Cho, K; Clark, WA; Jalil, JE; Tan, LB; Weber, KT, 1989
)
1.91
" Dose-response curves to carbachol and 5-HT showed that lithium treatment reduced the maximal agonist response without altering the EC50 value."( Subacute and chronic in vivo lithium treatment inhibits agonist- and sodium fluoride-stimulated inositol phosphate production in rat cortex.
Godfrey, PP; Grahame-Smith, DG; McClue, SJ; White, AM; Wood, AJ, 1989
)
0.28
" Dose-response studies revealed a dose-dependent increase in beta-adrenergic receptor-stimulated cAMP production."( Glucocorticoid administration increases receptor-mediated and forskolin-stimulated cyclic AMP accumulation in rat brain cerebral cortical slices.
Duman, RS; Enna, SJ; Strada, SJ, 1989
)
0.28
" In concordance with this decreased receptor density and increased affinity, the maximal contractile response of right ventricular trabeculae from failing right ventricles was decreased by 61%, and the dose-response curve to VIP was left-shifted approximately threefold."( Vasoactive intestinal peptide receptor in failing human ventricular myocardium exhibits increased affinity and decreased density.
Anderson, FL; Bristow, MR; Hershberger, RE, 1989
)
0.28
" The dose-response curves, however, were substantially shifted to the right with increase in EC50 for isoproterenol stimulation of adenylate cyclase."( Beta-adrenergic receptor adaptation after an acute exercise in rat myocardium.
Izawa, T; Komabayashi, T; Shinoda, S; Suda, K; Tsuboi, M, 1989
)
0.49
" Isoproterenol stimulated cyclic adenosine monophosphate (cAMP) production in a dose-dependent manner, and dose-response experiments revealed an effective concentration of ligand at which 50% of the maximum effect is observed (EC50) of 5-10 x 10(-8) mol/l isoproterenol for both WKY and SHR."( Beta-adrenergic receptor differences in cultured arterial smooth muscle cells between spontaneously hypertensive and Wistar-Kyoto rats.
Jazayeri, A; Meyer, WJ, 1989
)
1.19
" Reserpine in this dosage materially reduces arterial pressure and heart rate; these effects last at least 7 days."( Responses of the three-toed sloth, Bradypus tridactylus, to some commonly used pharmacologic agents. II. Chloralose and reserpine.
Da Costa, CP; Duarte, DP; Huggins, SE; Leal, AM, 1989
)
0.28
"The isoproterenol dose-response curve was used to assess quantitatively the degree of systemic beta-adrenoceptor blockade induced by metipranolol (Bétanol) and betaxolol (Bétoptic) eye drops."( [Comparison in healthy volunteers of the systemic beta adrenergic receptor blockade by beta blockader eye drops].
de Dieuleveult, C; Pinaud, M; Queinnec, MC; Souron, R, 1989
)
0.84
" Doses were calculated to produce plasma levels approximating those achieved after oral dosing (0."( Effects of dilevalol on forearm circulation in essential hypertension.
Cleroux, J; Giannattasio, C; Grassi, G; Mancia, G; Seravalle, G; Zanchetti, A, 1989
)
0.28
" Alpha-adrenergic responsiveness was estimated with DPD15 (the dosage of neosynephrine required for an increase of diastolic pressure of 15mmHg); beta-adrenergic responsiveness with CD25 (the dosage of isoproterenol required for an increase of heart rate of 25 beats/minute)."( Hyperkinetic hemodynamic pattern in some borderline hypertension: differential responses to alpha and beta agonists.
Fan, J; Yang, Q; Yi, G, 1989
)
0.46
" Lactate reduced isoproterenol-induced lipolysis in a dose-response fashion and such inhibition became significant only at 16 mmol/l lactate."( Influence of lactate on isoproterenol-induced lipolysis and beta-adrenoceptors distribution in human fat cells.
Cardone, F; Cignarelli, M; Corso, M; De Pergola, G; Di Paolo, S; Garruti, G; Giorgino, R; Nardelli, G, 1989
)
0.92
" Their dose-response curves showed that they had similar IC50's but the maximum inhibition differed among these agonists."( Inhibition of adenylate cyclase in bovine ciliary process and rabbit iris ciliary body to alpha 2-adrenergic agonists.
Elko, EE; Jin, Y; Tran, T; Yorio, T, 1989
)
0.28
" IBI at 10(-6) M shifted the dose-response curve of phenylephrine to the right with reduction in maxima."( Paradoxical effects of isothiocyanate analog of tolazoline on rat aorta and human platelets.
Feller, DR; Hamada, A; Miller, DD; Patil, PN; Shams, G; Venkataraman, BV, 1989
)
0.28
" By contrast, carbachol did not alter the dose-response profile to AR-L57."( A comparison of the cardiotonic effects of AR-L115 and AR-L57: evidence for distinct inotropic mechanisms.
Hayes, JS; Pollock, GD; Wilson, H; Wyss, VL,
)
0.13
" Dose-response curves with epinephrine (alpha 2 and beta agonist), with isoproterenol (beta agonist) and epinephrine + propranolol and adenosine deaminase, were studied."( Lipolytic response of adipocytes to epinephrine in sedentary and exercise-trained subjects: sex-related differences.
Beauville, M; Crampes, F; Garrigues, M; Marceron, M; Riviere, D, 1989
)
0.51
" Perfusion with adenosine for a minimum of 90 min followed by washout resulted in a 40% depression of the dose-response curve of left ventricular dP/dt to isoproterenol."( Persistent desensitization of the heart to the inotropic action of isoproterenol by adenosine.
Lee, JT; Newman, WH; Webb, JG, 1989
)
0.71
" This was associated with airway beta-adrenoceptor blockade as demonstrated by a shift in the isoproterenol dose-response curve."( Anticholinergic blockade of beta-blocker-induced bronchoconstriction.
Barnes, PJ; Dixon, CM; Fuller, RW; Ind, PW, 1989
)
0.5
" The dose-response relationship between insulin and inhibition of ISO-stimulated lipolysis showed that insulin sensitivity was increased and responsiveness unaltered in S and D compared to C adipocytes for incubations with both uncontrolled and controlled adenosine concentrations."( Antilipolytic action of insulin in adipocytes from starved and diabetic rats during adenosine-controlled incubations.
Bosman, J; Koopmans, SJ; Krans, HM; Radder, JK; Sips, HC, 1989
)
0.28
" Isoproterenol pretreatment also caused a rightward non-parallel shift in the methacholine dose-response curves for both isometric tension and myosin light chain phosphorylation."( Isoproterenol attenuates myosin phosphorylation and contraction of tracheal muscle.
de Lanerolle, P; Obara, K, 1989
)
2.63
" Atenolol displaced the dose-response curve to ICI 170777 to the right by 4 fold but displaced the isoprenaline dose-response curve to the right by 247 fold."( The cardiovascular pharmacology of ICI 170777 ((6RS)-6-methyl-5-(pyrid-4-yl)-3H,6H-1,3,4- thiadiazin-2-one) a novel compound with positive inotropic and vasodilator effects.
Collis, MG; Keddie, JR; Rouse, W, 1989
)
0.28
"In the present study, isolated atrial function in spontaneously diabetic BB Wistar rats maintained for 12 weeks on a low (BB-LI) and a high (BB-HI) dosage of insulin was examined."( Chronotropic function in spontaneously diabetic BB rats.
McGrath, GM; McNeill, JH; Ramanadham, S, 1989
)
0.28
" The contractile responses to VIP were unchanged after beta-adrenergic blockade with nadolol at a concentration (10 microM) that shifted the ISO dose-response curve two to three orders of magnitude to the right."( Contractile effects of cardiac neuropeptides in isolated canine atrial and ventricular muscles.
Balasubramaniam, A; Grupp, G; Grupp, IL; Rigel, DF, 1989
)
0.28
" The doses for each drug were selected based on the results of dose-response curves."( Adrenergic effects on internal cardiac defibrillation threshold.
Jones, DL; Klein, GJ; Rattes, MF; Sharma, AD; Szabo, T, 1987
)
0.27
" The dose-response curves to cumulative doses of xamoterol, a beta 1-adrenoceptor partial agonist, confirmed that the magnitude of the inotropic response was reduced during beta 1-stimulation in patients with an ejection fraction less than or equal to 35% when compared with patients with a greater ejection fraction."( Left ventricular sensitivity to beta-adrenoceptor-stimulating drugs in patients with ischemic heart disease and varying degrees of ventricular dysfunction.
Charlier, AA; Hanet, C; Marlow, HF; Pouleur, H; Rousseau, MF, 1987
)
0.27
" 45% and caused a marked rightward shift in the dose-response curve for insulin (EC50 103 +/- 34 mu units/ml)."( The interaction between the adenylate cyclase system and insulin-stimulated glucose transport. Evidence for the importance of both cyclic-AMP-dependent and -independent mechanisms.
Davies, JI; Lönnroth, I; Lönnroth, P; Smith, U, 1987
)
0.27
" We now report results of isoproterenol dose-response studies that indicate lower basal levels of cyclic AMP as well as diminished cyclic AMP levels in response to isoproterenol stimulation at concentrations ranging from 10(-10) to 10(-5) mol/L in drug-free, hospitalized patients with endogenous depression."( Blunted beta-adrenergic responsivity of peripheral blood mononuclear cells in endogenous depression. Isoproterenol dose-response studies.
Brown, RP; Halper, JP; Kocsis, JH; Mann, JJ; Peters, A; Sweeney, JA, 1988
)
0.79
" The inactivation of a small receptor fraction shifted the dose-response curves for isoprenaline and clonidine to the right but did not alter the maximum effect of the agonists (responsiveness)."( Adrenoceptor occupancy in isolated human fat cells and its relationship with lipolysis rate.
Arner, P; Engfeldt, P; Hellmér, J; Ostman, J; Wennlund, A, 1988
)
0.27
" Beta adrenergic agonist dose-response curves were obtained in all tissues in the presence and absence of the beta-2 selective antagonist, ICI 118,551."( Further evidence for a homogeneous population of beta-1-adrenoceptors in bovine coronary artery.
Coulombe, PR; Purdy, RE; Stupecky, GL, 1988
)
0.27
" Beta-receptor sensitivity was determined in membrane fractions from the left ventricle by analysis of the dose-response relationship between isoproterenol and the formation of c-AMP (pmol/min/mg protein)."( Effects of chronic beta-blockade on beta-receptors and adenylate cyclase activity in the canine heart.
Becker, DM; Euler, DE; Jones, SB; Romano, FD; Scanlon, PJ, 1988
)
0.48
" Displacement of the dose-response curve to IP to the right occurred in the acute phase group."( Trypanosoma cruzi (CL strain) infection in mice changes the chronotropic effect of isoproterenol in vitro.
Pereira, FE; Pires, JG, 1987
)
0.5
" From the right shifts of isoprenaline dose-response curves 0 to 84 hr after administration of propranolol and the beta-1 selective bisoprolol, in vivo beta blockade was assessed."( Beta adrenoceptor subtype binding activity in plasma and beta blockade by propranolol and beta-1 selective bisoprolol in humans. Evaluation with Schild-plots.
Belz, GG; Palm, D; Wellstein, A, 1988
)
0.27
" Ethanol also shifted the dose-response curve for stimulation of the enzyme by isoproterenol to the right."( Effects of ethanol in vitro on the beta adrenergic receptor-coupled adenylate cyclase system.
Bode, DC; Molinoff, PB, 1988
)
0.5
" Furthermore, the hormone caused a dose-dependent maximum 10-fold shift to the right of the dose-response curve for isoprenaline-induced lipolysis without changing the amplitude of the curve."( Effects of insulin on adrenoceptor binding and the rate of catecholamine-induced lipolysis in isolated human fat cells.
Arner, P; Engfeldt, P; Hellmér, J; Wahrenberg, H, 1988
)
0.27
"In animals injected with a bolus of isoproterenol, beta-adrenergic receptors in both mononuclear leukocytes (MNL) and heart were sequestered away from the cell surface, and the time course (0-120 min) and dose-response patterns were similar in the two tissues."( In vivo regulation of beta-adrenergic receptors on mononuclear leukocytes and heart. Assessment of receptor compartmentation after agonist infusion and acute aortic constriction in guinea pigs.
Carter, S; Insel, PA; Maisel, AS; Motulsky, HJ; Ziegler, MG, 1988
)
0.55
" Apamin inhibited the transmural nerve stimulation-induced relaxation and shifted the dose-response curve for VIP to the right."( Similarities between the relaxations induced by vasoactive intestinal peptide and by stimulation of the non-adrenergic non-cholinergic neurons in the rat stomach.
Kamata, K; Kasuya, Y; Sakamoto, A, 1988
)
0.27
" Dose-response curves to isoproterenol were determined in the presence and absence of adenosine deaminase."( Quantitative differences in the cyclic AMP-lipolysis relationships for isoproterenol and forskolin.
Allen, DO; Quesenberry, JT, 1988
)
0.81
" Propranolol and labetalol induced a dose-dependent, parallel shift to the right in the dose-response curves of isoproterenol effects on heart rate and diastolic blood pressure, indicating that both drugs are nonselective, competitive antagonists of beta-adrenergic receptors."( Beta blockade by oral propranolol and labetalol.
Carr, ME; Cubeddu, LX; Fuenmayor, NJ, 1985
)
0.48
" Bevantolol itself induced bradycardia, so that it was not possible to estimate the pA2 from nonparallel dose-response curves relating isoprenaline concentration to tachycardia."( Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile.
Dukes, ID; Vaughan Williams, EM, 1985
)
0.27
" The dose-response relationships of the alpha 2- and beta-selective agents clonidine and isoproterenol were not appreciably changed by caloric restriction."( Adrenergic regulation of lipolysis in abdominal adipocytes of obese subjects during caloric restriction: reversal of catecholamine action caused by relief of endogenous inhibition.
Fischer, B; Kather, H; Schlierf, G; Wieland, E; Wirth, A, 1985
)
0.49
"In a previous study, a high dosage (2."( Induction of oviposition in cycling Anolis carolinensis requires a beta-adrenoreceptor blocker and a high dosage of arginine vasotocin.
Austin, HB; Jones, RE; Summers, CH, 1985
)
0.27
" In trachea and right atria of the guinea-pig, tertatolol inhibited, in a concentration-dependent manner, the dose-response curves to isoproterenol; the relative potency of tertatolol was higher than that of propranolol."( Effects of tertatolol on post- and prejunctional beta adrenoceptors.
Herman, AG; Jordaens, FH; Laekeman, G; Majchrowicz, BB; Verbeuren, TJ; Zonnekeyn, LL, 1985
)
0.47
" Dose-response curves were constructed for the changes in these parameters with increasing doses of isoproterenol."( Effects of betaxolol, propranolol, and atenolol on isoproterenol-induced beta-adrenoceptor responses.
Riddell, JG; Shanks, RG, 1985
)
0.74
" Dose-response curves for stimulation of both rate and force by the beta 2-selective agonists procaterol and zinterol were shifted to a much greater extent by selective blockade of beta 1-adrenoceptors with metoprolol than by selective blockade of beta 2-adrenoceptors with ICI 118,551, suggesting that these compounds caused their effects by activating beta 1-adrenoceptors."( Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart.
Abel, PW; Juberg, EN; Minneman, KP, 1985
)
0.27
" Biotransformations are determined by environmental or genetic factors and by the associated therapy and can change dramatically from one patient to another (interindividual variability) or for the same patient by multiple dosing (intra-individual variability)."( [Metabolism of beta-adrenergic substances. Therapeutic implications].
Brès, J; Bressolle, F; Clauzel, AM; Pistre, MC; Rachmat, H,
)
0.13
"The effects of bucindolol a new nonselective beta blocker were studied after short-term dosing and for up to six months in eight patients with essential hypertension."( Bucindolol in essential hypertension.
Curzio, J; Reid, JL; Vincent, J, 1985
)
0.27
" The extent of bronchial beta-adrenoceptor blockade following one eyedrop in each eye of timolol 1% and L-714,465 1% was compared in six normal subjects, by measuring the displacement of the bronchodilator dose-response curve to isoprenaline following each drug compared to the isoprenaline dose-response curve after placebo eyedrops (methyl-cellulose)."( Bronchial beta-adrenoceptor blockade following eyedrops of timolol and its isomer L-714,465 in normal subjects.
Richards, R; Tattersfield, AE, 1985
)
0.27
" Isoproterenol dose-response curves were shifted significantly downward and to the right after previous treatment with and removal of isoproterenol."( Isoproterenol-induced desensitization to the positive inotropic effect of isoproterenol in ventricular strips isolated from carp heart (Cyprinus carpio).
Hirata, T; Kitazawa, T; Kondo, H; Temma, K, 1985
)
2.62
" Computer-assisted analysis of dose-response curves resulting from the inhibition of the binding of [125I]iodopindolol by the beta-1 and beta-2 selective compounds ICI 89,406 and ICI 118,551 revealed that approximately one-third of the beta adrenergic receptors on these cells were beta-1 receptors."( Selective regulation of beta-1 and beta-2 adrenergic receptors by atypical agonists.
Barrett, DA; Molinoff, PB; Neve, KA, 1985
)
0.27
" Studies of right ventricular papillary muscles from control and chronically beta-blocked cats demonstrated contractile and energetic properties as well as dose-response behavior and inotropic specificity suggestive of an increase in myocardial sensitivity to beta-adrenoceptor stimulation in the latter group."( Beta adrenergic receptor blockade of feline myocardium. Cardiac mechanics, energetics, and beta adrenoceptor regulation.
Cooper, G; Kent, RL; McGonigle, P; Watanabe, AM, 1986
)
0.27
" Treatment of intact vasa deferentia with increasing concentrations of BAAM resulted in a progressive rightward shift in the dose-response curve to isoprenaline or salbutamol followed by a decreased maximum response."( Binding of agonists and antagonists to beta-adrenoceptors in rat vas deferens: relationship to functional response.
Abel, PW; May, JM; Minneman, KP, 1985
)
0.27
" The NTLI response to epinephrine was competitively inhibited by propranolol, producing a parallel rightward shift of the epinephrine dose-response curve."( Regulation of neurotensin release from canine enteric primary cell cultures.
Barber, DL; Buchan, AM; Soll, AH; Walsh, JH, 1986
)
0.27
" Dose-response curves were constructed for the changes in heart rate, finger tremor, blood pressure and forearm blood flow produced by each infusion."( Effects of ICI 141,292 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man.
Finch, MB; McNeill, AJ; O'Connor, PC; Pringle, TH; Riddell, JG; Shanks, RG, 1986
)
0.27
" Amitraz did not significantly shift the dose-response curve to isoprenaline or acetylcholine but antagonized histamine rate responses competitively in the presence of propranolol (2 X 10(-6) M)."( The cardiac effects of amitraz in the guinea-pig in vivo and in vitro.
Pascoe, AL; Reynoldson, JA, 1986
)
0.27
" Airway responsiveness was measured by the ability of isoproterenol infusions to shift the histamine dose-response curve for airway constriction."( Differential recovery of beta adrenoreceptor antagonist and agonist high affinity binding sites in the guinea-pig lung after irreversible blockade.
Baker, SP; Muther, TF; Nelson, CA; Pitha, J, 1986
)
0.52
" PRA activity was significantly and markedly reduced by both bunolol and metoprolol shortly after dosing at a time when HR was significantly reduced but MBP was not."( Antihypertensive effects of 12 beta adrenoceptor antagonists in conscious spontaneously hypertensive rats: relationship to changes in plasma renin activity, heart rate and sympathetic nerve function.
Antonaccio, MJ; DeForrest, JM; High, J; Sybertz, E, 1986
)
0.27
"When dose-response curves are replicated, averaging the responses to each dose of drug reduces the slope of the mean curve."( A method for presenting and comparing dose-response curves.
Carpenter, JR, 1986
)
0.27
" Phentolamine, an alpha-adrenergic antagonist, and inhibitors of cyclooxygenase (ibuprofen, indomethacin, and acetylsalicylic acid) caused a shift to the right of the epinephrine dose-response curve, indicating antagonism of the response to epinephrine."( Interaction of epinephrine with isolated rabbit tracheal epithelial cells.
Liedtke, CM, 1986
)
0.27
" (+/-)-Propranolol caused rightward shifts, usually parallel, of the dose-response curves for (-)-isoprenaline."( The antinociceptive action of some beta-adrenoceptor agonists in mice.
Bentley, GA; Starr, J, 1986
)
0.27
" The reaction patterns were similar for isoprenaline and somatostatin, whereas salmefamol induced an inhibition of longer duration and with dissimilar dose-response kinetics."( Beta-adrenergic agonists inhibit gastric acid and pepsin secretion through somatostatin release in dogs.
Bech, K; Uvnäs-Moberg, K, 1986
)
0.27
" Propranolol 5 mg iv, the positive control, significantly shifted the isoproterenol dose-response curve to the right."( The assessment of the beta-blocking activity of urapidil: a new method.
Flanagan, PH; Galbraith, H; Jackson, SH; Jamieson, MJ; Patel, SS; Shepherd, AM; Stewart, W, 1986
)
0.5
" The isoproterenol-induced potentiation of the [3H]prostaglandin D2 binding gave a bell-shaped dose-response relationship (maximum response at 3 X 10(-8) M) in a stereospecific manner."( Beta 2-adrenergic regulation of prostaglandin D2 receptor in rabbit platelets.
Hanasaki, K; Ichikawa, A; Ikeda, M; Mizuno, Y; Shimonishi, M; Tomita, K; Yoshimura, S, 1987
)
0.79
" The dexamethasone action on VIP-stimulated cyclic AMP accumulation takes place within 48 h and is most apparent in the mid-range of the VIP dose-response curve."( Adrenocortical steroids modify neurotransmitter-stimulated cyclic AMP accumulation in the hippocampus and limbic brain of the rat.
Harrelson, AL; McEwen, BS; Rostene, W, 1987
)
0.27
" Dose-response curves for heart rate, diastolic blood pressure, forearm blood flow and finger tremor were constructed."( The assessment in man of the beta-adrenoceptor blocking activity and cardioselectivity of H-I 42 BS, a long acting beta-adrenoceptor blocking drug.
Deering, AH; Harron, DW; Pringle, TH; Scott, MG; Shanks, RG, 1987
)
0.27
" The suggestion is made that failure to recognize the nonlinearity of the dose-response curves for bronchodilators has resulted in underestimating their combined action."( Theophylline as a bronchodilator in COPD and its combination with inhaled beta-adrenergic drugs.
Jenne, JW, 1987
)
0.27
" In contrast, the (R)-glycol appeared to act as an irreversible antagonist, producing complex dose-response curves."( Comparative studies with the enantiomers of the glycol metabolite of propranolol and their effects on the cardiac beta-adrenoceptor.
Lyles, GA; Neilson, DG; Ogg, GD; Stevenson, IH, 1987
)
0.27
" In order to mimic the intrinsic effects of the partial agonist drugs, control dose-response curves for isoproterenol were determined in pithed rats in which the base-line heart rate was elevated by thoracic spinal cord stimulation."( Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
Cavero, I; Hicks, PE; Langer, SZ; Lefevre-Borg, F; Manoury, P, 1987
)
0.49
" Recordings were obtained 2 and 24 h following a single dose and 24 h after continuous dosage for 7 days."( Peripheral vascular effects of beta-adrenoceptor blockade: comparison of two agents.
Bowcock, SA; Camm, AJ; Cooke, ED; Maltz, MB; Smith, RE; Watkins, CJ, 1987
)
0.27
" Isoprenaline dose-response curves were constructed for cardiovascular parameters and finger tremor."( The assessment of the beta-adrenoceptor blocking activity and cardioselectivity of Koe 3290 in normal subjects.
McNeill, AJ; Pringle, TH; Riddell, JG; Shanks, RG, 1987
)
0.27
" Dose-response curves were also carried out for intravenous prenalterol, a partial beta 1-adrenergic agonist."( Age and sex differences in cardiovascular reactivity to adrenergic agonists, mental stress and isometric exercise in normal subjects.
Hjalmarson, A; Johansson, SR, 1988
)
0.27
" The dose-response curves were shifted to the right with advancing age, suggesting reduced beta-agonist potency of the maturing tissue."( Postnatal development of beta-adrenergic response in ventricular muscle of the rat heart.
Vornanen, M, 1988
)
0.27
"1 microM), followed by washout, produced concentration-dependent rightward shifts of the dose-response curve to cumulative additions of (-)-isoprenaline and oxymethylene-isoprenaline and reductions in the maximal response."( Persistent beta-adrenoceptor blockade with alkylating pindolol (BIM) in guinea-pig left atria and trachea.
Molenaar, P; Pitha, J; Russell, F; Summers, R, 1988
)
0.27
" Coronary flow resistance increased in a dose-response fashion with a maximum increase of 22."( The differential effects of alpha 2-adrenergic stimulation on the myocardium and coronary vessels in the isolated rat heart.
Fouad-Tarazi, FM; Hirakata, H, 1988
)
0.27
" Dose-response studies (required to increase heart rate or systolic blood pressure by 25 beats/min and 20mm Hg, respectively) were performed with phenylephrine, angiotensin and isoprenaline after each drug, and placebo administration and the effects of physiological pressor stimuli were compared."( Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine.
Bompart, F; Graham, BR; Liu, JB; Prichard, BN; Tomlinson, B, 1988
)
0.27
" A dose-response relationship between inhibition of alpha-MSH secretion and the concentration of Leu-enkephalin, with ED50 approximately 10(-9) M, was observed."( Modulation by Leu-enkephalin of peptide release from perifused neurointermediate pituitary. II. Inhibition of calcium-mediated secretion of alpha-MSH and beta-endorphin.
Al Zein, M; Koch, B; Lutz-Bucher, B, 1986
)
0.27
" Twice daily doses (50 mg/kg body wt) of the non-selective beta-adrenergic agonist, isoproterenol, for six days, increased Ca-ATPase specific activity of parotid gland by 17 per cent but that of submandibular gland was the same as controls; with dobutamine, the same dosage caused a 53 per cent decrease in submandibular activity and a 31 per cent decrease in parotid."( Ca-ATPase activity in salivary glands of rats treated with reserpine, isoproterenol, terbutaline or dobutamine.
Cheung, H; Schneyer, CA, 1987
)
0.73
" Dose-response and time-course studies revealed that baclofen has little influence on neurotransmitter recognition site affinity, but rather enhances the synthesis or accumulation of second messenger that occurs in response to these agents."( Characterization of the relationship between gamma-aminobutyric acid B agonists and transmitter-coupled cyclic nucleotide-generating systems in rat brain.
Enna, SJ; Karbon, EW, 1985
)
0.27
" Analysis of the NE-cAMP dose-response curve indicates that the stress reduces the maximum cAMP response to NE but does not increase the EC50 value of NE."( Reduction of the cyclic adenosine 3',5'-monophosphate response to catecholamines in rat brain slices after repeated restraint stress.
Platt, JE; Slucky, AV; Stone, EA; Trullas, R, 1985
)
0.27
" Dose-response curves were determined for either isoproterenol or dobutamine 30 min after treatment with hexamethonium (20mg/kg)."( Role of alpha-adrenergic receptors in the intrinsic inotropic selectivity of dobutamine in anesthetized dogs.
Gorczynski, RJ; Shaffer, JE, 1985
)
0.52
" Dose-response curves of isoproterenol revealed a progressive increase in the activation constant (Kact) with advancing age."( Age-related reduction of beta-adrenoceptor sensitivity in rat heart occurs by multiple mechanisms.
Banerjee, SP; Fan, TH, 1985
)
0.57
" Dose-response studies of the effect of epinephrine on adenosine-deaminase or isoproterenol-stimulated fat-cells demonstrate an inhibitory effect of epinephrine on lipolysis promoted by stimulation of alpha 2-adrenoceptors which occurs before the commonly described beta 1-adrenergic effect which promotes stimulation of lipolysis."( Fat cell adrenoceptors: inter- and intraspecific differences and hormone regulation.
Berlan, M; Carpene, C; Lafontan, M, 1985
)
0.5
" At each 7 biweekly evaluations, the patient's cumulative bronchodilator dose-response to inhaled isoproterenol (0."( The effect of procaterol treatment on beta-adrenergic bronchodilation and polymorphonuclear leukocyte responsiveness.
Arbabian, M; Borgen, L; Busse, WW; Ruoho, A; Sharpe, G; Smith, A, 1985
)
0.49
" In vitro perfusion of rat lungs with AA (3 X 10(-5)M for 20 min) reduced the relaxant effect of isoproterenol (ISO) on lung parenchymal strips, shown by a shift to the right of ISO dose-response curve, similar to that obtained using desensitizing concentration of specific beta-agonist."( Arachidonic acid metabolites induce beta-adrenoceptor desensitization in rat lung in vitro.
Abbracchio, MP; Cattabeni, F; Daffonchio, L; Giani, E; Hernandez, A; Omini, C, 1985
)
0.49
" At the agonal stage, the isoproterenol dose-response curve was shifted significantly to the right in myocardial membranes from endotoxic rats, but there was no significant decrease in maximum stimulated activity."( Alterations in beta-adrenergic stimulation of myocardial adenylate cyclase in endotoxic rats.
Jones, SB; Romano, FD, 1986
)
0.57
" This change occurs in parallel with a moderate rightward shift in the insulin dose-response curve."( Isoproterenol reduces insulin stimulation of hexose uptake by rat adipocytes via a postinsulin binding alteration.
Arsenis, G; Livingston, JN, 1986
)
1.71
" With bolus injections, atropine displaced the heart rate dose-response curve for atenolol to the right, implying reflex withdrawal of cardiac vagal tone, but did not alter the heart rate dose-response curve for propranolol."( Reflex vagal withdrawal and the hemodynamic response to intravenous isoproterenol in the presence of beta-antagonists.
Arnold, JM; McDevitt, DG, 1986
)
0.51
" Dose-response studies indicate the beta-adrenergic component of cyclic AMP stimulation is enhanced and the alpha 1-adrenergic component of cyclic GMP stimulation is diminished in LL pinealocytes."( See-saw signal processing in pinealocytes involves reciprocal changes in the alpha 1-adrenergic component of the cyclic GMP response and the beta-adrenergic component of the cyclic AMP response.
Klein, DC; Sugden, D; Vanecek, J; Weller, JL, 1986
)
0.27
" The differences observed in the dose-response curves of adenylate cyclase activity to isoproterenol or noradrenaline were prevented in the presence of clonidine (a alpha 2-agonist) or yohimbine (alpha 2-antagonist) respectively."( Occurrence of alpha 2-adrenergic effects on adenylate cyclase activity and (3H)-clonidine specific binding in brown adipose tissue from foetal rats.
Benito, M; Domínguez, MJ; Elliott, K; Fernández, M, 1986
)
0.49
" In contrast, dose-response curves for GTP-stimulation of basal and isoproterenol-stimulated adenylate cyclase display higher maximal responses in fasted rats under conditions restraining (2 mM Mg2+) but not promoting (10 mM Mg2+) the dissociation of Ns."( Fasting increases fat cell adenylate cyclase sensitivity to stimulatory agonists through enhanced ability of the stimulatory regulatory component Ns to dissociate.
Agli, B; Giudicelli, Y; Lacasa, D, 1986
)
0.51
" In studies with isolated rat hearts perfused in the Langendorff mode, the dose-response characteristics of forskolin have been characterized."( Forskolin and myocardial function in the normal, ischemic and reperfused rat heart.
Buschmans, E; Hearse, DJ; Manning, AS; Zucchi, R,
)
0.13
" Unstimulated water intake was similar between control and fasted groups, and parallel dose-response curves for the dipsogenic response induced by isoproterenol (10-50 micrograms/kg) were observed."( Possible mechanism for increased beta-adrenergic dipsogenic response in food-deprived rats.
Baker, SP; Katovich, MJ; Yeh, LF, 1986
)
0.47
"1% respectively; the dose-response curve for NE inhibitory action is described."( Quantitative evaluation of alpha- and beta-adrenoceptor modulation of [3H]choline release in guinea pig superior cervical ganglia.
Belluzzi, O; Bonifazzi, C; Perri, V; Travagli, RA, 1987
)
0.27
" p[NH]ppG increased forskolin sensitivity and caused a leftward shift in the forskolin dose-response curve."( Forskolin refractoriness. Exposure to the diterpene alters guanine nucleotide-dependent adenylate cyclase and calcium-uptake activity of cells cultured from the rat aorta.
Jamgotchian, N; Krall, JF, 1987
)
0.27
" This effect was evident by a decrease of the maximal response of the dose-response curves to isoprenaline, whereas the EC50 values did not change."( Dual effects of Haemophilus influenzae on guinea pig tracheal beta-adrenergic receptor function: involvement of oxygen-centered radicals from pulmonary macrophages.
Engels, F; Nijkamp, FP; Oosting, RS, 1987
)
0.27
" In the bronchus, functional evidence for such innervation was shown by the following results: a leftward shift in the noradrenaline inhibitory dose-response curve by the neuronal uptake blocker imipramine; the inhibition of uptake of 3H-L-noradrenaline by the neuronal uptake blockers imipramine, cocaine and phenoxybenzamine; and the induced release of noradrenaline and its metabolites by tyramine and electrical field stimulation using nerve-specific parameters; and selective inhibition of field-stimulated contractions by isoprenaline."( Sympathetic innervation of human tracheal and bronchial smooth muscle.
Davis, C; Kannan, MS, 1987
)
0.27
" To evaluate whether acute beta-adrenergic stimulation elicits comparable cardiovascular effects in animals of different age, a dose-response curve to intravenous injection of isoproterenol was performed in anesthetized rats."( Increased incidence of isoproterenol-induced ventricular fibrillation in aging rats.
Anversa, P; Guideri, G; Hiler, B; Olivetti, G; Ricci, R, 1987
)
0.78
"This paper describes an in vivo computer-based cumulative dose-response assay of the myocardial beta-adrenoceptor system."( An in vivo cumulative dose-response assay of the myocardial beta-adrenoceptor system.
Peterson, JT; Pohorecky, LA, 1987
)
0.27
" The dose-response curves were similar to controls, although the Nottingham Long-Evans control strain drank significantly less in response to some doses of the peptides."( Thirst in Brattleboro rats.
Fitzsimons, JT; Fuller, LM, 1988
)
0.27
"We tested the hypothesis that maximal bronchoconstriction in humans in vivo is limited by the maximal contractility of airway smooth muscle by comparison of complete in vivo and in vitro dose-response curves to methacholine in 10 nonasthmatic subjects who were scheduled for thoracotomy because of malignancies."( Comparison of maximal bronchoconstriction in vivo and airway smooth muscle responses in vitro in nonasthmatic humans.
de Jongste, JC; Kerrebijn, KF; Mons, H; Sterk, PJ; Timmers, MC; Willems, LN, 1988
)
0.27
" The frequency of panic attacks induced in patients was related to the dosage of isoproterenol; 79% of the patients who received a mean of 18."( Isoproterenol-induced panic attacks.
Balon, R; Berchou, R; Lycaki, H; Ortiz, A; Pohl, R; Rainey, JM; Weinberg, P; Yeragani, VK, 1988
)
1.94
" Whereas LV peak dP/dt and LV (dP/dt)/DP40 were significantly decreased after the low dosage of lidocaine, these indexes returned to control values after the 10th min of infusion of the high dosage."( Effects of lidocaine on myocardial contractility and baroreflex control of heart rate in conscious dogs.
Berdeaux, A; Edouard, A; Giudicelli, JF; Langloys, J; Noviant, Y; Samii, K, 1986
)
0.27
" Further increase in dosage of both prostaglandin synthesis inhibitors failed to induce further reduction of integrated areas of coronary vasodilatation."( Effects of prostaglandin synthesis inhibition on sympathetic-and parasympathetic-mediated coronary hemodynamic responses.
Condorelli, M; Cuocolo, A; de Luca, N; Patrignani, P; Ricciardelli, B; Trimarco, B; Volpe, M, 1986
)
0.27
" Results were similar for isoproterenol, although the positive inotropic effect occurred over a wider dosage range for this drug."( Milrinone effects in the isolated immature rabbit heart.
Ayres, N; Brannon, TS; Fixler, DE; Parrish, MD; Payne, A, 1988
)
0.58
" In the presence of a standard concentration of verapamil (73 nmol l-1), the dose-response curves for NECA, both for the isometric contraction and the atrial rate, were significantly shifted to the left."( Interactions of 5'-N-ethylcarboxamide adenosine (NECA), aminophylline and dipropyl-phenyl-xanthine (XAC) on the isolated guinea-pig atria.
Prostran, M; Varagic, VM,
)
0.13
"In clinical pharmacological studies, where it is not possible to describe the full dose-response curve, the construction of dose-response relationships ideally depends upon achieving a reproducible and readily measurable response for each dose administered."( A pragmatic approach to the pressor dose-response as an index of vascular reactivity and adrenoceptor function in man.
Elliott, HL; Reid, JL; Sumner, DJ; Vincent, J, 1987
)
0.27
" For each agent tested in this study, dose-response curves were established."( Micturition in the unanesthetized rat: spinal vs. peripheral pharmacology of the adrenergic system.
Durant, PA; Lucas, PC; Yaksh, TL, 1988
)
0.27
" The dose-response curves for drugs were constructed 8 weeks after treatment with STZ."( Changes in sensitivity of the rat stomach fundus to various drugs in streptozotocin-induced diabetic rats.
Kamata, K; Kasuya, Y; Sakamoto, A, 1988
)
0.27
" Their dose-response curve lay to the right of that for patients not given propranolol, and this indicates competitive inhibition."( Propranolol treatment in children with tetralogy of Fallot alters the response to isoprenaline after surgical repair.
Barazzone, C; Berner, M; Dayer, P; Friedli, B; Jaccard, C; Oberhansli, I; Rouge, JC, 1988
)
0.27
" The relatively limited cardiac output response and downward trend at the highest dosage of dopamine occurred with a reduction in heart rate and an increase in systemic vascular resistance."( Augmentation of cardiac output with intravenous catecholamines in unanesthetized hypoxemic newborn lambs.
Dreyer, WJ; Fisher, DJ; O'Laughlin, MP; Smith, EO, 1987
)
0.27
" Changes in hydrazinophthalazine-treated rats after dosing them with isoprenaline had a similar tendency but they were significantly lower than those found in healthy animals receiving isoprenaline only."( Effect of isoprenaline on tissue elastin content and serum elastolytic activity in normal and hydrazinophthalazine-treated rats.
Drózdz, M; Kucharz, E; Olczyk, K; Wieczorek, M, 1987
)
0.27
" This disparity reflects the greater bronchodilation effected by isoproterenol as a single agent than by epinephrine, in the dosing schedules and routes of administration chosen."( Treatment of acute asthma. Is combination therapy with sympathomimetics and methylxanthines indicated?
Fanta, CH; McFadden, ER; Rossing, TH, 1986
)
0.51
" The dose-response curve of renin secretion (as a proportion of total renal content) in response to isoproterenol was shifted downward."( Renin secretion by the spontaneously diabetic rat.
Cohen, AJ; McCarthy, DM; Rossetti, RR, 1986
)
0.49
" While all these hormones have the potential for stimulating BAT 5'-D, the dose-response relationships suggest that norepinephrine and insulin are the most potent."( Hormonal regulation of iodothyronine 5'-deiodinase in rat brown adipose tissue.
Larsen, PR; Silva, JE, 1986
)
0.27
" In the dose-response study, various doses of ISO (0."( Pineal N-acetyltransferase, pineal and serum melatonin response to isoproterenol stimulation in underfed male rats.
Brown, GM; Chik, CL; Ho, AK; Joshi, MG, 1987
)
0.51
" Furthermore, prolonged TCDD treatment shifted the dose-response curve for the positive inotropic effect of isoproterenol to the right with no statistically significant change in the maximal inotropic effect obtained with high concentrations of isoproterenol."( Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on guinea pig heart muscle.
Akera, T; Brewster, DW; Matsumura, F, 1987
)
0.49
" Because of the magnitude of this lightening response, four-point dose-response curves can be obtained."( A teleost skin bioassay for melanotropic peptides.
Castrucci, AM; Hadley, ME; Hruby, VJ, 1987
)
0.27
" Dose-response curves in low Ca2+ (0."( Extracellular calcium and altered vascular responsiveness in the deoxycorticosterone acetate-salt rat.
Field, FP; Soltis, EE, 1986
)
0.27
" The dose-response curve for the action of forskolin (2."( The effect of forskolin on the isometric contraction of the isolated hemidiaphragm of the rat.
Prostran, M; Varagić, VM, 1986
)
0.27
" Dosing the mice with phenidone, a dual inhibitor of the cyclo-oxygenase and lipoxygenase pathways of arachidonic acid metabolism, potentiated the neutrophil infiltration at 4 h but had no significant effect upon the subsequent mononuclear cell and eosinophil infiltration."( Effect of drugs on the increase in cell numbers in the peritoneal cavity of the actively sensitised mouse after intraperitoneal challenge with antigen.
Hatt, PA; Laycock, SM; Smith, H; Spicer, BA, 1986
)
0.27
" Control and polymer-exposed atria superfused with oxygen-saturated buffer yielded dose-response curves which were essentially identical with regard to maximal increase and potency of isoproterenol."( Inhibition of isoproterenol positive atrial chronotropic effect by methylmethacrylate polymer and monomer.
Born, CK; Campbell, MJ; Hamrick, ME; Ravis, WR; Willis, DW, 1986
)
0.82
" This preparation was used to examine the intrinsic mechanical properties of the trout heart, the dose-response effects of catecholamines and extracellular calcium on these properties, and the effects of catecholamines and extracellular calcium during exposure to acidotic conditions."( Intrinsic mechanical properties of the perfused rainbow trout heart and the effects of catecholamines and extracellular calcium under control and acidotic conditions.
Chancey, B; Farrell, AP; MacLeod, KR, 1986
)
0.27
" Infused peptide caused no significant change in the cumulative dose-response curve for inhaled isoprenaline."( Effect of infused vasoactive intestinal peptide on airway function in normal subjects.
Barnes, PJ; Blank, M; Bloom, SR; Cuss, FM; Palmer, JB; Warren, JB, 1986
)
0.27
"To ascertain the effect of theophylline on the cardiac chronotropic response to beta-adrenergic stimulation, isoproterenol dose-response curves in healthy young subjects were compared during saline and theophylline maintenance infusions."( Additive effect of theophylline on the cardiac response to isoproterenol.
Cusack, BJ; Morgan, ME; Nielson, CP; Vestal, RE, 1987
)
0.73
"The rationale for the objective assessment of dose-response curves (DRCs) is presented."( The analysis of dose-response curves--a practical approach.
Jackson, SH; Jamieson, MJ; Johnston, A; Shepherd, AM, 1987
)
0.27
" Dose-response dP/dtmax curves were obtained by stepped increases of agonist infusion (iv)."( Enhanced adrenergic sensitivity of the diabetic neonatal heart.
Downing, SE; Lee, JC, 1985
)
0.27
", a 1000-fold inhibition of the blood pressure/isoproterenol dose-response relationship."( Do catecholamines play a physiologic role in regulating corpus luteum function in the pseudopregnant rabbit?
Bill, CH; Gadsby, JE; Keyes, PL; Lucchesi, B; Schwartz, TS, 1985
)
0.53
" Nonetheless, PT treatment caused a rightward shift in the dose-response curve for insulin-stimulated glucose oxidation as well as a small reduction in insulin binding."( Action of insulin modulated by pertussis toxin in rat adipocytes.
Goren, HJ; Hollenberg, MD; Northup, JK, 1985
)
0.27
" 5) Pretreatment of membranes with cholera toxin facilitated cyclase activation proportionately more in ob/ob than in +/+ membranes; in addition, this treatment led to a shift to the left of the GTP dose-response curve in the ob/ob membranes."( Absence of the inhibitory effect of guanine nucleotides on adenylate cyclase activity in white adipocyte membranes of the ob/ob mouse. Effect of the ob gene.
Bégin-Heick, N, 1985
)
0.27
" Preconstriction was induced with norepinephrine and cumulative dose-response curves were obtained for the vasodilators."( Effects of magnesium on the action of vasodilatory agents.
Arnold, TH; Tackett, RL, 1985
)
0.27
" Propranolol also shifted the dose-response curves to the right, but was apparently more potent in preparations with basal tone than in tissues where high tone was induced by carbachol or K+."( Noradrenergic and non-noradrenergic relaxation at basal and high tone levels in the guinea-pig tracheal smooth muscle.
Abe, M; Furukawa, T, 1986
)
0.27
"Rats were injected intraperitoneally with isoproterenol in dosage of 40 mg/kg body weight and heart microsomal and mitochondrial fractions were isolated 3, 9 and 24 h later."( Adaptive changes in subcellular calcium transport during catecholamine-induced cardiomyopathy.
Beamish, RE; Dhalla, KS; Dhalla, NS; Ganguly, PK; Panagia, V; Pierce, GN, 1985
)
0.53
" Using an isolated perfused rat hindlimb preparation, dose-response curves for skeletal muscle oxygen consumption (VO2) and vascular resistance were obtained with control, endurance trained, and isoproterenol treated rats."( Effect of endurance training and chronic isoproterenol treatment on skeletal muscle sensitivity to norepinephrine.
Côté, C; Thibault, MC; Valliéres, J, 1985
)
0.72
" No long-lasting effect of the alpha-adrenergic blocker was apparent since the response to norepinephrine was not altered following a 1-hour washout of phentolamine after the isoproterenol dose-response curve."( Phentolamine and rat aortic smooth muscle responsiveness to potassium chloride, isoproterenol and norepinephrine.
Katovich, MJ; Soltis, EE, 1985
)
0.69
" Repetition of the dose-response to isoprenaline in the presence of the beta-adrenergic antagonist propranolol (0."( Isoprenaline-evinced disturbances in action potentials from hearts of young cardiomyopathic hamsters.
Rossner, KL, 1985
)
0.27
" Thus, determination of the 14C/3H ratio in newly synthesized triglycerides permits the assessment of adrenoceptor dose-response characteristics (lipolysis) of unweighed fragments of adipose tissue."( A radioisotopic method for the measurement of free fatty acid turnover and adrenoceptor response in small fragments of human adipose tissue.
Leibel, RL, 1985
)
0.27
" The dose-response curves of peripheral or coronary arteries to methoxamine showed no significant difference between diabetic and control sheep."( Coronary and peripheral vascular resistance in the anaesthetized diabetic sheep.
Heath, J; Hoffman, L; Kilpatrick, D; Yong, AC,
)
0.13
"3 Isoprenaline dose-response curves were shifted to the right in the cats administered oxyfedrine as well as in those administered propranolol."( The haemodynamic effects of prolonged oral administration of oxyfedrine, a partial agonist at beta-adrenoceptors: comparison with propranolol.
Parratt, JR, 1974
)
0.25
" Dose-response curves were obtained for intravenous infusions of adrenaline, noradrenaline, angiotensin, vasopressin and histamine."( Effects of infusions of catecholamines, angiotensin, vasopressin and histamine on hepatic blood volume in the anaesthetized cat.
Greenway, CV; Lautt, WW, 1972
)
0.25
" A study of dose-response relationships suggests a competitive interaction between MJ 1999 and DMAB."( Beta-adrenoceptor stimulating properties of para-dimethylaminobenzaldehyde.
Ghouri, MS; Shibata, S, 1970
)
0.25
" Chronotropic dose-response curves (non-cumulative) for beta-adrenoceptive antagonists were constructed from results in rats anaesthetized with pentobarbitone and depleted of catecholamines by pre-treatment with syrosingopine."( Comparative chronotropic activity of beta-adrenoceptive antagonists.
Barrett, AM; Carter, J, 1970
)
0.25
" When the doses required to produce these degrees of blockade were computed from the dose-response relations for blockade of the effects of cord stimulation by propranolol, they were found to be similar for effects on heart rate and air overflow."( Assessment of the effectiveness of -adrenoceptor blocking agents towards cardiac and bronchiolar responses of the pithed guinea-pig to electrical stimulation of the spinal outflow.
Burden, DT; Parkes, MW, 1972
)
0.25
" Type I sensitizations are appropriately described by determining the dose-ratio (horizontal shift of the dose-response curve) and type II sensitizations by assessing the change in the magnitude of the response."( A new approach to the measurement and classification of forms of supersensitivity of autonomic effector responses.
Kalsner, S, 1974
)
0.25
" After eight weeks on four capsules a day the patients in each group were allocated at random so that half continued on full dosage and half on a reducing regimen."( Long-term study of disodium cromoglycate in treatment of severe extrinsic or intrinsic bronchial asthma in adults. Brompton Hospital-Medical Research Council collaborative trial.
, 1972
)
0.25
" The NE dose-response curves shifted to the left."( Potentiation of the contractile effects of norepinephrine by hypoxia.
Cooper, T; Epstein, SE; Kent, KM, 1972
)
0.25
" All three catecholamines increased the rate of weight loss but isoprenaline was effective in a much smaller dosage than either adrenaline or noradrenaline."( The role of circulating catecholamines in sweat production in man.
Allen, JA; Roddie, IC, 1972
)
0.25
" In adult cats, cocaine (1 and 10 mug/ml) or denervation produced a shift to the left of dose-response curves to (-)-noradrenaline, whereas they failed to modify dose-response curves to (-)-isoprenaline."( Effects of cocaine or denervation on responses of isolated strips of cat spleen to (-)-noradrenaline and (-)-isoprenaline.
Granata, AR; Langer, SZ, 1973
)
0.25
" The method quickly produced accurate and reproducible dose-response curves."( Use of cumulative dose-response curves in potency comparisons of sympathomimetic amines on the cat soleus muscle.
Nott, MW; Raper, C, 1972
)
0.25
" Log dose-response curves obtained with a series of doses of salbutamol and isoetharine were flatter than those for isoprenaline and orciprenaline."( Comparison of the effects of isoprenaline, orciprenaline, salbutamol and isoetharine on the cardiovascular system of anaesthetized dogs.
Ekue, JM; Shanks, RG; Zaidi, SA, 1971
)
0.25
" Dose-heart rate curves of the foetus and pregnant ewe to isoprenaline and the shift to the right of the isoprenaline dose-response curves by propranolol were similar in both the ewe and the foetus."( Beta-adrenoceptive responses in the unanaesthetized ovine foetus.
Van Petten, GR; Willes, RF, 1970
)
0.25
" Grading of dosage and the use of dibenzyline revealed that these species exhibit alpha and beta adrenergic vascular responses in a manner qualitatively similar but quantitatively dissimilar to that for mammals."( Adrenergic blood pressure responses in the shark.
Borzelleca, JF; Schwartz, SL, 1969
)
0.25
" In either group, the dose-response curve of dP/dt to isoproterenol was shifted upward by AR-L, but the actions of the two drugs were additive without real synergism (e."( In vivo interaction of AR-L 115BS (Vardax) with the adrenergic nervous system.
Cohn, JN; Francis, GS; From, AH; Petein, M; Pierpont, GL,
)
0.38
" In anesthetized, bivagotomized dogs, isoprenaline dose-response relations for increase in heart rate and decrease in diastolic blood pressure were established."( Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs.
Harting, J; Schliep, HJ,
)
0.13
" Heart rate and contractile force dose-response curves to isoproterenol were equally shifted to the right in a dose-dependent, parallel fashion by constant infusion of ASL-8052."( Beta-blocking and hemodynamic effects of ASL-8052.
Gorczynski, RJ; Hwang, TF; Murthy, VS,
)
0.38
" This phosphorylation of the receptor is dose-dependent with respect to isoproterenol and exhibits a dose-response curve coincidental with that for isoproterenol-induced desensitization of adenylate cyclase."( Desensitization of turkey erythrocyte adenylate cyclase. Beta-adrenergic receptor phosphorylation is correlated with attenuation of adenylate cyclase activity.
Caron, MG; Lefkowitz, RJ; Nambi, P; Peters, JR; Sibley, DR, 1984
)
0.5
" Thus, the dose-dependent hemodynamic effects of isoprenaline were significantly attenuated by oxyfedrine pre-treatment with a shift of the dose-response curve to the right; this was attributed to a beta-antagonistic property of oxyfedrine."( [Mechanism of action of oxyfedrine as a partial beta receptor agonist].
Bette, L; Rettig, G; Schieffer, H; Sternitzke, N, 1984
)
0.27
" In the adipocyte there were no significant effects of receptor site loss on the isoprenaline dose-response curve."( Irreversible antagonism of beta-adrenoceptors with para-amino-benzyl-carazolol provides further evidence for an atypical rat adipocyte beta-adrenoceptor.
Bojanic, D; Nahorski, SR, 1984
)
0.27
" Quinidine inhibited T3 formation, with a dose-response curve which was similar over the concentrations studied to that of DL-propranolol."( Inhibition by propranolol of 3,5,3'-triiodothyronine formation from thyroxine in isolated rat renal tubules: an effect independent of beta-adrenergic blockade.
Campbell, DG; Heyma, P; Larkins, RG, 1980
)
0.26
" Propranolol, in a dosage insufficient to change MABP, decreased both CO and CBF."( Relationship of cerebral blood flow to cardiac output, mean arterial pressure, blood volume, and alpha and beta blockade in cats.
Davis, DH; Sundt, TM, 1980
)
0.26
" Dose-response curves to intra-arterial administration of arachidonic acid (12 to 200 microgram kg-1), bradykinin (0."( Responses to arachidonic acid and other dilator agonists and their modification by inhibition of prostaglandin synthesis in the canine hindlimb.
Morcillo, E, 1980
)
0.26
" beta-Adrenoceptor blocking agents were found to interact with isoproterenol in a manner consistent with a simple competitive antagonism provided that (1) the antagonist had little intrinsic stimulant action on the preparation under study, (2) the concentrations of antagonist used had no direct depressant action on the preparation, (3) precautions were taken to assure that the pattern of antagonism was not distorted by loss of agonist into tissue sinks, and (4) dose-response curves were normalized for changes in the baseline frequency or force in successive curves."( Comparative assessment of beta-adrenoceptor blocking agents as simple competitive antagonists in isolated heart muscle: similarity of inotropic and chronotropic blocking potencies against isoproterenol.
Blinks, JR; Gilmour, DP; Kaumann, AJ; McInerny, TK, 1980
)
0.69
"25 mg/kg, bucindolol caused approximately 1000-fold and 100-fold shifts to the right in the dose-response curves for isoprenaline-induced chronotropic activity and hypotensive activity, respectively."( Studies in the rat on bucindolol, a new antihypertensive agent with beta-adrenoceptor blocking properties.
Oates, HF; Stoker, LM; Stokes, GS, 1981
)
0.26
" Metoprolol, a selective beta-1 receptor antagonist, significantly inhibited the glandular enlargement induced by dobutamine or isoproterenol and produced a parallel shift in the isoproterenol dose-response curve."( Adrenergic beta receptors mediating submandibular salivary gland hypertrophy in the rat.
Brenner, GM; Wulf, RG, 1981
)
0.47
" Coefficients of determination were calculated from the individual dose-response curves."( Assessment of beta blockade with propranolol.
Goldberger, V; Hager, WD; Mayersohn, M; Perrier, D; Pieniaszek, HJ, 1981
)
0.26
" Log dose-response curves for increases in both heart rate (mostly beta 1), and amplitude of physiologic tremor (beta 2) were constructed for each subject in the control state and 2 hr after 10 or 40 mg propranolol, 200 mg sotalol, or placebo."( Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor.
Fish, A; Perucca, E; Pickles, H; Richens, A, 1981
)
0.53
" Cumulative dose-response curves to the agonists were constructed before and after incubation with and washout of the irreversible beta-adrenoreceptor antagonist, Ro 03-7894 1-(5-chloracetylaminobenzfuran-2-yl)-2-isopropylaminoethanol)."( Dissociation constants of isoprenaline and orciprenaline and their relative efficacies on guinea-pig isolated atria determined by use of an irreversible beta-adrenoceptor antagonist.
Broadley, KJ; Nicholson, CD, 1981
)
0.26
" Thus shifts of the dose-response curves in BP and HR were observed."( A simple method to determine the ratio of cardiac to vascular beta-receptor blockade in the rat in vivo.
Kudo, Y; Sokabe, H; Zehr, JE, 1981
)
0.26
" 3a was 16 times more potent than labetalol in beta-adrenergic receptor blockade and was effective in lowering blood pressure in acute trials on spontaneously hypertensive rats at a dosage of 15 mg/kg."( 2-(Isoxazolylethenyl)phenoxypropanolamines: a new class of beta-receptor antagonists with antihypertensive activity.
Franke, A; Frickel, FF; Gries, J; Lenke, D; Schlecker, R; Thieme, PD, 1981
)
0.26
" The time course of inhibition, the extent of inhibition, and the dose-response relationship did not differ between the groups."( Normal alpha 2-adrenergic responses in platelets from patients with asthma.
Davis, PB; Lieberman, P, 1982
)
0.26
" Dose-response experiments with five logarithmically increased doses of pentagastrin and one dose of isoprenaline showed unchanged calculated maximum response and an increase in half-maximum acid response."( Effect of isoprenaline on pentagastrin-stimulated gastric acid secretion in dogs with gastric fistula.
Andersen, D; Bech, K; Gottrup, F; Hovendal, CP, 1981
)
0.26
" In dose-response studies, isoproterenol dose-dependently stimulated somatostatin secretion."( Effect of food deprivation on rat gastric somatostatin and gastrin release.
Arnold, R; Creutzfeldt, W; Koop, H; Schwab, E, 1982
)
0.56
" Dose-response curves to the relaxant effects of isoprenaline, salbutamol, adrenaline and noradrenaline were determined on the partially contracted smooth muscles of the cat nictitating membrane following alpha-adrenoreceptor blockade in order to test the hypothesis of a causal relationship between the inhibition of neuronal uptake and denervation supersensitivity."( Denervation and beta-adrenoreceptors of the cat nictitating membrane.
Nickerson, M; Varma, DR, 1981
)
0.26
" 2 Isoprenaline heart rate dose-response curves showed parallel shifts to the right after oral prizidilol, indicating antagonism by this compound at beta-adrenoceptors in the heart."( An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride.
Curry, PV; Pitcher, DW; Trounce, JR, 1982
)
0.26
"In the isolated guinea-pig right atria and tracheal strips, both propranolol and YM-09538 caused a parallel shift of the dose-response curve for isoproterenol to the right, indicating that these two drugs block nonselectively the beta 1 1- and beta 2-adrenoceptors."( Comparison of airway obstruction induced by propranolol and YM-09538 (a combined alpha- and beta-adrenoceptor blocking drug).
Takenaka, T; Tomioka, K; Yamada, T, 1982
)
0.46
" The maximum of the dose-response curve to isoprenaline, constructed after incubation with Ro 03-7894 and a 3 hr bath-washout, was depressed by 89."( Comparison of the apparent irreversible beta-adrenoceptor antagonist Ro 03-7894 with propranolol in cardiac ventricular muscle by pharmacological and radioligand binding techniques.
Broadley, KJ; Rankin, A, 1982
)
0.26
" 4 The fact that the shift of the dose-response curve of isoprenaline-induced tachycardia was smaller after metoprolol than after propranolol supports the hypothesis that beta 2-adrenoceptors are present in the heart."( Relevance of selectivity and non-selectivity in beta-adrenoceptor blocking drugs.
Bonelli, J, 1982
)
0.26
" 2 The dosage of each drug administered double-blind was gradually increased over a period of 2 weeks and the dose to produce maximum inhibition of exercise-induced tachycardia was continued for one further week."( The effect of intrinsic sympathomimetic activity on beta-receptor responsiveness after beta-adrenoceptor blockade withdrawal.
Bhattacharjee, P; Cashin, J; Graham, BR; Prichard, BN; Tomlinson, B; Walden, RJ, 1982
)
0.26
" Alpha-2 adrenergic activation, achieved with 10 muM epinephrine and 30 muM propranolol, significantly inhibited forskolin-stimulated cyclic AMP accumulation and glycerol release, shifting the dose-response curves to the right."( Alpha-2 adrenergic activation inhibits forskolin-stimulated adenylate cyclase activity and lipolysis in human adipocytes.
Burns, TW; Bylund, DB; Forte, LR; Langley, PE; Terry, BE, 1982
)
0.26
" Dose-response curves to isoproterenol (0."( The effects of a beta-2 selective adrenergic receptor antagonist (ICI 118,551) on twitch tension in cat soleus muscle.
Halliday, SE; Rouse, W; Smith, HJ, 1983
)
0.57
" The dose-response curve with five doses of bethanechol with and without isoprenaline was in accordance with a non-competitive inhibition."( Effect of isoprenaline on bethanechol-stimulated gastric acid secrtion and mucosal blood flow in dogs with gastric fistula.
Bech, K; Hovendal, CP, 1982
)
0.26
" Dose-response experiments with five logarithmically increasing doses of bethanechol and one dose of isoprenaline showed inhibition of a non-competitive type."( Effect of isoprenaline on bethanechol-stimulated gastric antral motility in dogs with gastric fistula.
Bech, K; Hovendal, CP, 1982
)
0.26
" The two events generally paralleled one another when analyzed in terms of dose-response and time-response relationships."( Role of cyclic AMP in adrenergically-induced tracheal muscle relaxation.
Lau, YS; Lum, BK, 1983
)
0.27
"We have compared bronchodilator dose-response curves to inhaled salbutamol in seven normal and eight asthmatic subjects."( Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects.
Barnes, PJ; Pride, NB, 1983
)
0.27
" Pre-treatment of the rats with syrosingopine shifted the dose-response curve to the left (enhancement) while combined propranolol (800 micrograms/kg) and phentolamine (800 micrograms/kg) shifted the dose-response curve to the right (depression)."( Rat endometrial bioelectric activity in vivo and in vitro: effects of adrenaline.
Levin, RJ; Phillips, JC, 1983
)
0.27
" Results of the electrocardiographic studies in heavy rats, using the calculated LD20 dosage of isoproterenol with or without pretreatment of aminophylline, demonstrated that both mortality and the arrhythmia-inducing effect of isoproterenol were significantly potentiated by aminophylline but only mortality was increased in small rats."( Enhancement of cardiotoxic effects of beta-adrenergic bronchodilators by aminophylline in experimental animals.
Balazs, T; Bloom, S; Joseph, X; Whitehurst, VE,
)
0.35
" Photoinactivation of beta-adrenoceptors caused a considerable parallel shift in the dose-response curve of isoprenaline."( Relationship between intrinsic activity of beta-adrenoceptor agonist and amount of spare receptors in guinea pig taenia caecum.
Koike, K; Takayanagi, I, 1983
)
0.27
" Graded bolus injections of isoprenaline sulphate were given intravenously and control dose-response curves were drawn for the changes in heart rate and blood pressure."( Heart rate and blood pressure responses to intravenous boluses of isoprenaline in the presence of propranolol, practolol and atropine.
Arnold, JM; McDevitt, DG, 1983
)
0.27
" Using three beta-adrenoceptor agonists: terbutaline (beta 2), dobutamine (beta 1), and isoprenaline and monitoring atenolol's antagonism of the agonist effects on heart rate, airway elastance and soleus muscle tension, parallel shifts in dose-response curves for each agonist were observed on each parameter."( The determination of beta-adrenoceptor antagonist cardioselectivity "in vivo": atenolol in anaesthetized cats.
Kiyingi, KS; Temple, DM, 1983
)
0.27
" The dose-response analysis indicates that the concentration of epinephrine used (50 microM) is at or near the maximal effective dose."( The effect of catecholamines on H+ and NH+4 excretion in toad urinary bladder.
Frazier, LW, 1983
)
0.27
" However, the biphasic nature of the dose-response curves and the antagonist inhibition curves indicated additionally the presence of an alpha-component."( Quantitative differentiation of alpha- and beta-adrenergic respiratory responses in isolated hamster brown fat cells: evidence for the presence of an alpha 1-adrenergic component.
Cannon, B; Mohell, N; Nedergaard, J, 1983
)
0.27
"The dose-response curves of the beta-adrenergic agonists isoprenaline (mixed beta 1 and beta 2), prenalterol (beta 1-selective), noradrenaline (more beta 1 than beta 2) and salbutamol (beta 2-selective) were studied on adipose cells of the rat, in vitro."( Characterization of the beta-adrenoceptor of the adipose cell of the rat.
Curtis-Prior, PB; Tan, S, 1983
)
0.27
" At the lower temperature, supersensitivity to orciprenaline and isoprenaline was exhibited as shifts of the dose-response curves to the left and significant reductions in EC50 values."( Temperature-induced changes in dissociation constants (KA) of agonists at cardiac beta-adrenoceptors determined by use of the irreversible antagonist Ro 03-7894.
Broadley, KJ; Williams, RG, 1983
)
0.27
" The effects of isoprenaline on four parameters in the anaesthetized cat: heart rate, blood pressure, soleus muscle contractility and airway reactance, were measured and the modification of the isoprenaline dose-response relation by each of the antagonist drugs assessed."( The selectivity of beta-adrenoceptor antagonists on isoprenaline-induced changes in heart rate, blood pressure, soleus muscle contractility and airways function in anaesthetized cats.
Letts, LG; Richardson, DP; Temple, DM; Williams, LR, 1983
)
0.27
" Such a transformation will introduce error into the value of KA unless the pre- and postinactivation dose-response curves are also rectangular hyperbolas."( Analysis of dose-response curves and calculation of agonist dissociation constants using a weighted nonlinear curve fitting program.
Malta, E; McPherson, GA; Molenaar, P; Raper, C, 1983
)
0.27
" The ratios of beta 1- to alpha 1-adrenoceptor antagonism as calculated from the relative shifts of the isoprenaline and phenylephrine dose-response curves, were 3 to 1 for labetalol and about 7 to 1 for medroxalol."( Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties.
Elliott, HL; McLean, K; Meredith, PA; Reid, JL; Sumner, DJ, 1984
)
0.27
" Preincubation with cocaine, 10(-5) M, shifted the inhibitory dose-response curves of Iso and Orc to the left, 16."( Mechanism of action of isoprenaline, isoxuprine, terbutaline and orciprenaline on gravid human isolated myometrium. Influence of the neuronal uptake process.
Calixto, JB; Simas, CM, 1984
)
0.27
"6 mM) produced a non-parallel shift to the right of dose-response curves to (-)-isoprenaline in K+ depolarized uterine preparations from the guinea-pig."( Is Ro 03-7894 an irreversible antagonist at beta-adrenoceptor sites?
Krstew, E; Malta, E; McPherson, GA; Molenaar, P; Raper, C, 1984
)
0.27
"The influence of different baseline values (blood pressure, heart rate) on ED50- and Emax-values of isoprenaline dose-response curves (DRC) in the presence and absence of beta-blocking drugs was assessed in urethane-anesthetized rats."( Assessment of adrenergic beta-blockade in the anesthetized rat at different baseline values.
Brunner, F; Pöch, G, 1984
)
0.27
" Dose-response experiments with bethanechol and dopamine showed inhibition of a non-competitive type."( Dopaminergic and beta-adrenergic effects on gastric antral motility.
Andersen, D; Bech, K; Gottrup, F; Hovendal, CP, 1984
)
0.27
" Isoprenaline dose-response curves for systolic and diastolic blood pressure, heart rate and PRA showed similar parallel shifts after 1 day and 2 weeks of treatment."( Antihypertensive effect and degree of beta-adrenoceptor blockade after short-term and semi-chronic propranolol therapy.
Boer, P; Dorhout Mees, EJ; Leenen, FH, 1984
)
0.27
" The dose-response curves constructed with intra-arterial or intravenous isoprenaline behave similarly in the presence of both atenolol 50 mg and propranolol 40 mg."( Enhancement of physiological finger tremor by intravenous isoprenaline infusions in man: evaluation of its role in the assessment of beta-adrenoceptor antagonists.
Arnold, JM; McDevitt, DG, 1984
)
0.27
" Furthermore, dose-response studies, using direct systemic administration of the two beta-adrenoceptor antagonists, revealed that ICI 118,551 is about 60 times less potent than timolol in blocking isoprenaline-induced cardio-acceleration."( ICI 118,551: an effective ocular hypotensive agent with selectivity for the ciliary process beta 2-adrenoceptor and with minimal cardiac side effects.
Nathanson, JA, 1984
)
0.27
" No age differences were seen in the time course of amylase release following (-)-isoproterenol stimulation or in the (-)-isoproterenol dose-response curve."( Beta-adrenergic regulation of rat parotid gland exocrine protein secretion during aging.
Baum, BJ; Ito, H; Roth, GS, 1981
)
0.49
" During propranolol administration, all dose-response curves to isoproterenol were predictably shifted to the right."( Myocardial sensitivity to isoproterenol following abrupt propranolol withdrawal in conscious dogs.
Daniell, HB; Newman, WH; Walle, T; Webb, JG,
)
0.67
" Within a limited dose range, linear/log dose-response curves can be obtained after application of histamine or bradykinin."( Use of 125I-labeled human serum albumin for quantitation of microvascular permeability in rat skin: reevaluation of an old method for studies on substances with an enhancing effect on microvascular permeability.
Gerdin, B, 1981
)
0.26
" Similar dose-response curves for cyclic AMP production were obtained."( Catecholamine stimulation of testosterone production via cyclic AMP in mouse Leydig cells in monolayer culture.
Cooke, BA; Dix, CJ; Golding, M; Hunter, MG, 1982
)
0.26
" The equipotent beta-blocking dose of each drug was obtained by comparing isoproterenol dose-response curves."( Effects of equipotent blocking doses of acebutolol, acebutolol's primary metabolite, and propranolol on left ventricular hemodynamics in conscious awake dogs.
Griffin, G; Harrison, DC; Kernoff, R; Magder, S; Rubenson, D,
)
0.36
" Significantly, the dose-response curves for isoproterenol stimulation of lipolysis and respiration were both shifted by adenosine to higher agonist concentrations by the same order of magnitude, providing additional evidence for a tight coupling between lipolysis and respiration."( Control of brown adipose tissue lipolysis and respiration by adenosine.
Bukowiecki, LJ; Szillat, D, 1983
)
0.53
" Dose-response curves for isoproterenol and fluoride in the reconstituted system were similar to those reported for avian erythrocyte and liver membranes, respectively."( Reconstitution of a hormone-sensitive adenylate cyclase with membrane extracts from Neurospora and avian erythrocytes.
Flawiá, MM; Kornblihtt, AR; Reig, JA; Torres, HN; Torruella, M, 1983
)
0.57
" IPR administered to euthyroid rats in a dosage of 5 mg/kg/day for 4 days induced cardiomegaly."( Study of the factors influencing cardiac growth. I. Comparison of cardiomegaly induced by isoproterenol in euthyroid and thyroidectomized rats.
Nosztray, K; Szabó, J; Szegi, J; Takács, IE, 1984
)
0.49
" The mean log dose-response curve for the elderly group was displaced to the right and the mean maximum response was less than that for the young subjects."( Age and beta adrenoceptor-mediated function.
Chung, S; Dillon, N; Kelly, J; O'Malley, K, 1980
)
0.26
" This observation was substantiated from the vertical displacement of dose-response curves from four concentrations of isoprenaline added sequentially."( An apparent preferential antagonism by practolol of the positive inotropic responses of guinea-pig isolated atria to isoprenaline.
Broadley, KJ; Nicholson, CD, 1980
)
0.26
" Unexpected differences, not previously reportd, were found in the shapes of the cAMP accumulation dose-response curves of norepinephrine and isoproterenol."( Neonatal rat pinealocytes: typical and atypical characteristics of [125I]iodohydroxybenzylpindolol binding and adenosine 3',5'-monophosphate accumulation.
Auerbach, DA; Aurbach, GD; Klein, DC; Woodard, C, 1981
)
0.46
" The dose-response curve for isoprenaline was shifted to the right and downward in the presence of YC-93 in a concentration-dependent manner, and the positive inotropic action of calcium was also inhibited markedly by YC-93."( Dissociation of cyclic AMP and contractile responses to isoprenaline: effects of a dihydropyridine derivative, nicardipine (YC-93), on canine ventricular muscle.
Endoh, M; Taira, N; Yanagisawa, T, 1980
)
0.26
" Cumulative dose-response curves to the beta agonists (-)-isoproterenol and (-)-soterenol were obtained after mixing each agonist with (+/-)-sotalol at fixed ratios (Q = [antagonist]/[agonist])."( On the use of a dynamic approach to the estimation of dissociation constants for reversible competitive antagonists.
Amidon, GL; Buckner, CK, 1981
)
0.51
" The full isoproterenol dose-response curves were similar in all groups."( Unaltered lymphocyte beta-adrenoceptor responsiveness in hyperthyroidism and hypothyroidism.
Silas, JH; Smith, BM; Yates, RO, 1981
)
0.67
" Cumulative dose-response curves with epinephrine and norepinephrine showed graded contraction."( Adrenergic receptors and sympathetic agents in isolated human pulmonary arteries.
Boe, J; Simonsson, BG, 1980
)
0.26
" Three days post-AMI the dose-response curve for isoproterenol of right ventricular dP/dtmax was significantly depressed, while the inotropic effect of histamine was not impaired."( Impaired beta-adrenergic stimulation in the uninvolved ventricle post-acute myocardial infarction: reversible defect due to excessive circulating catecholamine-induced decline in number and affinity of beta-receptors.
Baumann, G; Blömer, H; Blümel, G; Erhardt, WD; Felix, SB; Ludwig, L; Riess, G, 1981
)
0.52
" Dose-response curves were determined for isoproterenol on cAMP levels, protein kinase activity and glycerol release."( Relationship among isoproterenol, cyclic AMP, cyclic AMP-dependent protein kinase and lipolysis in perfused fat cells.
Allen, DO; Long, KJ; Sengupta, K, 1981
)
0.86
" However, in the presence of 22 mM K+, but not tetrodotoxin, the dose-response and temporal relationships between isoproterenol and elevations in cAMP concentration were shifted to the right, whereas those for phosphorylase activation were shifted to the left."( Isoproterenol-induced restoration of contraction in K+-depolarized hearts: relationship to cAMP.
Friedman, WF; Ingebretsen, WR; Mayer, SE, 1981
)
1.92
" Dose-response curves to the racemate were always situated between the stereoisomers, approximately 2-fold to the right of (+)-dobutamine."( Alpha and beta adrenergic effects of the stereoisomers of dobutamine.
Murphy, PJ; Pollock, GD; Ruffolo, RR; Spradlin, TA; Waddell, JE, 1981
)
0.26
" Isoproterenol and acetylcholine were administered intra-arterially in progressively increasing bolus injections, and dose-response curves were constructed for changes in blood flows, arterial pressure, and heart rate."( Responses of the pelvic vascular bed to intra-arterial stimulation of beta-adrenergic and cholinergic receptors in pregnant and nonpregnant sheep.
Assali, NS; Brinkman, CR; Erkkola, R; Nuwayhid, B; Tabsh, K; Ushioda, E, 1981
)
1.17
" As indicated by dose-response curves, receptor occupancy of each occurs to an almost equal extent at suboptimal epinephrine concentrations."( Cyclic AMP-dependent and cyclic AMP-independent antagonism of insulin activation of cardiac glycogen synthase.
Angelos, KL; Ramachandran, C; Walsh, DA, 1982
)
0.26
" These recordings disclosed qualitative differences between the alpha-and Beta-inotropic response both in dose-response and time course experiments."( Differences between alpha-adrenergic and beta-adrenergic inotropic effects in rat heart papillary muscles.
Osnes, JB; Oye, I; Skomedal, T, 1982
)
0.26
" Tapering propranolol dosage is frequently used in the hope of preventing adverse withdrawal events but the success of such a maneuver has not been shown."( Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule.
Lutterodt, A; Nattel, S; Rangno, RE, 1982
)
0.26
" The release of free acids (FFA) into the incubation medium was measured after addition of increasing concentrations of catecholamines and the dose-response curves were evaluated."( Responsiveness of the trimmed rat subcutaneous adipose tissue beta-receptors to catecholamines in ontogenesis.
Mourek, J; Mühlbachová, E, 1982
)
0.26
" These actions of ritodrine were much the same as those of isoprenaline but the dose-response curves of all parameters were shifted to the right."( Effects of ritodrine, a beta 2-adrenoceptor agonist, on smooth muscle cells of the myometrium of pregnant rats.
Izumi, H; Kishikawa, T, 1982
)
0.26
" For this purpose, dose-response curves for isoproterenol before and after addition of propranolol (5 X 10(-9) to 10(-6) M) or phentolamine (10(-6) M) to the bath were determined."( [Analysis of the contraction induced by isoproterenol in isolated cerebral and femoral arteries of cat].
Marín, J; Salaices, M, 1982
)
0.79
" Full dose-response curves for isoproterenol were constructed in BP and HR."( The ratio of cardiac to vascular beta-receptor blockade of atenolol and propranolol in spontaneously hypertensive rats in vivo.
Kudo, Y; Sokabe, H, 1982
)
0.55
" Dose-response relation was obtained in terms of various doses of ISO and the increments of heart rate (deltaHR) produced by ISO."( Estimated affinity of isoproterenol to cardiac chronotropic beta-receptor and of phenylephrine to vasoconstrictive alpha-receptor of the systemic resistance vessels in human borderline hypertension.
Hirakawa, S; Ito, H; Tonai, N, 1983
)
0.58
" A role for cAMP-dependent protein kinase activation in regulating mucin secretion was strongly suggested by the following: (1) the kinase activity ratio increased rapidly after beta-adrenergic receptor stimulation; (2) dose-response relationship of the kinase activation following beta-adrenergic receptor activation correlated with isoproterenol induced mucin release; (3) termination of beta-adrenergic mediated mucin secretion caused a rapid decrease in the kinase activity ratio; (4) dibutyryl cyclic AMP stimulation caused an increase in the kinase ratio; whereas (5) pure cholinergic and pure alpha-adrenergic receptor stimulation had no effect on endogenous kinase activity."( Role of cyclic AMP-dependent protein kinase activation in regulating rat submandibular mucin secretion.
Barzen, KA; Deisher, LM; Quissell, DO, 1983
)
0.44
"7-fold) toward increased sensitivity in the dose-response curve for adenylate cyclase activation by isoproterenol."( Independent regulation of beta-adrenergic receptor and nucleotide binding proteins of adenylate cyclase. Developmental and denervation-dependent responses in rat parotid.
Ludford, JM; Talamo, BR, 1983
)
0.48
" Neither timolol (a nonselective beta-antagonist) nor atenolol (a beta 1-selective antagonist) had a significant effect on basal secretory rate, but both shifted the isoproterenol dose-response curve to the right without changing its slope, suggesting competitive antagonism."( Evidence that beta 1-adrenoceptor activation mediates isoproterenol-stimulated renin secretion in the rat.
Churchill, MC; Churchill, PC; McDonald, FD, 1983
)
0.71
" Satisfactory dose-response curves could be constructed for the isoprenaline enhanced increases in finger tremor."( An assessment of physiological finger tremor as an indicator of beta-adrenoceptor function.
Arnold, JM; McDevitt, DG, 1983
)
0.27
" Ouabain produced a monophasic dose-response curve in atria but a biphasic curve in papillary muscles."( Chronic diabetes decreases the ouabain inotropic response in rat left atria and papillary muscles.
McCullough, AL; McNeill, JH, 1983
)
0.27
" In the presence of YOH, the ISO dose-response curve therefore completely disappears."( Lipolysis in rat adipose tissue in vitro and its alpha 2 adrenergic control.
Horný, I; Kadrabová, M; Mühlbachová, E; Zámostný, V, 1983
)
0.27
" Furthermore, the dose-response curves for ACTH and forskolin were clearly shifted to the left in adipocytes from toxin-treated hamsters as compared to control adipocytes."( Effect of pertussis toxin on the hormonal regulation of cyclic AMP levels in hamster fat cells.
García-Sáinz, JA; Martínez-Olmedo, MA, 1983
)
0.27
" Time course and insulin dose-response experiments indicate an additional proximal alteration."( beta-Adrenergic desensitization by chronic insulin exposure in 3T3-L1 cultured adipocytes.
Olansky, L; Pohl, SL, 1984
)
0.27
" ED50 values and dissociation constants for norepinephrine (NE), epinephrine (EPI), isoproterenol (ISO), methoxamine (MET) and clonidine (CLO) were determined by analysis of dose-response data with and without partial inactivation of alpha receptors by phenoxybenzamine."( Characterization of the alpha adrenergic receptor properties of rabbit ear artery and thoracic aorta.
Purdy, RE; Stupecky, GL, 1984
)
0.49
" Pressor responsiveness was evaluated acutely on the basis of dose-response curves (0."( Pressor responses of rats to vasopressin: effect of sodium, angiotensin, and catecholamines.
Brunner, HR; Burnier, M, 1983
)
0.27
" Cumulative dose-response curves for isoproterenol, norepinephrine and methoxamine were made for the different groups."( In vitro contractile responses of the uterus from 'restricted diet' rats to adrenoceptor agonists. Influence of cyclo-oxygenase inhibitors.
Gimeno, AL; Gimeno, MA; Goldraij, A; Sterin, AB, 1983
)
0.54
" In isolated right atria IQB-M-81 did not block the positive chronotropic and inotropic responses to isoprenaline but shifted the dose-response curve to the right."( Comparison of three beta-amino anilides: IQB-M-81, lidocaine and tocainide, on isolated rat atria.
Barrigón, S; Tamargo, J; Tejerina, T, 1983
)
0.27
" For both tissue regions fasting induced a right-ward shift in the dose-response curve for the inhibitory effect of the alpha 2 agonist, clonidine, on theophylline-induced lipolysis, corresponding to a 10-fold decrease in sensitivity."( Influence of fasting on lipolytic response to adrenergic agonists and on adrenergic receptors in subcutaneous adipocytes.
Arner, P; Engfeldt, P; Kimura, H; Ostman, J; Wahrenberg, H, 1984
)
0.27
"It has been suggested that the use of a cumulative technique to obtain bronchodilator dose-response curves will cause a greater response than a non-cumulative technique, because sequential doses of drug will penetrate further into the lung."( Comparison of cumulative and non-cumulative techniques to measure dose-response curves for beta agonists in patients with asthma.
Britton, J; Tattersfield, A, 1984
)
0.27
" PY decreased the maximum inotropic and chronotropic responses to isoprenaline and caused a dose-response parallel shift of the Ca dose-response curve."( Inotropic and electrophysiological effects of PY 108-068 on isolated cardiac preparations.
Delgado, C; Diez, J; Tamargo, J; Tejerina, MT, 1984
)
0.27
" In normal Tyrode's solution, flurazepam (1 X 10(-6), 1 X 10(-5) and 1 X 10(-4) M) noncompetitively shifted the dose-response curves for CaCl2 downwards."( Ca2+-antagonistic effects of flurazepam, a benzodiazepine derivative, on isolated guinea-pig left atria.
Akutagawa, K; Ishii, K; Makino, M, 1983
)
0.27
" Cumulative dose-response curves for the effect of the four drugs on the blocking of slow action potentials (using Vmax as the indicator) were analyzed by Hill plots."( Calcium antagonist blockade of slow action potentials in cultured chick heart cells.
Li, T; Sperelakis, N, 1983
)
0.27
" Thus a bell-shaped dose-response curve resulted for the inhibition of isoprenaline by Mn2+."( Antagonism by manganese of isoprenaline dilatation of the guinea-pig isolated trachea.
Jamieson, DD; le Coutier, A; Quinn, RJ,
)
0.13
" No effects specific to cystic fibrosis serum were demonstrated using the following parameters for evaluation: (1) maximal stimulation of mucin release by a beta-adrenergic agonist, (-)-isoproterenol; (2) basal release (unstimulated secretion) of mucin material; and (3) the dose-response relationship for mucin release after beta-adrenergic receptor stimulation."( Effect of serum from normal and cystic fibrosis subjects on mucin secretion from dispersed rat submandibular cells.
Barzen, KA; Deisher, LM; McDonald, RJ; Quissell, DO, 1983
)
0.46
" The dose-response curve for Phe was markedly shifted to the left by papaverine in 6W rats, but slightly in 7M rats."( Age-dependent differences in the positive inotropic effect of phenylephrine on rat isolated atria.
Hashimoto, H; Nakashima, M; Sugino, N, 1983
)
0.27
" For the slow APs, the dose-response curves for isoproterenol versus Vmax (the maximum rate of rise of the APs), overshoot, and AP amplitude were linear between 10(-9) M and 10(-6) M (10(-5 M in some cases) in the juvenile and young adult rats."( Age-dependent changes in electrophysiologic characteristics of fast and slow action potentials in rat papillary muscle.
Balazs, T; Ehrreich, S; Johnson, G; Kojima, M; Sperelakis, N, 1983
)
0.52
" Dose-response curves were obtained one week prior to pretreatment and 24, 48, 72 and 168 hours after the last dose of propranolol."( Propranolol withdrawal-induced supersensitivity to the chronotropic effects of isoproterenol in the conscious rabbit.
Tenner, TE, 1983
)
0.49
" This study indicates that the bronchodilating effect of terbutaline administered via the spacer is dose-dependent at the first inhalation, and that succeeding inhalations show no dose-response effects."( Cumulative dose response study comparing clinical effects of two doses of terbutaline sulphate administered via a 750 ml spacer to asthmatic patients.
Franck, K; Laursen, LC; Munch, EP; Taudorf, E; Weeke, B, 1984
)
0.27
"Dose-response studies in vitro and in vivo revealed four types of alterations of dose-response curves along with changes in the baseline, two of them in accordance and two in disagreement with Wilder's law of initial value (LIV)."( The underlying bases of pharmacological results in agreement or disagreement with the law of initial value.
Brunner, F; Pöch, G, 1984
)
0.27
"Length-contractile force curves and dose-response curves of heart rate, blood pressure, and contractile force were recorded from the left ventricle of six anesthetized dogs in a control state."( Persistence of myocardial failure following removal of chronic volume overload.
Newman, WH; Privitera, PJ; Webb, JG, 1982
)
0.26
" Phentolamine produced parallel shift of the dose-response curves both for arteries and veins."( Analysis of vasospasm in hand arteries by in vitro pharmacology, hand angiography and finger plethysmography.
Arneklo-Nobin, B; Edvinsson, L; Eklöf, B; Haffajee, D; Owman, C; Thylén, U, 1983
)
0.27
" Exogenous adenosine (10(-6) M) depressed slow APs at low and high isoproterenol concentrations and shifted the isoproterenol dose-response curve to the right in the atrium."( Potentiation of slow action potentials with theophylline or "micro" adenosine deaminase.
Berne, RM; Knabb, MT; Rubio, R, 1983
)
0.5
" This was associated with a shift of the blood pressure dose-response curves to the left, and larger falls in mean, systolic and diastolic pressures (30."( Contribution of the vagus to the haemodynamic responses following intravenous boluses of isoprenaline.
Arnold, JM; McDevitt, DG, 1983
)
0.27
" The lowest dosage of fenoterol was as effective as the highest but had fewer adverse effects."( Comparison of fenoterol, isoproterenol, and isoetharine with phenylephrine aerosol in asthma.
Epstein, JD; Gruebel, BJ; Rotman, HH; Spellman, GG; Weg, JG,
)
0.43
" The dose-response curves for isoprenaline competition in binding of [125I]iodohydroxybenzylpindolol by dividing cells showed that the EC50 (effective concentration for half maximum activity) value for isoprenaline was higher in the presence of p[NH]ppG."( Characteristics of the beta-adrenergic adenylate cyclase system of developing rabbit bone-marrow erythroblasts.
Arnstein, HR; Setchenska, MS, 1983
)
0.27
" It is concluded that in suitable dosage (which varies for different vessels) noradrenaline is capable of enhancing flow and this might, at least in part, explain the increase in lymph flow resulting from noradrenaline infusion in living animals."( The effects of catecholamines on pumping activity in isolated bovine mesenteric lymphatics.
McHale, NG; Roddie, IC, 1983
)
0.27
" Dose-response relationships for isoproterenol (isopropylnoradrenaline, IPNA) showed that hearts from alcohol-treated animals did not respond as well as hearts from control animals at higher doses of IPNA."( The effects of chronic ethanol consumption on cardiac function in rats.
Chan, TC; Sutter, MC, 1982
)
0.55
" In a dose-response experiment the tumour and subcutaneous vascular beds seemed to be equally sensitive to noradrenaline."( Influence of vasoactive drugs on local tumor blood flow.
Lilja, J; Mattsson, J; Peterson, HI, 1982
)
0.26
" Dose-response curves for various vasoactive agents were obtained before and after exposure to captopril (2 x 10(-4) M) for 30 minutes."( Effect of in vitro administration of captopril on vascular reactivity of rat aorta.
Fregly, MJ; Kikta, DC,
)
0.13
" The dose-response curves to increasing doses of isoprenaline, norepinephrine or methacholine showed in hyperthyroid animals increased salivary secretion, while in hypothyroid animals the dose-response to the drug was reduced."( Effects of thyroid function on submaxillary gland sensitivity to autonomic nervous drugs.
Gamper, CH; Houssay, AB; Medina, JH; Tumilasci, OR,
)
0.13
" These data show that abrupt withdrawal of pindolol after long-term dosing leads to transient cardiac hyperresponsiveness of resting and exercise heart rate at the same time as persistent cardiac hyporesponsiveness to isoproterenol."( Cardiac hyper- and hyporesponsiveness after pindolol withdrawal.
Langlois, S; Rangno, RE; Stewart, J, 1982
)
0.45
" In isolated right atria, josamycin did not block the positive inotropic and chronotropic responses to isoprenaline but shifted the dose-response curve to Ca to the right."( A comparison of josamycin with macrolides and related antibiotics on isolated rat atria.
De Miguel, B; Tamargo, J; Tejerina, MT, 1982
)
0.26
" Phentolamine competitively antagonized ADR and PE-induced contractile responses of arteries while on veins, ISOP and PE dose-response curves (DRCs) were shifted to the right in the presence of propranolol."( Autonomic and autacoid activity in antigen-sensitized and control ovine pulmonary vein and artery.
Eyre, P; Mirbahar, KB, 1982
)
0.26
" When the dosage of isoproterenol was increased to 10 mg/kg and 2 injections of the drug were given (at 2 h intervals) pineal melatonin levels also did not exhibit a significant increase."( In vivo responses of the pineal gland of the Syrian hamster to isoproterenol or norepinephrine.
Lipton, JS; Petterborg, LJ; Reiter, RJ; Steinlechner, S, 1982
)
0.83
" Incubation of tissues with papaverine (1 hr) changed the usual dose-response curve to isoproterenol into a low, monotonous effect, independent of the agonist dose."( Papaverine-induced changes on cardiac inotropism with special reference to a D-propranolol antagonism.
Aramendía, P; Márquez, MT, 1982
)
0.49
"Cumulative dose-response curves were produced for the effect of different adrenergic agonists on the contractions of uterine strips from natural estrous and ovariectomized rats."( Inhibitory effects of some catecholamines on contractions of uterine strips isolated from estrous and spayed rats. Influence of endogenous and exogenous prostaglandins on the action of methoxamine.
Agostini, MC; Borda, E; Gimeno, AL; Gimeno, MF; Sterin-Borda, L, 1981
)
0.26
" Allopurinol at higher dosage diminished the noradrenaline-induced decrease of heart rate and increase of blood pressure."( [Effect of allopurinol on adrenergically induced changes in serum lipid levels, heart rate and blood pressure in normal and ischemic rabbits (author's transl)].
Förster, W; Lohse, M; Riedel, H; Sziegoleit, W, 1982
)
0.26
" He responded to ventilator support, transvenous pacing, and massive dosage of isoprenaline."( Self-poisoning with propranolol.
Fisher, MM; Ibels, LS; Tynan, RF, 1981
)
0.26
" The dose-response relation between alinidine and frequency is not altered by atropine, and alinidine does not block the positive chronotropic action of isoprenaline."( Pacemaker selectivity: influence on rabbit atria of ionic environment and of alinidine, a possible anion antagonist.
Millar, JS; Williams, EM, 1981
)
0.26
" Dose-response curves for tracheal vasodilatation to the three drugs were all parallel together, and trapidil was about 2700 time less potent than isoproterenol and about 3 times more potent than theophylline on a weight basis in producing tracheal vasodilatation."( Effects of trapidil on musculature and vasculature of the dog trachea in situ.
Maruyama, M; Satoh, K; Taira, N, 1981
)
0.46
" Dose-response characteristics showed that in AD-type fibers suppressive effect of adrenaline was always larger than that of noradrenaline, whilst in NA type fibers the two catecholamines caused the same degree of suppression of nerve activity."( Characteristics and functions of two types of efferent fibers in the adrenal nerve.
Hirano, T, 1981
)
0.26
" Maintenance dosing adjustments are then based on serum determinations and the presence of toxic effects."( Theophylline toxicity after the use of aminophylline in the treatment of cerebral vasospasm.
Bailey, RT; Blouin, RA; Rapp, RP; Young, B, 1981
)
0.26
" The chronotropic dose-response curves were made in both spontaneously beating atria while inotropic effects were derived from left atria driven at 1 Hz, 5 msec and voltage about 20 percent above threshold."( Interactions between sympathomimetic agonists and blocking agents: cardiac effects of phenylephrine and isoproterenol.
Aramendía, P; Márquez, MT; Mikulić, LE,
)
0.35
" (5) The left artial tension dose-response curves to histamine were not potentiated."( The effect of phosphodiesterase inhibitors on guinea-pig cardiac responses to histamine and isoprenaline.
Broadley, KJ; Wilson, C, 1980
)
0.26
" Dose-response curves obtained for carbachol and isoproterenol indicated that the maximum response to carbachol is greater than that to isoproterenol but that the threshold for response to isoproterenol is much lower than that to carbachol."( Autonomic control of lacrimal protein secretion.
Bromberg, BB, 1981
)
0.52
" Our findings suggest that the two effects have different dose-response relationships, with higher doses of adrenergic agonists needed to prevent EIA than to maintain bronchodilation."( Bronchodilation and inhibition of induced asthma by adrenergic agonists.
Beasley, PP; Eggleston, PA, 1981
)
0.26
" The greater efficacy of metaproterenol in asthmatic subjects but not in normal subjects can be explained by (1) different doses of the bronchodilator drug and (2) differing bronchodilator dose-response relationships in asthmatic and normal subjects."( Response to inhaled metaproterenol and isoproterenol in asthmatic and normal subjects.
Fairshter, RD; Wilson, AF, 1980
)
0.53
" The displacements of the dose-response curves for fenoldopam, dopexamine and dopamine were, however, non-parallel with significant depression of the maxima to 30."( Atypical antagonism of D1-receptor-mediated vasodilator response in the perfused kidney by SCH23390.
Broadley, KJ; Martin, SW, 1995
)
0.29
" In some test systems, replication of dose-response curves is not possible."( Use of resampling techniques to estimate the variance of parameters in pharmacological assays when experimental protocols preclude independent replication: an example using Schild regressions.
Corsi, M; Kenakin, TP; Krishnamoorthy, C; Lutz, MW; Menius, JA; Morgan, PH; Rimele, T, 1995
)
0.29
"As atrial natriuretic factor (ANF) is intimately involved in water and electrolyte homeostasis, dose-response studies were performed in the parotid as well as submaxillary glands of the rat with increasing doses of the atrial peptide to investigate its possible role as a sialogogic agent."( Atrial natriuretic factor enhances induced salivary secretion in the rat.
Bianciotti, LG; Colatrella, C; Elverdin, JC; Fernández, BE; Vatta, MS, 1994
)
0.29
" Dose-response curves to isoprenaline in beta N22 cells indicated that half-maximal down-regulation of Gs alpha was produced by approx."( Agonist regulation of cellular Gs alpha-subunit levels in neuroblastoma x glioma hybrid NG108-15 cells transfected to express different levels of the human beta 2 adrenoceptor.
Adie, EJ; Milligan, G, 1994
)
0.29
" When dose-response curves for the phosphodiesterase (PDE) inhibitor 3-isobutyl-1-methylxanthine (IBMX) were compared using perforated-patch vs."( Perforated-patch recording does not enhance effect of 3-isobutyl-1-methylxanthine on cardiac calcium current.
Kawamura, A; Wahler, GM, 1994
)
0.29
" In nonfailing ventricular myocardium, both DL-sotalol and D-sotalol shifted the dose-response curve for isoproterenol to higher concentrations (P < ."( Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions.
Fraedrich, G; Hasenfuss, G; Holubarsch, C; Just, H; Pieske, B; Posival, H; Ruf, T; Schneider, R, 1995
)
0.51
"Prospective, dose-response study."( Isoproterenol-dependent decrease in oxygen uptake and respiratory enzyme activities in rat myocardial tissue and mitochondria.
Boveris, A; Carreras, MC; Del Bosco, CG; Fernandez, S; Poderoso, JJ, 1995
)
1.73
" The results reveal that at a series of dosage combinations of AII [100 and 125 micrograms/kg, subcutaneously (SC)] and isoproterenol (ISOP) (10, 12."( Effect of administration of angiotensin II and isoproterenol, alone and in combination, on drinking and tail skin temperature of the rat.
Fregly, MJ; Rowland, NE, 1995
)
0.76
" The dose-response curve of isoprenaline/HR was significantly shifted to the right after hypoglycemia."( Reduced beta-adrenergic sensitivity in healthy volunteers induced by hypoglycemia.
Jaeger, R; Jorde, R; Sager, G; Trovik, TS, 1995
)
0.29
" Bronchodilator dose-response studies were performed by administering increasing doses of isuprel intravenously before and after treatment with salbutamol."( [Bronchial reactivity after regular inhalation of salbutamol].
Krasnowska, M; Małlolepszy, J; Passowicz-Muszyńska, E, 1995
)
0.29
"We exposed fetuses to high-altitude (3,820 m) hypoxemia from 30 to 130 days gestation, when we measured fetal heart rate, right and left ventricular outputs with electromagnetic flow probes, and arterial blood pressure during an isoproterenol dose-response infusion."( Effects of isoproterenol on the cardiovascular system of fetal sheep exposed to long-term high-altitude hypoxemia.
Gilbert, RD; Kamitomo, M; Ohtsuka, T, 1995
)
0.86
" Slope of log dose-response for heart rate and QS2i was similar with dobutamine and with isoprenaline, corresponding to stimulation of the same type of beta-adrenergic receptors (beta 1-subtype)."( Evaluation of cardiac beta 1-adrenergic sensitivity with dobutamine in healthy volunteers.
Chalon, S; Diquet, B; Lechat, P; Pousset, F; Thomaré, P, 1995
)
0.29
" Both of them inhibited the contraction of the left atrium and reversed the frequency-contraction response from positive to negative staircase in the higher dosage (500 and 1 mumol."( Effects of osthole on isolated guinea pig heart atria.
Li, L; Yang, L; Zhang, CL; Zhao, DK; Zhao, GS; Zhuang, FE, 1995
)
0.29
" Dose-response curves for the inhibition of ROS phagocytosis by forskolin and isoproterenol demonstrated that this process is exquisitely sensitive to these agonists, with an IC50 for these drugs of 33 nmol/l."( The phagocytosis of rod outer segments is inhibited by drugs linked to cyclic adenosine monophosphate production.
Abrams, TA; Hall, MO; Mittag, TW, 1993
)
0.51
" The five opioid peptides induced no changes in the dose-response curves with isoproterenol and forskolin."( Effects of opioid substances on cAMP response to the beta-adrenergic agonist isoproterenol in human mononuclear leukocytes.
Ioverno, A; Lotti, G; Musso, NR; Pende, A; Vergassola, C, 1995
)
0.75
" Immature rings were more sensitive to NECA than mature rings as demonstrated by a lower ED50 and steeper slope of the dose-response curve."( Mechanisms of increased sensitivity to A2 adenosine receptor stimulation in immature rabbit aortic rings.
Girling, PW; Matherne, GP; McDaniel, NL, 1993
)
0.29
" Dose-response curves for oxygen consumption and brown adipose tissue temperature were identical, whichever of the beta-adrenoceptor agonists was used."( The beta-adrenoceptor selectivity profile of BRL 37344 in the pithed rat.
Cawthorne, MA; Oriowo, MA; Ruffolo, RR; Sennitt, MV; Smith, SA, 1994
)
0.29
" Isolated atrial strips showed a right shift of their dose-response curve to isoprenaline in the presence of the highly selective beta 2-AR antagonist ICI 118,551 at concentrations above 1 x 10(-8) mol/L."( The effects of sympathomimetics on the cardiovascular system of sheep.
Allen, R; Alley, MR; Baxter, S; Burgess, C; Crane, J; Dallimore, JA; Davie, PS; Kealey, AS; Lapwood, KR; Pack, RJ, 1994
)
0.29
" Dose-response experiments demonstrated that isoproterenol antagonized the action of alpha-thrombin and a thrombin receptor peptide on endothelial permeability and that it lowered baseline permeability."( Isoproterenol antagonizes endothelial permeability induced by thrombin and thrombin receptor peptide.
Andersen, TT; DeMichele, MA; Leonhardt, S; Minnear, FL; Teitler, M, 1993
)
1.99
" Activation of thermogenesis with the selective beta 3-agonist BRL 35135 (BRL) reduced heat influx by both obese and lean rats at doses between 2 and 10 micrograms/kg, but no dose-response effects were evident within this range."( Effects of beta-adrenoceptor agonists and antagonists on thermoregulation in the cold in lean and obese Zucker rats.
Carlisle, HJ; Dubuc, PU; Stock, MJ, 1993
)
0.29
" The dose-response curve of adenylate cyclase to the GTP analogue, GppNHp, was modified by 5HT, which promotes a significantly higher maximal response without altering the potency of GppNHp."( Heterologous sensitization of adenylate cyclase activity by serotonin in the rat cerebral cortex.
Brunello, N; Perez, J; Racagni, G; Rovescalli, AC; Steardo, L; Vitali, S, 1993
)
0.29
" Dose-response curves for sodium nitroprusside, nitroglycerin, isoproterenol, amrinone, and PGE1 were then generated."( Pulmonary vascular smooth muscle relaxation by cGMP- versus cAMP-mediated mechanisms.
Banerjee, A; Fullerton, DA; Hahn, AR; Harken, AH, 1994
)
0.53
"The frequency-dependent electrophysiologic effects of sematilide (n = 11) and amiodarone (n = 22) were determined at (1) drug-free baseline, (2) during steady-state (> 48 hours) dosing with sematilide (455 +/- 5 mg/d [mean +/- SEM]) or after 10."( The effects of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans.
Follmer, C; Godfrey, R; Pruitt, C; Sager, PT; Uppal, P, 1994
)
0.29
" Dose-response relationships of ISO or rolipram show a close correlation of the half-maximal effective dose (ED50) for injury reversal and perfusate cAMP production."( Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor.
Barnard, JW; Prasad, VR; Seibert, AF; Smart, DA; Strada, SJ; Taylor, AE; Thompson, WJ, 1994
)
0.29
"1 mumol/site) appeared to produce greater shifts of the dose-response curve to BK (0."( Cutaneous permeability responses to bradykinin and histamine in the guinea-pig: possible differences in their mechanism of action.
Douglas, GJ; Khawaja, AM; Lawrence, L; Page, CP; Paul, W; Perez, AC; Schachter, M, 1994
)
0.29
" Concentration-response curves for activation of lipolysis by each agonist correlated well with the dose-response curves for activation of cAMP-dependent protein kinase (A-Kinase)."( Correlation of beta 3-adrenoceptor-induced activation of cyclic AMP-dependent protein kinase with activation of lipolysis in rat white adipocytes.
Cawthorne, MA; Kirkham, DM; Murphy, GJ; Young, P, 1993
)
0.29
" Moreover, metoprolol and atenolol, two beta 1- AR- selective antagonists, shift the isoproterenol dose-response curve to the right with high potency as well."( No functional atypical beta-adrenergic receptors in human omental adipocytes.
Van Ermen, A; Van Liefde, I; Vauquelin, G, 1994
)
0.51
"1 ml), and dose-response curves to levcromakalim (a KATP channel opener) or isoproterenol were constructed."( Role of potassium channels in hypoxic relaxation of porcine bronchi in vitro.
Croxton, TL; Fernandes, LB; Hirshman, CA; Lindeman, KS, 1994
)
0.52
" No patient required escalation of dosage or additional intervention such as intravenous beta-agonist therapy or mechanical ventilation."( Low-dose beta-agonist continuous nebulization therapy for status asthmaticus in children.
Eid, NS; Montgomery, VL, 1994
)
0.29
" The PTHrP dose-response curve was not affected by 10 microM indomethacin."( Renin stimulating properties of parathyroid hormone-related peptide in the isolated perfused rat kidney.
Helwig, JJ; Judes, C; Massfelder, T; Parnin, F; Saussine, C; Simeoni, U, 1993
)
0.29
" The human receptors were able to couple to the murine stimulatory G proteins (Gs), as shown by high affinity binding site dosage using the beta adrenoceptor agonist isoprenaline."( Specific atrial overexpression of G protein coupled human beta 1 adrenoceptors in transgenic mice.
Bertin, B; Briand, P; Makeh, I; Mansier, P; Rostene, W; Strosberg, AD; Swynghedauw, B, 1993
)
0.29
"6 MAC halothane did not significantly affect the dose-response relationship between isoproterenol and force."( Halothane and pertussis toxin-sensitive G proteins in airway smooth muscle.
Jones, KA; Morimoto, N; Warner, DO; Yamamoto, K, 1994
)
0.51
" important differences are noted in the dose-response of aldosterone secretion to adrenocorticotropin (ACTH), which is often shifted to a lower concentration sensitivity in cultured cells."( A model for studying regulation of aldosterone secretion: freshly isolated cells or cultured cells?
Balestre, MN; Chouinard, L; Gallo-Payet, N; Guillon, G; Payet, MD, 1993
)
0.29
" Water extract of Puhuang can clearly increase the survival rate and also raise the dosage of BaCl2 infusion necessary to cause the death of animals."( [Prevention of arrhythmia in rats by puhuang].
Fang, SM; Li, ZM; Zhang, XM; Zheng, RX, 1993
)
0.29
" Heart rates in response to isoproterenol dosing were fitted by linear regression, and horizontal shifts in the regression lines were examined between the three treatments."( Effect of tibenelast (a phosphodiesterase inhibitor) and theophylline on isoproterenol-stimulated heart rate, cyclic AMP and norepinephrine levels.
Bowsher, RR; Cerimele, BJ; McNay, JL; Rowe, H; Schwertschlag, US, 1993
)
0.81
" This increase in agonist affinity might, therefore, minimize the shift to the right seen in the dose-response curve to noradrenaline during acidosis."( The effect of acidosis on beta-adrenergic receptors in ferret cardiac muscle.
Nimmo, AJ; Orchard, CH; Than, N; Whitaker, EM, 1993
)
0.29
"01-1 microM, A2 selective) shifted the dose-response curve of adenosine in parallel to the right, but they shifted that of cAMP to the right and downwards."( Pharmacological analysis of vasodilation induced by extracellular adenosine 3',5'-cyclic monophosphate in the isolated and perfused canine coronary artery.
Chiba, S; Nakane, T, 1993
)
0.29
"Prospective dose-response study with each animal serving as it own control."( Effects of dopexamine on hemodynamics and oxygen consumption after beta blockade in lambs.
Rogers, BW; Sziszak, TJ; Sziszak, TL; Taylor, BJ, 1993
)
0.29
" Interaction between topical isoprenaline and timolol on intraocular pressure was studied in conscious rabbits through changes of the dose-response curves."( Evidence for a synergistic interaction between isoprenaline and timolol on intraocular pressure in conscious rabbits.
Garrido, M; Martinez de Ibarreta, MJ; Pablo, V; Santafe, J; Segarra, J, 1993
)
0.29
" While the nonmetabolizable adenosine analogue N6-(phenylisopropyl)adenosine (PIA) inhibited ADA-stimulated lipolysis, EGF affected neither ADA-stimulated lipolysis nor the dose-response curve for PIA."( Epidermal growth factor modulates the lipolytic action of catecholamines in rat adipocytes. Involvement of a Gi protein.
Ramírez, I; Soley, M; Tebar, F, 1993
)
0.29
" The dosage of the catecholamines had to be increased within the first two days of treatment in the noradrenaline-treated patients, but not in the dopamine-treated patients with septic shock."( Desensitization of rat cardiomyocyte adenylyl cyclase stimulation by plasma of noradrenaline-treated patients with septic shock.
Hallström, S; Kapsner, T; Pilz, G; Reithmann, C; Schlag, G; Werdan, K, 1993
)
0.29
" The dosage forms were tested on intraocular hypertensive-induced rabbits."( Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery.
Hoffman, M; Maincent, P; Marchal-Heussler, L; Sirbat, D, 1993
)
0.29
" The dose-response curve for melatonin shows an approximate 1000-fold shift in potency in the RCS rat."( Agonist-induced effects on cyclic AMP metabolism are affected in pigment epithelial cells of the Royal College of Surgeons rat.
Nash, MS; Osborne, NN, 1995
)
0.29
" Dosage of isoprenaline increased from 1 to 12 micrograms/min, and salbutamol increased from 4 to 64 micrograms/min during the trial."( Therapeutic trial of sympathomimetics in three cases of complete heart block in the fetus.
Allan, LD; Groves, AM; Rosenthal, E, 1995
)
0.29
" The dose of isoprenaline required to increase heart rate by 25 beats min-1 (I25) and the dose of phenylephrine required to increase systolic and diastolic blood pressure by 20 mm Hg (PS20 and PD20) were calculated using a quadratic fit to individual dose-response curves."( The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man.
Guy, S; McDermott, BJ; Riddell, JG; Shanks, RG; Tham, TC, 1995
)
0.29
" Detailed dose-response experiments were performed for NE and EPI, as well as ISO."( Adenylyl cyclase activation underlies intracellular cyclic AMP accumulation, cyclic AMP transport, and extracellular adenosine accumulation evoked by beta-adrenergic receptor stimulation in mixed cultures of neurons and astrocytes derived from rat cerebra
Li, Y; Rosenberg, PA, 1995
)
0.29
" Dose-response curves for the local and distant effects of ISO and FSK on ICa were used as an index of cAMP concentration changes near the sarcolemma."( cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists.
Fischmeister, R; Jurevicius, J, 1996
)
0.29
" Analysis of dose-response curves for different beta-agonists revealed that (i) both the basal and the maximally stimulated activity of AC were 2-fold lower in fa/fa rats than in Fa/fa rats; (ii) BRL37344 and CGP12177 (beta 3 agonists) were less potent in fa/fa than in Fa/fa rats (Kact."( Early alterations in the brown adipose tissue adenylate cyclase system of pre-obese Zucker rat fa/fa pups: decreased G-proteins and beta 3-adrenoceptor activities.
Bazin, R; Charon, C; Diot-Dupuy, F; Emorine, LJ; Krief, S; Strosberg, AD, 1995
)
0.29
" We used an isolated, electrically stimulated rat left atrium model to compare the dose-response curves to the muscarinic agonist carbachol and isoflurane under conditions of high (10(-6)M isoproterenol added to the bath) or low (10(-6)M propranolol) beta-adrenergic tone."( Myocardial depression by isoflurane is dependent on the underlying beta-adrenergic tone.
Mathew, BP; Thurston, TA, 1995
)
0.48
"We used the dorsal hand vein compliance technique to construct full dose-response curves to the beta 2-agonist isoproterenol (2 to 270 ng/min) in hand veins preconstricted with phenylephrine in 11 young white subjects and in 11 young Asian Indian subjects."( Impaired beta 2-adrenergic agonist-induced venodilation in Indians of Asian origin.
Adubofour, KO; Dachman, WD; Kapoor, C; Singarajah, C; Takahashi, B; Vajo, Z; Zafar, H, 1996
)
0.51
" Dose-response curves to isoproterenol (10(-9)-10(-8) M) and phenylephrine (10(-9)-10(-6) M) were also obtained."( Ricin depresses cardiac function in the rabbit heart.
Hsu, CH; Ma, L; Patterson, E; Robinson, CP; Thadani, U, 1996
)
0.6
" Each antagonist alone caused smaller shifts to the right in the dose-response curve to NE and, when present simultaneously, completely abolished the NE response."( Inducible expression of beta 1- and beta 2-adrenergic receptors in rat C6 glioma cells: functional interactions between closely related subtypes.
Esbenshade, TA; Guerrero, SW; Minneman, KP; Zhong, H, 1996
)
0.29
"Using an isolated, electrically stimulated rat left afrium model, the dose-response curves to the muscarinic agonist carbachol and the anesthetics ketamine and thiopental were compared under conditions of high (10(-6)M isoproterenol bath concentration) or low (10(-6)M propranolol) beta-adrenergic tone."( In vitro myocardial depression by ketamine or thiopental is dependent on the underlying beta-adrenergic tone.
Mathew, BP; Thurston, TA, 1996
)
0.48
" Beta-adrenergic blockade with propranolol shifted the agonist's dose-response curves for heart rate and contractility to the right; however, low doses of dobutamine exhibited a negative chronotropic effect and increased the total peripheral vascular resistance."( A novel catecholamine, arbutamine, for a pharmacological cardiac stress agent.
Abou-Mohamed, G; Caldwell, RW; Myers, T; Nagarajan, R, 1996
)
0.29
" The dose-response curve to BRL 37344-decreasing myocardial contractility was not modified by pretreatment with nadolol, but was shifted to the right by bupranolol, a nonselective beta-adrenoceptor antagonist."( Functional beta3-adrenoceptor in the human heart.
Charpentier, F; Gauthier, C; Langin, D; Le Marec, H; Tavernier, G, 1996
)
0.29
" Anesthetic requirements, circulatory variables, interventions, and isoproterenol dose-response curves (pre- and postoperatively) were determined."( Clonidine for major vascular surgery in hypertensive patients: a double-blind, controlled, randomized study.
Bayon, MC; Boucaud, C; Bouilloc, X; Brudon, JR; Butin, E; Danays, T; Frehring, B; Ghignone, M; Levron, JC; Petit, P; Quintin, L; Tassan, H; Tissot, S; Viale, JP, 1996
)
0.53
" Dose-response curves to carbachol and isoproterenol were constructed using isolated strips of tracheal smooth muscle, with or without epithelium."( A morphometric and functional study of the toxicity of atmospheric ammonia in the extrathoracic airways in pigs.
Ansay, M; Beerens, D; Charlier, G; Coignoul, F; Foliguet, B; Grignon, G; Gustin, P; Lambotte, JL; Prouvost, JF; Urbain, B; Vidic, B, 1996
)
0.56
" Isometric tension was measured and dose-response curves were constructed for levcromakalim (a KATP opener), Y-26763 (another KATP opener), isoprenaline and theophylline in guinea-pig isolated trachea that was challenged with ovalbumin or pretreated in vitro with either isoprenaline or the KATP openers."( Allergic responses reduce the relaxant effect of beta-agonists but not potassium channel openers in guinea-pig isolated trachea.
Dobashi, K; Houjou, S; Iizuka, K; Nakazawa, T, 1996
)
0.29
" Dose-response curves on cyclic AMP mediated activation of PKA confirmed the previously reported reduction in activation of PKA in patients with major depression but demonstrated that this reduction occurs without a change in the EC50 values of cyclic AMP (approximately 20 nmol/L)."( Beta-adrenoceptor-linked protein kinase A (PKA) activity in human fibroblasts from normal subjects and from patients with major depression.
Eiring, A; Manier, DH; Shelton, RC; Sulser, F, 1996
)
0.29
" Dose-response curves plotted as percentage change from baseline versus concentration of drug were determined for acetylstrophanthidin, isoproterenol, isobutylmethylxanthine, and milrinone."( Decreased inotropic but relatively preserved relaxation response to cyclic adenosine monophosphate-dependent agents in myopathic human myocardium.
Bruce, E; Flemmal, K; Grossman, W; Gutstein, DE; Gwathmey, JK; Markis, JE; Morgan, JP; Ransil, BJ; Travers, KE, 1996
)
0.5
" The dose-response curve for the inhibition of ISS by isoprenaline was positioned to the left of that for the calcium current."( Characterization of a beta-adrenergically inhibited K+ current in rat cardiac ventricular cells.
Scamps, F, 1996
)
0.29
" Dose-response curves for dopexamine, isoprenaline, noradrenaline and impromidine on heart rate, blood pressure and myocardial contractility (dP/dt:integrated isometric tension) were obtained in untreated dogs and compared to those measured in dogs which had been pretreated with propranolol (8 mg kg-1 day-1), atenolol (6 mg kg-1 day-1), isoprenaline (0."( Changes in cardiovascular responsiveness to dopexamine and beta 1- and beta 2-adrenoceptor function after the chronic treatment of beta-adrenoceptor antagonists and agonists in anaesthetized dogs.
Chang, DH; Einstein, R, 1996
)
0.29
" Subjects underwent either passive HUT (45 min, 60 degrees without drug dosing for 48 subjects in group S (S1) and 17 in group V (V1), or HUT with isoproterenol infusion at progressive doses (2 then 5 micrograms/min) after 30 minutes of passive tilting for 28 patients in group S (S2) and 18 in group V (V2)."( Prospective evaluation of high-dose or low-dose isoproterenol upright tilt protocol for unexplained syncope in young adults.
Bodart, JC; Burlaton, JP; Carlioz, R; Graux, P; Guyomar, Y; Haye, J; Hubert, E; Lequeuche, B; Letourneau, T, 1997
)
0.75
" Furthermore, isoproterenol dose-response relationships of these contractile parameters were blunted in the hypothyroid animals and augmented in the hyperthyroid animals compared with euthyroid control animals."( Measurement of intraventricular pressure and cardiac performance in the intact closed-chest anesthetized mouse.
Lorenz, JN; Robbins, J, 1997
)
0.66
" Increasing the concentration of insulin during the incubation allowed construction of dose-response curves of insulin inhibition of lipolysis."( Antilipolytic effect of insulin and insulin receptor messenger RNA expression in adipocytes of infants, children, and adults.
Ehrén, H; Hildingsson, U; Kamel, A; Marcus, C; Norgren, S, 1997
)
0.3
" At low leptin concentrations (<1 nM), the insulin sensitivity was reduced leading to a shift to the right in the dose-response curve."( Leptin impairs metabolic actions of insulin in isolated rat adipocytes.
Ertl, J; Gerl, M; Müller, G; Preibisch, G, 1997
)
0.3
" Rauwolscine (10 microM) enhanced epinephrine effects, shifting the dose-response curve for epinephrine to the left (EC50 = 120 nM); however, beta-antagonists inhibited epinephrine-induced cAMP accumulation."( Effect of epinephrine on cAMP accumulation in cultured rat inner medullary collecting duct cells.
Jeffries, WB; Umemura, S; Yasuda, G, 1997
)
0.3
" A similar rightward shift of the dose-response curve was observed for the effects of adenosine on developed left ventricular pressure (LVP) and of carbachol (0."( Beta-blockade reduces effects of adenosine and carbachol by transregulation of inhibitory receptors and Gi proteins.
Borst, MM; Kübler, W; Marquetant, R; Strasser, RH, 1997
)
0.3
"), the heart rate dose-response curves to isoprenaline were shifted to the right of those determined in matched groups of vehicle-pretreated animals."( Celiprolol: agonist and antagonist effects at cardiac beta 1- and vascular beta 2-adrenoceptors determined under in vivo conditions in the rat.
Alda, O; Alvarez-Guerra, M; Garay, RP, 1997
)
0.3
"Inotropic dose-response curves were compared in 12 patients who were studied 3 to 15 months after transplantation (early) and 17 patients who were studied 23 to 156 months after transplantation (late) with isoproterenol (uptake1-independent) and epinephrine (uptake1-dependent)."( Time-dependent decrease of presynaptic inotropic supersensitivity: physiological evidence of sympathetic reinnervation after heart transplantation.
Gross, T; Koglin, J; Uberfuhr, P; von Scheidt, W, 1997
)
0.48
" The first goal of the study was to investigate the role of melatonin on myocardial contractility in isolated rat papillary muscle using dose-response curves to melatonin, to isoproterenol and calcium either in the presence or in the absence of melatonin (0."( Effects of melatonin in isolated rat papillary muscle.
Abete, P; Bianco, S; Cacciatore, F; Calabrese, C; Ferrara, N; Napoli, C; Rengo, F, 1997
)
0.49
" Dose-response curves for the effects of isoprenaline (non selective beta-agonist), salbutamol (beta2-agonist), dobutamine (beta1-agonist) on ICa were obtained in the absence and presence of various concentrations of ICI 118551 (beta2-antagonist), metoprolol (beta1-antagonist) and xamoterol (partial beta1-agonist) to derive EC50 (i."( Pharmacological characterization of the receptors involved in the beta-adrenoceptor-mediated stimulation of the L-type Ca2+ current in frog ventricular myocytes.
Fischmeister, R; Jurevicius, J; Skeberdis, VA, 1997
)
0.3
" These anti-muscarinic M2 receptor antibodies shifted the dose-response relationship of the beta-adrenoceptor agonist isoproterenol to higher concentrations whereas preimmune rabbit immunoglobulin G (IgG) or antibodies against the N-terminus of the beta 1-adrenoceptor had no effect."( Anti-M2 muscarinic receptor antibodies inhibit beta-adrenoceptor-mediated inotropic response in rat myocardium.
Fu, ML; Hjalmarson, A; Hoebeke, J; Osnes, JB; Schiander, IG; Skomedal, T, 1997
)
0.51
" Finally, to rule out the possibility that the conteracting effect of L-NMMA may not be specifically related to insulin action, dose-response curves to phenylephrine (0."( Insulin modulation of an endothelial nitric oxide component present in the alpha2- and beta-adrenergic responses in human forearm.
Barbato, E; Fontana, D; Iaccarino, G; Izzo, R; Lembo, G; Trimarco, B; Vecchione, C, 1997
)
0.3
" Contractile responsiveness in the IH was determined using a modified Langendorff preparation to evaluate the dose-response relationship between isoproterenol and 1) peak developed pressure/g of left ventricular wet weight and 2) maximal rate of pressure development (+dP/dt/P)."( Reduced cardiac contractile responsiveness to isoproterenol in obese rabbits.
Carroll, JF; Cockrell, K; Hester, RL; Jones, AE; Mizelle, HL; Reinhart, GA, 1997
)
0.76
" However, administration of isoproterenol at either dosage had no significant effect on the incidence of gastric cancers and the labeling index of antral epithelial cells."( Promotion by the alpha-adrenoceptor agonist phenylephrine, but not by the beta-adrenoceptor agonist isoproterenol, of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats.
Baba, M; Iishi, H; Iseki, K; Nakaizumi, A; Sakai, N; Tatsuta, M; Uehara, H; Yano, H, 1998
)
0.81
"Serum sex hormones, lymphocyte beta2-adrenoceptor parameters, and bronchodilator and systemic dose-response curves (DRCs) to albuterol (Salbutamol) (100 to 1,600 microg) were measured at both on and off periods."( Beta2-adrenoceptor regulation and function in female asthmatic patients receiving the oral combined contraceptive pill.
Lipworth, BJ; McFarlane, LC; Tan, KS, 1998
)
0.3
"1 microM), both caused rightward shifts in the dose-response curve for the inhibition of histamine release by isoprenaline."( Salmeterol inhibition of mediator release from human lung mast cells by beta-adrenoceptor-dependent and independent mechanisms.
Chong, LK; Cooper, E; Peachell, PT; Vardey, CJ, 1998
)
0.3
"In rats, a toxic dosage of isoproterenol caused characteristic myocardial damage that subsequently resulted in mild heart failure."( Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system.
Bruckschlegel, G; Elsner, D; Griese, D; Grimm, D; Kromer, EP; Muders, F; Pfeifer, M; Riegger, GA; Schunkert, H, 1998
)
0.87
" There was no effect of NPY on postjunctional ACh or isoprenaline agonist dose-response curves."( Exogenous NPY modulation of cardiac autonomic reflexes and its pressor effect in the conscious rabbit.
Angus, JA; Serone, AP; Wright, CE, 1998
)
0.3
" Using the dorsal hand vein compliance technique, dose-response curves were constructed for the two vasoactive agents in 10 Mexican-American and 10 White American volunteers."( Variability in vascular responsiveness between Mexican-Americans and White Americans.
Adubofour, KO; Dachman, WD; Kapoor, C; Rackleff, D, 1998
)
0.3
" Inhibition of NOS and guanylate cyclase increased the dose-response curve of isoproterenol on contractility."( Role of nitric oxide in cardiac beta-adrenoceptor-inotropic response.
Borda, E; Cremaschi, G; Genaro, A; Perez Leiros, C; Sterin-Borda, L; Vila Echagüe, A, 1998
)
0.53
" In this study, both LMF and Zn-alpha2-glycoprotein have been shown to stimulate glycerol release from isolated murine epididymal adipocytes with a comparable dose-response profile."( Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients.
Barber, MD; Hirai, K; Hussey, HJ; Price, SA; Tisdale, MJ, 1998
)
0.3
" DCITC attenuated the maximal (-)-isoprenaline-mediated relaxation of a phenylephrine contracted aorta in a concentration-dependent manner and shifted the dose-response curves for (-)-isoprenaline to the right."( Irreversible binding of a carbostyril-based agonist and antagonist to the beta-adrenoceptor in DDT1 MF-2 cells and rat aorta.
Baker, SP; Dennis, DM; Deyrup, MD; Gelband, CH; Greco, PG; Otero, DH, 1998
)
0.3
" Concentrations of 1, 10 and 100 nM of BAAM caused dose-dependent rightward shifts in the dose-response curve for the isoprenaline inhibition of histamine release."( Influence of receptor reserve on beta-adrenoceptor-mediated responses in human lung mast cells.
Chong, LK; Drury, DE; Ghahramani, P; Peachell, PT, 1998
)
0.3
" Dose-response curves for isoprenaline-induced force of contraction showed unchanged maximum effects but significantly increased pD2 values."( Functional coupling of overexpressed beta 1-adrenoceptors in the myocardium of transgenic mice.
Böhm, M; Flesch, M; Kilter, H; Mansier, P; Schnabel, P; Swynghedauw, B; Zolk, O, 1998
)
0.3
" Dose-response curves for both adrenergic agonists showed that HC increased linearly as a function of the log of the isoproterenol and epinephrine concentration."( Effect of beta-adrenergic agonists on paracellular width and fluid flow across outflow pathway cells.
Alvarado, JA; Chen, J; Franse-Carman, L; Murphy, CG; Underwood, JL, 1998
)
0.51
"Isoproterenol has been suggested as an alternative marker for epidural test dosing in children receiving halothane anesthesia."( Simulation of an epidural test dose with intravenous isoproterenol in sevoflurane- and halothane-anesthetized children.
Glaser, C; Kozek, ME; Kozek-Langenecker, SA; Krenn, CG; Marhofer, P; Semsroth, M, 1998
)
1.99
"Isoproterenol has been suggested as an alternative marker for epidural test dosing in children receiving halothane anesthesia."( Simulation of an epidural test dose with intravenous isoproterenol in sevoflurane- and halothane-anesthetized children.
Glaser, C; Kozek, ME; Kozek-Langenecker, SA; Krenn, CG; Marhofer, P; Semsroth, M, 1998
)
1.99
" Pretreatment with atropine shifted the dose-response curve of acetylcholine to the right and the maximal response was reduced by 9%, 49% and 77% respectively with pretreatment with atropine 10(-8), 10(-7) and 10(-6) mole/kg."( Effects of atropine, isoproterenol and propranolol on the rabbit bladder contraction induced by intra-arterial administration of acetylcholine and ATP.
Horan, P; Levin, RM; Liu, SP, 1998
)
0.62
" Hypothermia shifted the dose-response curves to the right for the negative chronotropic and inotropic effects of verapamil and for the negative chronotropic and positive inotropic effects of zatebradine, but not for the negative chronotropic and positive inotropic effects of E-4031."( Effects of low temperature on the chronotropic and inotropic responses to zatebradine, E-4031 and verapamil in isolated perfused dog atria.
Chiba, S; Furukawa, Y; Hoyano, Y; Kasama, M; Oguchi, T, 1998
)
0.3
" Dose-response curves for adenosine inhibition of isoproterenol-stimulated lipolysis demonstrated that chronic culture with bST decreased adipose tissue responsiveness and sensitivity to adenosine."( Effect of somatotropin, insulin, and glucocorticoid on lipolysis in chronic cultures of adipose tissue from lactating cows.
Bauman, DE; Lanna, DP, 1999
)
0.56
" These effects were well maintained after chronic dosing with no signs of beta1-adrenoceptor desensitization."( Ketotifen and cardiovascular effects of xamoterol following single and chronic dosing in healthy volunteers.
Brodde, OE; Daul, AE; Karl, I; Mennicke, K; Philipp, T; Schäfers, RF, 1999
)
0.3
"Using the dorsal hand vein technique, full dose-response curves to bradykinin (0."( Role of nitric oxide in isoprenaline and sodium nitroprusside-induced relaxation in human hand veins.
Blaschke, TF; Chalon, S; Hoffman, BB; Moreno, H; Tejura, B; Urae, A, 1999
)
0.3
" Analysis of the dose-response curves of beta-adrenergic agonists yielded an EC50 of 5 x 10-9 and 1 x 10-11 M for adrenaline and isoproterenol, respectively."( Beta-adrenergic agonists regulate cell membrane fluctuations of human erythrocytes.
Gulayev, N; Korenstein, R; Levin, S; Moses, A; Tuvia, S, 1999
)
0.51
" There was a significant decrease with age in the maximal relaxation to cholera toxin as well as a rightward shift in the dose-response curve."( Impaired cholera toxin relaxation with age in rat aorta.
Chapman, J; Mader, SL; Schutzer, WE; Watts, VJ, 1999
)
0.3
"Phenylephrine dose-dependently contracted ciliary artery smooth muscle, and bunazosin (1 microM) shifted this dose-response curve to the right."( Effects of beta antagonists on mechanical properties in rabbit ciliary artery.
Hayashi, E; Hayashi-Morimoto, R; Ishikawa, H; Sato, Y; Yoshitomi, T, 1999
)
0.3
" A theoretical dual component analysis indicated that the observed dose-response curves could be constructed as the resultant of a stimulatory and an inhibitory component."( A dual component analysis explains the distinctive kinetics of cAMP accumulation in brown adipocytes.
Bronnikov, GE; Cannon, B; Nedergaard, J; Zhang, SJ, 1999
)
0.3
" Dose-response curves after extracellular isoproterenol- or Ca(2+)-stimulation were recorded."( Effects of the calcium channel antagonist mibefradil on haemodynamic parameters and myocardial Ca(2+)-handling in infarct-induced heart failure in rats.
Meissner, A; Min, JY; Sandmann, S; Unger, T, 1999
)
0.57
" The dose-response curve to the beta3- and the beta2-agonists was shifted by the appropriate antagonist but not by the antagonist at the other beta-adrenoceptor."( Separate roles for beta2- and beta3-adrenoceptors in memory consolidation.
Gibbs, ME; Summers, RJ, 2000
)
0.31
" However, in Lewis rats amphetamine treatment increased the dose-response curve of forskolin stimulation."( Different activity of adenylyl cyclase in prefrontal cortex in three rat strains. The effect of amphetamine.
Hynie, S; Klenerová, V; Sída, P, 1998
)
0.3
" In the present study, we evaluated the influences of epinephrine and isoproterenol on the onset of TdP each time D0870 was given to 6 anesthetized open-chest dogs at a dosage of 20 mg/kg, 5 times every 40 minutes, by the simultaneous measurements of surface electrocardiogram and epicardial monophasic action potential (MAP)."( Influences of catecholamines on the sudden death induced in dogs by an antifungal agent, D0870.
Aldridge, A; Duffy, PA; Harada, T; Matsunaga, T; Mitsui, T; Murano, H; Shibutani, Y, 2000
)
0.54
"5, 15, and 40 mg nadolol or propranolol (both beta1- and beta2-adrenergic receptor antagonists) at random, after which isoproterenol (beta1-, beta2-, and beta3-adrenergic receptor agonist) was infused in an individually determined dosage (range, 19 to 35 ng/kg x min) that increased energy expenditure by 25% without pretreatment."( In vivo beta3-adrenergic stimulation of human thermogenesis and lipid use.
Blaak, EE; Saris, WH; Schiffelers, SL; van Baak, MA, 2000
)
0.52
" Cocaine shifted the dose-response curve of noradrenaline to the left and enhanced its maximal effects."( Post-junctional mechanisms involved in the potentiation of cardiac adrenergic responses by cocaine.
Bechara, G; El-Bizri, NM; Khoury, HA; Sabra, R; Sharaf, LH, 2000
)
0.31
" Subsequent experiments under prazosin treatment established the apoptosis dose-response curves for the increasingly beta(2)-selective AR agonists isoproterenol (ISO) (beta(1) approximately beta(2)) and albuterol (ALB) (beta(2)>beta(1))."( Beta-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes.
Jamali, NZ; Lucchinetti, E; Shafiq, SA; Siddiqui, MA; Xu, W; Zaugg, M, 2000
)
0.51
" When isoproterenol was perfused, a dose-response increase in glycerol production was induced in both tissues."( In vivo lipolysis in adipose tissue from two anatomical locations measured by microdialysis.
Macarulla, MT; Portillo, MP; Torres, MI; Villaro, JM, 2000
)
0.79
"The effect of dietary olive oil and fish oil on the lipolytic dose-response of the beta3-adrenergic agonists, epinephrine, isoproterenol, BRL-37344, and CGP-12177, in adipocytes was studied in pregnant and virgin rats either untreated or under hyperinsulinemic-euglycemic conditions."( Changes in dietary fatty acids modify the decreased lipolytic beta3-adrenergic response to hyperinsulinemia in adipocytes from pregnant and nonpregnant rats.
Amusquivar, E; Cacho, J; Herrera, E, 2000
)
0.51
" The dose-response curve for L-750355-induced glycerolemia lies to the left of that for tachycardia."( L-750355, a human beta3-adrenoceptor agonist; in vitro pharmacology and profile of activity in vivo in the rhesus monkey.
Bach, T; Candelore, MR; Cascieri, MA; Cioffe, C; Deng, L; Fisher, MH; Forrest, MJ; Hegarty-Friscino, B; Hom, G; MacIntyre, E; Marko, O; Ok, HO; Strader, C; Szumiloski, J; Tota, L; Vicario, P; Weber, AE; Wyvratt, M, 2000
)
0.31
" This technique has potential applications in drug screening, such as measuring the dose-response curve of isoproterenol, a beta-adrenergic agonist with a positive chronotropic effect."( Cell-transistor hybrid systems and their potential applications.
Knoll, W; Offenhäusser, A, 2001
)
0.52
" Measurements were made in two ways, firstly, by pre-incubating the atria with a given concentration of atenolol followed by an isoprenaline dose-response curve and, secondly, by measuring the response to isoprenaline followed by addition of atenolol."( The relative importance of the time-course of receptor occupancy and response decay on apparent antagonist potency in dynamic assays.
Corsi, M; Kenakin, T, 2000
)
0.31
" Dose-response curves to acetylcholine and isoproterenol were carried out in absence and presence of the NO synthesis inhibitor NG-nitro-L-arginine methyl ester (LNAME), the inhibitor of the cyclo-oxygenase, indomethacin and KCI."( Relevance of endothelium-derived hyperpolarizing factor in the effects of hypertension on rat coronary relaxations.
Cachofeiro, V; Cediel, E; de las Heras, N; Lahera, V; Navarro-Cid, J; Ruilope, LM; Sanz-Rosa, D; Vázquez-Pérez, S, 2001
)
0.57
" In separate experiments, cumulative dose-response curves to alpha- (phenylephrine) and beta- (isoproterenol) adrenoreceptor agonists were generated in conscious and propofol-anesthetized dogs."( Pulmonary vascular effects of propofol at baseline, during elevated vasomotor tone, and in response to sympathetic alpha- and beta-adrenoreceptor activation.
Kim, SO; Kondo, U; Murray, PA; Nakayama, M, 2001
)
0.53
" Bronchial rings were incubated with normal or immune serum (100 microl ml(-1) for 2 h) and dose-response curves to TDI (0."( Serum-mediated relaxant response to toluene diisocyanate (TDI) in isolated guinea-pig bronchi.
Boschetto, P; Chitano, P; De Marzo, N; Fabbri, LM; Faggian, D; Jovine, L; Mapp, CE; Plebani, M, 2001
)
0.31
" In the preliminary session a dose-response curve to the vasoconstrictor effect of phenylephrine was constructed and the dose producing 50-75% maximal response was determined for each individual."( Comparison of the effects of nadolol and bisoprolol on the isoprenaline-evoked dilatation of the dorsal hand vein in man.
Abdelmawla, AH; Bradshaw, CM; Langley, RW; Szabadi, E, 2001
)
0.31
" A dose-response curve of the effect of the beta2-adrenergic-receptor agonist isoproterenol was constructed (dose range, 4 to 480 ng per minute)."( The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization.
Byrne, DW; Dishy, V; Kim, RB; Sofowora, GG; Stein, CM; Wood, AJ; Xie, HG, 2001
)
0.54
" Arjunolic acid at an effective dosage of 15 mg/kg body wt."( Experimental myocardial necrosis in rats: role of arjunolic acid on platelet aggregation, coagulation and antioxidant status.
Arutselvan, N; Balakrishna, K; Kumar, DA; Manikandan, P; Manohar, BM; Puvanakrishnan, R; Sumitra, M, 2001
)
0.31
" The human preparations were exposed to concentrations of 8 x 10(-9), 8 x 10(-8) and 8 x 10(-6) M FK506 followed by a cumulative dose-response curve with isoprenaline as a non-selective beta-adrenoceptor agonist."( FK506 does not affect cardiac contractility and adrenergic response in vitro.
Domeier, E; Grapow, M; Hakim, K; Janssen, PM; Kögler, H; Milting, H; Prestle, J; Seidler, T; Wangemann, T; Zeitz, O; Zerkowski, HR, 2001
)
0.31
" Moreover, ACh and Ca(2+) dose-response studies showed that accumulation of cAMP shifted the dose-response curves to the low concentration side, suggesting that it increases Ca(2+) sensitivity in the fusion of the exocytotic cycle."( cAMP modulation of Ca(2+)-regulated exocytosis in ACh-stimulated antral mucous cells of guinea pig.
Fujiwara, S; Imai, Y; Katsu, K; Kojima, K; Nakahari, T; Shimamoto, C, 2002
)
0.31
" Drugs functionally or structurally related to clonidine, such as oxymetazoline, alpha-methylnorepinephrine and moxonidine, did not have their dose-response curves altered."( Contractile responses of the rat vas deferens after epithelium removal.
Garcez-do-Carmo, L; Jurkiewicz, A; Jurkiewicz, NH; Okpalaugo, EO, 2002
)
0.31
"min-1, and the dosage could be tapered off before surgery without return of bradycardia."( [A case of bradycardia in a patient with secondary hypothyroidism].
Imasyuku, Y; Ishii, T; Iwashita, N; Kitagawa, H; Takahashi, K, 2002
)
0.31
" The dose-response curves for the effects of noradrenaline on blood pressure were altered in streptozotozin-induced diabetic rats."( Blood pressure responsiveness to sympathetic agonists in anaesthetised diabetic rats.
Casis, O; Espiña, L; Gallego, M, 2002
)
0.31
" Under basal cardiac conditions, the dose-response curves of the three peptides from 10(-8) to 10(-7) M showed a significant calcium-dependent negative inotropism that involved neither the endocardial endothelium nor the adrenergic and muscarinic receptors."( Vasostatins exert negative inotropism in the working heart of the frog.
Colombo, B; Corti, A; Longhi, R; Mannarino, C; Mazza, R; Tota, B, 2002
)
0.31
" The dose-response curve to isoproterenol in naive sphincters or sphincters pre-treated with atropine indicated that muscarinic blockade decreased the EC(50) rather than potentiated maximal beta-adrenergic relaxation."( Muscarinic blockers potentiate beta-adrenergic relaxation of bovine iris sphincter.
Barilan, A; Geyer, O; Nachman-Rubinstein, R; Oron, Y, 2003
)
0.61
" Insulin responsiveness of the lipolytic and lipogenic pathways was analyzed by dose-response experiments, giving evidence for the involvement of improved insulin responsiveness in the enhanced lipogenic and reduced lipolytic activities of adipocytes in early pregnancy."( Fat accumulation in the rat during early pregnancy is modulated by enhanced insulin responsiveness.
Cacho, J; Crespo-Solans, MD; del Campo, S; Herrera, E; Ramos, MP, 2003
)
0.32
" In addition, dose-response relationships of alpha- and beta-adrenergic receptor stimulation were evaluated after application of an alpha- and beta-adrenergic receptor agonist, respectively in different dosages."( Milking characteristics and their relation to adrenergic receptor mRNA expression and ligand binding in the mammary gland of dairy cows.
Bruckmaier, RM; Inderwies, T; Pfaffl, MW, 2003
)
0.32
" The smaller dosage of isoproterenol (10 mg/kg) rendered no significant damage in the acute postinjection period but 3 weeks later it induced the thickening of extracellular matrix around cardiac cells and the increase in KRP and tubulin content by 26 and 32%, correspondingly."( Alterations in myocardial ultrastructure and protein expression after a single injection of isoproterenol.
Dudnakova, TV; Kapelko, VI; Lakomkin, VL; Shekhonin, BV; Shirinsky, VP; Tsyplenkova, VG, 2003
)
0.85
" A dose-response relationship to Moli1901 was observed in non-CF participants, but a greater range of variability within the CF participants contributed to the lack of a clear dose-response relationship in this group."( A phase I trial of intranasal Moli1901 for cystic fibrosis.
Boyle, MP; Guggino, WB; Molina, L; Zeitlin, PL, 2004
)
0.32
" Dose-response curves for carbachol and isoproterenol showed a shift to the left in rat detrusor smooth muscles from partially obstructed bladder when compared with the results obtained in detrusor muscles from sham-operated bladder."( Doxazosin effects on cholinergic and adrenergic responses in rat isolated detrusor smooth muscle preparations from obstructed bladder.
Kukul, E; Usta, C; Yalçinkaya, M, 2004
)
0.59
" Dose-response curves for isoproterenol on insulin background were also assessed in the presence and absence of a selective antagonist for beta(2)-adrenoceptor, ICI, at the dose of 5 x 10(-8) mol/L."( Insulin-induced changes in beta-adrenergic response: an experimental study in the isolated rat papillary muscle.
Abete, P; Cacciatore, F; Calabrese, C; Corbi, G; Ferrara, N; Iaccarino, G; Leosco, D; Longobardi, G; Paolisso, G; Rengo, F; Scarpa, D; Trimarco, B, 2005
)
0.63
" After the dose-response curve was obtained, the author measured the inotropic response to 1 micromol/L of isoproterenol in the presence of the cumulative dose of remifentanil."( Effects of remifentanil on the contractility of failing human heart muscle.
Moravec, CS; Ogletree, ML; Sprung, J, 2005
)
0.54
" After 21 days, rats fed casein 0% presented: (a) a significant shift to the left of the dose-response curves (DRC) to the autonomic agonists-norepinephrine (NE), methoxamine, isoproterenol (ISO) and methacholine; (b) increased food consumption (p<0."( Protein free diet feeding: effects on sympathetic activity and salivary evoked secretion in the submandibular gland of the rat.
Bianciotti, LG; Boyer, P; Chiarenza, AP; Elverdin, JC; Luchelli, MA; Vacas, MI; Vatta, M, 2006
)
0.53
" Rats treated with low dosage intermedin1-53 (5 nmol/kg/day, 2 days) showed 21% (P<0."( Intermedin1-53 protects the heart against isoproterenol-induced ischemic injury in rats.
Chang, JK; Geng, B; Gerns, H; Jia, YX; Pan, CS; Qi, YF; Tang, CS; Wen, JK; Xiao, Y; Yang, J; Yang, JH; Zhang, J; Zhao, J, 2006
)
0.6
" Thus, a range of low Iso doses can cause myocardial lesions, and serum cTnT levels can be monitored to detect the onset and progression of this type of acute cardiac injury in rats; however, careful attention to dosing and sampling times is critical to interpretation."( Serum cardiac troponin T as a biomarker for acute myocardial injury induced by low doses of isoproterenol in rats.
Herman, E; Knapton, A; Lipshultz, SE; Rifai, N; Sistare, F; Zhang, J, 2006
)
0.55
" In a dose-response study (0."( Characterization of troponin responses in isoproterenol-induced cardiac injury in the Hanover Wistar rat.
Brady, S; Chen, C; Curtis, M; Evans, G; Griffiths, W; Scudamore, C; Turton, J; Whayman, M; Williams, T; Wilson, S; York, M, 2007
)
0.6
" Using the organ bath technique, cumulative dose-response curve of isoproterenol was constructed and average EC50 calculated."( Interaction between beta2 adrenergic receptor polymorphisms determines the extent of isoproterenol-induced vasodilatation ex vivo.
Caraco, Y; Elami, A; Khalaila, JM, 2007
)
0.8
" At 10(-7) M of ST-91, the antagonism was characterized by a rightward shift of isoproterenol dose-response curve (A50=6."( alpha2B-adrenoceptor agonist ST-91 antagonizes beta2-adrenoceptor-mediated relaxation in rat mesenteric artery rings.
Gyires, K; Kató, E; Lipták, L; Mátyus, P; Rónai, AZ; Shujaa, N, 2008
)
0.57
" In integral animal experiments: acute myocardium ischemia model rats established by subcutaneous injection of isoprenaline were used, they were administered with MDG-1 in dosage of 10, 20 and 40 mg/kg respectively, and controlled with propranolol."( [Protective effect of Ophiopogonis polysaccharide MDG-1 on experimental myocardial ischemic rats].
Feng, Y; Xu, DS; Zheng, Q, 2007
)
0.34
" By 48 hours the hearts of rats dosed with 125-500 mug/kg Iso had developed interstitial fibrosis, and serum cTnT had declined to near control levels (0."( Isoproterenol-induced cardiotoxicity in sprague-dawley rats: correlation of reversible and irreversible myocardial injury with release of cardiac troponin T and roles of iNOS in myocardial injury.
Herman, EH; Knapton, A; Lipshultz, SE; Weaver, JL; Zhang, J, 2008
)
1.79
" Dose-response curves were constructed for dopamine and isoprenaline that induced falls or increases in renal blood flow, respectively."( Inhibition of Ang II and renal sympathetic nerve influence dopamine-and isoprenaline-induced renal haemodynamic changes in normal Wistar-Kyoto and spontaneously hypertensive rats.
Abdulla, MH; Abdullah, NA; Anand Swarup, KR; Hazim, AI; Johns, EJ; Khan, MA; Rathore, HA; Sattar, MA, 2008
)
0.35
" Results of structure-activity relationship (SAR) studies and cassette dosing evaluation in dogs showed several analogues (namely, 6h, 6j, 6o, 7e, and 9e) to have an excellent balance of in vitro potency and selectivity, pharmacokinetic (PK) profile, and an in vivo OAB model."( Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5.
Araki, T; Hamada, K; Hamashima, H; Hattori, K; Imamura, E; Imanishi, M; Ishikawa, H; Itou, S; Matsui, S; Matsumura, Y; Nakajima, Y; Nakano, K; Sakurai, M; Takamura, F; Toda, S; Tomishima, Y; Ueshima, K; Unami, N; Washizuka, K; Yamamoto, N; Yamamoto, T, 2009
)
0.35
" Dose-response curves to Iso (0."( Phospholemman and beta-adrenergic stimulation in the heart.
Chan, TO; Cheung, JY; Feldman, AM; Gao, E; Koch, WJ; Li, J; Philipson, KD; Song, J; Tucker, AL; Wang, J; Zhang, XQ, 2010
)
0.36
" Dose-response relationships of arterial BP after acute AngII infusion were similar in both genotypes."( Atrap deficiency increases arterial blood pressure and plasma volume.
Castrop, H; Gess, B; Oppermann, M; Schweda, F, 2010
)
0.36
" Subcutaneous ECG leads were implanted, and 2 days following the second injection, each rat was dosed with 25 mg·kg(-1) verapamil per os, and an ECG was recorded over 4 h after dosing."( Drug-disease interaction: reduced verapamil response in isoproterenol-induced myocardial injury in rats.
El-Kadi, AO; Hanafy, S; Jamali, F, 2010
)
0.61
" Dose-response curves to isoproterenol showed that the beating rate increased by 113."( Serum withdrawal after embryoid body formation does not impair cardiomyocyte development from mouse embryonic stem cells.
Abete, P; Della-Morte, D; Galizia, G; Parisi, S; Passaro, F; Pastore, L; Rengo, F; Salvatore, F; Tarantino, C; Testa, G, 2011
)
0.67
" Isoprenaline (ISO), a β-adrenoceptor agonist, was infused at variable dosage and duration using either subcutaneously implanted osmotic minipumps or daily injections, in an attempt to establish the relevant treatment protocol."( Myocardial structural, contractile and electrophysiological changes in the guinea-pig heart failure model induced by chronic sympathetic activation.
Olesen, SP; Osadchii, OE; Soltysinska, E, 2011
)
0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" To investigate the role of adenylyl cyclase, phosphodiesterase, and the cAMP-signaling cascade in generating sex differences in the β-adrenergic contractile response, dose-response studies were performed in isolated perfused male and female hearts using forskolin, 3-isobutyl-1-methylxanthine (IBMX), and 8-(4-chlorophenylthio)adenosine 3',5'-cyclic monophosphate (CPT-cAMP)."( Sex differences and the effects of ovariectomy on the β-adrenergic contractile response.
Chandrasekera, PC; Lasley, RD; McIntosh, VJ, 2011
)
0.37
" An improved method for measuring the absorbed fraction of analogues dosed to rats, which considers the glucuronidated fraction is presented."( The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating hydantoin or uracil rings.
Barrett, VJ; Bevan, NJ; Butchers, PR; Conroy, R; Emmons, A; Ford, AJ; Jeulin, S; Looker, BE; Lunniss, GE; Morrison, VS; Mutch, PJ; Perciaccante, R; Procopiou, PA; Ruston, M; Smith, CE; Somers, G, 2011
)
0.37
") and shifted the dose-response curve for isoprenaline to higher agonist concentrations without altering HVC responses."( Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses.
Baker, JG; Fretwell, L; Gardiner, SM; Hill, SJ; Kemp, P; March, J, 2011
)
0.37
"Leonurus at a dosage of 16 g/kg may improve the systolic function; Leonurus at a dosage of 8 g/kg may improve the diastolic function, down-regulate the expression of collagen and normalize the ratio of I/III collagen."( [Protective effects of Leonurus japonicas on myocardial remodeling induced by isoproterenol in rats].
Gu, YP; Guo, W; Liu, Y; Lv, R; Wei, HC; Yuan, BP; Zhang, C, 2011
)
0.6
"During ablation of LSP atrial fibrillation, in addition to pulmonary vein antrum and posterior wall isolation, ablation of nonpulmonary vein triggers disclosed by high dosage of isoproterenol seems to be of utmost importance to achieve long-term success after a single procedure."( How to ablate long-standing persistent atrial fibrillation?
Di Biase, L; Natale, A; Santangeli, P, 2013
)
0.58
" This reduction was maintained throughout chronic dosing at day 15."( Interleukin-1β induces a reversible cardiomyopathy in the mouse.
Abbate, A; Mezzaroma, E; Seropian, IM; Toldo, S; Van Tassell, BW, 2013
)
0.39
" Notably, cells aligned on the biomimetic platform responded detectably down to a dosage of 3 nM E-4031, which is lower than the IC50 in the hERG channel assay."( Integrated platform for functional monitoring of biomimetic heart sheets derived from human pluripotent stem cells.
Chen, A; Fowlkes, C; Grosberg, A; Khine, M; Lee, E; Santiago, K; Tu, R, 2014
)
0.4
" Plasma miR-208 was consistently increased through 24 h after dosing in rats administered with isoproterenol, whereas plasma concentrations of cardiac troponin (cTn) showed transient elevation."( Plasma miR-208 as a useful biomarker for drug-induced cardiotoxicity in rats.
Kondo, C; Morikawa, Y; Nishimura, Y; Tonomura, Y; Torii, M; Uehara, T; Yamate, J, 2015
)
0.64
" Reduction of miR-1/133a dosage induced a longQT phenotype in mice especially at low heart rates."( MiRNA-1/133a clusters regulate adrenergic control of cardiac repolarization.
Bachmann, A; Besser, J; Boettger, T; Braun, T; Fleischmann, BK; Malan, D; Sasse, P; Wietelmann, A; Wystub, K, 2014
)
0.4
" This method has been applied in the determination of isoproterenol in dosage forms and in biological fluids."( Selective separation and determination of isoproterenol on thin layers of bismuth silicate ion-exchanger.
, 2015
)
0.93
" Dose-response curves were created between the concentration of isoproterenol or insulin and the amount of glycerol released."( Influence of adipocyte size and adipose depot on the in vitro lipolytic activity and insulin sensitivity of adipose tissue in dairy cows at the end of the dry period.
Claeys, E; De Koster, J; Fievez, V; Hermans, K; Hostens, M; Hulpio, L; Opsomer, G; Van den Broeck, W; Van Eetvelde, M, 2016
)
0.67
" Then paricalcitol was administered intraperitoneally to isoproterenol-injected rats at a dosage of 200 ng three times a week for 3 weeks."( Paricalcitol Attenuates Cardiac Fibrosis and Expression of Endothelial Cell Transition Markers in Isoproterenol-Induced Cardiomyopathic Rats.
Cheng, PW; Hsiao, M; Lai, CC; Liou, JC; Liu, CP; Lu, PJ; Lu, WH; Sun, GC; Tseng, CJ, 2016
)
0.9
" Linear parametric models, widely used for estimating dose-response relationships, have several limitations."( Using machine learning to model dose-response relationships.
Linden, A; Nallamothu, BK; Yarnold, PR, 2016
)
0.43
"Generalized estimating equations and ODA both identified many statistically significant dose-response relationships, separately by race and for pooled data."( Using machine learning to model dose-response relationships.
Linden, A; Nallamothu, BK; Yarnold, PR, 2016
)
0.43
"Given its unique advantages and greater analytic flexibility, maximum-accuracy machine-learning methods like ODA should be considered as the primary analytic approach in dose-response applications."( Using machine learning to model dose-response relationships.
Linden, A; Nallamothu, BK; Yarnold, PR, 2016
)
0.43
" However, it is still lacking of dose-response relationship of SND in cardiovascular disease at the metabolic level."( Serum metabolomics analysis reveals that obvious cardioprotective effects of low dose Sini decoction against isoproterenol-induced myocardial injury in rats.
Chen, C; Chen, J; Li, F; Li, J; Ma, X; Shi, M; Sun, Y; Xiong, Y; Zhou, J, 2017
)
0.67
"The cardioprotective effect was observed in SND pretreatment groups, especially in low dosage SND group."( Serum metabolomics analysis reveals that obvious cardioprotective effects of low dose Sini decoction against isoproterenol-induced myocardial injury in rats.
Chen, C; Chen, J; Li, F; Li, J; Ma, X; Shi, M; Sun, Y; Xiong, Y; Zhou, J, 2017
)
0.67
" At the end of dosing left ventricular functions was assessed to estimate its effect on cardiac functions."( Cardiaprotective effect of crocetin by attenuating apoptosis in isoproterenol induced myocardial infarction rat model.
Ge, Z; Li, Y; Zhang, W, 2017
)
0.69
" To induce MI, ISO was subcutaneously injected into the rats for two consecutive days at a dosage of 85mg/kg/day."( Cardioprotective effect of nesfatin-1 against isoproterenol-induced myocardial infarction in rats: Role of the Akt/GSK-3β pathway.
Adiguzel, D; Barutcigil, A; Celik-Ozenci, C; Dalaklioglu, S; Kuscu, N; Ozdem, S; Tasatargil, A, 2017
)
0.71
" Wistar rats were dosed once with either isoproterenol (1."( miR-21-5p as a potential biomarker of inflammatory infiltration in the heart upon acute drug-induced cardiac injury in rats.
De Ron, P; Fleming, A; Fleurance, R; Gryshkova, V; McGhan, P; Nogueira da Costa, A; Valentin, JP, 2018
)
0.75
" This dosing schedule caused daily drug-free periods of at least 6 h as evidenced by propranolol plasma concentrations and cardiac β-adrenergic responsiveness."( Intermittent β-adrenergic blockade downregulates the gene expression of β-myosin heavy chain in the mouse heart.
Ambrosio, C; Barbagallo, F; Catalano, L; Grò, MC; Maccari, S; Marano, G; Matarrese, P; Molinari, P; Pace, V; Patrizio, M; Rizzi, R; Stati, T; Vezzi, V, 2020
)
0.56
" It is experimentally demonstrated that this system can monitor the dosage effect of both drugs."( Development of a cardiac-and-piezoelectric hybrid system for application in drug screening.
Hsu, YH; Huang, YH; Yang, CF, 2020
)
0.56
" The ß-adrenergic agonist isoproterenol hydrochloride is used for its cardiac effects in a variety of different dosing regimens with high doses causing acute cardiomyocyte necrosis."( Type 2 MI induced by a single high dose of isoproterenol in C57BL/6J mice triggers a persistent adaptive immune response against the heart.
Baxan, N; Bedard, O; Benson, L; Boyle, JJ; Branca, J; Forte, E; Harding, SE; Hasham, MG; Ng, FS; Panahi, M; Rosenthal, N; Sattler, S, 2021
)
1.18
" Group II (scopoletin) animals were pre-treated orally with a 50-mg dosage of scopoletin for 28 days."( Cardioprotective Role of Scopoletin on Isoproterenol-Induced Myocardial Infarction in Rats.
Ibrahim, IAA; Rong, N; Yang, R; Zhang, W, 2023
)
1.18
" In the present study, different dosage regimens (25, 50, and 100 mg/kg/d for three weeks) of naringenin (NAR) were orally gavaged in an isoprenaline (ISO) (7."( Naringenin Attenuates Isoprenaline-Induced Cardiac Hypertrophy by Suppressing Oxidative Stress through the AMPK/NOX2/MAPK Signaling Pathway.
He, B; He, Y; Li, Y; Xia, T; Zeng, C; Zhang, C, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
sympathomimetic agentA drug that mimics the effects of stimulating postganglionic adrenergic sympathetic nerves. Included in this class are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.
beta-adrenergic agonistAn agent that selectively binds to and activates beta-adrenergic receptors.
bronchodilator agentAn agent that causes an increase in the expansion of a bronchus or bronchial tubes.
cardiotonic drugA drug that has a strengthening effect on the heart or that can increase cardiac output.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
catecholsAny compound containing an o-diphenol component.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Isoprenaline Action Pathway478

Protein Targets (95)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency0.36630.01846.806014.1254AID624148
thioredoxin reductaseRattus norvegicus (Norway rat)Potency11.79580.100020.879379.4328AID488773; AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency79.43280.141337.9142100.0000AID1490
GLS proteinHomo sapiens (human)Potency5.92560.35487.935539.8107AID624146; AID624170
TDP1 proteinHomo sapiens (human)Potency26.60860.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency11.37060.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency7.94330.180013.557439.8107AID1468
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency19.33510.001022.650876.6163AID1224838; AID1224893
regulator of G-protein signaling 4Homo sapiens (human)Potency21.22620.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.19500.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency14.43550.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.02240.001530.607315,848.9004AID1224841; AID1259401
cytochrome P450 2D6Homo sapiens (human)Potency38.90180.00108.379861.1304AID1645840
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency14.12540.035520.977089.1251AID504332
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.00840.001628.015177.1139AID1224843; AID1224895; AID1259393
activating transcription factor 6Homo sapiens (human)Potency0.53540.143427.612159.8106AID1159516
Histone H2A.xCricetulus griseus (Chinese hamster)Potency55.19650.039147.5451146.8240AID1224845
beta-2 adrenergic receptorHomo sapiens (human)Potency1.29950.00586.026332.6427AID485366
hexokinase-4 isoform 1Homo sapiens (human)Potency28.18382.511913.800328.1838AID743205
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency79.43280.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency0.01060.006026.168889.1251AID488953
glucokinase regulatory proteinHomo sapiens (human)Potency28.18382.511913.800328.1838AID743205
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency15.79230.00378.618923.2809AID2667; AID2668
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency10.59010.000627.21521,122.0200AID743219
gemininHomo sapiens (human)Potency33.49830.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.90740.005612.367736.1254AID624032
D(1A) dopamine receptorSus scrofa (pig)Potency18.49270.00378.108123.2809AID2667
2,3-bisphosphoglycerate-independent phosphoglycerate mutaseLeishmania major strain FriedlinPotency23.93417.568615.230621.3313AID504548
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.84920.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)993.10000.11007.190310.0000AID1209455; AID1449628
Beta-2 adrenergic receptorHomo sapiens (human)IC50 (µMol)0.24600.00020.93267.2000AID625205
Beta-2 adrenergic receptorHomo sapiens (human)Ki0.20360.00000.66359.5499AID1061255; AID1061256; AID1298705; AID1798549; AID41344; AID625205
Beta-1 adrenergic receptorHomo sapiens (human)IC50 (µMol)0.33300.00021.46819.0000AID625204
Beta-1 adrenergic receptorHomo sapiens (human)Ki0.88890.00011.33919.9840AID40389; AID625204
Beta-2 adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.21250.00301.17839.7724AID41608; AID41884
Beta-2 adrenergic receptorRattus norvegicus (Norway rat)Ki0.67610.00050.35461.6000AID41344
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)IC50 (µMol)1.77000.11003.26419.0330AID625146
Beta-3 adrenergic receptorHomo sapiens (human)Ki18.62090.00302.30986.0450AID41935
D(2) dopamine receptorHomo sapiens (human)Ki30.00000.00000.651810.0000AID1298707; AID1298708
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00021.874210.0000AID33132
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki35.50000.00010.949010.0000AID37462
Beta-1 adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.21250.00300.07870.3250AID41608; AID41884
Beta-1 adrenergic receptorRattus norvegicus (Norway rat)Ki0.37500.00000.667310.0000AID40409; AID40414
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00031.09147.7625AID33132
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Ki21.00000.00000.929610.0000AID37106
D(1A) dopamine receptorHomo sapiens (human)Ki50.00000.00010.836310.0000AID1298706
D(4) dopamine receptorHomo sapiens (human)Ki2.90000.00000.436210.0000AID1298710
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00031.09147.7625AID33132
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Ki21.00000.00000.970810.0000AID37106
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00031.06917.7625AID33132
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Ki21.00000.00000.937510.0000AID37106
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00021.270410.0000AID33132
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Ki35.50000.00000.575110.0000AID37462
Beta-3 adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.21250.00300.07870.3250AID41608; AID41884
Beta-1 adrenergic receptorMus musculus (house mouse)Ki0.22000.00010.13100.5500AID1298704
D(3) dopamine receptorHomo sapiens (human)Ki4.70000.00000.602010.0000AID1298709
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00001.819410.0000AID33132
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki35.50000.00000.965010.0000AID37462
Beta-2 adrenergic receptorCanis lupus familiaris (dog)IC50 (µMol)0.66670.00012.45965.2000AID220922; AID41472
Beta-2 adrenergic receptor Bos taurus (cattle)Ki0.11000.00160.09040.1400AID40685; AID40692
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NPYLR7BAedes aegypti (yellow fever mosquito)EC50 (µMol)0.03900.03902.289918.3000AID1259426
Beta-1 adrenergic receptor Cavia porcellus (domestic guinea pig)EC50 (µMol)0.02290.00030.01160.0398AID414892; AID42047
Beta-2 adrenergic receptorHomo sapiens (human)EC50 (µMol)0.05470.00000.311110.0000AID1061254; AID1298715; AID1298719; AID1404508; AID1424835; AID1481935; AID1543325; AID1617014; AID1783430; AID1906919; AID246461; AID264375; AID344248; AID349761; AID350869; AID366406; AID41160; AID414892; AID420991; AID426895; AID426896; AID429598; AID44542; AID483557; AID606103; AID611239; AID623252
Beta-2 adrenergic receptorHomo sapiens (human)Kd0.29280.00000.62888.9130AID1626022; AID1626023; AID426242; AID770362
Beta-1 adrenergic receptorHomo sapiens (human)EC50 (µMol)0.10000.00010.49146.0000AID1424836; AID1481933; AID1543326; AID1783429; AID1906920; AID246460; AID264377; AID317596; AID344246; AID349760; AID350867; AID366404; AID387246; AID41160; AID414891; AID420992; AID426897; AID426898; AID44399; AID483559; AID611237; AID623254
Beta-2 adrenergic receptorRattus norvegicus (Norway rat)EC50 (µMol)0.00700.00701.61003.0000AID41601
Beta-3 adrenergic receptorHomo sapiens (human)EC50 (µMol)0.07300.00010.455310.0000AID1238567; AID1424837; AID1481920; AID246462; AID264374; AID317595; AID326592; AID326595; AID344247; AID349762; AID350871; AID366403; AID387245; AID41160; AID414894; AID41513; AID41634; AID420990; AID426893; AID426894; AID429597; AID44570; AID483560; AID611236; AID623255
Beta-1 adrenergic receptorRattus norvegicus (Norway rat)EC50 (µMol)0.00700.00701.53003.0000AID41601
Beta-2 adrenergic receptorMus musculus (house mouse)EC50 (µMol)0.98000.98000.98000.9800AID41445
Beta-adrenergic receptor kinase 1Homo sapiens (human)Kd0.20000.17005.579122.4940AID1799821
Alpha-1D adrenergic receptorHomo sapiens (human)EC50 (µMol)0.00150.00151.72275.6000AID220909
Beta-3 adrenergic receptorMus musculus (house mouse)EC50 (µMol)0.98000.98000.98000.9800AID41445
Beta-3 adrenergic receptorRattus norvegicus (Norway rat)EC50 (µMol)0.04700.00010.71753.0000AID220926; AID41601
Vasopressin V1a receptorRattus norvegicus (Norway rat)EC50 (µMol)1.00000.00010.26541.0000AID426896
Beta-1 adrenergic receptorMus musculus (house mouse)EC50 (µMol)0.98000.98000.98000.9800AID41445
Alpha-1A adrenergic receptorHomo sapiens (human)EC50 (µMol)0.00150.00010.50987.1000AID220909
Alpha-1B adrenergic receptorHomo sapiens (human)EC50 (µMol)0.00150.00011.30105.6000AID220909
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)EC50 (µMol)0.00300.00301.29038.3000AID426895
Histamine H2 receptorCavia porcellus (domestic guinea pig)EC50 (µMol)0.03980.00030.57191.2023AID414892
Taste receptor type 2 member 38Homo sapiens (human)EC50 (µMol)0.00490.00491.36102.3000AID1619522
Taste receptor type 2 member 39Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619538
Taste receptor type 2 member 40Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619534
Taste receptor type 2 member 41Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619533
Taste receptor type 2 member 43Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619521
Taste receptor type 2 member 31Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619527
Taste receptor type 2 member 45Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619523
Taste receptor type 2 member 46Homo sapiens (human)EC50 (µMol)0.00490.00493.09838.6000AID1619524
Taste receptor type 2 member 30Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619537
Taste receptor type 2 member 19Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619532
Taste receptor type 2 member 20Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619536
Taste receptor type 2 member 50Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619525
Taste receptor type 2 member 60Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619535
Oxytocin receptorRattus norvegicus (Norway rat)EC50 (µMol)0.00300.00300.00300.0030AID426895
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)EC50 (µMol)0.00300.00301.02226.8600AID426895
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)EC50 (µMol)0.00300.00300.86696.8600AID426895
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)EC50 (µMol)0.00300.00301.11276.8600AID426895
Beta-2 adrenergic receptor Bos taurus (cattle)Kd0.33000.00061.47759.1200AID40694
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)EC50 (µMol)0.00300.00301.39378.3000AID426895
Taste receptor type 2 member 42Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619528
Beta-2 adrenergic receptorCavia porcellus (domestic guinea pig)EC50 (µMol)0.01570.00020.88438.2000AID1543326; AID1617018; AID44542; AID623255
Beta-2 adrenergic receptorCavia porcellus (domestic guinea pig)Kd0.02510.00020.54774.4668AID1190659
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)EC50 (µMol)0.00300.00300.90516.8600AID426895
Taste receptor type 2 member 16Homo sapiens (human)EC50 (µMol)0.00490.00490.15500.2500AID1619529
Taste receptor type 2 member 14Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619530
Taste receptor type 2 member 13Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619518
Taste receptor type 2 member 10Homo sapiens (human)EC50 (µMol)0.00490.00492.50255.0000AID1619531
Taste receptor type 2 member 9Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619539
Taste receptor type 2 member 8Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619517
Taste receptor type 2 member 7Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619519
Taste receptor type 2 member 5Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619526
Taste receptor type 2 member 4Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619540
Taste receptor type 2 member 3Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619520
Taste receptor type 2 member 1Homo sapiens (human)EC50 (µMol)0.00490.00490.00490.0049AID1619516
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)EC50 (µMol)0.00300.00300.90516.8600AID426895
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-1 adrenergic receptor Cavia porcellus (domestic guinea pig)ED250.00340.00340.00460.0071AID1146181
Beta-2 adrenergic receptorHomo sapiens (human)Km0.05000.05000.05000.0500AID41335
Beta-1 adrenergic receptorRattus norvegicus (Norway rat)EC20 (µMol)0.00020.00020.06010.1200AID40397
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (257)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral fear responseD(4) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(4) dopamine receptorHomo sapiens (human)
response to amphetamineD(4) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
adult locomotory behaviorD(4) dopamine receptorHomo sapiens (human)
positive regulation of sodium:proton antiporter activityD(4) dopamine receptorHomo sapiens (human)
positive regulation of kinase activityD(4) dopamine receptorHomo sapiens (human)
response to histamineD(4) dopamine receptorHomo sapiens (human)
social behaviorD(4) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
fear responseD(4) dopamine receptorHomo sapiens (human)
regulation of circadian rhythmD(4) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(4) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(4) dopamine receptorHomo sapiens (human)
rhythmic processD(4) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(4) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(4) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
inhibitory postsynaptic potentialD(4) dopamine receptorHomo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationD(4) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(4) dopamine receptorHomo sapiens (human)
chemical synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
desensitization of G protein-coupled receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
negative regulation of the force of heart contraction by chemical signalBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
tachykinin receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
heart developmentBeta-adrenergic receptor kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationBeta-adrenergic receptor kinase 1Homo sapiens (human)
viral genome replicationBeta-adrenergic receptor kinase 1Homo sapiens (human)
receptor internalizationBeta-adrenergic receptor kinase 1Homo sapiens (human)
positive regulation of catecholamine secretionBeta-adrenergic receptor kinase 1Homo sapiens (human)
negative regulation of striated muscle contractionBeta-adrenergic receptor kinase 1Homo sapiens (human)
symbiont entry into host cellBeta-adrenergic receptor kinase 1Homo sapiens (human)
cardiac muscle contractionBeta-adrenergic receptor kinase 1Homo sapiens (human)
negative regulation of relaxation of smooth muscleBeta-adrenergic receptor kinase 1Homo sapiens (human)
regulation of the force of heart contractionBeta-adrenergic receptor kinase 1Homo sapiens (human)
protein phosphorylationBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
apoptotic processAlpha-1A adrenergic receptorHomo sapiens (human)
smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
activation of phospholipase C activityAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1A adrenergic receptorHomo sapiens (human)
adult heart developmentAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of cell population proliferationAlpha-1A adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAlpha-1A adrenergic receptorHomo sapiens (human)
response to hormoneAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of autophagyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of action potentialAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
calcium ion transport into cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
cell growth involved in cardiac muscle cell developmentAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase C signalingAlpha-1A adrenergic receptorHomo sapiens (human)
pilomotor reflexAlpha-1A adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-1B adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of cardiac muscle contractionAlpha-1B adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1B adrenergic receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorCanis lupus familiaris (dog)
regulation of smooth muscle contractionBeta-2 adrenergic receptorCanis lupus familiaris (dog)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorCanis lupus familiaris (dog)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorCanis lupus familiaris (dog)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorCanis lupus familiaris (dog)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorCanis lupus familiaris (dog)
positive regulation of lipophagyBeta-2 adrenergic receptorCanis lupus familiaris (dog)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 38Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 38Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 39Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 39Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 40Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 40Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 41Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 41Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 43Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 43Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 31Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 31Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 45Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 45Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 46Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 46Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 30Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 30Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 19Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 19Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 20Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 20Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 50Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 50Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 60Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 60Homo sapiens (human)
sensory perception of bitter tasteTaste receptor type 2 member 60Homo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptor Bos taurus (cattle)
regulation of smooth muscle contractionBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of MAPK cascadeBeta-2 adrenergic receptor Bos taurus (cattle)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptor Bos taurus (cattle)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of autophagosome maturationBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of lipophagyBeta-2 adrenergic receptor Bos taurus (cattle)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 42Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 42Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 16Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 16Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 14Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 14Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 13Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 13Homo sapiens (human)
positive regulation of cytokinesisTaste receptor type 2 member 13Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 10Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 10Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 9Homo sapiens (human)
biological_processTaste receptor type 2 member 9Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 9Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 8Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 8Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 7Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 7Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 5Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 5Homo sapiens (human)
chemosensory behaviorTaste receptor type 2 member 5Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 4Homo sapiens (human)
respiratory gaseous exchange by respiratory systemTaste receptor type 2 member 4Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 3Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 3Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (48)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(4) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
protein bindingD(4) dopamine receptorHomo sapiens (human)
potassium channel regulator activityD(4) dopamine receptorHomo sapiens (human)
SH3 domain bindingD(4) dopamine receptorHomo sapiens (human)
dopamine bindingD(4) dopamine receptorHomo sapiens (human)
identical protein bindingD(4) dopamine receptorHomo sapiens (human)
metal ion bindingD(4) dopamine receptorHomo sapiens (human)
epinephrine bindingD(4) dopamine receptorHomo sapiens (human)
norepinephrine bindingD(4) dopamine receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityD(4) dopamine receptorHomo sapiens (human)
neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
serotonin bindingD(4) dopamine receptorHomo sapiens (human)
protein kinase activityBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled receptor kinase activityBeta-adrenergic receptor kinase 1Homo sapiens (human)
protein bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
ATP bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
Edg-2 lysophosphatidic acid receptor bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
beta-adrenergic receptor kinase activityBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled receptor bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1B adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1B adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1B adrenergic receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorCanis lupus familiaris (dog)
protein homodimerization activityBeta-2 adrenergic receptorCanis lupus familiaris (dog)
norepinephrine bindingBeta-2 adrenergic receptorCanis lupus familiaris (dog)
G protein-coupled receptor activityTaste receptor type 2 member 38Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 38Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 39Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 39Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 40Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 40Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 41Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 41Homo sapiens (human)
protein bindingTaste receptor type 2 member 41Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 43Homo sapiens (human)
taste receptor activityTaste receptor type 2 member 43Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 43Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 31Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 31Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 45Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 45Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 46Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 46Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 30Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 30Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 19Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 19Homo sapiens (human)
protein bindingTaste receptor type 2 member 19Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 20Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 20Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 50Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 50Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 60Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 60Homo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptor Bos taurus (cattle)
protein homodimerization activityBeta-2 adrenergic receptor Bos taurus (cattle)
norepinephrine bindingBeta-2 adrenergic receptor Bos taurus (cattle)
bitter taste receptor activityTaste receptor type 2 member 42Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 42Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 16Homo sapiens (human)
protein bindingTaste receptor type 2 member 16Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 16Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 14Homo sapiens (human)
taste receptor activityTaste receptor type 2 member 14Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 14Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 13Homo sapiens (human)
taste receptor activityTaste receptor type 2 member 13Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 13Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 10Homo sapiens (human)
protein bindingTaste receptor type 2 member 10Homo sapiens (human)
taste receptor activityTaste receptor type 2 member 10Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 10Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 9Homo sapiens (human)
taste receptor activityTaste receptor type 2 member 9Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 9Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 8Homo sapiens (human)
protein bindingTaste receptor type 2 member 8Homo sapiens (human)
taste receptor activityTaste receptor type 2 member 8Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 8Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 7Homo sapiens (human)
taste receptor activityTaste receptor type 2 member 7Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 7Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 5Homo sapiens (human)
protein bindingTaste receptor type 2 member 5Homo sapiens (human)
taste receptor activityTaste receptor type 2 member 5Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 5Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 4Homo sapiens (human)
taste receptor activityTaste receptor type 2 member 4Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 4Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 3Homo sapiens (human)
taste receptor activityTaste receptor type 2 member 3Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 3Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 1Homo sapiens (human)
taste receptor activityTaste receptor type 2 member 1Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (55)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorMus musculus (house mouse)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
centrosomeD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
membraneD(4) dopamine receptorHomo sapiens (human)
postsynapseD(4) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
dendriteD(4) dopamine receptorHomo sapiens (human)
cytoplasmBeta-adrenergic receptor kinase 1Homo sapiens (human)
cytosolBeta-adrenergic receptor kinase 1Homo sapiens (human)
plasma membraneBeta-adrenergic receptor kinase 1Homo sapiens (human)
ciliumBeta-adrenergic receptor kinase 1Homo sapiens (human)
membraneBeta-adrenergic receptor kinase 1Homo sapiens (human)
presynapseBeta-adrenergic receptor kinase 1Homo sapiens (human)
postsynapseBeta-adrenergic receptor kinase 1Homo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
nucleusAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
caveolaAlpha-1A adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
nucleusAlpha-1B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
caveolaAlpha-1B adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorCanis lupus familiaris (dog)
Golgi apparatusBeta-2 adrenergic receptorCanis lupus familiaris (dog)
receptor complexBeta-2 adrenergic receptorCanis lupus familiaris (dog)
plasma membraneTaste receptor type 2 member 38Homo sapiens (human)
membraneTaste receptor type 2 member 38Homo sapiens (human)
membraneTaste receptor type 2 member 38Homo sapiens (human)
plasma membraneTaste receptor type 2 member 39Homo sapiens (human)
membraneTaste receptor type 2 member 39Homo sapiens (human)
membraneTaste receptor type 2 member 39Homo sapiens (human)
plasma membraneTaste receptor type 2 member 40Homo sapiens (human)
membraneTaste receptor type 2 member 40Homo sapiens (human)
membraneTaste receptor type 2 member 40Homo sapiens (human)
plasma membraneTaste receptor type 2 member 41Homo sapiens (human)
membraneTaste receptor type 2 member 41Homo sapiens (human)
membraneTaste receptor type 2 member 41Homo sapiens (human)
plasma membraneTaste receptor type 2 member 43Homo sapiens (human)
membraneTaste receptor type 2 member 43Homo sapiens (human)
motile ciliumTaste receptor type 2 member 43Homo sapiens (human)
ciliary membraneTaste receptor type 2 member 43Homo sapiens (human)
membraneTaste receptor type 2 member 43Homo sapiens (human)
plasma membraneTaste receptor type 2 member 31Homo sapiens (human)
membraneTaste receptor type 2 member 31Homo sapiens (human)
membraneTaste receptor type 2 member 31Homo sapiens (human)
plasma membraneTaste receptor type 2 member 45Homo sapiens (human)
membraneTaste receptor type 2 member 45Homo sapiens (human)
membraneTaste receptor type 2 member 45Homo sapiens (human)
plasma membraneTaste receptor type 2 member 46Homo sapiens (human)
membraneTaste receptor type 2 member 46Homo sapiens (human)
ciliary membraneTaste receptor type 2 member 46Homo sapiens (human)
membraneTaste receptor type 2 member 46Homo sapiens (human)
plasma membraneTaste receptor type 2 member 30Homo sapiens (human)
membraneTaste receptor type 2 member 30Homo sapiens (human)
membraneTaste receptor type 2 member 30Homo sapiens (human)
plasma membraneTaste receptor type 2 member 19Homo sapiens (human)
membraneTaste receptor type 2 member 19Homo sapiens (human)
membraneTaste receptor type 2 member 19Homo sapiens (human)
plasma membraneTaste receptor type 2 member 20Homo sapiens (human)
membraneTaste receptor type 2 member 20Homo sapiens (human)
plasma membraneTaste receptor type 2 member 50Homo sapiens (human)
membraneTaste receptor type 2 member 50Homo sapiens (human)
membraneTaste receptor type 2 member 50Homo sapiens (human)
plasma membraneTaste receptor type 2 member 60Homo sapiens (human)
membraneTaste receptor type 2 member 60Homo sapiens (human)
membraneTaste receptor type 2 member 60Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
early endosomeBeta-2 adrenergic receptor Bos taurus (cattle)
Golgi apparatusBeta-2 adrenergic receptor Bos taurus (cattle)
receptor complexBeta-2 adrenergic receptor Bos taurus (cattle)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneTaste receptor type 2 member 42Homo sapiens (human)
membraneTaste receptor type 2 member 42Homo sapiens (human)
membraneTaste receptor type 2 member 42Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulumTaste receptor type 2 member 16Homo sapiens (human)
trans-Golgi networkTaste receptor type 2 member 16Homo sapiens (human)
plasma membraneTaste receptor type 2 member 16Homo sapiens (human)
external side of plasma membraneTaste receptor type 2 member 16Homo sapiens (human)
membraneTaste receptor type 2 member 16Homo sapiens (human)
membraneTaste receptor type 2 member 16Homo sapiens (human)
plasma membraneTaste receptor type 2 member 14Homo sapiens (human)
membraneTaste receptor type 2 member 14Homo sapiens (human)
membraneTaste receptor type 2 member 14Homo sapiens (human)
plasma membraneTaste receptor type 2 member 13Homo sapiens (human)
membraneTaste receptor type 2 member 13Homo sapiens (human)
membraneTaste receptor type 2 member 13Homo sapiens (human)
plasma membraneTaste receptor type 2 member 10Homo sapiens (human)
membraneTaste receptor type 2 member 10Homo sapiens (human)
membraneTaste receptor type 2 member 10Homo sapiens (human)
plasma membraneTaste receptor type 2 member 9Homo sapiens (human)
membraneTaste receptor type 2 member 9Homo sapiens (human)
plasma membraneTaste receptor type 2 member 8Homo sapiens (human)
membraneTaste receptor type 2 member 8Homo sapiens (human)
membraneTaste receptor type 2 member 8Homo sapiens (human)
plasma membraneTaste receptor type 2 member 7Homo sapiens (human)
membraneTaste receptor type 2 member 7Homo sapiens (human)
membraneTaste receptor type 2 member 7Homo sapiens (human)
plasma membraneTaste receptor type 2 member 5Homo sapiens (human)
membraneTaste receptor type 2 member 5Homo sapiens (human)
membraneTaste receptor type 2 member 5Homo sapiens (human)
plasma membraneTaste receptor type 2 member 4Homo sapiens (human)
membraneTaste receptor type 2 member 4Homo sapiens (human)
ciliary membraneTaste receptor type 2 member 4Homo sapiens (human)
membraneTaste receptor type 2 member 4Homo sapiens (human)
plasma membraneTaste receptor type 2 member 3Homo sapiens (human)
membraneTaste receptor type 2 member 3Homo sapiens (human)
membraneTaste receptor type 2 member 3Homo sapiens (human)
plasma membraneTaste receptor type 2 member 1Homo sapiens (human)
membraneTaste receptor type 2 member 1Homo sapiens (human)
membraneTaste receptor type 2 member 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (483)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1148412Agonist activity at beta-1 adrenergic receptor in guinea pig atria assessed as effect on force of atrial contraction in presence of reserpine1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Synthesis and adrenergic activity of benzimidazole bioisosteres of norepinephrine and isoproterenol.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID40389Binding Affinity against human Beta-1 adrenergic receptor expressed in Chinese hamster ovary(CHO) cells was measured by using [125I]ICYP radioligand1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
2-Amino-4-benzyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridines: novel selective beta3-adrenoceptor agonists.
AID611239Agonist activity at human adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating hydantoin or uracil rings.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID344252Ratio of Cmax for drug to Cmax for 4'-{2-[(R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-ethyl}-3-isopropoxy-biphenyl-4-carboxylic acid in beagle dog at 0.1 mg/kg, po by cassette assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.
AID1190660Agonist activity at adrenergic beta2 receptor in Hartley guinea pig tracheal ring assessed as bronchorelaxation activity against histamine-induced contraction2015Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
Insights on the role of boron containing moieties in the design of new potent and efficient agonists targeting the β2 adrenoceptor.
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID40397Mean concentration required to increase basal rate of rat atria by 20 beats per minute2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4'-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence.
AID220922Agonistic activity towards beta-2 adrenoceptor. IC50, the mean concentration required to produce 50% inhibition of uterine contraction2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.
AID580169Induction of lipolysis in mouse C3H10T1/2 assessed as glycerol concentration at 10 uM relative to control2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Discovery of new inhibitor for PDE3 by virtual screening.
AID36177Intrinsic activity was expressed as the ratio between maximal response elicited by compound and that elicited by full agonist NE towards Alpha-2 adrenergic receptor of isolated guinea pig ileum1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.
AID220927Activity compared to that observed following forskolin (10e -5).2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.
AID1543325Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay
AID414900Agonist activity at beta-1 adrenergic receptor in guinea pig trachea assessed as inhibition of electrical stimulation-induced contraction in guinea pig trachea after 3 hrs washout2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups.
AID611237Agonist activity at human adrenergic beta1 receptor expressed in CHO cells assessed as cAMP accumulation2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating hydantoin or uracil rings.
AID414916Selectivity assessed as difference in pEC50 for human cloned beta2 adrenergic receptor and pEC50 for human cloned beta-1 adrenergic receptor2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID264376Selectivity for human beta3 adrenergic receptor over beta-2 adrenergic receptor expressed in CHO cells by stimulation of cAMP production2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.
AID171675Change in systolic blood pressure after iv administration of 0.625 mg/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1617014Agonist activity at human beta2 adrenergic receptor expressed in CHOK1 cells co-expressing Galpha15 assessed as increase in calcium influx by measuring fluorescence intensity by FLIPR assay
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID39966Intrinsic activity was expressed as the ratio between maximal response elicited by compound and that elicited by full agonist ISO towards Beta-1 adrenergic receptor of isolated guinea pig atria1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.
AID40529Agonistic activity for Beta-1 adrenergic receptor was estimated from it's chronotropic effect on rat atria2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4'-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence.
AID611236Agonist activity at human adrenergic beta3 receptor expressed in CHO cells assessed as cAMP accumulation2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating hydantoin or uracil rings.
AID1543327Selectivity ratio of compound effect for agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells to compound effect for agonist activity at human beta1 adrenergic receptor expressed in HEK293 cells
AID41314Compound was tested for beta adrenergic receptor activity in isolated guinea pig tracheal strip1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Conformational effects on the activity of drugs. 11. Stereostructural models for the direct activation of the alpha- and beta-adrenergic receptor.
AID1864500Substrate activity at human OCT1 overexpressed in HEK293 cells at 2.5 uM incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID41313Compound was tested for beta adrenergic receptor activity in isolated guinea pig atria1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Conformational effects on the activity of drugs. 11. Stereostructural models for the direct activation of the alpha- and beta-adrenergic receptor.
AID580171Induction of lipolysis in mouse C3H10T1/2 assessed as glycerol concentration2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Discovery of new inhibitor for PDE3 by virtual screening.
AID59673Effective dose required for the maximum heart rate in anesthetized dogs.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols.
AID41166Evaluated for the efficacy in stimulating cAMP synthesis by beta-2 adrenergic receptor in human platelets1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
3,4-O-diacetylisoproterenol. Preparation, structure proof, and beta-receptor effect.
AID229659Selectivity ratio (Beta-1EC50/ Beta-3EC50)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres.
AID1123874Inhibition of histamine-induced asthma-like syndrome in guinea pig assessed as time delay in appearance of coughing at 1.25 mg/kg, po treated 30 mins before histamine challenge (Rvb = 6.13 mins)1979Journal of medicinal chemistry, Mar, Volume: 22, Issue:3
New bronchodilators. Synthesis and bronchodilating activity of some 3-(alkoxymethyl)-alpha-(N-substituted aminomethyl)-4-hydroxybenzyl alcohols.
AID40387Drug concentration which produces cAMP response equal to 50% of its maximal response against human beta-1-adrenoceptor in chinese hamster ovary cells was determined1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
2-Amino-4-benzyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridines: novel selective beta3-adrenoceptor agonists.
AID513151Agonist activity at human biamane labelled beta-2 adrenergic receptor delta 5-C271/Trp135 mutant assessed as stimulation of [35S]GTPgammaS binding [35S]GTPgammaS binding assay2006Nature chemical biology, Aug, Volume: 2, Issue:8
Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor.
AID420991Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Discovery of novel acetanilide derivatives as potent and selective beta3-adrenergic receptor agonists.
AID41474Inhibition of spontaneous contractions in isolated rat uterus2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4'-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence.
AID1906919Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis
AID1061253Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as stimulation of cAMP accumulation relative to isoproterenol2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Comparative molecular field analysis of fenoterol derivatives interacting with an agonist-stabilized form of the β₂-adrenergic receptor.
AID246460Agonistic activity was assessed by measuring cAMP accumulation in CHO cell lines expressing cloned human Beta-1 adrenergic receptor2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist.
AID1238575Agonist activity at human alpha1A-adrenergic receptor expressed in HEK293 cells assessed as calcium flux by fluorescence assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
AID349762Agonist activity at human recombinant beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5.
AID264375Activity at human beta-2 adrenergic receptor expressed in CHO cells by stimulation of cAMP production2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.
AID1146181Agonist activity at beta-1 adrenergic receptor in guinea pig right atria assessed as increase in contraction rate of spontaneously beating right atria1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Adrenergic agents. 8.1 Synthesis and beta-adrenergic agonist activity of some 3-tert-butylamino-2-(substituted phenyl)-1-propanols.
AID39965Inhibitory activity against beta-1 adrenergic receptor in guinea pig atria is determined1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1481922Agonist activity at recombinant human alpha1A adrenergic receptor expressed in HEK293 cells assessed as intercellular Ca mobilization by Fura-2AM dye-based fluorescence assay
AID317596Agonist activity at human beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by EIA2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.
AID344248Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immuno assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.
AID1424835Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay2018European journal of medicinal chemistry, May-25, Volume: 152Synthesis and biological evaluation of β
AID33255Compound was tested for Alpha adrenergic receptor in isolated rat vas deferens1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Conformational effects on the activity of drugs. 11. Stereostructural models for the direct activation of the alpha- and beta-adrenergic receptor.
AID708938Positive inotropic activity in C57BL/6 mouse Langendorff perfused heart assessed as left ventricular developed pressure at 100 uM measured for 20 mins2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
O2-sulfonylethyl protected isopropylamine diazen-1-ium-1,2-diolates as nitroxyl (HNO) donors: synthesis, β-elimination fragmentation, HNO release, positive inotropic properties, and blood pressure lowering studies.
AID1150831Bronchodilator activity in dog assessed as time of inhibition of carbachol or histamine-induced bronchoconstriction at 50 to 240 mg/kg, id relative to control1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects.
AID1136379Agonist activity at beta-adrenoceptor in Sprague-Dawley rat fat cells assessed as cAMP accumulation per 10 mins at 10'-6 M1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and beta-adrenoceptor activity of the erythro and threo isomers of substituted alpha-hydroxytrimetoquinol.
AID88758Agonistic potency against BETA1-AR expressed in CHO cells by using CRE-LUC assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Synthesis and human beta-adrenoceptor activity of 1-(3,5-diiodo-4- methoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-6-ol derivatives in vitro.
AID1148409Agonist activity at beta-1 adrenergic receptor in guinea pig atria assessed as effect on atrial rate1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Synthesis and adrenergic activity of benzimidazole bioisosteres of norepinephrine and isoproterenol.
AID171642Change in diastolic blood pressure after iv administration of 0.625 mg/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID1146180Agonist activity at beta-2 adrenergic receptor in guinea pig tracheal chain assessed as relaxation of spontaneously contracted tracheal smooth muscle1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Adrenergic agents. 8.1 Synthesis and beta-adrenergic agonist activity of some 3-tert-butylamino-2-(substituted phenyl)-1-propanols.
AID623253Intrinsic activity at at human beta2 receptor expressed in CHO cells assessed as cAMP accumulation2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating a urea group.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1481935Agonist activity at recombinant human beta2 adrenergic receptor expressed in CHO cells assessed as accumulation of cyclic AMP after 30 mins
AID40267Intrinsic activity expressed as the percentage of maximal analogue response relative to the maximal response(100%) of isoproterenol against human beta-1-adrenoceptor using cAMP-RIA assay1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
2-Amino-4-benzyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridines: novel selective beta3-adrenoceptor agonists.
AID1404508Agonist activity at human beta2-AR expressed in CHOK1 cells co-expressing Galpha15 measured after 21 secs to 120 secs by Calcium-4 dye based FLIPR assay
AID76809Positive inotropic activity in isolated left guinea pig atria.1986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
Cardiotonic agents. 1. Synthesis and structure-activity relationships in a new class of 3-, 4-, and 5-pyridyl-2(1H)-quinolone derivatives.
AID580170Induction of lipolysis in human Adipocyte assessed as glycerol concentration at 10 uM relative to control2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Discovery of new inhibitor for PDE3 by virtual screening.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID41341Drug concentration which produces cAMP response equal to 50% of its maximal response against human beta-2-adrenoceptor in chinese hamster ovary cells was determined1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
2-Amino-4-benzyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridines: novel selective beta3-adrenoceptor agonists.
AID392784Binding interaction with platelet assessed as spin lattice relaxation rate enumerated as normalized affinity index at given concentration and fixed temperature by NMR relaxation experiment2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Interaction study of bioactive molecules with fibrinogen and human platelets determined by 1H NMR relaxation experiments.
AID349760Agonist activity at human recombinant beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5.
AID174353Cyclic AMP accumulation in Rat brain cerebral cortical slices by the compound, activity expressed as % conversion1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Stereoselective syntheses of the trans-decahydroquinoline-5-carboxylic acid epimers. Diastereomeric zwitterionic probes of gamma-aminobutyric acid related biological properties in vitro and in vivo.
AID1636403Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 2.2 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID426893Agonist activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID426894Agonist activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.
AID1146185Intrinsic activity at beta-2 adrenergic receptor in guinea pig tracheal chain assessed as relaxation of spontaneously contracted tracheal smooth muscle relative to papaverine1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Adrenergic agents. 8.1 Synthesis and beta-adrenergic agonist activity of some 3-tert-butylamino-2-(substituted phenyl)-1-propanols.
AID41634Agonistic activity for Beta-3 adrenergic receptor as relaxing ability of isolated ferret detrusor basal tone2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4'-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence.
AID496772Modulation of neurological behavior in zebrafish assessed as effect on touch response by high-throughput screening2010Nature chemical biology, Mar, Volume: 6, Issue:3
Rapid behavior-based identification of neuroactive small molecules in the zebrafish.
AID366406Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.
AID414892Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups.
AID56247Cardiovascular activity (heart rate) (0.31 ug/kg) in dog before beta-blockade1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents.
AID1298714Displacement of [3H]RX821002 from alpha-2 receptor in porcine cortical membranes2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID40415Tested for binding affinity against beta-1 adrenergic receptor in rat brain using [3H]-CGP- 26505 as radioligand1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.
AID1061254Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as stimulation of cAMP accumulation2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Comparative molecular field analysis of fenoterol derivatives interacting with an agonist-stabilized form of the β₂-adrenergic receptor.
AID41297Intrinsic activity against beta adrenergic receptor in isolated guinea pig tracheal strip1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Conformational effects on the activity of drugs. 11. Stereostructural models for the direct activation of the alpha- and beta-adrenergic receptor.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID41939In vitro beta adrenergic receptor activity against beta-3 adrenergic receptor in rat epididymal fat pads by stimulation of glycerol release from adipocytes.1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent.
AID234917Selectivity for beta3-AR over beta2-AR was determined2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4'-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1481948Agonist activity at beta3 adrenergic receptor in marmoset urinary bladder smooth muscle strips assessed as induction of KCl-precontracted muscle relaxation treated every 20 mins
AID1060999Agonist activity at guinea pig trachea beta2-adrenergic receptor assessed as relaxation of histamine-induced tracheal ring contraction2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors.
AID1783430Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation2021European journal of medicinal chemistry, Nov-15, Volume: 2248-Hydroxyquinolin-2(1H)-one analogues as potential β
AID350871Agonist activity at human beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Synthesis and evaluation of novel phenoxypropanolamine derivatives containing acetanilides as potent and selective beta3-adrenergic receptor agonists.
AID1150830Bronchodilator activity in dog assessed as time of inhibition of carbachol or histamine-induced bronchoconstriction at 0.3 to 2 mg/kg, iv relative to control1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects.
AID42047Agonistic activity (beta-1 adrenergic receptor) for the percent maximal increase in contraction rate of isolated guinea pig atria1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Effect of fluorine substitution on the adrenergic properties of 3-(tert-butylamino)-1-(3,4-dihydroxyphenoxy)-2-propanol.
AID179663Evaluated for the efficacy in stimulating cAMP synthesis by beta-1 adrenergic receptor in rat cerebral cortex.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
3,4-O-diacetylisoproterenol. Preparation, structure proof, and beta-receptor effect.
AID708935Effect on heart rate in C57BL/6 mouse Langendorff perfused heart at 100 uM measured for 20 mins2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
O2-sulfonylethyl protected isopropylamine diazen-1-ium-1,2-diolates as nitroxyl (HNO) donors: synthesis, β-elimination fragmentation, HNO release, positive inotropic properties, and blood pressure lowering studies.
AID1148417Agonist activity at beta-2 adrenergic receptor in guinea pig trachea assessed as tracheal relaxation1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Synthesis and adrenergic activity of benzimidazole bioisosteres of norepinephrine and isoproterenol.
AID317600Ratio of AUC for drug to AUC for [4-(4-{2-[(R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-ethyl}-phenoxy)-phenoxy]-acetic acid in dog at 0.32 or 1.0 mg/kg, po by cassette assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.
AID1906938Antiinflammatory activity in Sprague- Dawley rat model of ovalbumin induced allergic asthma assessed as reduction in histamine release from lung fragments at 1 umol/L administered 5 mins prior to allergen challenge and measured after 10 mins in presence o
AID647421Agonist activity at beta2 adrenoceptor in guinea pig assessed as relaxation of histamine-induced tracheal ring contraction2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD.
AID735055Agonist activity at beta2-adrenoceptor in guinea pig trachea assessed as relaxation of histamine-induced precontracted tracheal rings2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dual β₂-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD.
AID37106Compound was evaluated for alpha adrenergic binding affinity towards Alpha-2 adrenergic receptor of rat brain1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.
AID1146179Selectivity ratio of ED25 for beta-adrenergic receptor in guinea pig right atrial muscle to ED50 for beta-adrenergic receptor in guinea pig tracheal tissue1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Adrenerigic agents. 7.1 Synthesis and beta-adrenergic agonist activity of several 2-pyridylethanolamines.
AID708936Positive inotropic activity in C57BL/6 mouse Langendorff perfused heart assessed as rate of relaxation at 100 uM measured for 20 mins2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
O2-sulfonylethyl protected isopropylamine diazen-1-ium-1,2-diolates as nitroxyl (HNO) donors: synthesis, β-elimination fragmentation, HNO release, positive inotropic properties, and blood pressure lowering studies.
AID496763Psychostimulant activity in zebrafish assessed as increase in high intensity light-induced motor response at 10 to 100 uM by photomotor response assay2010Nature chemical biology, Mar, Volume: 6, Issue:3
Rapid behavior-based identification of neuroactive small molecules in the zebrafish.
AID1298713Displacement of [3H]prazosine from alpha-1 receptor in porcine cortical membranes2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID57846Cardioselectivity expressed as change in blood pressure for 50% increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID60580Inotropic potency expressed as 100 percent increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID41472Compound was evaluated for its binding affinity towards beta-2 adrenergic receptor in rat soleus membrane by displacing (-)-isoproterenol (50 uM)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent.
AID264434Activity against human beta-1 adrenergic receptor expressed in CHO cells by stimulation of cAMP production relative to R-(-)-isoproterenol2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.
AID326595Agonist activity at human adrenergic beta3 receptor expressed in CHO cells assessed as [3H]cAMP levels by radiolabeled ligand based assay2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Stereospecific synthesis and bio-activity of novel beta(3)-adrenoceptor agonists and inverse agonists.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1148410Agonist activity at beta-1 adrenergic receptor in guinea pig atria assessed as effect on atrial rate in presence of reserpine1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Synthesis and adrenergic activity of benzimidazole bioisosteres of norepinephrine and isoproterenol.
AID41601Beta adrenergic receptor agonistic activity for the stimulation of accumulation of cyclic AMP in cultured C6 glioma cells1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Effect of fluorine substitution on the adrenergic properties of 3-(tert-butylamino)-1-(3,4-dihydroxyphenoxy)-2-propanol.
AID1148411Agonist activity at beta-1 adrenergic receptor in guinea pig atria assessed as effect on force of atrial contraction1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Synthesis and adrenergic activity of benzimidazole bioisosteres of norepinephrine and isoproterenol.
AID192742Maximum rate of rise of the left ventricular isovolumetric pressure was measured after iv administration of 0.625 mg/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID1298705Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID1906922Relaxant activity in Hartley guinea pig tracheal strips model of histamine-induced smooth muscle contraction at 8 x 10^-6 mol/L relative to control
AID1123873Inhibition of histamine-induced asthma-like syndrome in guinea pig assessed as time delay in appearance of anoxia at 5 mg/kg, po treated 30 mins before histamine challenge (Rvb = 5.08 mins)1979Journal of medicinal chemistry, Mar, Volume: 22, Issue:3
New bronchodilators. Synthesis and bronchodilating activity of some 3-(alkoxymethyl)-alpha-(N-substituted aminomethyl)-4-hydroxybenzyl alcohols.
AID1298721Agonist activity at ARMS2-PK-tagged D2S receptor (unknown origin) transfected in HEK293 cells after 5 hrs by beta-arrestin assay2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID88765Agonistic potency against BETA2-AR expressed in CHO cells by using CRE-LUC assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Synthesis and human beta-adrenoceptor activity of 1-(3,5-diiodo-4- methoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-6-ol derivatives in vitro.
AID1148420Ratio of relative activity for guinea pig beta-2 adrenergic receptor to relative activity for guinea pig beta-1 adrenergic receptor1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Synthesis and adrenergic activity of benzimidazole bioisosteres of norepinephrine and isoproterenol.
AID41445Effective concentration against 125I]iodocyanopindolol(ICYP) binding to beta adrenergic receptor was determined1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Conjugates of catecholamines. 5. Synthesis and beta-adrenergic activity of N-(aminoalkyl)norepinephrine derivatives.
AID41324Intrinsic activity expressed as the percentage of maximal analogue response relative to the maximal response(100%) of isoproterenol against human beta-2-adrenoceptor1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
2-Amino-4-benzyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridines: novel selective beta3-adrenoceptor agonists.
AID1481920Agonist activity at recombinant human beta3 adrenergic receptor expressed in CHO cells assessed as accumulation of cyclic AMP after 30 mins
AID41484Agonistic activity for Beta-2 adrenergic receptor was assessed by it's inhibitory effect on spontaneous contractions in isolated rat uterus2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4'-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence.
AID234276Selectivity is expressed as the ratio of ED50 on hind limb perfusion pressure to the ED50 on heart rate1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols.
AID1424840Reduction in histamine-induced muscle contractions in Dunkin-Hartley guinea pig tracheal smooth muscle ring by measuring muscle tone2018European journal of medicinal chemistry, May-25, Volume: 152Synthesis and biological evaluation of β
AID220914Agonistic activity towards beta-1 adrenoceptor. EC20 value, which is the concentration required to increase 20 beats/minute in the rat atria2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.
AID1626024Binding affinity to inactive/G protein-uncoupled human beta2-AR by immobilized artificial membrane HPLC analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID426896Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.
AID606103Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.
AID35810Intrinsic activity against alpha-2 receptor in isolated guinea pig ileum1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.
AID1783423In vivo agonist activity at beta2 adrenergic receptor isolated from guinea pig tracheal smooth muscle assessed as inhibition of histamine-induced tracheal smooth muscle contraction by measuring maximal relaxant effect relative to control2021European journal of medicinal chemistry, Nov-15, Volume: 2248-Hydroxyquinolin-2(1H)-one analogues as potential β
AID1150883Cardiotoxicity in spontaneously respiring dog assessed as time of increase in heart rate at 0.3 to 2 mg/kg, iv relative to control1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects.
AID70530Free energy of binding to turkey erythrocyte beta receptor1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Mapping the turkey erythrocyte beta receptor: a distance geometry approach.
AID1150884Cardiotoxicity in spontaneously respiring dog assessed as time of increase in heart rate at 50 to 240 mg/kg, id relative to control1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects.
AID181372The compound was evaluated for the intrinsic activity compared to (-)-isoproterenol.1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Carbostyril derivatives having potent beta-adrenergic agonist properties.
AID41943Dose necessary to produce 50% of the isoprenaline effect to inhibit GDP binding to beta-3 adrenergic receptor in brown adipose tissue (BAT mitochondria) of rats after subcutaneous administration.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Selective beta 3-adrenergic agonists of brown adipose tissue and thermogenesis. 1. [4-[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]acetates.
AID1134137Antiallergic activity in antiovalbumin serum sensitized guinea pig lung slices assessed as inhibition of ovalbumin-induced histamine release at 0.3 uM preincubated for 5 mins followed by ovalbumin challenge measured after 15 mins by fluorometric analysis 1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Drug-induced modifications of the immune response. 1. Substituted 1-phenylisoquinolines.
AID1150791Bronchodilator activity in dog assessed as degree of inhibition of carbachol or histamine-induced bronchoconstriction at 0.3 to 2 mg/kg, iv relative to control1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects.
AID1783428Selectivity ratio of EC50 for agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells to EC50 for agonist activity at human beta1 adrenoreceptor overexpressed in HEK293 cells2021European journal of medicinal chemistry, Nov-15, Volume: 2248-Hydroxyquinolin-2(1H)-one analogues as potential β
AID1136378Agonist activity at beta-adrenoceptor in Sprague-Dawley rat adipocytes assessed as maximal stimulation of adenylate cyclase activity in plasmalemma measured as cAMP formation at 10'-8 M after 10 mins by scintillation counting1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and beta-adrenoceptor activity of the erythro and threo isomers of substituted alpha-hydroxytrimetoquinol.
AID1298709Displacement of [3H]spiperone from human D3 receptor expressed in CHO cells2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID41335Evaluated for the affinity in stimulating cAMP synthesis by beta-2-adrenoceptor in human platelets.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
3,4-O-diacetylisoproterenol. Preparation, structure proof, and beta-receptor effect.
AID230167The intrinsic activity is given as the ratio of the maximum stimulation with forskolin (10e-5 M)2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4'-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence.
AID73725Effective concentration for increasing potency force in guinea pig isolated left atria1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID40694Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID1146056Agonist activity at beta-adrenoceptor in guinea pig trachea assessed as relaxation of spontaneously contracted tracheal smooth muscle1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Adrenergic agents. 6. Synthesis and potential beta-adrenergic agonist activity of some meta-substituted p-hydroxyphenylethanolamines related to salbutamol.
AID1144289Decrease in blood pressure in rat at 0.150 mg/kg1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
2,3-Dihydroxyphenethanolamine as an adrenergic agent.
AID336963Coronary dilatory activity in perfused guinea pig heart assessed as minimum effective concentration
AID59952The change in cardiac contractile force was determined after 0.1 mg/kg iv administration with 0.5 mg/kg, iv propranolol in dog (p<0.05)1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
4-Aroyl-1,3-dihydro-2H-imidazol-2-ones, a new class of cardiotonic agents.
AID1906921Selectivity ratio of EC50 for beta1 adrenoceptor (unknown orgin) expressed in HEK293 cells to EC50 for human beta2 adrenoceptor (unknown orgin) expressed in HEK293 cells
AID264432Activity against human beta-3 adrenergic receptor expressed in CHO cells by stimulation of cAMP production relative to R-(-)-isoproterenol2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.
AID387245Agonist activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as cAMP accumulation2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human beta(3)-adrenergic receptor agonists: Part IV.
AID220909In vitro beta-adrenergic activity against beta-1 adrenergic receptor by stimulation of rate of contraction of guinea pig atria1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent.
AID36448Tested for binding affinity against alpha-1 adrenergic receptor in rat brain using [3H]-Prazosin as radioligand1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.
AID40685Compound was evaluated for beta adrenergic binding affinity towards beta-2 receptor of bovine lung1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.
AID246462Agonistic activity was assessed by measuring cAMP accumulation in CHO cell lines expressing cloned human Beta-3 adrenergic receptor2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist.
AID1543329Agonist activity at beta2 adrenergic receptor in Dunkin-Hartley guinea pig trachea assessed as reduction in histamine-induced muscle contraction relative to control
AID425696Inhibition of beta2 adrenergic receptor expressed in HEK293 cells co-transfected with PKA fragments Reg-F[1] and cat-F[2]-fused renilla luciferase assessed as effect on receptor regulated PKA activation at 1 uM after 30 mins by protein-fragment complement2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID420995Intrinsic activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay relative to isoproterenol2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Discovery of novel acetanilide derivatives as potent and selective beta3-adrenergic receptor agonists.
AID1146065Intrinsic activity at beta-adrenoceptor in guinea pig trachea assessed as relaxation of spontaneously contracted tracheal smooth muscle relative to papaverine1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Adrenergic agents. 6. Synthesis and potential beta-adrenergic agonist activity of some meta-substituted p-hydroxyphenylethanolamines related to salbutamol.
AID41884The compound was evaluated for the inhibition of [125I]cyanopindolol binding to beta adrenergic receptor in rat reticulocyte membrane.1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Carbostyril derivatives having potent beta-adrenergic agonist properties.
AID234627Concentration ratio of beta-3 (EC50) to beta2 (EC50)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1424836Agonist activity at human beta1 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay2018European journal of medicinal chemistry, May-25, Volume: 152Synthesis and biological evaluation of β
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID88767Intrinsic activity against Beta3-AR expressed in CHO cells by using CRE-LUC assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Synthesis and human beta-adrenoceptor activity of 1-(3,5-diiodo-4- methoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-6-ol derivatives in vitro.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1150858Cardiotoxicity in spontaneously respiring dog assessed as degree of increase in heart rate at 50 to 240 mg/kg, id relative to control1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID60584Inotropic potency expressed as 50 percent increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID1783429Agonist activity at human beta1 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation2021European journal of medicinal chemistry, Nov-15, Volume: 2248-Hydroxyquinolin-2(1H)-one analogues as potential β
AID56242Cardiovascular activity (blood pressure) (0.31 ug/kg) in dog before beta-blockade1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents.
AID611238Intrinsic activity at human adrenergic beta2 receptor expressed in CHO cells assessed as cyclic AMP accumulation relative to isoprenaline2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating hydantoin or uracil rings.
AID59640Compound was tested in anesthetized dogs for inhibition of bronchoconstriction (equipotent dose at ED50) Mean ED50 value, obtained at a dose of 0.054 ug/kg1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
erythro-5-[1-Hydroxy-2-(isopropylamino)butyl]-7-hydroxycarbostyril, a terbutaline-type derivative of the bronchodilator procaterol.
AID169094In vitro concentration required to produce 50% relaxation of rat detrusor2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.
AID41160Evaluated for Beta adrenergic receptor agonistic property in isolated guinea pig atria1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Syntheses and adrenergic agonist properties of ring-fluorinated isoproterenols.
AID1298710Displacement of [3H]spiperone from human D4.4 receptor expressed in CHO cells2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID708937Positive inotropic activity in C57BL/6 mouse Langendorff perfused heart assessed as rate of contraction at 100 uM measured for 20 mins2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
O2-sulfonylethyl protected isopropylamine diazen-1-ium-1,2-diolates as nitroxyl (HNO) donors: synthesis, β-elimination fragmentation, HNO release, positive inotropic properties, and blood pressure lowering studies.
AID429597Agonist activity at human recombinant adrenergic beta3 receptor expressed in CHO cells assessed as stimulation of cAMP level after 1 hr by enzyme immunoassay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6.
AID1906920Agonist activity at beta1 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis
AID44414concentration-response expressed as a percent of the maximal response to R-(-) isoprenaline (ISO)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres.
AID220911In vitro beta-adrenergic activity against beta-1 adrenergic receptor by the inhibition of insulin stimulated [14C]- glucose incorporation into glycogen in isolated rat soleus muscle1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent.
AID1481933Agonist activity at recombinant human beta1 adrenergic receptor expressed in CHO cells assessed as accumulation of cyclic AMP after 30 mins
AID59674Effective dose required for the maximum hind limb perfusion pressure(HLPP) in anesthetized dogs.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols.
AID42202Intrinsic activity against beta-1 adrenergic receptor in isolated guinea pig atria1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.
AID344249Intrinsic activity at human recombinant beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immuno assay relative to isoproterenol2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.
AID503294Agonist activity at beta-2-adrenergic receptor expressed in HEK293 cells assessed as induction of receptor interaction with beta-arrestin by EYFP based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID317598Intrinsic activity at human beta3 adrenergic receptor expressed in CHO cells assessed as ratio between maximal effect of drug to maximal effect of isoproterenol by EIA2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.
AID623254Agonist activity at human beta1 receptor expressed in CHO cells assessed as cAMP accumulation2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating a urea group.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID426895Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.
AID366405Ratio of EC50 for human cloned beta-1 adrenergic receptor to EC50 for human cloned beta3 adrenergic receptor2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.
AID36050Compound was evaluated for alpha adrenoceptor agonistic activity towards Alpha-2 adrenergic receptor of isolated guinea pig ileum1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.
AID1146175Agonist activity at beta-adrenergic receptor in guinea pig right atrial muscle assessed as rate of contraction of spontaneously beating atria1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Adrenerigic agents. 7.1 Synthesis and beta-adrenergic agonist activity of several 2-pyridylethanolamines.
AID73727Effective concentration for increasing potency rate in guinea pig isolated right atria1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID1424838Selectivity ratio of pEC50 for human beta2 adrenergic receptor expressed in HEK293 cells to pEC50 for human beta1 adrenergic receptor expressed in HEK293 cells2018European journal of medicinal chemistry, May-25, Volume: 152Synthesis and biological evaluation of β
AID1061256Displacement of [3H]-CGP-12177 from human beta2 adrenergic receptor expressed in HEK cells by liquid scintillation counting analysis2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Comparative molecular field analysis of fenoterol derivatives interacting with an agonist-stabilized form of the β₂-adrenergic receptor.
AID41016Inhibitory activity against beta-2 adrenergic receptor in guinea pig tracheal strip is determined1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.
AID1147939Partition coefficient, log P of the compound in CHCl3-H2O system at 4 ug/ml at pH 7.41976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Adrenergic sulfonanilides. 4. Centrally active beta-adrenergic agonists.
AID326592Agonist activity at human adrenergic beta-3 receptor expressed in CHO cells assessed as cAMP levels by DELFIA method2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Stereospecific synthesis and bio-activity of novel beta(3)-adrenoceptor agonists and inverse agonists.
AID350867Agonist activity at human beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Synthesis and evaluation of novel phenoxypropanolamine derivatives containing acetanilides as potent and selective beta3-adrenergic receptor agonists.
AID1298722Agonist activity at ARMS2-PK-tagged D2S receptor (unknown origin) transfected in HEK293 cells after 5 hrs by beta-arrestin assay relative to quinpirole2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID1424843Intrinsic clearance in human liver microsomes at 10 uM after 10 mins in presence of NADPH by LC/MS/MS analysis2018European journal of medicinal chemistry, May-25, Volume: 152Synthesis and biological evaluation of β
AID1626023Displacement of [3H]DHA from inactive/G protein-uncoupled human beta2-AR expressed in CHO cell membranes assessed as intrinsic Kd by liquid scintillation counting2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
AID1150793Bronchodilator activity in dog assessed as degree of inhibition of carbachol or histamine-induced bronchoconstriction at 125 to 250 mg/kg, it relative to control1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects.
AID392783Binding interaction with fibrinogen assessed as spin lattice relaxation rate enumerated as normalized affinity index at given concentration and fixed temperature by NMR relaxation experiment2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Interaction study of bioactive molecules with fibrinogen and human platelets determined by 1H NMR relaxation experiments.
AID1146174Agonist activity at beta-adrenergic receptor in guinea pig tracheal tissue assessed as bronchodilator activity1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Adrenerigic agents. 7.1 Synthesis and beta-adrenergic agonist activity of several 2-pyridylethanolamines.
AID366409Ratio of Cmax for drug to Cmax for {3-[((7S)-7-{[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]phenoxy}acetic acid hydrochloride in dog at 0.32 or 0.2 mg/kg, po by cassette dosing assay2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.
AID1148418Agonist activity at beta-2 adrenergic receptor in guinea pig trachea assessed as tracheal relaxation in presence of reserpine1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Synthesis and adrenergic activity of benzimidazole bioisosteres of norepinephrine and isoproterenol.
AID201136KA value was evaluated for the production cyclic AMP in SF-49 lymphoma cell1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Conjugates of catecholamines. 5. Synthesis and beta-adrenergic activity of N-(aminoalkyl)norepinephrine derivatives.
AID59375Intrinsic sympathomimetic activity (ISA), calculated as the percent of maximum change in hind limb perfusion pressure (HLPP)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols.
AID59970The change in mean arterial blood pressure was determined after 0.1 ug/kg iv administration in dog.1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
4-Aroyl-1,3-dihydro-2H-imidazol-2-ones, a new class of cardiotonic agents.
AID1783427Agonist activity at human beta2 adrenoreceptor in HEK293 cells assessed as cAMP accumulation by measuring intrinsic activity relative to control2021European journal of medicinal chemistry, Nov-15, Volume: 2248-Hydroxyquinolin-2(1H)-one analogues as potential β
AID336964Cardiotropic activity in perfused guinea pig heart assessed as minimum effective concentration
AID1298704Displacement of [3H]CGP12177 from mouse beta1 receptor expressed in HEK293 cells2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID1864498Substrate activity at human OCT3 overexpressed in HEK293 cells at 2.5 uM incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1298716Agonist activity at human beta2 receptor expressed in HEK293 cells cotransfected with Gqs5 protein assessed as [3H]IP3 accumulation after 120 mins by scintillation counting assay in presence of myo-[3H]-inositol relative to isoprenaline2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID770362Binding affinity to beta-2 adrenergic receptor (unknown origin) at 1 to 10000 nM2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis.
AID1298717Agonist activity at human D2S receptor expressed in HEK293 cells cotransfected with Gqi5 protein assessed as [3H]IP3 accumulation after 120 mins by scintillation counting assay in presence of myo-[3H]-inositol2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID1543332Agonist activity at beta2 adrenergic receptor in Dunkin-Hartley guinea pig trachea assessed as reduction in histamine-induced muscle contraction by measuring onset time
AID344247Agonist activity at human recombinant beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immuno assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.
AID59969The change in mean arterial blood pressure was determined after 0.1 mg/kg iv administration with 0.5 mg/kg, iv propranolol in dog (p<0.05)1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
4-Aroyl-1,3-dihydro-2H-imidazol-2-ones, a new class of cardiotonic agents.
AID503306Antiproliferative activity against human PC3 cells at 2 uM after 120 hrs by MTT assay relative to DMSO2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID496767Psychostimulant activity in zebrafish assessed as increase in high intensity light-induced motor response at < 10 uM by photomotor response assay2010Nature chemical biology, Mar, Volume: 6, Issue:3
Rapid behavior-based identification of neuroactive small molecules in the zebrafish.
AID513149Displacement of [3H]dihydroalprenolol from human beta-2 adrenergic receptor delta 5-C271/W135 mutant labeled with bimane by competition binding assay2006Nature chemical biology, Aug, Volume: 2, Issue:8
Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor.
AID76920Compound was tested for relative intrinsic activity in guinea pig isolated atrium right atria1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID249451Ratio of agonistic activity to produce cAMP by stimulating beta-2 and beta-3 adrenergic receptor in chinese hamster ovary cells2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist.
AID41013Compound was evaluated for beta adrenoceptor agonistic activity towards beta 2 receptor of isolated guinea pig tracheal strip1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.
AID56246Cardiovascular activity (heart rate) (0.31 ug/kg) in dog after beta-blockade.1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents.
AID1636462Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 3 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NADP2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID326593Intrinsic activity at human adrenergic beta-3 receptor expressed in CHO cells assessed as cAMP levels relative to R-(-)-isoproterenol2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Stereospecific synthesis and bio-activity of novel beta(3)-adrenoceptor agonists and inverse agonists.
AID1123872Inhibition of histamine-induced asthma-like syndrome in guinea pig assessed as time delay in appearance of anoxia at 1.25 mg/kg, po treated 30 mins before histamine challenge (Rvb = 5.08 mins)1979Journal of medicinal chemistry, Mar, Volume: 22, Issue:3
New bronchodilators. Synthesis and bronchodilating activity of some 3-(alkoxymethyl)-alpha-(N-substituted aminomethyl)-4-hydroxybenzyl alcohols.
AID56244Cardiovascular activity (contractility) (0.31 ug/kg) in dog after beta-blockade1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents.
AID77604Maximum response compared to maximum response to isoprenaline.1986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
Cardiotonic agents. 1. Synthesis and structure-activity relationships in a new class of 3-, 4-, and 5-pyridyl-2(1H)-quinolone derivatives.
AID1146003Induction of magnesium accumulation in rat adipocyte plasma membrane vesicles assessed as increase of magnesium level per gram of protein per 30 mins at 1 x 10'-5 M by fluorescence assay1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Evidence for separate peptide sequences related to the lipolytic and magnesium-accumulating activities of ACTH. Analogy with adrenergic receptors.
AID337195Cardiotropic activity in perfused guinea pig heart assessed as positive chronotropy
AID425695Inhibition of beta2 adrenergic receptor expressed in HEK293 cells co-transfected with PKA fragments Reg-F[1] and cat-F[2]-fused renilla luciferase assessed as effect on receptor regulated PKA activation at 1 uM after 30 mins by protein-fragment complement2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID193761Change in heart rate after iv administration of 0.625 mg/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID366404Agonist activity at human cloned beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.
AID344250Selectivity ratio of EC50 for human recombinant beta-1 androgen receptor to EC50 for human recombinant beta3 androgen receptor2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.
AID57843Cardioselectivity expressed as change in blood pressure for 100% increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID483559Agonist activity at human recombinant beta-1 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.
AID496768Anxiolytic activity in zebrafish assessed as decrease in high intensity light-induced motor behavior at <10 uM by photomotor response assay2010Nature chemical biology, Mar, Volume: 6, Issue:3
Rapid behavior-based identification of neuroactive small molecules in the zebrafish.
AID220926Agonistic activity towards beta-3 adrenoceptor. EC50, the mean concentration required to produce 50% relaxation of detrusor before the addition in the ferret detrusor2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.
AID33132Inhibitory concentration required for displacement of Alpha adrenergic receptor specific ligand, 2-[ [ [(2,6-dimethoxyphenoxy) ethyl]amino]methyl]benzodioxan ([3H]WB-4101) from rat brain cerebral cortical membranes1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Syntheses and adrenergic agonist properties of ring-fluorinated isoproterenols.
AID1129266Stimulation of lipolysis in mouse 3T3L1 cells at 10 uM after 48 hrs by glycerol release assay2014Journal of natural products, Apr-25, Volume: 77, Issue:4
Illudins C2 and C3 stimulate lipolysis in 3T3-L1 adipocytes and suppress adipogenesis in 3T3-L1 preadipocytes.
AID40402Compound was evaluated for its binding affinity towards beta-1 adrenergic receptor in rat heart membrane by displacing [125I]- iodocyanopindolol1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent.
AID91268Intrinsic activity against BETA1-AR expressed in CHO cells by using CRE-LUC assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Synthesis and human beta-adrenoceptor activity of 1-(3,5-diiodo-4- methoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-6-ol derivatives in vitro.
AID1238567Agonist activity at human recombinant beta3-adrenergic receptor expressed in CHO cells assessed as increase of cAMP level after 30 mins2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
AID1298708Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID1298712Selectivity index, ratio of Ki for human D2S receptor to Ki for human beta2 receptor2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID350869Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Synthesis and evaluation of novel phenoxypropanolamine derivatives containing acetanilides as potent and selective beta3-adrenergic receptor agonists.
AID483560Agonist activity at human recombinant beta3 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID41917Intrinsic activity expressed as the percentage of maximal analogue response relative to the maximal response(100%) of isoproterenol against human beta-3-adrenoceptor using cAMP-RIA assay1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
2-Amino-4-benzyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridines: novel selective beta3-adrenoceptor agonists.
AID1626022Displacement of [3H]DHA from inactive/G protein-uncoupled human beta2-AR expressed in CHO cell membranes by liquid scintillation counting2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
AID219072Compound is tested for EC50, the mean concentration required to produce 50% relaxation of ferret detrusor in vitro2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.
AID1298715Agonist activity at human beta2 receptor expressed in HEK293 cells cotransfected with Gqs5 protein assessed as [3H]IP3 accumulation after 120 mins by scintillation counting assay in presence of myo-[3H]-inositol2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID483557Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.
AID37155Intrinsic activity was expressed as the ratio between maximal response elicited by compound and that elicited by full agonist NE towards alpha 1 receptor of isolated rat vas deferens1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.
AID76783Positive inotropic effect in isolated left guinea pig atria.1986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
Cardiotonic agents. 2. Synthesis and structure-activity relationships in a new class of 6-, 7-, and 8-pyridyl-2(1H)-quinolone derivatives.
AID40850Intrinsic activity as ratio between maximal response compared to full agonist ISO at beta 2 receptor of isolated guinea pig tracheal strip1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.
AID1134668Increase in heart rate in iv dosed anesthetized mongrel dog1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Isomers of erythro-5-(1-hydroxy-2-isopropylaminobutyl)-8-hydroxycarbostyril, a new bronchodilator.
AID606104Intrinsic activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr relative to formoterol2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.
AID414894Agonist activity at human cloned beta3 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups.
AID1150885Cardiotoxicity in spontaneously respiring dog assessed as time of increase in heart rate at 125 to 250 mg/kg, it relative to control1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects.
AID1150832Bronchodilator activity in dog assessed as time of inhibition of carbachol or histamine-induced bronchoconstriction at 125 to 250 mg/kg, it relative to control1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects.
AID1298707Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID770364Induction of Mitochondrial biogenesis in rabbit RPT cells at 10 to 3000 nM after 24 hrs by FCCP-OCR assay relative to control2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis.
AID44566concentration-response expressed as a percent of the maximal response to R-(-) isoproterenol (ISO)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres.
AID1543330Agonist activity at beta2 adrenergic receptor in Dunkin-Hartley guinea pig trachea assessed as reduction in histamine-induced muscle contraction
AID623256Metabolic stability in human liver microsomes assessed as compound turn over ratio relative to verapamil2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating a urea group.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1864499Substrate activity at human OCT2 overexpressed in HEK293 cells at 2.5 uM incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID426898Agonist activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.
AID41933Drug concentration which produces cAMP response equal to 50% of its maximal response against human beta-3-adrenoceptor expressed in chinese hamster ovary cells was determined1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
2-Amino-4-benzyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridines: novel selective beta3-adrenoceptor agonists.
AID1617018Agonist activity at beta2 adrenergic receptor in guinea pig tracheal smooth muscle assessed as inhibition of histamine-induced tracheal smooth muscle contraction by measuring spasmolysis preincubated for 15 mins in presence of beta adrenergic receptor ant
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1298718Agonist activity at human D2S receptor expressed in HEK293 cells cotransfected with Gqi5 protein assessed as [3H]IP3 accumulation after 120 mins by scintillation counting assay in presence of myo-[3H]-inositol relative to quinpirole2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID1783424In vivo agonist activity at beta2 adrenergic receptor isolated from guinea pig tracheal smooth muscle assessed as inhibition of histamine-induced tracheal smooth muscle contraction2021European journal of medicinal chemistry, Nov-15, Volume: 2248-Hydroxyquinolin-2(1H)-one analogues as potential β
AID58655Ionotropic selectivity expressed as change in heart rate for 100 percent increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID229660Selectivity ratio (Beta-2EC50/ Beta-3EC50)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres.
AID317597Ratio of EC50 for human beta3 adrenergic receptor over EC50 for human beta-1 adrenergic receptor2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.
AID59953The change in cardiac contractile force was determined after 0.1 ug/kg iv administration in dog.1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
4-Aroyl-1,3-dihydro-2H-imidazol-2-ones, a new class of cardiotonic agents.
AID40692Tested for binding affinity against beta-2 adrenergic receptor in bovine lung using [3H]DHA as radioligand1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.
AID366403Agonist activity at human cloned beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.
AID414917Selectivity assessed as difference in pEC50 for human cloned beta2 adrenergic receptor and pEC50 for human cloned beta3 adrenergic receptor2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups.
AID56243Cardiovascular activity (blood pressure) (0.31 ug/kg)in dog after beta-blockade1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents.
AID41513Concentration required to effect a 50% relaxation of rat ferret detrusor basal tone2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4'-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence.
AID252256Ratio of agonistic activity to produce cAMP by stimulating beta-1 and beta-3 adrenergic receptor in chinese hamster ovary cells2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist.
AID1543326Agonist activity at human beta1 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay
AID1146184Selectivity ratio of ED25 for beta-1 adrenergic receptor in guinea pig right atria to ED50 for beta-2 adrenergic receptor in guinea pig tracheal chain1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Adrenergic agents. 8.1 Synthesis and beta-adrenergic agonist activity of some 3-tert-butylamino-2-(substituted phenyl)-1-propanols.
AID1146002Induction of magnesium accumulation in rat adipocyte plasma membrane vesicles assessed as increase of intravesicular magnesium level per 30 mins at 1 x 10'-5 M by fluorescence assay1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Evidence for separate peptide sequences related to the lipolytic and magnesium-accumulating activities of ACTH. Analogy with adrenergic receptors.
AID1424841Reduction in histamine-induced muscle contractions in Dunkin-Hartley guinea pig tracheal smooth muscle ring by measuring muscle tone relative to control2018European journal of medicinal chemistry, May-25, Volume: 152Synthesis and biological evaluation of β
AID56245Cardiovascular activity (contractility) (0.31 ug/kg) in dog before beta-blockade.1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents.
AID264433Activity against human beta-2 adrenergic receptor expressed in CHO cells by stimulation of cAMP production relative to R-(-)-isoproterenol2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.
AID40861Inhibitory activity against beta-2 adrenergic receptor in guinea pig tracheal strip is determined1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.
AID264377Activity at human beta-1 adrenergic receptor expressed in CHO cells by stimulation of cAMP production2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.
AID1123875Inhibition of histamine-induced asthma-like syndrome in guinea pig assessed as time delay in appearance of coughing at 5 mg/kg, po treated 30 mins before histamine challenge (Rvb = 6.13 mins)1979Journal of medicinal chemistry, Mar, Volume: 22, Issue:3
New bronchodilators. Synthesis and bronchodilating activity of some 3-(alkoxymethyl)-alpha-(N-substituted aminomethyl)-4-hydroxybenzyl alcohols.
AID420994Intrinsic activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay relative to isoproterenol2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Discovery of novel acetanilide derivatives as potent and selective beta3-adrenergic receptor agonists.
AID1298706Displacement of [3H]SCH23390 from human D1 receptor expressed in HEK293 cells2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID40416Evaluated for the affinity in stimulating cAMP synthesis by beta-1 adrenergic receptor in rat cerebral cortex.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
3,4-O-diacetylisoproterenol. Preparation, structure proof, and beta-receptor effect.
AID623255Agonist activity at human beta3 receptor expressed in CHO cells assessed as cAMP accumulation2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating a urea group.
AID1636513Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 25.3 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID40409Compound was evaluated for beta adrenergic binding affinity towards Beta-1 adrenergic receptor of rat brain1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.
AID40686Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID414891Agonist activity at human cloned beta-1 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups.
AID1783426Myorelaxant effect in guinea pig model of histamine-induced smooth muscle contraction assessed as time of onset of action measured over 12 hrs2021European journal of medicinal chemistry, Nov-15, Volume: 2248-Hydroxyquinolin-2(1H)-one analogues as potential β
AID1190659Agonist activity at adrenergic beta2 receptor in Hartley guinea pig tracheal ring at basal tone assessed as bronchorelaxation activity2015Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
Insights on the role of boron containing moieties in the design of new potent and efficient agonists targeting the β2 adrenoceptor.
AID1424837Agonist activity at human beta3 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay2018European journal of medicinal chemistry, May-25, Volume: 152Synthesis and biological evaluation of β
AID1150857Cardiotoxicity in spontaneously respiring dog assessed as degree of increase in heart rate at 0.3 to 2 mg/kg, iv relative to control1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects.
AID234915Selectivity for beta3-AR over beta1-AR was determined2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4'-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence.
AID1146067Separation ratio of ED25 at beta-adrenoceptor in guinea pig atria to ED50 for beta-adrenoceptor in guinea pig trachea1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Adrenergic agents. 6. Synthesis and potential beta-adrenergic agonist activity of some meta-substituted p-hydroxyphenylethanolamines related to salbutamol.
AID201138KD constant value was evaluated for the displacement of ICYP (iodocyanopindolol) binding in SF-49 lymphoma cell1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Conjugates of catecholamines. 5. Synthesis and beta-adrenergic activity of N-(aminoalkyl)norepinephrine derivatives.
AID44570Activity against human beta 3 adrenergic receptor (AR), expressed in CHO cells.2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres.
AID41935Binding Affinity against human Beta-3 adrenergic receptor expressed in Chinese hamster ovary(CHO) cells was measured by using [125I]ICYP radioligand1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
2-Amino-4-benzyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridines: novel selective beta3-adrenoceptor agonists.
AID246461Agonistic activity was assessed by measuring cAMP accumulation in CHO cell lines expressing cloned human Beta-2 adrenergic receptor2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist.
AID429598Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as stimulation of cAMP level after 1 hr by enzyme immunoassay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6.
AID177146In vivo dose required to lower the intrabladder pressure of the anesthetized rat by 50% over that before compound administration2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.
AID366407Agonist activity at human cloned beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation relative to isoproterenol2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.
AID513150Displacement of [3H]dihydroalprenolol from human beta-2 adrenergic receptor delta 5-C271/W135 mutant by competition binding assay2006Nature chemical biology, Aug, Volume: 2, Issue:8
Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor.
AID42183Compound was evaluated for beta adrenoceptor agonistic activity towards Beta-1 adrenergic receptor of isolated guinea pig atria1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.
AID366408Ratio of AUC for drug to AUC for {3-[((7S)-7-{[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]phenoxy}acetic acid hydrochloride in dog at 0.32 or 0.2 mg/kg, po by cassette dosing assay2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.
AID426897Agonist activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.
AID176028The compound was evaluated for its ability to stimulate adenylate cyclase activity1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Carbostyril derivatives having potent beta-adrenergic agonist properties.
AID513154Binding affinity to human beta-2 adrenergic receptor delta 5-C271/W135 mutant expressed in Spodoptera frugiperda Sf9 cells2006Nature chemical biology, Aug, Volume: 2, Issue:8
Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor.
AID317595Agonist activity at human beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by EIA2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.
AID1298719Agonist activity at PK-tagged beta2 receptor (unknown origin) transfected in HEK293 cells after 90 mins by beta-arrestin assay2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID420992Agonist activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Discovery of novel acetanilide derivatives as potent and selective beta3-adrenergic receptor agonists.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID44545Agonistic activity (beta2- adrenergic) for the percent maximal relaxation of isolated guinea pig trachea1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Effect of fluorine substitution on the adrenergic properties of 3-(tert-butylamino)-1-(3,4-dihydroxyphenoxy)-2-propanol.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID1906934Antiinflammatory activity in Sprague- Dawley rat model of ovalbumin induced allergic asthma assessed as reduction in histamine release from lung fragments at 1 umol/L administered 5 mins prior to allergen challenge and measured after 10 mins
AID1061255Displacement of [3H]-(R,R')-methoxyfenoterol from human beta2 adrenergic receptor expressed in HEK cells by liquid scintillation counting analysis2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Comparative molecular field analysis of fenoterol derivatives interacting with an agonist-stabilized form of the β₂-adrenergic receptor.
AID1462124Antiobesity activity in mouse 3T3L1 cells assessed as glycerol release at 1 uM after 24 hrs relative to control2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Isolation and lipolytic activity of eurycomanone and its epoxy derivative from Eurycoma longifolia.
AID44399Activity against human beta 1 adrenergic receptor (AR), expressed in CHO cells.2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID513152Partial agonist activity at human biamane labelled beta-2 adrenergic receptor delta 5-C271/Trp135 mutant assessed as bimane response by fluorescence spectroscopy2006Nature chemical biology, Aug, Volume: 2, Issue:8
Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor.
AID623252Agonist activity at human beta2 receptor expressed in CHO cells assessed as cAMP accumulation2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating a urea group.
AID344251Selectivity ratio of EC50 for human recombinant beta2 androgen receptor to EC50 for human recombinant beta3 androgen receptor2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.
AID58658Ionotropic selectivity expressed as change in heart rate for 50 percent increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID41344Binding Affinity against human beta-2 adrenergic receptor expressed in Chinese hamster ovary(CHO) cells was measured by using [125I]ICYP radioligand1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
2-Amino-4-benzyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridines: novel selective beta3-adrenoceptor agonists.
AID513146Binding affinity to human beta-2 adrenergic receptor delta 5-C271 mutant expressed in Spodoptera frugiperda Sf9 cells2006Nature chemical biology, Aug, Volume: 2, Issue:8
Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor.
AID611235Metabolic stability in human liver microsomes with 125 pmol/mL P450 assessed as compound turnover ratio at 5 uM after 30 mins by LC-MS method relative to verapamil2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating hydantoin or uracil rings.
AID1424844Half life in human liver microsomes at 10 uM by LC/MS/MS analysis2018European journal of medicinal chemistry, May-25, Volume: 152Synthesis and biological evaluation of β
AID44396concentration-response expressed as a percent of the maximal response to R-(-) isoproterenol (ISO)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres.
AID35880Intrinsic activity was expressed as the ratio between maximal response elicited by compound and that elicited by full agonist NE towards Alpha-1 adrenergic receptor of isolated rat vas deferens1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.
AID264374Activity at human beta-3 adrenergic receptor expressed in CHO cells by stimulation of cAMP production2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.
AID420993Intrinsic activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay relative to isoproterenol2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Discovery of novel acetanilide derivatives as potent and selective beta3-adrenergic receptor agonists.
AID36450Tested for alpha adrenergic activity against alpha-1 receptor from isolated rat vas deferens1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.
AID35920Tested for binding affinity against alpha-2 adrenergic receptor in rat brain using [3H]- rauwolscine as radioligand1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.
AID37462Compound was evaluated for alpha adrenergic binding affinity towards alpha-1 receptor of rat brain1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.
AID88771Agonistic potency against Beta3-AR expressed in CHO cells by using CRE-LUC assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Synthesis and human beta-adrenoceptor activity of 1-(3,5-diiodo-4- methoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-6-ol derivatives in vitro.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID88760Intrinsic activity against BETA2-AR expressed in CHO cells by using CRE-LUC assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Synthesis and human beta-adrenoceptor activity of 1-(3,5-diiodo-4- methoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-6-ol derivatives in vitro.
AID337194Cardiotropic activity in perfused guinea pig heart assessed as positive ionotropy
AID41608Inhibitory concentration required for displacement of Beta adrenergic receptor specific ligand [3H]dihydroalprenolol from rat brain cerebral cortical membranes1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Syntheses and adrenergic agonist properties of ring-fluorinated isoproterenols.
AID44542Activity against human beta 2 adrenergic receptor (AR), expressed in CHO cells2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres.
AID1298720Agonist activity at PK-tagged beta2 receptor (unknown origin) transfected in HEK293 cells after 90 mins by beta-arrestin assay relative to isoprenaline2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
AID426242Binding affinity to human adrenergic beta2 receptor2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.
AID387247Selectivity for human cloned adrenergic beta-1 receptor over human cloned adrenergic beta3 receptor expressed in CHO cells2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human beta(3)-adrenergic receptor agonists: Part IV.
AID317599Ratio of Cmax for drug to Cmax for [4-(4-{2-[(R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-ethyl}-phenoxy)-phenoxy]-acetic acid in dog at 0.32 or 1.0 mg/kg, po by cassette assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID77605Intrinsic activity calculated as the ratio of the maximum response to the compound to the maximum response to isoprenaline.1986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
Cardiotonic agents. 2. Synthesis and structure-activity relationships in a new class of 6-, 7-, and 8-pyridyl-2(1H)-quinolone derivatives.
AID78134Compound was evaluated in vitro by SDT (Schultz-Dale Test) against isolated guinea pig lung strips repeatedly challenged with antigen in the presence of an antihistamine (H1) at a concentration 30 uM.1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Acidic furo[3,2-b]indoles. A new series of potent antiallergy agents.
AID59285Compound was tested in anesthetized dogs for increase in heart rate (equipotent dose at ED25) Mean ED25 value, obtained at a dose of 0.021 ug/kg1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
erythro-5-[1-Hydroxy-2-(isopropylamino)butyl]-7-hydroxycarbostyril, a terbutaline-type derivative of the bronchodilator procaterol.
AID234626Concentration ratio of beta-3 (EC50) to beta-1 (EC50)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.
AID40414Compound was evaluated for the inhibition of binding of [3H]dihydroalprenolol from beta-1 adrenergic receptor of rat cerebral cortical membranes1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Effect of fluorine substitution on the adrenergic properties of 3-(tert-butylamino)-1-(3,4-dihydroxyphenoxy)-2-propanol.
AID483558Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation at 10 mM after 30 to 45 mins relative to isoprenaline2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.
AID76919Compound was tested for or relative intrinsic activity in guinea pig isolated atrium left atria1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID387246Agonist activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as cAMP accumulation2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human beta(3)-adrenergic receptor agonists: Part IV.
AID35811Tested for alpha adrenergic activity against alpha-2 receptor from isolated guinea pig ileum1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.
AID41296Intrinsic activity against beta adrenergic receptor in isolated guinea pig atria1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Conformational effects on the activity of drugs. 11. Stereostructural models for the direct activation of the alpha- and beta-adrenergic receptor.
AID59374Intrinsic sympathomimetic activity (ISA, calculated as the percent of maximum change in heart rate (HR)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols.
AID349761Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5.
AID1150792Bronchodilator activity in dog assessed as degree of inhibition of carbachol or histamine-induced bronchoconstriction at 50 to 240 mg/kg, id relative to control1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects.
AID1134667Bronchodilatory activity in iv dosed mongrel dog assessed as inhibition of histamine-induced bronchospasm administered 1 min prior to histamine challenge1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Isomers of erythro-5-(1-hydroxy-2-isopropylaminobutyl)-8-hydroxycarbostyril, a new bronchodilator.
AID235309Ratio of the dose raising the rat heart rate to 500bpm, to ED50 for inhibition of GDP binding to beta-3 adrenergic receptor1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Selective beta 3-adrenergic agonists of brown adipose tissue and thermogenesis. 1. [4-[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]acetates.
AID1146059Agonist activity at beta-adrenoceptor in guinea pig atria assessed as cardiac stimulant activity by measuring change in rate of contraction of right atrial muscle1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Adrenergic agents. 6. Synthesis and potential beta-adrenergic agonist activity of some meta-substituted p-hydroxyphenylethanolamines related to salbutamol.
AID264378Selectivity for human beta-3 adrenergic receptor over beta-1 adrenergic receptor expressed in CHO cells by stimulation of cAMP production2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.
AID420990Agonist activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Discovery of novel acetanilide derivatives as potent and selective beta3-adrenergic receptor agonists.
AID1150859Cardiotoxicity in spontaneously respiring dog assessed as degree of increase in heart rate at 125 to 150 mg/kg, it relative to control1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID386483Antagonist activity at alpha2A adrenergic receptor expressed in HEK293 cells assessed as blockade of secreted alkaline phosphatase activity at 1 uM after 6 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
Hemopressin is an inverse agonist of CB1 cannabinoid receptors.
AID344246Agonist activity at human recombinant beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immuno assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.
AID36449Intrinsic activity against alpha-1 receptor in isolated rat vas deferens1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.
AID513148Agonist activity at human Beta-2 adrenergic receptor delta 5-C271/Trp135 mutant assessed as decrease in bimane fluorescence intensity by fluorescence spectroscopy2006Nature chemical biology, Aug, Volume: 2, Issue:8
Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1798549beta2 Adrenergic Receptor Binding Assay from Article 10.1021/jm800613s: \\Synthesis of bivalent beta2-adrenergic and adenosine A1 receptor ligands.\\2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Synthesis of bivalent beta2-adrenergic and adenosine A1 receptor ligands.
AID1799821Inhibition Assay from Article : \\Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor.\\1989The Journal of biological chemistry, Aug-15, Volume: 264, Issue:23
Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor.
AID1346312Mouse beta3-adrenoceptor (Adrenoceptors)2004European journal of pharmacology, Jan-26, Volume: 484, Issue:2-3
Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors.
AID1346297Human beta3-adrenoceptor (Adrenoceptors)2004Naunyn-Schmiedeberg's archives of pharmacology, Feb, Volume: 369, Issue:2
Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.
AID1346297Human beta3-adrenoceptor (Adrenoceptors)1995European journal of pharmacology, Nov-30, Volume: 291, Issue:3
Carazolol: a potent, selective beta 3-adrenoceptor agonist.
AID1346260Human beta1-adrenoceptor (Adrenoceptors)1996European journal of pharmacology, Nov-21, Volume: 315, Issue:3
Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors.
AID1346312Mouse beta3-adrenoceptor (Adrenoceptors)1995European journal of pharmacology, Nov-30, Volume: 291, Issue:3
Carazolol: a potent, selective beta 3-adrenoceptor agonist.
AID1346297Human beta3-adrenoceptor (Adrenoceptors)1997Annual review of pharmacology and toxicology, , Volume: 37Structure and function of the beta 3-adrenergic receptor.
AID1347018Rat beta3-adrenoceptor (Adrenoceptors)1995European journal of pharmacology, Nov-30, Volume: 291, Issue:3
Carazolol: a potent, selective beta 3-adrenoceptor agonist.
AID1346260Human beta1-adrenoceptor (Adrenoceptors)1988Proceedings of the National Academy of Sciences of the United States of America, Dec, Volume: 85, Issue:24
Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta 2-adrenergic receptors.
AID1346297Human beta3-adrenoceptor (Adrenoceptors)2004European journal of pharmacology, Jan-26, Volume: 484, Issue:2-3
Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors.
AID1346297Human beta3-adrenoceptor (Adrenoceptors)1996European journal of pharmacology, Nov-21, Volume: 315, Issue:3
Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors.
AID1346250Human beta2-adrenoceptor (Adrenoceptors)1996European journal of pharmacology, Nov-21, Volume: 315, Issue:3
Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors.
AID1346297Human beta3-adrenoceptor (Adrenoceptors)1997British journal of pharmacology, Jan, Volume: 120, Issue:2
Effects of (-)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29,350)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017088 (58.22)18.7374
1990's6069 (20.68)18.2507
2000's3285 (11.19)29.6817
2010's2302 (7.84)24.3611
2020's606 (2.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.65 (24.57)
Research Supply Index10.36 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index129.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (69.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials803 (2.61%)5.53%
Reviews583 (1.89%)6.00%
Case Studies389 (1.26%)4.05%
Observational5 (0.02%)0.25%
Other29,000 (94.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (19)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Clinical Trial to Investigate the Influence of Cytochrome P450 2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamics Characteristics of Carvedilol in Healthy Korean Volunteers [NCT02286934]Phase 124 participants (Actual)Interventional2014-09-30Completed
Autoimmune Basis for Postural Tachycardia Syndrome [NCT02725060]58 participants (Anticipated)Interventional2016-02-29Enrolling by invitation
Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome [NCT05658692]Phase 41,000 participants (Anticipated)Interventional2022-10-01Recruiting
Comparison of the Clinical Utility of Atropine and Isoprenaline in the Invasive Diagnosis of Arrhythmias [NCT06082388]200 participants (Anticipated)Interventional2023-11-09Not yet recruiting
The Pathophysiology of Orthostatic Hypotension [NCT00748059]Phase 110 participants (Actual)Interventional1996-12-31Completed
Electromechanical Profiling of Arrhythmogenic Substrates and Triggers in the Long-QT Syndrome [NCT04074122]150 participants (Anticipated)Observational2020-01-01Not yet recruiting
ß2 Adrenergic Receptor Polymorphisms and Vasodilation of Internal Mammary Artery Induced by Isoproterenol [NCT00226551]100 participants Interventional1999-08-31Completed
Pharmacological Modulation of the Intrarenal Pressure During Endourological Procedures in the Upper Urinary Tract [NCT00428428]Phase 2/Phase 312 participants (Actual)Interventional2007-02-28Completed
Study to Measure BIS and Awareness in Patients Receiving Isoproterenol During Catheter Ablation for Atrial Fibrillation [NCT01377636]20 participants (Actual)Interventional2009-08-31Completed
Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences [NCT05997732]Phase 430 participants (Anticipated)Interventional2023-10-31Recruiting
Augmented Interoceptive Exposure Training for the Fear of Food in Anorexia Nervosa [NCT03019081]25 participants (Actual)Interventional2017-01-31Active, not recruiting
Decision Support for Intraoperative Low Blood Pressure [NCT02726620]22,435 participants (Actual)Interventional2017-01-05Completed
Neural Basis of Meal Related Interoceptive Dysfunction in Anorexia Nervosa [NCT02615119]97 participants (Actual)Interventional2015-10-01Completed
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity [NCT05219799]Early Phase 172 participants (Anticipated)Interventional2023-03-14Recruiting
RIRS - A Method of Treating the ESWL Resistant Kidney Stone [NCT00323843]Phase 210 participants Interventional2006-06-30Active, not recruiting
Determinants of Chronotropic Incompetence in Patients With Heart Failure and a Preserved Ejection Fraction (HFpEF) [NCT02524145]40 participants (Actual)Interventional2015-06-30Completed
Adenosine Study in Paroxysmal Atrial Fibrillation [NCT03032965]Phase 2131 participants (Actual)Interventional2011-10-31Completed
A Pilot Study: Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas [NCT00624416]Phase 1/Phase 210 participants (Actual)Interventional2007-10-31Completed
The Pathophysiological Role of Adrenergic Antibodies in Postural Tachycardia Syndrome (Aims #1&2) [NCT02673996]125 participants (Anticipated)Observational2016-01-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00624416 (3) [back to overview]The Number of Subjects Elected to Have the Lipoma Removed.
NCT00624416 (3) [back to overview]The Average Percent Volume Reduction in the Lipoma.
NCT00624416 (3) [back to overview]The Number of Lipoma Increased in Volume.
NCT01377636 (9) [back to overview]BIS Change
NCT01377636 (9) [back to overview]Number of Participants Who Developed Ischemia or ST Segment Changes
NCT01377636 (9) [back to overview]Number of Participants Who Follow Verbal Command to Squeeze Hands
NCT01377636 (9) [back to overview]Number of Participants With Amnesia or No Recall During Steady State
NCT01377636 (9) [back to overview]Number of Participants With an Increase in BIS Readings During Steady State
NCT01377636 (9) [back to overview]Number of Participants With Change in Blood Pressure
NCT01377636 (9) [back to overview]Number of Participants With New Arrhythmia During Steady State.
NCT01377636 (9) [back to overview]Number of Participants With Significant Change in Heart Rate
NCT01377636 (9) [back to overview]Number of Participants With Spontaneous Musculoskeletal Movement
NCT02524145 (2) [back to overview]Cardiac Beta-receptor Sensitivity
NCT02524145 (2) [back to overview]Central Command Regulation of Heart Rate
NCT02726620 (43) [back to overview]Average Use of Cardiovascular Drugs: Phenylephrine
NCT02726620 (43) [back to overview]Depth and Duration of Intraoperative Hypotension - Threshold MAP 50 mmHg
NCT02726620 (43) [back to overview]Depth and Duration of Intraoperative Hypotension - Threshold MAP 55 mmHg
NCT02726620 (43) [back to overview]Depth and Duration of Intraoperative Hypotension - Threshold MAP 60 mmHg
NCT02726620 (43) [back to overview]Depth and Duration of Intraoperative Hypotension - Threshold MAP 65 mmHg
NCT02726620 (43) [back to overview]Depth and Duration of Intraoperative Hypotension - Threshold MAP 70 mmHg
NCT02726620 (43) [back to overview]Depth and Duration of Intraoperative Hypotension - Threshold MAP 75 mmHg
NCT02726620 (43) [back to overview]Estimated Intraoperative Blood Loss
NCT02726620 (43) [back to overview]In-hospital Mortality
NCT02726620 (43) [back to overview]Incidence of a MAP < 50 mmHg
NCT02726620 (43) [back to overview]Incidence of a MAP < 50 mmHg for > 10 Minutes
NCT02726620 (43) [back to overview]Incidence of a MAP < 50 mmHg for > 20 Minutes
NCT02726620 (43) [back to overview]Incidence of a MAP < 55 mmHg
NCT02726620 (43) [back to overview]Incidence of a MAP < 55 mmHg for > 10 Minutes
NCT02726620 (43) [back to overview]Incidence of a MAP < 55 mmHg for > 20 Minutes
NCT02726620 (43) [back to overview]Incidence of a MAP < 60 mmHg
NCT02726620 (43) [back to overview]Incidence of a MAP < 60 mmHg for > 10 Minutes
NCT02726620 (43) [back to overview]Incidence of a MAP < 60 mmHg for > 20 Minutes
NCT02726620 (43) [back to overview]Intraoperative Administration of Intravenous Fluids
NCT02726620 (43) [back to overview]Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 50 mmHg
NCT02726620 (43) [back to overview]Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 55 mmHg
NCT02726620 (43) [back to overview]Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 60 mmHg
NCT02726620 (43) [back to overview]Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 65 mmHg
NCT02726620 (43) [back to overview]Postoperative Rise in Creatinine Levels
NCT02726620 (43) [back to overview]Time to Discharge Readiness at the Postanesthesia Care Unit (PACU)
NCT02726620 (43) [back to overview]Timing of Cardiovascular Drugs for MAP < 50 mmHg
NCT02726620 (43) [back to overview]Timing of Cardiovascular Drugs for MAP < 55 mmHg
NCT02726620 (43) [back to overview]Timing of Cardiovascular Drugs for MAP < 60 mmHg
NCT02726620 (43) [back to overview]Timing of Cardiovascular Drugs for MAP < 65 mmHg
NCT02726620 (43) [back to overview]Usage Frequency of Cardiovascular Drugs: Ephedrine
NCT02726620 (43) [back to overview]Usage Frequency of Cardiovascular Drugs: Ephinephrine
NCT02726620 (43) [back to overview]Usage Frequency of Cardiovascular Drugs: Glycopyrrolate
NCT02726620 (43) [back to overview]Usage Frequency of Cardiovascular Drugs: Norepinephrine
NCT02726620 (43) [back to overview]Usage Frequency of Cardiovascular Drugs: Phenylephrine
NCT02726620 (43) [back to overview]30-day Mortality
NCT02726620 (43) [back to overview]Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 55 mmHg
NCT02726620 (43) [back to overview]Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 60 mmHg
NCT02726620 (43) [back to overview]Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 65 mmHg
NCT02726620 (43) [back to overview]Average Use of Cardiovascular Drugs: Ephedrine
NCT02726620 (43) [back to overview]Average Use of Cardiovascular Drugs: Epinephrine
NCT02726620 (43) [back to overview]Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 50 mmHg
NCT02726620 (43) [back to overview]Average Use of Cardiovascular Drugs: Glycopyrrolate
NCT02726620 (43) [back to overview]Average Use of Cardiovascular Drugs: Norepinephrine
NCT03032965 (8) [back to overview]Incidence of Death
NCT03032965 (8) [back to overview]Incidence of Pulmonary Vein Stenosis
NCT03032965 (8) [back to overview]Incidence of Stroke
NCT03032965 (8) [back to overview]Number of Pulmonary Veins That Recovered Conduction During Repeat Ablation Procedures in Both Groups
NCT03032965 (8) [back to overview]Number of Subjects Who Need Repeat Ablations
NCT03032965 (8) [back to overview]Incidence of Atrio-esophageal Fistula
NCT03032965 (8) [back to overview]Freedom From Any Atrial Arrhythmias
NCT03032965 (8) [back to overview]Incidence of Cardiac Perforation

The Number of Subjects Elected to Have the Lipoma Removed.

(NCT00624416)
Timeframe: After four weeks up to one year.

Interventionparticipants (Number)
Prednisolone and Isoproteronol8

[back to top]

The Average Percent Volume Reduction in the Lipoma.

(NCT00624416)
Timeframe: Baseline and 4 weeks

InterventionPercent Volume reduction (cc^3) (Mean)
Prednisolone and Isoproteronol50

[back to top]

The Number of Lipoma Increased in Volume.

(NCT00624416)
Timeframe: After four weeks of treatment up to one year.

InterventionLipomas (Number)
Prednisolone and Isoproteronol9

[back to top]

BIS Change

The BIS scale ranges from 0 to 100. The individual's baseline BIS was measured continuously and was maintained in an anesthetic steady state with minimum variance prior to isoproterenol. A deviation from the mean in excess of 3 points (2 STD) was defined categorically as a positive response and was counted dichotomously.The difference between Pre-BIS and Post-BIS was calculated. (NCT01377636)
Timeframe: Within 20 minutes of starting isoproterenol infusion

Interventionunits on a scale (Mean)
Pre and Post Isoproterenol Infusion24.6

[back to top]

Number of Participants Who Developed Ischemia or ST Segment Changes

The (ST) segment on the EKG was monitored for changes suggestive of demand ischemia. An observable EKG change compared to baseline was defined categorically as a positive response and was counted dichotomously. (NCT01377636)
Timeframe: Within 20 minutes of starting isoproterenol infusion

Interventionparticipants (Number)
Pre and Post Isoproterenol Infusion2

[back to top]

Number of Participants Who Follow Verbal Command to Squeeze Hands

"Increasing doses of isoproterenol (5,10,15,20 mcg/minute) were administered to patients undergoing catheter ablation for atrial fibrillation. Ability to follow verbal commands before and after isoproterenol infusion was assessed by asking subjects to squeeze my hands." (NCT01377636)
Timeframe: Within 20 minutes of starting isoproterenol infusion

Interventionparticipants (Number)
Isoproterenol, BIS, Forearm Test10

[back to top]

Number of Participants With Amnesia or No Recall During Steady State

Increasing doses of isoproterenol (5,10,15,20 mcg/minute) were administered to patients undergoing catheter ablation for atrial fibrillation. Specific pre-determined test words were spoken to the subject during administration of isoproterenol. After anesthesia, patients were tested for possible recall of those specific words. If no words were recalled, the result was categorically defined as amnesia. (NCT01377636)
Timeframe: Within one hour of completing anesthesia

Interventionparticipants (Number)
Isoproterenol, BIS, Forearm Test20

[back to top]

Number of Participants With an Increase in BIS Readings During Steady State

Increasing doses of isoproterenol (5,10,15,20 mcg/minute) were administered to patients undergoing catheter ablation for atrial fibrillation. BIS levels were measured continuously before and after isoproterenol administration. Number of participants with increase in BIS reading during anesthetic steady state are reported below. The BIS scale ranges from 0 to 100. The individual's baseline BIS was measured continuously and was maintained in an anesthetic steady state with minimum variance prior to isoproterenol. A deviation from the mean in excess of 3 points (2 STD) was defined categorically as a positive response and was counted dichotomously. (NCT01377636)
Timeframe: During time of Electrophysiology (EP) studies.

Interventionparticipants (Number)
Pre and Post Isoproterenol Infusion19

[back to top]

Number of Participants With Change in Blood Pressure

Non-Invasive Blood Pressure (NIBP) is measured routinely as part of an anesthetic. Pre- and Post Blood Pressures where noted. An increase or decrease of 10 percent or more was defined as a significant change in systolic blood pressure. (NCT01377636)
Timeframe: Within 20 minutes of starting isoproterenol infusion

Interventionparticipants (Number)
Pre and Post Isoproterenol Infusion13

[back to top]

Number of Participants With New Arrhythmia During Steady State.

Increasing doses of isoproterenol (5,10,15,20 mcg/minute) were administered to patients undergoing catheter ablation for atrial fibrillation after return to sinus rhythm. If a non-sinus arrhythmia resulted from the infusion, the arrhythmia was defined categorically as a positive response and was counted dichotomously. (NCT01377636)
Timeframe: Within 20 minutes of start of isoproterenol

Interventionparticipants (Number)
Pre and Post Isoproterenol Infusion4

[back to top]

Number of Participants With Significant Change in Heart Rate

Heart rate measured by standard EKG monitor during anesthesia. Pre- and Post Heart rates where noted. An increase of 8 percent or more was defined as a significant change in heart rate. (NCT01377636)
Timeframe: Within 20 minutes of starting isoproterenol infusion

Interventionparticipants (Number)
Pre and Post Isoproterenol Infusion18

[back to top]

Number of Participants With Spontaneous Musculoskeletal Movement

Increasing doses of isoproterenol (5,10,15,20 mcg/minute) were administered to patients undergoing catheter ablation for atrial fibrillation. Patients under steady state total venous anesthesia (TIVA) with propofol and remifentanil infusions with BIS around 50 normally do not move even in the absence of neuromuscular blockade. Spontaneous movement appearing like restlessness during sleep is unusual. Several patients under anesthesia after isoproterenol appear to wake up and move spontaneously. (NCT01377636)
Timeframe: Within 20 minutes of starting isoproterenol infusion

Interventionparticipants (Number)
Isoproterenol, BIS, Forearm Test12

[back to top]

Cardiac Beta-receptor Sensitivity

Cardiac beta-receptor sensitivity will be measured by calculating slope of heart rate versus isoproterenol serum level. (NCT02524145)
Timeframe: 1 day; primary outcome was complete for each subject in 1 day

Interventionbeats per ng/kg/min ISO (Mean)
Healthy Seniors0.254
HFpEF0.156
Healthy Young0.365

[back to top]

Central Command Regulation of Heart Rate

Heart rate response to static hand grip immediately followed by supra-systolic arm occlusion and release will determine adequacy on central command control over heart rate response during exercise. (NCT02524145)
Timeframe: 1 day; primary outcome was complete for each subject in 1 day

Interventionbeats per minute (Mean)
Healthy Seniors93
HFpEF89

[back to top]

Average Use of Cardiovascular Drugs: Phenylephrine

Cardiovascular drugs as defined under interventions. Average use for each drug will be calculated. Cardiovascular drugs that were given in <1% of cases are not reported, as the average dosage would be meaningless. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmg (Median)
Usual Care Group0.90
Hypotension Decision Support1.30

[back to top]

Depth and Duration of Intraoperative Hypotension - Threshold MAP 50 mmHg

Depth and duration of intraoperative hypotension will be modeled by calculating areas under the threshold for mean arterial pressures (MAPs). Thresholds will vary from 75 mmHg to 50 mmHg in 5 mmHg decrements. Together these variables represent the depth and duration of intraoperative hypotension. To optimize goodness of fit of these variables, the decremental steps may be increased to 10 mmHg and more restrictive lowest and highest thresholds may be chosen for the statistical analysis. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionmmHg*minute (Median)
Usual Care Group19
Hypotension Decision Support19

[back to top]

Depth and Duration of Intraoperative Hypotension - Threshold MAP 55 mmHg

Depth and duration of intraoperative hypotension will be modeled by calculating areas under the threshold for mean arterial pressures (MAPs). Thresholds will vary from 75 mmHg to 50 mmHg in 5 mmHg decrements. Together these variables represent the depth and duration of intraoperative hypotension. To optimize goodness of fit of these variables, the decremental steps may be increased to 10 mmHg and more restrictive lowest and highest thresholds may be chosen for the statistical analysis. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionmmHg*minute (Median)
Usual Care Group23
Hypotension Decision Support23

[back to top]

Depth and Duration of Intraoperative Hypotension - Threshold MAP 60 mmHg

Depth and duration of intraoperative hypotension will be modeled by calculating areas under the threshold for mean arterial pressures (MAPs). Thresholds will vary from 75 mmHg to 50 mmHg in 5 mmHg decrements. Together these variables represent the depth and duration of intraoperative hypotension. To optimize goodness of fit of these variables, the decremental steps may be increased to 10 mmHg and more restrictive lowest and highest thresholds may be chosen for the statistical analysis. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionmmHg*minute (Median)
Usual Care Group57
Hypotension Decision Support52

[back to top]

Depth and Duration of Intraoperative Hypotension - Threshold MAP 65 mmHg

Depth and duration of intraoperative hypotension will be modeled by calculating areas under the threshold for mean arterial pressures (MAPs). Thresholds will vary from 75 mmHg to 50 mmHg in 5 mmHg decrements. Together these variables represent the depth and duration of intraoperative hypotension. To optimize goodness of fit of these variables, the decremental steps may be increased to 10 mmHg and more restrictive lowest and highest thresholds may be chosen for the statistical analysis. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionmmHg*minute (Median)
Usual Care Group96
Hypotension Decision Support86

[back to top]

Depth and Duration of Intraoperative Hypotension - Threshold MAP 70 mmHg

Depth and duration of intraoperative hypotension will be modeled by calculating areas under the threshold for mean arterial pressures (MAPs). Thresholds will vary from 75 mmHg to 50 mmHg in 5 mmHg decrements. Together these variables represent the depth and duration of intraoperative hypotension. To optimize goodness of fit of these variables, the decremental steps may be increased to 10 mmHg and more restrictive lowest and highest thresholds may be chosen for the statistical analysis. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionmmHg*minute (Median)
Usual Care Group273
Hypotension Decision Support235

[back to top]

Depth and Duration of Intraoperative Hypotension - Threshold MAP 75 mmHg

Depth and duration of intraoperative hypotension will be modeled by calculating areas under the threshold for mean arterial pressures (MAPs). Thresholds will vary from 75 mmHg to 50 mmHg in 5 mmHg decrements. Together these variables represent the depth and duration of intraoperative hypotension. To optimize goodness of fit of these variables, the decremental steps may be increased to 10 mmHg and more restrictive lowest and highest thresholds may be chosen for the statistical analysis. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionmmHg*minute (Median)
Usual Care Group485
Hypotension Decision Support417

[back to top]

Estimated Intraoperative Blood Loss

The estimated blood loss in mL during the surgical procedure (NCT02726620)
Timeframe: During the surgical procedure: an expected average of 2 hours

InterventionmL (Median)
Usual Care Group100
Hypotension Decision Support75

[back to top]

In-hospital Mortality

Hospital mortality rate during a single hospital admission after the surgery (NCT02726620)
Timeframe: All postoperative days during a single hospital admission, expected median of 5 days

InterventionParticipants (Count of Participants)
Usual Care Group487
Hypotension Decision Support137

[back to top]

Incidence of a MAP < 50 mmHg

Incidence of a mean arterial pressure (MAP) < 50 mmHg during anesthesia for 1 minute or more. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group7781
Hypotension Decision Support2196

[back to top]

Incidence of a MAP < 50 mmHg for > 10 Minutes

Incidence of a mean arterial pressure (MAP) < 50 mmHg for a cumulative duration of all hypotensive episodes of more than 10 minutes during the anesthetic phase of the procedure. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group1159
Hypotension Decision Support326

[back to top]

Incidence of a MAP < 50 mmHg for > 20 Minutes

Incidence of a mean arterial pressure (MAP) < 50 mmHg for a cumulative duration of all hypotensive episodes of more than 20 minutes during the anesthetic phase of the procedure. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group304
Hypotension Decision Support85

[back to top]

Incidence of a MAP < 55 mmHg

Incidence of a mean arterial pressure (MAP) < 55 mmHg during anesthesia for 1 minute or more. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group10991
Hypotension Decision Support3045

[back to top]

Incidence of a MAP < 55 mmHg for > 10 Minutes

Incidence of a mean arterial pressure (MAP) < 55 mmHg for a cumulative duration of all hypotensive episodes of more than 10 minutes during the anesthetic phase of the procedure. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group3181
Hypotension Decision Support759

[back to top]

Incidence of a MAP < 55 mmHg for > 20 Minutes

Incidence of a mean arterial pressure (MAP) < 55 mmHg for a cumulative duration of all hypotensive episodes of more than 20 minutes during the anesthetic phase of the procedure. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group1223
Hypotension Decision Support284

[back to top]

Incidence of a MAP < 60 mmHg

Incidence of a mean arterial pressure (MAP) < 60 mmHg during anesthesia for 1 minute or more. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group13779
Hypotension Decision Support3798

[back to top]

Incidence of a MAP < 60 mmHg for > 10 Minutes

Incidence of a mean arterial pressure (MAP) < 60 mmHg for a cumulative duration of all hypotensive episodes of more than 10 minutes during the anesthetic phase of the procedure. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group6989
Hypotension Decision Support1723

[back to top]

Incidence of a MAP < 60 mmHg for > 20 Minutes

Incidence of a mean arterial pressure (MAP) < 60 mmHg for a cumulative duration of all hypotensive episodes of more than 20 minutes during the anesthetic phase of the procedure. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group3632
Hypotension Decision Support792

[back to top]

Intraoperative Administration of Intravenous Fluids

Total amount (mL) of intravenous fluids (as defined under interventions) administered during the surgical procedure. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionmL (Median)
Usual Care Group1500.00
Hypotension Decision Support1400.00

[back to top]

Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 50 mmHg

Average concentrations of propofol infusion rates during MAP < 50 mmHg episodes (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmcg/kg/min (propofol) (Median)
Usual Care Group65.00
Hypotension Decision Support50.00

[back to top]

Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 55 mmHg

Average concentrations of propofol infusion rates during MAP < 55 mmHg episodes (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmcg/kg/min (propofol) (Median)
Usual Care Group63.95
Hypotension Decision Support50.00

[back to top]

Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 60 mmHg

Average concentrations of propofol infusion rates during MAP < 60 mmHg episodes (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmcg/kg/min (propofol) (Median)
Usual Care Group61.07
Hypotension Decision Support50.00

[back to top]

Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 65 mmHg

Average concentrations of propofol infusion rates during MAP < 65 mmHg episodes (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmcg/kg/min (propofol) (Median)
Usual Care Group60.10
Hypotension Decision Support48.59

[back to top]

Postoperative Rise in Creatinine Levels

Absolute values for serum creatinine before and after surgery will be compared. When multiple postoperative creatinine measurements are made, the maximum difference is reported. (NCT02726620)
Timeframe: Within 7 days after surgery

Interventionmg/dL (Median)
Usual Care Group0.00
Hypotension Decision Support0.00

[back to top]

Time to Discharge Readiness at the Postanesthesia Care Unit (PACU)

The time from arriving at the postanesthesia care unit (PACU) until the time the patient is considered ready for discharge (in minutes). (NCT02726620)
Timeframe: A specific time frame on the day of surgery: from the start of admission to the PACU to discharge from the PACU, an expected average of 4 hours

Interventionminutes (Median)
Usual Care Group67
Hypotension Decision Support60

[back to top]

Timing of Cardiovascular Drugs for MAP < 50 mmHg

Cardiovascular drugs as defined under interventions. Time of first administration of cardiovascular drug relative to the time at which the mean arterial pressure (MAP) drops below 50 mmHg. Per patient the average time to first administration of all hypotensive episodes was calculated. That average time is used as the outcome variable. A negative value indicates that administration occurred before the drop in MAP. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionminutes (Median)
Usual Care Group1
Hypotension Decision Support0

[back to top]

Timing of Cardiovascular Drugs for MAP < 55 mmHg

Cardiovascular drugs as defined under interventions. Time of first administration of cardiovascular drug relative to the time at which the mean arterial pressure (MAP) drops below 55 mmHg. Per patient the average time to first administration of all hypotensive episodes was calculated. That average time is used as the outcome variable. A negative value indicates that administration occurred before the drop in MAP. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionminutes (Median)
Usual Care Group1
Hypotension Decision Support0.5

[back to top]

Timing of Cardiovascular Drugs for MAP < 60 mmHg

Cardiovascular drugs as defined under interventions. Time of first administration of cardiovascular drug relative to the time at which the mean arterial pressure (MAP) drops below 60 mmHg. Per patient the average time to first administration of all hypotensive episodes was calculated. That average time is used as the outcome variable. A negative value indicates that administration occurred before the drop in MAP. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionminutes (Median)
Usual Care Group0.8
Hypotension Decision Support1.5

[back to top]

Timing of Cardiovascular Drugs for MAP < 65 mmHg

Cardiovascular drugs as defined under interventions. Time of first administration of cardiovascular drug relative to the time at which the mean arterial pressure (MAP) drops below 60 mmHg. Per patient the average time to first administration of all hypotensive episodes was calculated. That average time is used as the outcome variable. A negative value indicates that administration occurred before the drop in MAP. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionminutes (Median)
Usual Care Group2
Hypotension Decision Support1.14

[back to top]

Usage Frequency of Cardiovascular Drugs: Ephedrine

Cardiovascular drugs as defined under interventions. Frequency of patients receiving the drug. Cardiovascular drugs that were given in <1% of cases are not reported. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group9310
Hypotension Decision Support2718

[back to top]

Usage Frequency of Cardiovascular Drugs: Ephinephrine

Cardiovascular drugs as defined under interventions. Frequency of patients receiving the drug. Cardiovascular drugs that were given in <1% of cases are not reported. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group1215
Hypotension Decision Support409

[back to top]

Usage Frequency of Cardiovascular Drugs: Glycopyrrolate

Cardiovascular drugs as defined under interventions. Frequency of patients receiving the drug. Cardiovascular drugs that were given in <1% of cases are not reported. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group11093
Hypotension Decision Support1257

[back to top]

Usage Frequency of Cardiovascular Drugs: Norepinephrine

Cardiovascular drugs as defined under interventions. Frequency of patients receiving the drug. Cardiovascular drugs that were given in <1% of cases are not reported. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group762
Hypotension Decision Support233

[back to top]

Usage Frequency of Cardiovascular Drugs: Phenylephrine

Cardiovascular drugs as defined under interventions. Frequency of patients receiving the drug. Cardiovascular drugs that were given in <1% of cases are not reported. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group12211
Hypotension Decision Support3685

[back to top]

30-day Mortality

Vanderbilt University Medical Center: combination of in-hospital mortality and 'alive-index' (which checks for visits to the hospital in the electronic healthcare record as indication of being alive at 30 days) (NCT02726620)
Timeframe: 30 days after surgery

InterventionParticipants (Count of Participants)
Usual Care Group511
Hypotension Decision Support143

[back to top]

Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 55 mmHg

Average concentrations of inhalational anesthesia during MAP < 55 mmHg episodes (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

,
InterventionEndTidal% (other) (Median)
Sevoflurane (EndTidal %)Isoflurane (EndTidal %)Desflurane (EndTidal %)
Hypotension Decision Support1.250.674.65
Usual Care Group1.340.684.60

[back to top]

Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 60 mmHg

Average concentrations of inhalational anesthesia during MAP < 60 mmHg episodes (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

,
InterventionEndTidal% (other) (Median)
Sevoflurane (EndTidal %)Isoflurane (EndTidal %)Desflurane (EndTidal %)
Hypotension Decision Support1.250.672.33
Usual Care Group1.350.684.36

[back to top]

Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 65 mmHg

Average concentrations of inhalational anesthesia during MAP < 65 mmHg episodes (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

,
InterventionEndTidal% (other) (Median)
Sevoflurane (EndTidal %)Isoflurane (EndTidal %)Desflurane (EndTidal %)
Hypotension Decision Support1.270.682.31
Usual Care Group1.350.684.10

[back to top]

Average Use of Cardiovascular Drugs: Ephedrine

Cardiovascular drugs as defined under interventions. Average use for each drug will be calculated. Cardiovascular drugs that were given in <1% of cases are not reported, as the average dosages would be meaningless. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmg (Median)
Usual Care Group20
Hypotension Decision Support15

[back to top]

Average Use of Cardiovascular Drugs: Epinephrine

Cardiovascular drugs as defined under interventions. Average use for each drug will be calculated. Cardiovascular drugs that were given in <1% of cases are not reported, as the average dosage would be meaningless. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmg (Median)
Usual Care Group1.00
Hypotension Decision Support0.70

[back to top]

Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 50 mmHg

Average concentrations of inhalational anesthesia during MAP < 50 mmHg episodes (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

,
InterventionEndTidal% (other) (Median)
Sevoflurane (EndTidal %)Isoflurane (EndTidal %)Desflurane (EndTidal %)
Hypotension Decision Support1.230.654.70
Usual Care Group1.320.654.28

[back to top]

Average Use of Cardiovascular Drugs: Glycopyrrolate

Cardiovascular drugs as defined under interventions. Average use for each drug will be calculated. Cardiovascular drugs that were given in <1% of cases are not reported, as the average dosage would be meaningless. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmg (Median)
Usual Care Group0.40
Hypotension Decision Support0.40

[back to top]

Average Use of Cardiovascular Drugs: Norepinephrine

Cardiovascular drugs as defined under interventions. Average use for each drug will be calculated. Cardiovascular drugs that were given in <1% of cases are not reported, as the average dosage would be meaningless. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmg (Median)
Usual Care Group0.62
Hypotension Decision Support0.70

[back to top]

Incidence of Death

Number of deaths within 90 days of the procedure. (NCT03032965)
Timeframe: with 90 days of the procedure

InterventionParticipants (Count of Participants)
Adenosine and Isoproterenol0
Isoproterenol0

[back to top]

Incidence of Pulmonary Vein Stenosis

Number of subjects who develop Symptomatic pulmonary vein stenosis (NCT03032965)
Timeframe: 6 months post-procedure

InterventionParticipants (Count of Participants)
Adenosine and Isoproterenol0
Isoproterenol0

[back to top]

Incidence of Stroke

Number of subjects who develop stroke within 30 days after procedure. (NCT03032965)
Timeframe: peri-procedural (0 to 30 days after procedure)

InterventionParticipants (Count of Participants)
Adenosine and Isoproterenol0
Isoproterenol0

[back to top]

Number of Pulmonary Veins That Recovered Conduction During Repeat Ablation Procedures in Both Groups

Prevalence of recovery of conduction into pulmonary veins during repeat ablation procedures in both groups. This is determined by surgeon assessment using a circular mapping catheter to identify recovery of conduction into the pulmonary veins. (NCT03032965)
Timeframe: post-procedure (6 months)

Interventionpulmonary veins (Count of Units)
Adenosine and Isoproterenol29
Isoproterenol28

[back to top]

Number of Subjects Who Need Repeat Ablations

Number of participants who had one or more repeat ablation procedures due to documented recurrence of Symptomatic AF or atrial flutter/tachycardia. (NCT03032965)
Timeframe: date of ablation to 6 months after procedure

InterventionParticipants (Count of Participants)
Adenosine and Isoproterenol12
Isoproterenol9

[back to top]

Incidence of Atrio-esophageal Fistula

Number of subjects who develop connection between heart and the esophagus (NCT03032965)
Timeframe: within 4 weeks

InterventionParticipants (Count of Participants)
Adenosine and Isoproterenol0
Isoproterenol0

[back to top]

Freedom From Any Atrial Arrhythmias

Primary endpoint of the study will be number of participants who are free from any atrial arrhythmias after a single ablation procedure in the absence of antiarrhythmic drug therapy (NCT03032965)
Timeframe: 2- 14 months after Ablation procedure

InterventionParticipants (Count of Participants)
Adenosine and Isoproterenol24
Isoproterenol23

[back to top]

Incidence of Cardiac Perforation

Number of subjects who develop perforation of heart during ablation (NCT03032965)
Timeframe: within 24 hours

InterventionParticipants (Count of Participants)
Adenosine and Isoproterenol0
Isoproterenol0

[back to top]